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“…all parts of the body which have a function, is used in moderation and 
exercised in labours in which each is accustomed, become thereby healthy, 
well-developed, and age more slowly, but if unused and left idle they become 
liable to disease, defective in growth, and age quickly.” 
- Hippocrates, 450 B.C. 
 
 
 
“Lack of activity destroys the good condition of every human being while 
movement and methodological exercise save it and preserve it.” 
- Plato, 350 B.C.  
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ABSTRACT    
 
The purpose of this thesis was to extend our understanding of the assessment 
and interpretation of aerobic exercise function of paediatric patients with cystic 
fibrosis (CF). The first investigation sought to establish (1) the validity of 
traditional criteria to verify maximal oxygen ( V̇ O2max) during a maximal 
cardiopulmonary exercise test (CPET); and (2) the utility of supramaximal 
verification (Smax) to confirm V̇ O2max. Traditional criteria significantly 
underreported V̇O2max, whilst Smax was shown to provide a valid measurement in 
this patient group. The reproducibility of this CPET protocol, over the short- (48 
h) and medium- (4-6 weeks) term, was then established in study two. V̇O2max 
was repeatedly determined with no learning effect over 48 h (typical error (TE): 
∆150 mL; ∆9.3%) and 4-6 weeks (TE: ∆160 mL; ∆13.3%). Supplementary 
maximal and submaximal CPET parameters should be incorporated for a 
comprehensive evaluation of a patient, however they are characterised by 
greater variability over time. The influence of mild-to-moderate CF on aerobic 
exercise function and the matching of muscle O2 delivery-to-O2 utilisation during 
ramp incremental exercise to exhaustion were then examined in study three. 
Aerobic function was impaired in CF, indicated by very likely reduced fat-free 
mass normalised V̇O2max (mean difference, ±90% CI: -7.9 mL∙kg
-1∙min-1, ±6.1), 
very likely lower V̇O2 gain (-1.44 mL∙min
-1∙W-1, ±1.12) and a likely slower V̇O2 
mean response time (MRT) (11 s, ±13). Arterial oxygen saturation was lower in 
CF, supporting the notion that centrally mediated O2 delivery may be impaired 
during ramp incremental exercise. Although a faster rate of fractional O2 
extraction would be expected in the face of reduced O2 delivery, this was not 
observed, suggesting additional impairment in O2 extraction and utilisation at 
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the periphery in CF. The fourth study then demonstrated the clinical utility of 
CPET to assess the response to 12 weeks treatment with Ivacaftor, using a 
case-based design. Whilst one patient with relatively mild disease demonstrated 
no meaningful change in V̇O2max, the second demonstrated a 30% improvement 
in V̇O2max, due to increased O2 delivery and extraction. Furthermore, changes in 
aerobic function were detected earlier than spirometric indices of pulmonary 
function. This study demonstrated that CPET represents an important and 
comprehensive clinical assessment tool and its use as an outcome measure in 
the functional assessment of patients is encouraged. Study five investigated the 
V̇O2 kinetics in this patient group. During moderate intensity cycling, the phase II 
V̇O2 time constant (τ) (p = 0.84, effect size (ES) = 0.11) and overall MRT (p = 
0.52, ES=0.33) were not slower in CF. However, both were slowed during very 
heavy intensity cycling (p = 0.02, ES = 1.28 and p = 0.01, ES = 1.40, 
respectively) in CF. Cardiac output and muscle deoxygenation dynamics were 
unaltered in CF, however, the arterial-venous O2 content difference (C(a-v̅)O2) 
was reduced (p=0.03) during VH and ∆C(a-v̅)O2 correlated with the phase II τ (r= 
-0.85; p=0.02) and MRT (r = -0.79; p=0.03) in CF. This study showed that 
impaired oxidative muscle metabolism in this group is exercise intensity-
dependent and mechanistically linked to an intrinsic intramuscular impairment, 
which limits O2 extraction and utilisation. In conclusion, this thesis has provided 
guidelines for a valid and reproducible CPET protocol for children and 
adolescents with mild-to-moderate CF, demonstrated the utility of CPET as 
clinical outcome measure and furthered our understanding of the factors 
responsible for impaired aerobic exercise function in this patient group.  
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shaded circles) and untrained (○ open circles) girl during 
ramp incremental cycling exercise. This data 
demonstrates a rightward shift of the sigmoidal [HHb] 
response as a result of training, indicating a better 
matching of O2 delivery-to-O2 utilisation and the muscle 
level. Image taken from McNarry et al. (2011) with 
permission. 
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Figure 2.19 Sigmoid models of normalised changes in deoxygenated 
haemoglobin concentration ([HHb]) plus myoglobin 
concentration (percentage of peak amplitude) as a 
function of relative (percentage peak) work rate for 
young adults (YA) versus older adults (OA). Image taken 
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from Gravelle et al. (2012) with permission. 
   
Figure 2.20 Suggested schematic of the interpretation of data from a 
cardiopulmonary exercise test in patients with cystic 
fibrosis. Image taken from Urquart & Vendrusculo (2015) 
with permission. 
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Chapter 3 General Methods  
 
Figure 3.1 The equipment used during all exercise testing which 
comprises this thesis.  Consent was provided to include 
these photographs within this thesis. (Consent for 
photography and publication was obtained from all of 
these participants and their parent(s)/guardian(s)). 
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Figure 3.2 
 
An example pulmonary oxygen uptake (V̇O2) response 
during the combined ramp incremental and 
supramaximal cardiopulmonary exercise testing protocol 
used to determine V̇O2max.      
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Figure 3.3 
 
Schematic illustration of the exercise testing protocol. M, 
moderate-intensity exercise (90% GET); VH, very heavy-
intensity exercise (∆60%).    
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Figure 3.4 
 
Example profile determination of a V̇O2 plateau. In this 
case, the response was -3.7% which was classified as a 
linear V̇ O2 response upon exhaustion during a ramp 
incremental test.    
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Figure 3.5 Example dataset from a paediatric patient with cystic 
fibrosis in the purpose built software (LabVIEW, National 
Instruments, Newbury, UK) used to identifiy the gas 
exchange threshold (GET).  Following averaging of the 
data and removal of the respiratory compensation point, 
Panel A shows the inflection point identified by the 
software in a plot of expired carbon dioxide ( V̇ CO2) 
against pulmonary oxygen uptake ( V̇ O2). This 
intersection point between the two regression lines 
marks a disproportionate increase in V̇CO2 relative to 
V̇O2, in accordance with the V-slope method (Beaver et 
al., 1986).  Panel B then demonstrates the subsequent 
identification and confirmation of this point using the 
ventilatory equivalents for V̇O2 and V̇CO2 (Wasserman et 
al., 2004).   
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Figure 3.6 
 
Example identification of the pulmonary oxygen uptake 
(V̇O2) mean response time (MRT) in a paediatric patient 
with cystic fibrosis. In this case, the derived MRT was 55 
seconds. The black solid line represents the backward 
extrapolation of the regression line fitted through the 
linear portion of the V̇O2 response.   
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Figure 3.7 
 
Example profile of the pulmonary oxygen uptake (V̇O2) 
kinetic response of a paediatric patient with cystic 
fibrosis. Panels A and B represent the V̇ O2 kinetic 
response to 4 averaged transitions during moderate 
intensity exercise. Note that averaging to 5 s intervals, as 
demonstrated in Panel B, improves the signal-to-noise 
ratio from Panel A and, therefore, the confidence 
associated with the derived kinetic parameters. The red 
line denotes the monoexponential fit and the black trace 
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denotes the residuals of the response.   
 
Figure 3.8 
 
Example visual identification of the V̇O2 slow-component 
during very heavy intensity cycling exercise in a 
paediatric patient with cystic fibrosis. The vertical green 
line denotes the onset of the slow component, defined as 
the point at which a plateau in the estimated phase II τ 
was followed by a consistent and progressive increase 
(~120 s in this case). 
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Figure 3.9 Example profile of the pulmonary oxygen uptake (V̇O2) 
kinetic response of a female paediatric patient (13.8 y; 
1.47 m; 41.5 kg; ∆F508/2186delA) with cystic fibrosis 
during moderate (●) and very heavy (○) intensity cycling 
exercise. The vertical dotted lines represent the different 
phases (I, II and III) of the V̇O2 kinetic response. Notice 
that during moderate intensity exercise, following phase 
II (~120 s), the V̇O2 response has attained a steady-
state. In contrast, during very heavy exercise, following 
phase II (~120 s), a steady-state is not achieved due to 
the emergence of a V̇ O2 slow-component, which 
increases the O2 cost of exercise towards V̇O2max, which 
in this patient was 1.68 L·min-1. Figure taken from 
Williams et al. (2014).  
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Chapter 4 A protocol to determine valid ?̇?O2max in young cystic 
fibrosis patients 
 
   
Figure 4.1       Bland and Altman plots for the secondary criteria 
typically used during CPET of young CF patients. Plots 
189 
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show the mean bias (floating dotted line) and 95% 
confidence limits (floating dashed lines) for the oxygen 
uptake (V̇O2) recorded at an RER of ≥ 1.00 (A), an RER 
of ≥ 1.10 and (B) a heart rate of 180 beats·min-1 (C) 
compared with the actual V̇O2 recorded at exhaustion 
from the traditional ramp test in absolute terms (top row) 
and as a percentage of the difference (bottom row). 
 
Figure 4.2 
 
The agreement between the peak oxygen uptake 
(V̇O2peak) recorded at exhaustion during ramp and Smax 
testing. Plots show the mean bias (floating dotted line) 
and 95% confidence limits (floating dashed lines) for the 
V̇ O2 recorded at exhaustion during ramp and Smax 
exercise in absolute terms (A) and as a percentage of 
the difference (B), according to Bland and Altman (1986).   
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Chapter 5 Reproducibility of maximal cardiopulmonary 
exercise testing for young cystic fibrosis patients 
 
 
Figure 5.1 
 
Line of identity plot for peak oxygen uptake over both the 
short- [48 h (A)] and the medium-term [4–6 weeks (B)]. 
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Chapter 6 
 
Impaired aerobic function in young patients with 
cystic fibrosis during ramp exercise 
 
 
 
 
Figure 6.1 
 
 
Sigmoid models of normalised muscle deoxygenation 
(%Δ[HHb]) during ramp incremental exercise as a 
function of percentage peak oxygen uptake for 2 
representative young cystic fibrosis patients (● black 
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circles) of the leftward and rightward response patterns 
and their healthy age- and gender-matched control 
participants (dashed line; ○ white circles). 
 
Figure 6.1 
 
The relationship between maximal oxygen uptake 
( V̇O2max) and changes in end-exercise arterial oxygen 
saturation (SpO2) and the maximal oxygen pulse in 
young cystic fibrosis patients. 
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Chapter 7 
 
Effect of Ivacaftor on the aerobic function of children 
with cystic fibrosis (G551D mutation): A case study 
perspective 
 
 
 
Figure 7.1 
 
High-resolution computed tomography images for case A 
and case B pre-treatment with orally administered 
Ivacaftor. Case A microbiology: Mycobacterium 
abscessus, Stenotrophomonas maltophilia, allergic 
bronchopulmonary aspergillosis in remission. Case B 
microbiology: Intermittent Pseudomonas aeruginosa and 
previous Achromobacter xylosoxidans. 
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Figure 7.2 
 
Percentage change from baseline in body mass index, 
forced expiratory volume in 1 second (Stanojevic et al., 
2009), and body mass normalised maximal oxygen 
uptake (V̇O2max) in 2 patients with cystic fibrosis (CF) with 
the G551D-CFTR mutation [A (14-year-old female; • 
black circles) and B (16-year-old male; ◦ white circles)] at 
the start of Ivacaftor (day 0) and following 6, 12, and 20 
weeks of treatment. Exercise testing was not performed 
at 20 weeks and the magnitude of change is presented 
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in relation to the typical error of measurements in young 
patients with CF over a 4- to 6-week period (in line with 
Saynor et al., 2013b). 
 
Chapter 8 
 
Pulmonary O2 uptake dynamics are slowed in young 
patients with cystic fibrosis during very heavy but 
not moderate intensity cycling exercise 
 
 
 
Figure 8.1 
 
Mean V̇ O2 profile for cystic fibrosis (○ white circles) 
versus healthy (● black circles) children and adolescents 
during moderate (A, C) and very heavy (B, D) intensity 
cycling exercise. Figures C and D provide the normalised 
to end-exercise so that the differences in the phase II 
region of the V̇ O2 response can be observed. The 
vertical dotted line illustrates the onset of exercise from a 
10 W baseline. Data are presented as 5 s averages. 
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Figure 8.2 
 
Mean [HHb] profile for cystic fibrosis (○ white circles) and 
healthy (● black circles) young people during moderate 
(A,C) and very heavy (B,D) intensity cycling exercise. 
Figures C and D provide the normalised to end-exercise 
so that the differences in the phase II region of the [HHb] 
response can be observed The vertical dotted line 
denotes the onset of exercise from a 10 W baseline. 
Data are presented as 5 s averages. 
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Figure 8.3 
 
Group mean heart rate (A), fat-free mass (FFM) 
normalised stroke volume (B), FFM normalised cardiac 
output (C) and FFM normalised arterial-venous O2 
content difference [C(a-v̅)O2] (D) dynamics of young cystic 
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fibrosis patients (○ white circles) and healthy age- and 
gender-matched controls (● black circles) during 
moderate (1) and very heavy (2) intensity cycling 
exercise. The vertical dotted line denotes the onset of 
exercise from a 10 W baseline. Data are mean and SD 
and 30 s averages. * denotes P < 0.05, i.e. significant 
mean difference between CF patients and healthy 
controls, whilst + denotes a statistical trend (p = 0.07). 
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CHAPTER ONE 
Introduction 
 
1.1 Cystic Fibrosis 
 
Cystic fibrosis (CF) is the most common inherited, life-shortening disease 
amongst the Caucasian population for which there is currently no cure. In 1985 
the genetic defect in CF (located on the long arm of chromosome 7) was 
discovered, with the gene defect identified by full-length sequencing in 1989 
(Kerem et al., 1989). Specifically, this defect is expressed as a disruption in the 
CF transmembrane conductance regulator (CFTR) protein. This protein 
functions primarily as a cyclic adenosine monophosphate (cAMP)-activated and 
adenosine triphosphate (ATP)-gated chloride (Cl-) channel, found in the 
membranes of cells that line passageways of the lungs, liver, pancreas, 
intestines, reproductive tract, and skin. Abnormal CFTR alters the ion transport 
necessary for proper function of epithelial structure. Consequently, patients are 
characterised by excessively viscous mucus in almost all organs, including the 
lungs, gastrointestinal and endocrine systems, which causes a progressive 
decline in the function of these organs (Cuthbert, 1991).  
 
When this irregularity occurs in the lungs, abnormal thick and dry mucus 
ensues, resulting in a vicious cycle of bronchial airway obstruction, bacterial 
infection, and inflammation. The resulting obstructive syndrome causes 
progressive disability and, as this cycle continues, lung tissue is progressively 
destroyed, with eventual respiratory failure. Patients therefore experience 
progressive lung disease, malabsorption and pancreatic insufficiency can cause 
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malnutrition, steatorrhea and reduced skeletal muscle mass (Davies et al., 
2007). Not only does CFTR act as an epithelial chloride channel, it is also 
located in the vascular endothelium (Tousson et al., 1998), where it is reported 
to affect the lung endothelial barrier function (Brown et al., 2014) and act as a 
negative regulator of endothelial inflammatory responses (Scott-Ward & Shute, 
2014). As such, endothelial dysfunction has recently been documented in 
young, relatively well patients with CF (Poore et al., 2013). CFTR is also 
expressed in skeletal muscle (Lamhonwah et al., 2010), which may have 
consequences on skeletal muscle function. Although the complexity of CF is 
becoming increasingly problematic as the life expectancy of patients extends, 
respiratory failure remains the leading cause of morbidity and mortality in this 
patient group (Dassios et al., 2015).  
 
CF currently affects over 10,583 people in the United Kingdom (UK), with ~ 
4,000 under the age of 16 y. Although the natural history of CF is a progressive 
loss of lung function that leads to death, with early diagnosis and improved 
aggressive therapeutic interventions, survival into the third and fourth decade of 
life is now common. As such, the most recent UK CF Registry report (2014) 
predicts a median survival age of 40.1 y for people with CF; a substantial 
improvement when compared to 8 y of age in 1974, 11 y in 1986 and 29 y in 
1992 (Orenstein & Higgins, 2005). This improved outlook is primarily due to 
earlier diagnosis, the introduction of newborn screening and developments in 
pharmacological therapies for CF.  
 
The CFTR defect in CF can be classified in 5-6 classes, based on the specific 
genetic defect, which are outlined in Chapter 2. These classifications range 
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from complete loss of protein function to marginal dysfunction and play a 
significant role in the patient’s disease severity (Lubumba et al., 2012). Although 
traditional treatment regimens focused on alleviating manifestations secondary 
to CFTR dysfunction in patients with CF, landmark research over recent years 
has initiated ‘The beginning of effective therapy for cystic fibrosis’ (Davis, 2015). 
Ivacaftor is a CFTR potentiator that increases the open time of activated CFTR 
at the cell surface, thereby restoring the Cl--transport activity. Ivacaftor was 
initially targeted at patients with the Gly551Asp mutation, the third most 
common genotype in the world (6% of the UK population according to the 
CFTR2 Global Database). However it has more recently been licensed for 
patients with other mutations in which the CFTR protein reaches the plasma 
membrane but does not open appropriately. More recently, a landmark study 
has demonstrated potential pharmacological therapy, which combined Ivacaftor 
with an experimental therapy, Lumacaftor (VX-809). This combined therapy 
(Lumacaftor-Ivacaftor) targets patients homozygous for the most challenging 
Phe508del CFTR mutation (Wainwright et al. 2015), and in July 2015 was 
approved as Orkambi® by the Food and Drug Administration (FDA). This marks 
a new beginning in the treatment and clinical management of individuals living 
with CF.   
 
1.2  Exercise testing in the clinical management of patients with CF 
Whilst the recent increase in the treatment and survival age of patients with CF 
should be considered a success, this now presents an ongoing challenge for 
modern medicine. The increased prognosis associated with CF now provides 
clinical care teams with the challenge of fostering an optimal quality of life (QoL) 
for this ageing patient population. Developing and enhancing additional 
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treatment modalities to facilitate this is therefore a clinical priority. Besides 
pharmacological treatments, exercise forms an integral role in the management 
of CF and its importance has been recognised since the identification of CF as 
a clinical syndrome, given that exercise intolerance has always been a hallmark 
of disease progression (Orenstein & Higgins, 2005). Accordingly, the British 
Thoracic Society and the Association of Chartered Physiotherapists in 
Respiratory Care (ATS/ACCP, 2003) recommend exercise should be an integral 
component of the clinical management of CF. It is important that the utility of 
exercise testing as a clinical tool is not ignored. The utilisation of exercise 
should not only be for rehabilitative purposes, but should also include 
comprehensive exercise assessments of patients’ health and function.  
 
Exercise testing is a valuable investigative tool within both the clinical 
management and scientific investigation of young people with chronic diseases. 
Pulmonary function can predict survival in patients with CF (Nixon et al. 1992) 
and forced expiratory volume in 1 s (FEV1) and arterial oxygen saturation 
(SpO2) are typically used to stratify CF disease severity and referrals for lung 
transplantation (Augurten et al., 2001; Kerem et al., 1992; Sharples et al., 
1993). However, resting measurements cannot accurately predict patients’ 
exercise performance and how well they will cope with activities of daily living 
(ADL) that require rapid changes in metabolic rate and co-ordination of the 
cardiorespiratory and muscular systems. Notably, the European Cystic Fibrosis 
Society (ECFS) Exercise Working Group has recently promoted 
cardiopulmonary exercise testing (CPET) as the exercise testing method of 
choice for patients with CF (Hebestreit et al., 2015). Furthermore, the ECFS 
Clinical Trials Network Standardisation Committee has recently called for 
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research assessing the validity, reproducibility and feasibility of outcome 
measures utilised in the assessment of patients with CF and the most 
appropriate exercise test for paediatric patients (Bradley et al., 2012).  
 
CPET is considered the gold standard assessment of patients’ aerobic fitness, 
as it allows for the evaluation of health status and (dys)function, alongside the 
cause(s) of any change in patients’ clinical and aerobic fitness status (Palange 
et al., 2007). Furthermore, in patients with CF, clinical utility of CPET derived 
measurement of peak oxygen uptake ( V̇ O2peak) has been demonstrated in 
evaluating patients’ prognosis (Moorcroft et al., 1997; Nixon et al., 1992; Pianosi 
et al., 2005; Stanghelle et al., 1992), risk of hospitalisation for respiratory 
exacerbations (Pérez et al., 2014) and QoL (de Jong et al., 1997). Valid and 
reproducible exercise testing may also provide superior utility to assess how 
patients respond to clinical therapeutic interventions. For example, intravenous 
antibiotics (IVABs) or gene mutation targeted therapies, in establishing 
thresholds for transplantation in more advanced CF, or to assist in the 
prescription of more individualised exercise training programmes (Stevens & 
Williams, 2007). Comprehensive analysis of gas exchange, using a treadmill or 
cycle ergometer, is thus suggested to pose far superior value than current 
clinical assessments and provide clinicians with more useful information 
(Ferrazza et al., 2009).  
 
Specifically, CPET is a valuable tool to assess exercise performance and 
determine the possible underlying cause(s) of exercise limitation in patients with 
chronic diseases, such as CF (Ferrazza et al., 2009; Palange et al., 2007). The 
pulmonary, cardiovascular, metabolic, digestive and muscular systems are all 
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adversely affected by pulmonary disease itself and associated factors, such as 
hypoactivity (Ferrazza et al., 2009). CPET offers the unique simultaneous 
evaluation of all of these systems, which are essential for exercise, under 
conditions of metabolic stress (Wasserman et al., 2004). The principle of CPET 
for populations with disease is that exercise forces these systems to the limits of 
their tolerable ranges, enabling observation of abnormal response patterns. The 
necessary coordination of the respiratory, cardiovascular and muscular systems 
required for the rapid adjustments when changing from one metabolic rate to 
another is particularly sensitive to dysfunction at multiple steps along the O2 
transport and utilisation pathway (Wasserman et al., 2004). Therefore, when 
compared with their healthy counterparts, CPET makes it possible to observe 
reduced function and any abnormalities in the physiological adaptation to 
exercise in patient groups (Ferrazza et al., 2009).  
 
1.3  Current provision of exercise testing for patients with CF 
Due to the recognised clinical utility of exercise testing within CF, current 
standards for the management of this disease recommend at least annual 
exercise testing of patients (Cystic Fibrosis Trust, 2011). Information obtained 
from such testing should provide clinicians with valuable functional and 
prognostic insight that common clinical assessment cannot, thereby informing 
patients’ subsequent clinical management. However, current provision in many 
centres fails to achieve the recommendation to annually test patients and 
exercise testing, particularly CPET, remains dramatically underused, despite 
equipment often being available (Barker et al., 2004; Kaplan et al., 1991; 
Stevens et al., 2010). A survey of UK CF clinics (Stevens et al., 2010) 
highlighted that in addition to a mismatch between recommendation and 
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provision of exercise testing, those tests which are being performed are 
generally varied, simplistic and crude in nature. These observations are 
comparable with clinics in Germany (Barker et al., 2004) and the US (Kaplan et 
al., 1991). Whilst crude exercise tests, such as shuttle walk and step tests, can 
offer some indication regarding patients’ fitness levels, they are often 
submaximal, limited in the information they provide and often lack the capability 
to demonstrate when a submaximal effort has been provided. Current 
cardiopulmonary evaluations within clinical practice are therefore limited in both 
their prognostic value and their ability to accurately measures patients’ aerobic 
fitness levels.  
Promisingly, Stevens and colleagues’ survey (Stevens et al., 2010) highlighted 
that health professionals within UK CF clinics recognise the importance of 
exercise testing within clinical practice, in line with observations in Germany 
(Barker et al., 2004; Kaplan et al., 1991). However, before the clinical utilisation 
of CPET can advance, clarification of the optimal CPET protocol and feasibility 
of its implementation in the clinical setting is required. Identification of a 
reproducible and valid exercise test that allows clinical teams to monitor disease 
progression and/or the response to therapeutic interventions is therefore 
essential (Stevens & Williams, 2007). To date, no study has formally 
established an up-to-date ‘gold standard’ valid and reproducible protocol for 
determining maximal oxygen uptake (V̇O2max) in children and adolescents with 
CF. Until such a study is undertaken, inferences regarding exercise training, 
pharmacologic interventions and disease-related changes cannot be discerned 
with certainty. Moreover, knowledge regarding the validity and reproducibility of 
CPET is needed if strategies are to be devised to enhance implementation of 
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more detailed cardiopulmonary assessments within the healthcare of young CF 
patients.  
 
1.4 Assessment of exercise (dys)function in patients with CF  
Since the preservation of aerobic fitness and pulmonary function are important 
for the prognosis and QoL of people with CF, it is important to establish a 
database regarding the extent of exercise impairment and to identify the 
factor(s) responsible for impaired aerobic metabolism during exercise. Although 
previous studies (e.g. Bongers et al., 2012; Bongers et al., 2014; Hjeltnes et al., 
1984; Moser et al., 2000) have documented reduced V̇ O2max in paediatric 
patients with CF, suggesting impaired aerobic exercise function, this requires 
clarification using a valid and reproducible CPET protocol. Furthermore, 
although documenting exercise (dys)function in people with CF has received 
increased attention over recent years (e.g. Bongers et al., 2012; Bongers et al., 
2014; de Meer et al., 1999; Moser et al., 2000; Rosenthal et al., 2009; Wells et 
al., 2011; Werkman et al., 2015), there remains limited evidence regarding 
which factors are responsible for impaired aerobic exercise function in relatively 
well children and adolescents with CF.  
While impaired aerobic oxidative metabolism has been described in CF 
patients, it remains unclear whether this is a result of impaired O2 delivery (e.g., 
Klijn et al., 2003; Moser et al., 2000), the capacity of skeletal muscle to extract 
and utilise O2 (e.g., de Meer et al., 1995; Kusenbach et al., 1999; Rosenthal et 
al., 2009; Wells et al., 2011) or a combination of these factors. Since 
physiological abnormalities in people with CF may affect the transport, 
extraction and utilisation of O2 to the contracting muscles, assessing the 
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dynamics of V̇O2 in conjunction with measures at the central and peripheral 
levels is needed. The past decade has seen the development of non-invasive 
techniques such as thoracic bioelectrical impedance cardiography, which 
enables the assessment of cardiac function, and near-infrared spectroscopy 
(NIRS), which allows the estimated matching of O2 delivery-to-O2 utilisation 
within the muscle microcirculation to be measured (e.g. DiMenna et al., 2010; 
Ferreira et al., 2007). Although these non-invasive techniques are suitable for 
use in paediatric groups, their application within CF-related exercise studies is 
poor. To date, no study has utilised these techniques in conjunction with the 
V̇O2 response to investigate the cause(s) of reduced aerobic function during 
CPET. Such a study will enable the co-ordination and function of the 
respiratory, cardiovascular and muscular systems to be characterised during 
exercise. These measurements can offer unique insight into the exercise 
responses of clinical populations (Mattei et al., 2004; Poole & Jones, 2012), and 
is key to understanding further the mechanisms by which this disease 
modulates exercise function of young people with CF. 
Whilst exhaustive exercise testing has been a focus of previous research 
investigating the exercise impairment in people with CF, documenting the 
kinetics of V̇O2 at the onset and offset of constant work rate (CWR) exercise can 
also provide a non-invasive window into the metabolic activity of skeletal muscle 
during exercise (Poole & Jones, 2012). As such, studies investigating this 
response in children and adolescents with CF would provide a valuable means 
of developing our understanding of oxidative skeletal muscle metabolism in this 
group. The collective conclusion from existing literature (for a review see 
Williams et al., 2014) shows that the dynamics of V̇O2 at exercise onset, and 
thereby the control of mitochondrial oxidative phosphorylation, is impaired in 
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CF. However, all previous studies have contained methodological issues (see 
Chapter 2), such as incorrect handling and analysis of the data, prescription of 
exercise intensities and the use of semi-supine cycling. Consequently, a robust 
study measuring the V̇ O2 kinetics of children and adolescents with CF is 
warranted. Documenting the response in conjunction with measures at the 
central and peripheral levels will also provide important information concerning 
how well children and adolescents with CF can match O2 delivery-to-O2 
utilisation during CWR exercise. 
 
1.5   Objectives of this thesis 
In line with the preceding Introduction, through a series of chapters and 
experimental studies this thesis aims to extend the current evidence base 
concerning the assessment and interpretation of aerobic exercise function in 
paediatric patients with mild-to-moderate CF. Specifically, this thesis will:   
 Chapter 2 – Provide a comprehensive review of the literature concerning  
the assessment and interpretation of aerobic exercise (dys)function in 
patients with CF and the factors purported to play a role in the 
impairment of aerobic metabolism;  
 Chapter 3 - Provide an overview of the general methods utilised in the 
experimental studies which contribute to this thesis;  
 Chapter 4 - Examine the issues surrounding the validity of assessing 
aerobic exercise function, specifically V̇O2max, in this patient group during 
exhaustive incremental exercise testing; 
 Chapter 5 - Establish the reproducibility of CPET to determine the key 
parameters of aerobic function in children and adolescents with CF and 
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provide the typical error (TE) necessary to determine a clinically 
meaningful change; 
 Chapter 6 – Demonstrate, using a case study approach, the clinical 
application of CPET to assess the effect of a therapeutic intervention 
(Ivacaftor) on aerobic exercise (dys)function in paediatric CF; 
 Chapter 7 – Determine whether children and adolescents with mild-to-
moderate CF present with impaired aerobic exercise function using a 
valid and reproducible ramp incremental exercise test, in addition to 
exploring O2 delivery and/or O2 extraction limitations;  
 Chapter 8 – Provide a comprehensive investigation into whether the 
pulmonary V̇ O2 and muscle deoxygenation (deoxyhaemoglobin + 
myoglobin ([HHb])) kinetics during moderate (MOD) and very heavy (VH) 
intensity CWR exercise are impaired in children and adolescents with CF 
and an exploration into the limitng factor(s).  
 
The experimental hypotheses for the experimental studies are provided in their 
respective chapters. Finally, Chapter 10 will provide a summary of the primary 
findings of the experimental studies conducted as part of this thesis, highlighting 
their novel contribution to the study of exercise (dys)function in young people 
with CF. Finally, remaining gaps in the evidence base and avenues for future 
research will be presented.  
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CHAPTER TWO 
Literature Review 
 
2.1.  Pathophysiology of CF  
 
‘The child will soon die whose forehead tastes salty when kissed’ 
(Almanac of Children’s Songs and Games. Switzerland, 1857) 
 
CF is an autosomal recessive, predominantly Caucasian, disease caused by a 
defect on a single gene. In 1985 the genetic defect responsible for CF (located 
on the long arm of chromosome 7) was discovered and subsequently identified 
by full-length sequencing in 1989 (Kerem et al., 1989). Specifically, this defect is 
expressed as a disruption in the CFTR protein. CFTR mutations are currently 
grouped into 6 classes, depending on the effects elicited on the protein (Wang 
et al., 2014). These classifications range from complete loss of protein function 
to marginal dysfunction and play a significant role in determining the magnitude 
of disease severity (Lubumba et al., 2012). Although the majority of patients 
with CF are homozygous for the Phe508del (∆F508) CFTR mutation (Table 
2.1), the CF Mutation Database (CFTR1) currently lists 1,991 CFTR mutations.  
Table 2.1. The most common single mutations in UK registered (2012) patients with 
cystic fibrosis. (Data adapted from the UK CF Registry Report, 2013. Approximately 
96% of registered patients have been genotyped, with ∆F508 the most common 
genotype). 
Mutation Class Number Percent 
DF508 II 7971 90.7 
G551D III 471 5.6 
R117H IV 361 4.3 
G542X I 307 3.6 
621+1G ->T I 180 2.1 
N1303K II 111 1.3 
1717-1G->A I 106 1.3 
1898+1G->A I 95 1.1 
DI507 II 85 1.0 
R560T III 83 1.0 
3659delC II 82 1.0 
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Classes I-III are generally considered to be more severe than classes IV-VI, 
which retain varying degrees of CFTR function. The ∆F508 mutation is a class II 
mutation, which results in defective processing of the CFTR protein. ∆F508 
remains to be the most common CFTR mutation in the world, with a prevalence 
of 91% and 90% in the UK and Ireland, respectively. G542X is a class I 
mutation, whereby a premature stop codon causes complete lack of protein 
expression, whilst G551D is an example of a class III mutation, leading to 
defective chloride channel gating and a more simple target for pharmacological 
intervention. The G551D mutation is the third most common in the world, with a 
prevalence of 14% and 6% in the UK and Ireland, respectively. In addition to 
classic CF, some mutations, generally milder genetic variants which retain 
residual CFTR function, can lead to isolated milder symptoms. These patients 
have been classified as atypical CF, non-classical CF, CFTR-related disorders, 
low-risk genotypes, or mild variant CF (Griesenbach & Alton, 2015).  
The CFTR protein functions primarily as a cAMP-activated and ATP-gated 
chloride channel in the apical membrane of epithelial cells throughout the body. 
Abnormal CFTR alters the ion homeostasis and, thereby, the ion transport 
necessary for proper function of epithelial structure (Figure 2.1). Consequently, 
individuals with CF are characterised by excessively viscous mucus in almost 
all organ systems, including the respiratory, gastrointestinal, reproductive and 
endocrine systems, which causes a progressive decline in their function 
(Cuthbert, 1991). CF therefore affects multiple organs, including the lungs, liver, 
intestine, pancreas, vas deferens in males, and the skin. People with CF 
therefore experience progressive lung disease, malabsorption and pancreatic 
insufficiency, commonly resulting in some degree of malnutrition, steatorrhea 
and reduced skeletal muscle mass (Davies et al., 2007; Lubamba et al., 2012). 
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Furthermore, since CF affects the development of the vas deferens and this can 
also become obstructed by mucus, sperm are not released and infertility 
characterises males. Mucus can also make fertilisation problematic in females 
with CF. CFTR also regulates the flow of electrolytes and fluid across cellular 
membranes and the defective CFTR evident in CF is associated with reduced 
conductance of Cl- ions across the apical membrane of epithelial cells (Figure 
2.1), causing the elevated sodium and Cl- levels which are characteristic of the 
disease (60 mEq·dL·-1 is highly suggestive for diagnosis).  
 
 
 
 
 
 
 
 
 
 
When this irregularity in ion transport across the epithelial cell membranes 
occurs in the lungs, abnormally thick and dry mucus ensues, resulting in a 
vicious cycle of bronchial airway obstruction, bacterial infection, and 
inflammation. The resulting bronchiectasis causes irreversible anatomic and 
Figure 2.1. Ion water transport across airway epithelial cells. Choride (Cl-) and 
sodium (Na+) transport across the apical membrane of airway epithelial cells 
regulate water transport. The “low volume” hypothesis postulates that, in cystic 
fibrosis patients, Cl- transport is impaired and Na+ absorption is upregulated, 
which leads to increased water absorption from the airways into the tissue and 
depletion of the airway surface liquid. Figure taken from Griesenbach & Alton 
(2015) with permission.  
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histologic pathogenic changes to the airways (Figure 2.2), with grossly dilated 
airways, thickened bronchial walls and luminal structures commonly evident 
upon clinical examination. The bronchiectasis in patients with CF is typically 
more severe than that experienced by patients with non-CF bronchiectasis 
(Morrisey, 2007). This pulmonary obstructive syndrome causes progressive 
disability and, as the vicious cycle of infection and inflammation continues, lung 
tissue is progressively destroyed. This progressive fibrosis and destruction 
causes a loss of functional lung tissue and, eventually, leads to respiratory 
compromise and respiratory failure. Despite advances in the clinical treatment 
of CF, respiratory failure still remains the leading cause of morbidity and 
mortality in this patient group (Dassios, 2015).  
 
 
 
 
CF is a complex multisystem disease and, as pulmonary function and life 
expectancy continue to improve in this patient group, extrapulmonary 
complications (e.g., hepatic and gastrointestinal issues) will increasingly 
Figure 2.2. Severe bronchiectasis in a patients with end-stage cystic fibrosis 
(CF) shown in both chest radiograph (left) and computed tomogram (right) 
images. For reasons that are not fully understood, the upper lobes are often 
most severely affected in CF, although this patient has severe bronchiectasis 
throughout the whole of the right lung. Note the presence of indwelling 
intravenous catheter (a “port-a-cath”) on the right lateral chest wall. Images 
taken from Davies et al. (2007) with permission.   
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contribute to morbidity and mortality. A similar pathologic process to that 
observed in the lungs occurs in the gastrointestinal tract, pancreas and 
hepatobiliary system (Lavelle et al., 2015). More specifically, abnormal CFTR 
function, with reduced bicarbonate and other ion transport levels through the 
apical surface of epithelial cells, can affect the intestinal tract, including the liver 
and pancreas (Munck et al., 2015). Thick mucus causes luminal obstruction and 
pancreatic involvement can result in exocrine and endocrine insufficiency, 
pancreatic atrophy, and/or fatty replacement.  
Exocrine insufficiency reportedly characterises approximately 85% of people 
with CF, which results in malabsorption of nutrients, including fats and protein. 
This malabsorption can lead to frequent fatty and foul-smelling stools and 
abdominal pain. Furthermore, CF has traditionally been associated with 
malnutrition, secondary to malabsorption, inadequate intake, and increased 
energy expenditure (Hanna & Weiner, 2015). Nutritional status is also linked to 
the development of bone disease in CF and poor nutritional status is associated 
with significantly worse pulmonary function (Steinkamp & Wiedemann, 2002) 
and malnutrition is associated with a rapid progression of disease and worse 
prognosis (Sinaasappel et al., 2002; Yen et al., 2013). 
A new concern in this aging patient population is the risk of overweight and 
obesity. One study a decade ago reported that 9% of UK based patients with 
CF, who are homozygous for the ∆F508 mutation, were overweight and 1% 
obese (Kastner-Cole et al., 2005). However, a more recent study from the 
Children’s Hospital in Pittsburgh, United States of America, reported that 15% of 
their paediatric patients were overweight and 8% were obese, despite the 
majority being pancreatic insufficient (Hanna & Weiner, 2015). This observation 
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is comparable with a recent Canadian study in adults with CF, which noted that 
18.4% were overweight or obese (Stephenson et al., 2013). As such, whilst 
nutritional management traditionally includes a high calorie, high fat diet, 
pancreatic enzyme replacement therapy, vitamin and mineral replacement, and 
enteral support as required (Schindler et al., 2015), there is increasing clinical 
interest in muscle maintenance and protein intake (Engelen et al., 2014).  
The prevention and management of CF related diabetes (CFRD), which is more 
common in classes I-III, is also now of increasing clinical concern. The 
abnormalities of glucose metabolism in CF represent a continuum from normal, 
through pre-diabetic, to overt diabetes and the pathogenesis is characterised by 
post-prandial rather than pre-prandial hyperglycaemia (Perano et al., 2014). 
CFRD impacts both nutritional status and pulmonary function (Bizzarri et al., 
2006; Hameed et al., 2015; Moran et al., 2009) and mortality rate is reportedly 
substantially higher than CF patients without CFRD (Hayes et al., 2015; Moran 
et al., 2009). As the life expectancy of patients with CF continues to rise, there 
is new evidence demonstrating vascular complications are seen in both the 
small and large vessels, with associations with CFRD now being observed 
(Perano et al., 2015).  
CFTR not only acts as an epithelial Cl- channel, but it has also been located in 
the vascular endothelium (Tousson et al., 1998), where it reportedly affects the 
lung endothelial barrier function (Brown et al., 2014) and acts as a negative 
regulator of endothelial inflammatory responses (Scott-Ward & Shute, 2014). In 
support of this, endothelial dysfunction has recently been documented in young, 
relatively well patients with CF (Poore et al., 2013). More recently, it has been 
demonstrated that CFTR is expressed in skeletal muscle cells (Lamhonwah et 
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al., 2010) and in vitro study of leucocyte mitochondria in patients with CF 
demonstrates that properties of complex I of the respiratory chain are 
significantly altered (Dechecci et al., 1988). Furthermore, absence of CFTR 
from skeletal muscle has been shown to dysregulate calcium (Ca2+) 
homeostasis, augment inflammatory or atrophic gene expression signatures 
and increase diaphragm weakness (Divangahi et al., 2009). CFTR has also 
been found in ventricular myocytes of several mammalian species, including 
mice, rats, swine, simians and humans (Duan et al., 1999; Gao et al., 2007; Tilly 
et al., 1996; Warth et al., 1996). Recent evidence also suggests a role of CFTR 
in the regulation of cardiomyocyte contraction (Sellers et al., 2010). 
Furthermore, external factors, such as cigarette smoke, have been shown to 
alter CFTR function in the lungs as well as extrapulmonary tissues (Cantin et 
al., 2006; Raju et al., 2013).    
 
2.2.   Incidence of CF and predicted survival age  
 
The life expectancy of patients with CF continues to improve due to a 
combination of aggressive antibiotic treatment, improved emphasis on 
nutritional status and physiotherapy, and the development of CFTR potentiator 
treatments. However, CF remains the most common inherited life shortening 
disease amongst the Caucasian population and currently affects ~ 10,000 
people in the UK (with 87% of these included in the most recent UK CF Registry 
Report (UK Cystic Fibrosis Registry, 2013). Approximately 4,000 of these 
patients are below the age of 16 y and their treatment is managed within 
paediatric care. The outlook for people with CF has substantially improved over 
the last 40 y, with the most recent UK CF Registry report from 2012 (UK Cystic 
Fibrosis Registry, 2013) reporting a median age at death of 28 y (Figure 2.3) 
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and predicting a median survival age of 38.8 y and > 57% of patients > 16 y of 
age either working or studying. 
 
 
 
 
 
 
 
 
 
 
 
 
 
This marks a continued and substantial improvement from the predicted median 
survival age of 8 y in 1974, 11 y in 1986 and 29 y in 1992 (Orenstein & Higgins, 
2005). Despite the improved outlook for the new generation of patients with CF, 
there were still 106 recorded deaths in the UK in 2012, with a median age of 28 
y (Figure 2.3).  
 
More recently, the mortality trends in CF patients across Europe were 
documented for the first time. It was demonstrated that, across the 27 European 
countries, the mean age at death and potential years of life lost increased for 
both genders from 1994 to 2010. However, there is a continued downward trend 
of CF mortality throughout Europe, with differences by both country and gender 
Figure 2.3. Age distribution of deaths in patients with cystic fibrosis (CF) in the 
United Kingdom in 2012. There were 106 recorded deaths in 2012. The median 
age at death was 28 y (minimum, 5 y; maximum, 72 y; 95% confidence interval, 
29 y). At this time the oldest male patient on UK CF Registry was 83 y and the 
oldest female patient was 81 y. Data taken from the most recent UK CF 
Registry Report (2013).  
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(Quintana-Gallego et al., 2016). The mean age at death across Europe 
increased from 17.6 y to 30.3 y in females and from 21.5 y to 29.8 y in males 
(Figure 2.4), with similar patterns observed in individual countries and the peak 
age being 20-24 y. The highest age-standardised mortality rates were observed 
for Ireland and the UK.  
 
 
 
 
 
 
 
 
 
A number of factors are responsible for the improved prognosis associated with 
CF, including developments in specialist centre care, better nutritional support, 
and improved treatment of pulmonary complications with the aggressive use of 
antibiotic treatments, improvements in the control of infection and boosts in 
exocrine pancreatic function, in addition to the development of CFTR-modifying 
drugs for some genotypes. Furthermore, the implementation of newborn 
screening for CF in many European countries, North America and Australia has 
also contributed to the improved outlook for patients with CF. Newborn 
screening was introduction in the UK in 2007, through the development of the 
Figure 2.4. Mean age of death in Europe between 1994 and 2010. 
Solid lines represent the regression lines for age-standardised mortality 
for males (blue) and females (red). Data taken from Quintana-Gallego 
et al. (2016) with permission.  
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CF UK Newborn Screening Programme Centre, and initial indications suggest 
that early diagnosis may improve survival, with newborn screened patients 
having superior weight and pulmonary function later in life than patients 
diagnosed in response to symptom development (UK Cystic Fibrosis Registry, 
2013). Promisingly, of the 63% of children with complete data born in 2012, 
79% were identified by newborn screening. Projections of 40 y and > 50 y have 
been made for the median survival age of CF patients born in 1990 (Elborn et 
al., 1991) and 2000 (Dodge et al., 2007), respectively. These predictions are not 
unfounded, particularly when the recent advances in the pharmacological 
treatment of CF are considered.  
 
2.3  Advancements in the medical treatment of CF 
There remains no cure for CF. Traditionally, the clinical management of CF is 
focused on alleviating the manifestations that are secondary to CFTR 
dysfunction. IVABs are typically utilised to provide short-term improvements in 
clinical status and pulmonary function and, in more severe disease, lung 
transplantation can increase prognosis. Although clinical interventions such as 
IVABs do provide acute improvements, they are not a long-term management 
option. Over the past 20 y, a number of therapies (e.g., novel antibiotics, such 
as inhaled tobramycin and macrolides, novel mucolytics, dornase alpha (a 
recumbent DNase) and hypertonic saline; Figure 2.4) have progressed from 
clinical trials to the mainstream clinical treatment of CF (Griesenbach & Alton, 
2015). Disappointingly, the development of pulmonary mutation-independent 
gene therapy for patients with CF has demonstrated no clinical benefit as yet 
(Griesenbach et al., 2013). However, a particularly exciting area of development 
  
62 
 
has been the ongoing development of pharmacological treatments to target the 
defective CFTR responsible for CF.  
Over recent years, pioneering research has developed gene mutation targeted 
therapies which mark the beginning of a new era in the treatment and clinical 
management of CF. CFTR potentiators are defined as agents that potentiate 
mutated but apically localised CFTR (Griesenbach & Alton, 2015), which may 
be of benefit for class III and IV mutations. Initial research has focused on an 
orally administered CFTR potentiator (Figure 2.4), VX-770, otherwise known as 
Ivacaftor, and most recently marketed under the name Kalydeco®. Ivacaftor 
(VX-809) is a CFTR potentiator that increases the open time of activated CFTR 
at the cell surface, thereby restoring the Cl--transport activity. Ivacaftor was 
initially targeted at patients with Gly551Asp mutation. However, more recently it 
has been licensed for patients with other mutations, in which the CFTR protein 
reaches the plasma membrane but does not open appropriately.  
To date, improvements in QoL, incidence of pulmonary exacerbations, 
respiratory symptoms, pulmonary function, body mass, and biomarkers of 
CFTR activity (sweat Cl- and nasal potential difference) have been reported 
following treatment with Ivacaftor in patients heterozygous for the G551D 
mutation with mild-to-moderate pulmonary disease, without substantial adverse 
effects (Accurso et al., 2010; McKone et al., 2012; Ramsey et al., 2011). 
Furthermore, administration of Ivacaftor has revealed improvements in the 
pulmonary function (5.2 ± 5.6% predicted FEV1) of severely ill patients (< 40% 
predicted FEV1) (Hebestreit et al., 2013) and lung clearance index (95% CI -
2.88 to -1.44) in children aged 6-11 y (Davies et al., 2013). More recently, it has 
also been demonstrated that Ivacaftor has comparable efficacy in eight other 
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class III CFTR gating mutations (de Boeck et al., 2014). However, existing 
evidence suggests that Ivacaftor is ineffective in patients homozygous for 
F508del (Flume et al., 2012) and that additional treatments are needed to 
accompany a CFTR potentiator.  
 
 
 
 
 
 
 
 
 
 
 
CFTR correctors (Figure 2.5), agents that correct the processing defect of class 
II mutations, may therefore present benefit to patients who are homozygous for 
F508del. The CFTR corrector Lumacaftor (also called VX-809) has been shown 
to reduce sweat Cl-, but not to improve pulmonary function when administered 
in isolation to patients with the F508del mutation (Clancy et al., 2012). 
Subsequently, the combination of Ivacaftor and Lumacaftor was assessed in 
homozygote and compound heterozygote F508del patients, to investigate 
whether Lumacaftor can transport CFTR to the apical membrane and Ivacaftor 
Figure 2.5. Cystic fibrosis transmembrane conductance regulator (CFTR) 
pharmacological modulators have different modes of action. A, Read-through 
compounds which include aminoglycoside antibiotics (e.g., gentamicin, tobramycin) act 
by suppressing premature termination codons, thus permitting translation to continue to 
the normal termination of the transcript and thus increasing the total amount of 
complete CFTR being produced in the cell. B, Correctors (e.g. VX-809 also known as 
Lumacaftor; VX-661) potentially promote folding of mutant CFTR protein, allowing it to 
escape ER degradation and reach the cell surface, thus increasing the number of 
channels present at the plasma membrane. C, Stabilisers include compounds (e.g., 
HGF) that enhance CFTR retention/anchoring at the cell surface, thus also contributing 
to increase the number of channels present at the cell surface. D, Potentiators (e.g., 
VX-770 also known as Ivacaftor) activate CFTR, i.e., increase the probability (P0) of the 
channel by regulating its gating and possible also the conductance. Taken from Bell et 
al. (2015).  
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will restore its function (Boyle et al. 2014). The co-administration did improve 
pulmonary function, however the improvement was less than Ivacaftor 
treatment in class III mutations and appears less effective in F508del compound 
heterozygotes (Boyle et al., 2014). More recently, it has been demonstrated that 
the combination of Lumacaftor-Ivacaftor can provide benefit for patients with CF 
who are homozygous for the most challenging Phe508del CFTR mutation 
(Wainwright et al., 2015). Promisingly, in July 2015 this combined therapy was 
licensed under the name Orkambi® for use in patients with CF.  
The identification and licensing of Kalydeco® and Orkambi® represent a 
milestone in the treatment of CF. These treatments provide the first ‘proof-of-
concept’ that the molecular defect in CFTR is targetable and correctable. 
However, it has recently been highlighted that new outcome measures are 
needed in the new era of therapeutic CFTR modulation (Bodewes et al., 2015). 
Bodewes et al. (2015) highlighted that the current clinical end-points of 
pulmonary function and body mass index (BMI) have limitations in the clinical 
trials assessing the development of new drugs which target CFTR protein 
function, largely due to their insensitivity to change and the limited mechanistic 
insight that they provide. Although the review by Bodewes and colleagues 
(2015) focused on gastrointestinal endpoints, comprehensive exercise testing 
may provide other feasible and informative outcome measures. The sensitivity 
of common clinical assessments, such as spirometry and body mass, to detect 
change in early disease has been questioned (Welsh et al., 2010). Therefore, a 
comprehensive assessment of physiological (dys)function of the organ systems 
under controlled metabolic stress, through detailed exercise testing, warrants 
further investigation in CF.  
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2.4 Cardiopulmonary exercise testing as a clinical outcome measure in CF   
2.4.1 Current use of CPET within the clinical management of patients with CF 
The utilisation of exercise within the clinical management of individuals with CF 
includes both exercise training and testing. A survey conducted by Stevens and 
colleagues in 2010 demonstrated that CPET is underutilised as an assessment 
tool for patients with CF in the UK (Stevens et al., 2010). Of the clinics that 
responded (51% response rate), only 38.9% of paediatric and 27.8% of adult 
patients had performed an exercise test in the preceding 12 months, most as 
part of an annual review process. This is concerning given that the current 
management guidelines from the UK CF Trust recommend at least annual 
exercise testing (CF Trust Guidelines) and is not only an issue in the UK, with 
similar observations across Germany and the US (Barker et al., 2009; Kaplan et 
al., 1991).  
Of the tests performed, the majority were field based tests, including the 6 min 
walk test (6MWT), 12 min walk test, incremental shuttle walk test, endurance 
shuttle walk test, and step tests, with only a small number of treadmill and cycle 
based testing protocols reported (Stevens et al., 2010).  This is despite 
acceptance by clinical and exercise physiologists that maximal CPET provides 
the most objective assessment of the extent and/or mechanism(s) of exercise 
(dys)function. Interestingly, CF clinical care teams did recognise the value of 
exercise testing. When UK clinics were asked to rank the importance of 
exercise testing on a scale from 1 ‘not important’ to 5 ‘very important’, the mean 
and median respondent scores were 3.5 and 4.0, respectively. Primary issues 
precluding the uptake of exercise testing as a standard clinical assessment tool 
included availability of equipment and issues regarding methodology and 
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interpretation of the results, due to a lack of expertise and/or training on the 
topic.  
Since pulmonary function may remain stable or improve when high-resolution 
computed tomography (HRCT) scores worsen (de Jong et al., 2004) and is not 
a strong predictor of maximal aerobic fitness ( V̇ O2peak) in mild respiratory 
disease (Pianosi et al., 2005), there is a need for more sensitive and 
comprehensive assessment methods in paediatric patients with mild-to-
moderate CF. Not only does CPET provide a comprehensive physiological 
evaluation of patients’ (dys)function, but the derived parameters have been 
shown to provide indices of prognostic stratification in patients with CF. More 
specifically, a higher V̇O2peak is associated with an improved prognosis (Nixon et 
al., 1992; Moorcroft et al., 1997; Pianosi et al., 2005), QoL (de Jong et al., 1997) 
and a reduced risk of hospitalisation for pulmonary exacerbations (Pérez et al., 
2014).  
In view of this, although CPET has been an established clinical assessment 
method for decades, the European CF Society (ECFS) Collaborative Exercise 
Working Group and other international CF associations have this year promoted 
CPET as the exercise testing method of choice for this patient group (Hebestreit 
et al., 2015). Moreover, the ECFS Clinical Trials Network Standardisation 
Committee recently called for research to 1) assess the validity, reproducibility 
and feasibility of the outcome measures used in the assessment of patients with 
CF and 2) determine the most appropriate exercise test for paediatric patients 
(Bradley et al., 2012).  
A more standardised approach to CPET as an outcome measure in CF care 
and research would enable a normative database to develop and thresholds for 
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‘abnormal’ function and clinical deterioration to be established. Furthermore, 
establishing a patient’s exercise (dys)function and physiological response 
profile will enable exercise prescription to be more individualised relative to 
fitness levels and training goals, since it is currently too generalised and 
underutilised within UK clinics (Stevens et al., 2010). The implementation of 
routine CPET in CF will also enable the prognostic value of exercise parameters 
to be examined alongside more common clinical outcome measures, such as 
parameters of pulmonary function, body mass, QoL, hospital admissions and 
drug administration. Furthermore, since there has been a marked improvement 
in the median survival age of patients with CF over recent years (Dodge et al., 
2007), the earlier publications regarding the prognostic value of CPET in 
patients with CF (Moorcroft et al., 1997; Nixon et al., 1992; Pianosi et al., 2005) 
are outdated and therefore urgently require updating in the new generation of 
children and adolescents with CF. Whether submaximal CPET-derived 
parameters may also provide sensitive predictors or mortality rate in 
adolescents with CF also warrants further investigation, particularly given recent 
evidence that the ventilatory equivalent for O2 (V̇E/V̇O2) is a strong predictor of 
mortality rate in adolescents with CF (Hulzebos et al., 2014).   
 
2.4.2  Current use of CPET as an outcome for clinical trials in patients with CF 
Pulmonary function and structural investigations and/or measures of nutritional 
status are traditionally relied upon to measure disease severity and progression 
in CF, but they cannot predict exercise capacity and are often not sensitive to 
change in mild-to-moderate disease. As a short-term intervention, IVABs can 
restore FEV1 to baseline within 7 days in adult patients (Daniels et al., 2013) 
and have been shown to improve pulmonary function (FEV1: + 9.5%) in 
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paediatric patients following a 14 day course of treatment (Pike et al., 2001). 
Although IVABs may provide intermediary benefit and patients reportedly feel 
better, whether pulmonary function is sensitive enough to detect these 
improvements immediately so that patients can be sent home and/or stop 
treatment requires further investigation. CPET may therefore provide a more 
detailed clinical assessment than current standard outcome measures to inform 
medication and therapy strategies, assist with pre-transplant stratification and 
evaluate responses to clinical intervention. However, the use of CPET as an 
outcome in therapeutic trials still remains in its infancy (Bell & Morris, 2010).  
To date, a few studies have investigated the impact of a course of IVABs on the 
exercise function of patients with CF using step and shuttle tests (Pike et al., 
2001; Cox et al., 2011). Pike et al. (2001) utilised the 3 min step test and 
observed reductions in heart rate (HR) and dyspnoea, in addition to increased 
SpO2 upon exhaustion. Conversely, although 14 days of home IVABs enhanced 
pulmonary function in children with CF (FEV1: + 12 ± 4%), performance on the 
modified shuttle test did not improve (Cox et al., 2011). Similarly, there is limited 
evidence concerning the influence of new gene mutation targeted therapies, 
such as Ivacaftor, on the exercise function of patients with CF. To date, only two 
of the published clinical trials investigating the efficacy of this new era of 
treatments have utilised any form of exercise testing, both using the 6MWT. In 
the case study of a female who was homozygous for the G551D mutation, 
Harrison et al. (2013) observed an improvement in exercise performance within 
2 weeks of treatment, with the distance walked increased from 150 m to 550 m. 
The majority of this improvement was observed within 2 weeks of initiation of 
Ivacaftor and continued to increase for the following 50 weeks. This continued 
improvement is in contrast to the response observed in heterogenous 
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individuals, who appear to experience a plateau in functional capacity (Davies 
et al., 2013). However, the subjective nature of the 6MWT provides little insight 
into the mechanistic explanations of the improvement in aerobic exercise 
function.  
More recently, a case study has demonstrated that Ivacaftor improved maximal 
aerobic fitness (V̇O2peak) in a 27 y old male with CF (F508del/G551D mutation). 
Quon et al. (2015) performed CPET pre- and post-treatment and demonstrated 
a 16% improvement in FEV1, in addition to a 14% improvement in CPET 
derived V̇ O2peak and significantly reduced exertional dyspnoea. The authors 
attributed these improvements, at least in part, to improved ventilatory function, 
including improvements in breathing pattern (increased tidal volume and 
reduced breathing frequency) and dynamic operating lung volumes (increased 
inspiratory reserve volume and inspiratory capacity) and decreases in dynamic 
mechanical ventilatory constraints. However, the authors focused only on 
pulmonary factors and did not include any other central or peripheral indices, to 
help us understand the matching of O2 delivery-to-utilisation during exercise.   
Despite the promising results shown by administering Ivacaftor in people with 
CF, no studies have yet assessed the influence of these ground-breaking 
treatment strategies on the aerobic exercise function of patients using a robust 
testing protocol. To objectively quantify physical functional changes following 
different pharmacological treatments, CPET should be included within future 
research. Furthermore, the utility and sensitivity of CPET versus current clinical 
outcome measures in clinical trials requires attention. There is also a need for 
more standardised, comprehensive exercise testing in the evaluation of 
exercise training programmes in patients with CF.  
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Supervised exercise training provides several benefits to individuals with CF, 
including alleviation of dyspnoea and improved exercise tolerance (Cerny et al., 
2013), maintained pulmonary function, improved sputum clearance (Dwyer et 
al., 2011; Hebestreit et al., 2001), training of the respiratory muscles (Houston 
et al., 2013), delayed reduction in bone mineral density (Tejero García et al., 
2011) and improved psychosocial health (Hebestreit et al., 2014). Exercise 
training may also be important in the management of CFRD, since exercise is 
known to improve glycaemic control and inflammation in type I diabetes mellitus 
(Galassetti et al., 2013) and can notably improve glucose tolerance and insulin 
sensitivity in healthy adolescent boys (Cockcroft et al., 2015). Aerobic fitness 
and pulmonary function may be modifiable with exercise training interventions in 
CF (Radtke et al., 2015) and V̇O2peak was one of 3 primary outcome measures in 
the most recent Cochrane review on the topic (Radtke et al., 2015). However, 
there are concerns regarding the validity of V̇ O2peak measured using the 
currently employed CPET protocols.  
2.4.3 Current exercise testing protocols for patients with CF 
There has been much debate over recent years regarding the most appropriate 
testing protocol and guidelines to implement for this patient group. A key 
contributor to the poor uptake of CPET in clinical practice is that the 
measurement of V̇O2peak using CPET remains somewhat of a mystery for many 
clinicians (Bell & Morris, 2010). Consequently, clinical tests which are being 
performed are generally simplistic, varied and crude in nature. Maximal and 
submaximal field tests, such as shuttle walk and step tests are currently the 
most commonly used in children and adolescents with CF (Stevens et al., 
2010). These protocols are attractive for use in the clinical setting, since thet are 
  
71 
 
low cost, simple to administer and do not require specialist ergometers or 
equipment to measure pulmonary gas exchange and ventilation.  
Whilst the modified shuttle test is reportedly valid and reproducible for use in 
adults with CF (Bradley et al., 1999; Bradley et al., 2000), there is no evidence 
in paediatric patients with milder disease. However, both the 10 m and 20 m 
shuttle tests have been validated against treadmill determined V̇O2peak and are 
reportedly valid and reproducible in paediatric patients with CF (Selvadurai et 
al., 2003). Shuttle and step tests are, however, limited in the information they 
provide, since they merely provide a crude indication of performance with gross 
measurement (e.g., distance walked or number of steps) and the limiting 
factor(s) (e.g., changes in HR and SpO2) (Lesser et al., 2010; Narang et al., 
2003). Recent evidence also shows that distance walked during the 6MWT 
does not appear to significantly correlate (r = 0.09) with V̇O2max in children and 
adolescents with CF (Lesser et al., 2010). Furthermore, from a practical point of 
view, many of the healthier new generation of children and adolescents with CF 
are also now capable of completing even modified versions of these tests, 
although the proportion is currently not known. Maximal CPET is based on the 
principle that the respiratory, cardiovascular and muscular systems are forced 
to the limits of their tolerable ranges, meaning that abnormal response patterns 
can be observed (Ferrazza et al., 2009). Current crude shuttle and step tests 
fail to elicit such a response due to their submaximal nature, which is indicated 
by the fact that 6MWT distance appears to significantly correlate with V̇O2peak in 
healthy children (r = 0.59) but not those with CF (r = 0.09) (Lesser et al., 2010).  
Over recent years there has been a focus on developing CPET protocols for 
people with CF that are time efficient and do not require the measurement of 
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pulmonary gas exchange during exercise, which may increase clinical uptake. 
The Steep Ramp Test (SRT) has recently been introduced as a simple, short 
duration incremental exercise test for healthy children and adolescents 
(Bongers et al., 2013) and those with CF (Bongers et al., 2015; Werkman et al., 
2011) and does not require measurements of pulmonary gas exchange 
(Bongers et al., 2015; Werkman et al., 2011). The primary outcome measure is 
peak work rate (Wpeak), which is then used to estimate V̇O2peak. In healthy 
children, the SRT is reportedly both a valid and reproducible tool to predict 
V̇O2peak (Bongers et al., 2013). For the validity assessment, 38 children (17 boys 
and 21 girls; 1.85 ± 3.20 y) performed the SRT and a regular CPET with 
respiratory gas analysis, with both tests completed within a two week period. A 
strong correlation between SRT derived Wpeak and the V̇O2peak achieved during 
CPET was found (r = 0.96), and yielded the following prediction equation 
(Equation 2.1):  
 
V̇O2peak (mL·min
-1) = (8.262 Wpeak SRT) + 177.096 
(R2 = 0.917, SEE = 237.4). 
Equation 2.1 
Reproducibility was assessed in a separate subgroup of participants (n = 37, 17 
boys and 20 girls; 13.86 ± 3.22 y). An intraclass correlation coefficient (ICC) of 
0.99 was reported for Wpeak, obtained from two SRTs completed within two 
weeks, with limits of agreement of +24.5 to -37.5 W.  
The validity of the SRT has also been investigated against CPET in 40 children 
and adolescents (17 boys and 23 girls; 14.7 ± 1.7 y; FEV1 86 ± 18% predicted) 
with CF (Bongers et al., 2015). Although a strong correlation was present 
between Wpeak attained during the SRT and CPET-derived V̇O2peak (r = 0.82), 
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peak values for HR (168 ± 14 vs. 182 ± 12 b·min-1), minute ventilation (V̇E) (59.2 
± 19.5 vs. 72.0 ± 20.2 L·min-1) and V̇O2 (36.9 ± 7.5 vs. 41.5 ± 7.6 mL·kg
-1·min-1) 
were significantly lower when using the SRT compared with CPET and Wpeak 
was higher (252 ± 60 vs. 174 ± 46 W). These findings are in contrast with an 
earlier study from the same research group that reported similar V̇O2peak values 
(38.9 7.4 vs. 38.8 8.5 mL·min-1·kg-1) in adolescents with CF (n = 16, 8 males 
and 8 females; 14.7 1.7 y; FEV1 81 ± 22% predicted) during CPET and the SRT 
(Werkman et al., 2011). However, the study design in the earlier work by 
Werkman et al. (2011) differed, with the CPET followed by the SRT. Whilst the 
SRT may indeed provide an alternative field based test for children and 
adolescents with CF when gas analysis is not possible, it is limited by the 
physiological information that it can provide and the short duration of the test. 
Specifically, the SRT only measures Wpeak to estimate V̇O2peak, and thus does 
not quantify other parameters of aerobic function (Whipp et al., 1981; Whipp et 
al., 1982), such as the V̇O2 mean response time (MRT), gas exchange threshold 
(GET) and the O2 cost of exercise ( V̇ O2 gain; ∆ V̇ O2/∆WR) and additional 
markers of ventilatory efficiency. These markers are also effort independent and 
the potential of submaximal parameters, such as the slope of V̇ E/ V̇ CO2 
(ventilatory drive), to provide superior prognostic indices in adolescents with CF 
has been raised (Hulzebos et al., 2014).  
Efforts have also recently been made to develop CF-specific linear regression 
models (see Equation 2.2) which can predict V̇O2peak from the Wpeak obtained 
during cycle based CPET, using the Godfrey protocol (Werkman et al., 2014).  
 
V̇O2peak (mL·min
-1) = 377.0 – 178.4 x Sex (0 = female / 1 = male) + 10.1 x Wpeak 
Equation 2.2 
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Werkman et al. (2014) found a strong prediction model (R = 0.91; R2 = 0.85; 
standard error of the estimate (SEE) = 172.57) to estimate V̇O2peak (mL·min
-1) 
using Wpeak and gender in adolescents with CF (FEV1 = 37-147% predicted), 
when direct V̇O2peak assessment is not possible. Furthermore, the regression 
model (Equation 2.2) showed potential to discriminate between patients in 
different prognosis clusters based on their exercise capacity. To note however, 
although a 95% prediction interval was reported, the predicted V̇O2peak was 
significantly different (107 mL·min-1) to directly measured V̇O2peak, however this 
was a difference that was within the SEE of the model.  
 
The Godfrey protocol (Godfrey, 1971) appears to be the preferred CPET 
protocol at present for children and adolescents with CF. In line with this, the 
ECFS have recently recommended the Godfrey cycle ergometer protocol, with 
monitoring of SpO2 and pulmonary gas exchange, as the protocol of choice for 
patients > 10 y of age (Hebestreit et al., 2015). The Australasian and North 
American consensus statements are anticipated to further support these 
recommendations. This protocol consists of a 3 min warm-up, followed by ‘step’ 
increases in work rate each minute until exhaustion. However, some argue that 
a ramp protocol, whereby exercise intensity is increased linearly throughout 
exercise rather than step increments each minute, may be more appropriate for 
children and adolescents with chronic disease, since the linear increase in work 
rate may be better to depict the progressive changes in V̇O2 during CPET 
(Bongers et al., 2013).  
Another potential issue with the Godfrey protocol (Godfrey et al., 1971) is  the 
work rate increments, which are derived solely based on the individual's height 
(10 W·min-1 < 120 cm; 15 W·min-1; 120–150 cm; 20 W·min-1 > 150 cm). 
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Although this method does attempt to individualise work load increments for 
children and adolescents with CF, it is reported that smaller, healthier children 
reach exhaustion in approximately 4 min, while larger healthy children exercise 
for approximately 10 min (Godfrey, 1971). In line with this, there is evidence of 
short test durations of approximately 4 min within the CF paediatric exercise 
testing literature (e.g., Kent et al., 2012). Clinically, this protocol may often be 
modified to counter this issue. Since a test duration of approximately 10 min is 
suggested to provide optimal cardiopulmonary assessment (Buchfuhrer et al., 
1983), recent experimental work sought to determine a CF-specific linear 
regression model (see Equation 2.3) for children and adolescents to predict 
Wpeak based on standard anthropometric and pulmonary function 
measurements, which could then calculate individualised workload increments 
to reach volitional exhaustion in ~ 10 min (Hulzebos et al., 2014).  
Wpeak (W) = 142.865 + 2.998 x Age (y) – 19.206 x Sex (0 = male, 1 = female) + 
1.328 x Height (cm) + 23.362 x FEV1 (L·min
-1) 
Equation 2.3 
R = 0.89, R2 = 0.79, SEE = 21.0 
When the authors extrapolated the equation to the model validation group there 
was no significant difference between predicted and measured Wpeak (164.6 ± 
38.6 vs. 166.5 ± 38.1 W, respectively). Furthermore, when the developed 
protocol (increments per min = predicted Wpeak / 10) was validated in a 
subgroup of 14 adolescents with CF, there was no significant difference 
between measured and estimated Wpeak (197 ± 50 vs. 186 ± 38 W, 
respectively). The variance in time to exhaustion was also reduced with use of 
this protocol compared with the traditional Godfrey method (9.7 – 12.0 vs. 7-8 – 
12.0 min, respectively). Hulzebos et al. (2014) therefore concluded that their 
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model to predict Wpeak from standard anthropometric variables is valid and that 
dividing the predicted Wpeak by 10 to determine individualised workload 
increments for the maximal exercise test will allow participants to achieve true 
cardiopulmonary exhaustion in the recommended 10 min time frame, which will 
prevent short test durations that mean additional key parameters of aerobic 
function cannot be determined. Ultimately, this approach will provide more 
optimal CF-specific exercise testing of comparable test duration across a wide 
variety of ages and disease states.  
Although there has been increased attention surrounding exercise testing 
protocols for children and adolescents with CF over the past decade, one 
primary consideration when choosing the most appropriate exercise testing 
protocol should be how accurately it depicts aerobic fitness and the key 
physiological parameters of interest. In addition to the considerations outlined 
above, there remain some validity concerns regarding the determination of 
V̇ O2max in children and adolescents with CF using protocols such as the 
Godfrey. Prior to implementation of CPET within the clinical management of 
children and adolescents with CF, clarification of the optimal protocol and 
feasibility within the clinical setting is required (Stevens & Williams, 2007).  
 
2.4.4 Validity considerations for CPET in paediatric patients with CF 
V̇O2max is widely accepted to be the best single measure of an individual’s 
aerobic fitness; representing the integrated capacity of the pulmonary, 
cardiovascular and muscular systems to uptake, transport and utilise O2 during 
intense exercise (Poole et al., 2008). However, there are still issues that 
confound its interpretation in paediatric populations. Although V̇ O2max is 
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traditionally identified by a plateau in V̇O2 upon exhaustion, despite increasing 
work rate (Armstrong & Welsman, 1994; Rowland, 1993), it has been 
established that only a minority of young people display a V̇ O2 plateau 
(Armstrong & Welsman, 1994; Armstrong et al., 1996; Barker et al., 2011). As 
such, the term V̇O2peak has been accepted as the standard outcome measure for 
paediatric populations (Rowland, 1994), defined as the highest V̇O2 attained 
during an exhaustive exercise test. However, the prevalence of a V̇O2 plateau 
upon exhaustion in children and adolescents with CF requires confirmation. 
Furthermore, despite the reported clinical utility of V̇O2peak in CF, its validity 
using CPET must also be established.  
Specifically, given that few children and adolescents satisfy the traditional V̇O2 
plateau criterion, reliance therefore falls upon secondary criteria, encompassing 
subjective indicators of effort (sweating, facial flushing, hyperpnoea) and 
objective secondary criteria (HR, respiratory exchange ratio (RER) and/or post-
exercise blood lactate concentration (La[B])) to verify a maximal effort and 
confirm V̇O2max. Such criteria are, however, dependant on arbitrary values and 
have been deemed unsuitable for healthy children (Barker et al., 2011; Robben 
et al., 2013), adults (Poole et al., 2008) and ambulatory paediatric patients with 
spina bifida (de Groot et al., 2009) due to their variability and tendency to 
underestimate V̇ O2max. It is therefore conceivable that such secondary 
verification criteria may be equally unsuitable for children and adolescents with 
CF, however no study has yet investigated their validity in this patient group and 
their use remains common practice within the CF literature (e.g. Werkman et al., 
2011).  
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Controversy therefore surrounds traditional test procedures and whether they 
provide a high degree of confidence that ‘true’ V̇O2max has been obtained (Day 
et al., 2003; Duncan et al., 1997; Howley et al., 1995; Taylor et al., 1955). A 
number of recent investigations (Barker et al., 2011; Day et al., 2003; Foster et 
al., 2007; Hawkins et al., 2007; Midgley et al., 2006; Midgley et al., 2007a; 
Midgley et al., 2009; Poole et al., 2008; Rossiter et al., 2006; Scharhag-
Rosenberger et al., 2011) have reported the utility of a procedure termed the 
‘verification phase’ in healthy adults and young people. This method involves a 
traditional ramp incremental exercise test preceding an individualised 
supramaximal verification phase (Smax), to confirm V̇O2max. Theoretically, if a 
similar V̇O2peak is achieved during both tests then the traditional V̇O2 plateau 
criterion can be satisfied (Hill & Lupton, 1923). The utility, safety and clinical 
feasibility for children and adolescents with CF are not known. To date, only one 
study has sought to validate V̇O2peak in patients with CF using supramaximal 
exercise (Werkman et al., 2011). However, in this study only adolescents were 
tested and the SRT was employed as the supramaximal verification phase, 
rather than an individualised work rate based on the preceding ramp test.  
Thus far, one study has established the utility of Smax verification in children and 
adolescents with a chronic disease. de Groot et al. (2009) investigated the use 
of a 3 min Smax verification protocol to confirm a maximal effort in twenty 
children with spina bifida who were ambulatory (n = 20, 9 males and 11  
females; 10.3 ± 4.9 y). In line with data from healthy children (e.g., Barker et al., 
2011; Robben et al., 2013), only 65% of the participants achieved a V̇O2 plateau 
upon exhaustion, 65% met the secondary criteria for HR, whilst 80% achieved 
an RER greater than 1.00. Only 7/10 children met all three of the secondary 
verification criteria. When the group was viewed as a whole, no significant 
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differences were found between the incremental test and Smax derived V̇O2peak 
values (34.1 vs. 34.8 mL·kg-1·min-1, respectively). However, on an individual 
patient level, 5 children showed a clinically relevant increase in V̇O2peak with Smax 
verification testing. Interestingly, of the five children who did not meet ≥ 2 of the 
secondary verification criteria, a meaningful increase in V̇O2peak with Smax was 
observed. However, conversely, the participant who failed to meet any 
secondary criteria did not increase V̇ O2peak during the Smax exercise test. 
Furthermore, of the children who did increase V̇O2peak during Smax, one had met 
all 3 secondary verification criteria, three had met 2 and one had met 1. This 
finding that traditional secondary criteria are varied and may significantly 
underreport V̇ O2max confirms previous findings in healthy children and 
adolescents (Barker et al., 2011).  
No study has formally established an up-to-date ‘gold standard’ valid and 
reproducible testing protocol for ascertaining ‘true’ V̇ O2max in children and 
adolescents with mild-to-moderate CF. Until a study is undertaken, inferences 
regarding exercise training, pharmacologic interventions and disease-related 
changes cannot be discerned with certainty in this population. The safety and 
feasibility of implementing such testing is also of clinical interest. A lack of 
research supported guidelines for V̇O2max determination may contribute to errors 
in measurement and interpretation; measures upon which clinical decisions can 
be made, or an incorrect decision as to whether ‘true’ V̇O2max has changed in 
response to therapeutic intervention or disease progression (Midgley et al., 
2006). It is important that new conceptual advances within exercise physiology 
continue to be incorporated within clinical practice. For modern clinical CPET 
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guidelines to be established, a valid and robust protocol to determine ‘true’ 
V̇O2max is essential.  
 
2.4.5 Reproducibility considerations for CPET in paediatric patients with CF 
Quantifying reproducibility enables researchers and clinicians to understand the 
variation associated with outcome measures (Hopkins, 2000) and to determine 
meaningful changes (Atkinson & Nevill, 1998). Interpreting data in relation to 
normative data and the TE of the measurement enables researchers and 
clinicians to determine clinically meaningful changes. To define the minimal 
physiologic improvement in variables such as V̇O2max, that reflects a disease-
related decline or the positive effect of a given therapeutic intervention, the 
minimally clinically important difference must be established (Ferrazza et al., 
2009). Furthermore, reproducibility over time is critical when evaluating the 
efficacy of CF treatments (e.g., antimicrobials, mucolytics and gene mutation 
targeted therapies) which may accrue over weeks or months, as well as 
monitoring exercise training interventions. Consequently, inferences regarding 
therapeutic interventions or disease-related changes in CPET derived 
parameters cannot currently be discerned with certainty in these patients until 
the TE in outcome measures is established. There is some evidence 
concerning the minimally clinically important difference for more crude or 
submaximal exercise tests in adults (Barry & Gallagher, 2007; Bradley et al., 
2000) and children with CF (e.g. Cunha et al., 2009; Gulmans et al., 1996). 
However, to date, there are no data concerning the reproducibility of CPET-
derived maximal and submaximal outcome measures using a protocol that 
ensures the determination of ‘true’ V̇O2max in paediatric patients with mild-to-
moderate CF.  
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Regarding the reproducibility of CPET for people with CF, there is limited data. 
Two previous studies have reported the utility of incremental CPET, using 
traditional verification criteria, in adults with CF (Gruet et al., 2010; McKone et 
al., 1999). McKone et al. (1999) investigated the reproducibility of incremental 
ramp testing (15 W·min-1) in adults with stable CF (n = 9, 6 males and 3 
females; 26.3 ± 8.3 y; FEV1 56% predicted). With three tests performed over a 
28 day period, there were no significant differences in V̇O2, V̇ E, respiratory 
frequency, HR or SpO2 at rest, exhaustion or 40% and 70% of Wpeak across the 
three tests. Coefficients of variation for peak V̇O2, V̇E, respiratory frequency, HR 
and SpO2 of 6.9%, 6.2%, 5.8%, 3.0% and 1.1% were reported, respectively. 
Similarly, Gruet et al. (2010) reported a coefficient of variation of 8.5% for 
V̇O2peak determined using incremental CPET (12 W·min
-1) across a 4 week 
period in adults with CF (n = 31, 25 males and 6 females; 26.9 ± 6.0 y; FEV1 
52% predicted). 
From a paediatric perspective, only one study has reported the reproducibility of 
CPET in children with CF (Kent et al., 2012). Using the Godfrey protocol, Kent 
et al. (2012) sought to determine the coefficients of variation for HR (5.6%), 
SpO2 (5.2%) and Wpeak (8.9%) in children with CF (n = 16, 9 males and 7 
females; 8.7 ± 1.8 y; FEV1 88.1 ± 17.4% predicted), using two tests completed 
within a 1 week period. This study did, however, encompass a number of 
methodological limitations that confound the interpretation and application of its 
findings. Firstly, the design was such that an intermittent sprint cycle test was 
completed within the same testing session as the subsequent incremental 
CPET. This may have contributed to the short and insufficient ramp test 
durations recorded (~ 4 min). Furthermore, only limited, parameters of 
physiological function were presented and no measures of pulmonary gas 
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exchange were obtained. There is, therefore, a need to investigate the 
reproducibility of maximal and submaximal CPET parameters in children and 
adolescents with CF and the utility of Smax verification.  
 
# 
2.5 CPET measurements of interest in the assessment of aerobic exercise 
(dys)function 
2.5.1 Standard parameters of interest from incremental CPET 
Although much of the focus over recent years has been on the clinical utility of 
V̇ O2peak as the primary outcome measure from CPET in patients with CF, 
additional maximal and submaximal parameters can offer value. A CPET 
provides a large number of important parameters, including but not limited to 
gas exchange and metabolic data (V̇O2, V̇CO2, GET, ventilatory equivalents for 
O2 (V̇E/V̇O2) and CO2 (V̇E/V̇CO2), O2 pulse, SpO2 via pulse oximetry, end-tidal O2 
and CO2), in conjunction with test duration and work rate. These additional 
parameters are often overlooked in favour of the final maximal parameters 
obtained at exhaustion, particularly V̇O2, work rate, HR and SpO2. However, 
submaximal values should assist with diagnostic and prognostic evaluations 
and need to be incorporated more fully in patient reports (Wasserman et al., 
2004). No one single parameter should be used exclusively; rather, it is the 
integration of the exercise responses as a whole, which adds value when 
utilising CPET compared with other exercise testing methods.  
V̇O2max represents the gold standard measure of aerobic fitness and provides an 
indication of how well patients’ lungs, pulmonary and cardiovascular circulation 
(large and small vessels), and skeletal muscles function in an integrated 
manner during exercise (see Figure 2.6). However, a more comprehensive 
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assessment of patients’ cardiorespiratory fitness may be gained through 
quantification of submaximal parameters of aerobic function (i.e., lactate 
threshold (LT) or its non-invasive equivalent the GET), the kinetics of V̇O2 
(MRT) and work efficiency (V̇O2 gain or ∆V̇O2/∆WR). These three parameters, 
combined with  V̇O2max, provide the four key parameters of aerobic exercise 
function (Whipp et al., 1982).  
From a practical viewpoint, outcome measures which can assess patients’ 
function at submaximal intensities, similar to ADLs, are also important. 
Figure 2.6. Schematic to illustrate the relationship between muscle O2 
consumption and pulmonary O2 uptake. O2 is inspired from the atmosphere and 
delivered by the cardiovascular system to the working muscles, where it is 
consumed by the mitochondria to produce adenosine triphosphate (ATP). The 
deoxygenated blood is then transported back to the pulmonary circulation 
enabling muscle V̇ O2 to be estimated from the pulmonary O2 exchange, 
although there will be temporal misalignment owing to the venous volume and 
O2 stores between the muscle and lung. VT, tidal volume; f, breathing 
frequency; SV, stroke volume; HR, heart rate; ?̇?, cardiac output; ?̇?CO2, muscle 
CO2 production; ?̇?O2, muscle O2 utilisation; creat-PO4, creatine phosphate; pyr-
lac, pyruvate-lactate. Taken from Jones & Poole (2005) with permission.  
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Furthermore, submaximal parameters may be especially useful in the clinical 
environment when patients may be unwilling or unable to provide a maximal 
effort. Additionally, the GET can improve independently of any changes in 
V̇O2max in individuals with CF (Casaburi et al., 1991), and is often used in the 
prescription of individualised exercise intensities within specific intensity 
domains (i.e., at a percentage of the GET or using the delta (∆) concept), as 
recently demonstrated in paediatric patients with mild-to-moderate CF (Stevens 
et al., 2011). 
Although there is evidence concerning the determination of the GET in adults 
with CF (Gruber et al., 2014; Sexauer et al., 2003; Shah et al., 1998), there is a 
need to confirm how identifiable and reproducible these parameters are for use 
in children and adolescents with mild-to-moderate CF disease. Promisingly, 
Visschers and colleagues (2015) recently determined the utility and 
reproducibility of four different non-invasive methods for determining the 
ventilatory threshold (VT) in 15 children with CF and 15 children with a 
surgically corrected dextro-transposition of the great arteries. In children with 
CF, the V-slope, ventilatory equivalent method, and the end-tidal pressure of O2 
(PETO2) method were all comparable and reproducible methods to determine 
the VT during exhaustive incremental CPET. The V-slope method (Beaver et al. 
1986) did show the best inter-rater reproducibility for the V̇O2 at the ventilatory 
threshold (ICC: 0.92), compared with the ventilatory equivalent (ICC: 0.84) and 
PETO2 (ICC: 0.87) methods, however it was recommended that a combination of 
the three methods may improve the accuracy and reproducibility of 
determination. The feasibility of this practice may, however, be poor and using 
all three methods could be particularly time consuming.  However, the V-slope 
method, with verification using the ventilatory equivalent method and PETO2 is 
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recommended and has been used within this thesis. The reproducibility of 
additional submaximal parameters of interest warrants determination.  
Ventilatory function is best examined by relating V̇O2 and V̇CO2 dynamics to V̇E 
(Akkerman et al., 2010), through the slope of the V̇E/V̇CO2 response and the O2 
uptake efficiency slope (OUES). The OUES is useful since it is, theoretically, 
resistant to early test termination and intra- and inter-rater variability (Akkerman 
et al., 2010). Although these parameters possess documented utility to identify 
the presence and severity of ventilatory inefficiency of the heart/lungs and/or 
response to intervention in heart failure patients, their uptake within the 
assessment of patients with respiratory disease has been scarce (Bongers et 
al., 2012). The OUES is suggested to offer a submaximal measure of 
cardiopulmonary fitness, which could be useful when patients are not able to 
provide a maximal effort. However, it was recently suggested that this measure 
is limited by its ability to distinguish between children with mild-to-moderate CF 
and their healthy peers (Bongers et al., 2012). Bongers et al. (2012) aimed to 
investigate whether the OUES may provide an alternative to V̇O2peak in children 
and adolescents with mild-to-moderate CF (n = 22, 13 males and 9 females; 
15.7 ± 1.5 y; FEV1 81.5 ± 15.6% predicted) when a maximal effort is not 
possible. Whilst the authors concluded that the OUES is of limited value as a 
measure of cardiopulmonary exercise capacity in children with mild-to-moderate 
CF, since the OUES provides an efficiency measure and should not be 
considered a surrogate for V̇ O2max, its utility in the assessment of aerobic 
exercise (dys)function  requires further investigation.  
Furthermore, questions have been raised regarding whether submaximal 
parameters may provide better prognostic markers than V̇O2peak in patients with 
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CF (Hulzebos et al., 2014). Using data from 127 adolescents with CF (n = 127, 
77 males and 50 females; 12.7 ± 0.9 y; FEV1 77.7 ± 15.6% predicted), Hulzebos 
et al. (2014) built a multivariate model comprising BMI, FEV1%predicted, predicted 
V̇ O2peak relative to body mass, peak V̇ E, peak  V̇ E/ V̇ O2 and V̇ E/ V̇ CO2, and 
breathing reserve. Subsequently, the Cox proportional hazards method was 
used to determine the best combination of these parameters to predict mortality 
and/or the need for lung transplantation in this patient group. The predictors 
BMI (hazard ratio = 5.54, 95% CI = 1.82-16.83), FEV1%predicted (hazard ratio = 
17.13, 95% CI = 3.76-78.06) and peak V̇E/V̇O2 (hazard ratio = 5.92, 95% CI = 
1.27-27.63) provided the best prediction model. More specifically, patients with 
all 3 risk factors had a significantly higher risk of mortality compared with 
patients presenting with none or 1 and patients with two of the aforementioned 
factors. However, univariate analyses still revealed predicted V̇O2peak relative to 
body mass to be a significant predictor of mortality in adolescents with CF. 
 
2.5.2 Pulmonary ?̇?O2 kinetics 
Although CPET is a clinically useful tool for assessing aerobic exercise 
(dys)function in children and adolescents with CF, CWR exercise testing 
protocols may also be insightful. More specifically, although the measurement 
of maximal aerobic fitness and the response to incremental ramp exercise is of 
clear clinical and investigational value, children and adolescents with CF rarely 
exercise at their maximal metabolic rate. Furthermore, exercising at or near 
V̇O2max does not truly represent the rate at which aerobic energy transfer adapts 
to the changing metabolic demands faced by the O2 transport and utilisation 
pathways (Figure 2.6) during day-to-day challenges. Accordingly, assessing the 
speed of the V̇O2 response to an altered work rate (termed ‘V̇O2 kinetics’) can 
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provide important information regarding the integrated capacity to transport (see 
Figure 2.6) and utilise O2 to support the increased rate of ATP turnover in the 
contracting myocytes and, thereby, provide a non-invasive insight of the 
contribution of skeletal muscle oxidative metabolism to energy turnover (e.g. 
Barstow et al., 1996; Brittain et al., 2001; Burnley et al., 2002; Chin et al., 2007; 
Gerbino et al., 1996; Grassi et al., 1997; Gurd et al., 2006; Jones et al., 2004; 
Koppo et al., 2004; Pringle et al., 2003). Whilst an indication of the V̇O2 kinetic 
response at the onset of exercise can be gained by determining the MRT during 
ramp incremental exercise, a more appropriate assessment of the V̇O2 kinetic 
response is provided by analysing repeated transitions to a range of 
submaximal work rates.  
At the onset of exercise, an immediate increase in ATP production in the active 
muscle cell is required in order to meet the increased metabolic demand (Jones 
& Poole, 2005). However, measurements at the muscle level demonstrate a 
delayed matching between the ATP supplied by oxidative phosphorylation 
(Equation 2.4) and the rate of ATP turnover occurring within the myocyte 
(Figures 2.7 and 2.8a).  
 
3 ADP + 3 Pi +NADH + H
+ + ½ O2               3 ATP + NAD
+ + H2O     Equation 2.4. 
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During a step transition to a higher metabolic rate, muscle O2 consumption 
(mV̇O2) rises, following an exponential time course until the oxidative rate is 
coupled to the rate of muscle ATP turnover, assuming that the rate of ATP 
turnover is constant during exercise. However, since mV̇O2 rises appreciably 
slower than ATP turnover at the cross-bridges, a steady-state matching 
between ATP utilisation and ATP supply through oxidative ATP resynthesis 
might not be achieved until at least 2 min following the onset of exercise (Jones 
& Poole, 2005; also see Figures 2.7 and 2.8a). This delay has been termed the 
O2 deficit. The magnitude of the O2 deficit indicates the non-oxidative 
contributions of ATP resynthesis to the ATP turnover rate. Consequently, a 
larger O2 deficit is associated with a greater depletion of muscle [PCr] and, 
particularly at higher work rates, a greater production of lactic acid through 
anaerobic glycolysis to meet the energy demand during of exercise. A depletion 
Figure 2.7. Schematic to demonstrate the typical response of muscle O2 
consumption following a ‘step’ transition to moderate intensity constant work rate 
exercise. Adenosine triphosphate (ATP) turnover at the cross-bridges increases 
instantly, however muscle V̇O2 increases relatively slowly. Note that a steady-
state is attained following ~ 2 min after the increase in exercising work rate in this 
example. The red line denotes the square wave increase in ATP demand 
necessary to sustain exercise. Adapted from Jones & Poole (2005) with 
permission.  
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of high-energy muscle phosphates and a reduction in muscle pH have both 
been implicated in the fatigue process (Fitts, 1994), such that faster V̇O2 kinetics 
should be associated with enhanced exercise tolerance. If people with CF 
present with prolonged V̇O2 kinetics, they would thereby incur a greater O2 
deficit than their healthy counterparts (Figure 2.9), which may have implications 
for exercise tolerance.  
 
 
 
 
 
 
 
 
Since capturing the mV̇O2 kinetic response necessitates invasive and technical 
procedures, which are inherently unsuitable for use with children and 
adolescents, it is standard practice to infer mV̇O2 by measuring the dynamic 
changes in breath-by-breath pulmonary V̇O2 at the mouth. There are, however, 
differences in the response profile measured at the muscle versus mouth. 
Specifically, unlike the exponential rise in mV̇O2 measured at the periphery (see 
Figures 2.7 and 2.8a), the rise in pulmonary V̇O2 kinetics during moderate 
intensity CWR exercise is characterised by three phases (see Figure 2.8b) 
(Whipp et al., 1982; Whipp & Ward, 1992).  
Figure 2.8. Schematic of the rise in muscle (A) and pulmonary V̇O2 (B) at 
the onset of moderate-intensity exercise. Adapted from Armstrong & 
Barker (2009) with permission. The red line denotes the square wave 
increase in energetic (ATP) demand required in order to sustain exercise.  
A B 
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The first of the three phases present in the pulmonary V̇O2 kinetic response 
during moderate intensity CWR is termed phase I, or the cardio-dynamic phase. 
This phase indicates an initial rise in V̇O2 due to an immediate rise in cardiac 
output (?̇?) (Barstow et al., 1990; Yoshida et al., 1993), which subsequently 
increases pulmonary blood flow and perfusion. Although m V̇ O2 increases 
immediately at exercise onset, the rise in V̇O2 measured at the mouth typically 
takes 15 to 20 s, due to the muscle-to-lung transit delay causing a delayed 
arrival of deoxygenated blood at the lungs. This point is marked by a fall in 
PETO2 and increase in the end-tidal partial pressure of CO2 (PETCO2), reflecting 
the arrival of deoxygenated blood at the lungs. The increasing ?̇? response then 
Figure 2.9. Examples of the O2 deficit that would be incurred by individuals with 
different values for the phase II time constant (τ) following the onset of a constant 
work rate square wave exercise transition. For the same increase in metabolic 
rate, represented by the V̇ O2 achieved in the steady-state (phase III), an 
individual with fast V̇O2 kinetics would incur a much smaller O2 deficit that would 
individuals with slower V̇O2 kinetics. It would be expected that a person with a 
chronic disease, such as cystic fibrosis, would present with slower V̇O2 kinetics 
and thereby incur a greater O2 deficit than their healthy counterpart.  Image taken 
from Jones & Poole (2005) with permission.   
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drives an exponential rise (phase II) in V̇O2 towards a new steady-state (phase 
III) (Whipp & Ward, 1992).  
Once the delay caused by the muscle-to-lung transit time has been accounted 
for, it has been shown that the phase II (or alternatively termed ‘fundamental’) 
region of the pulmonary V̇O2 response during moderate intensity CWR exercise 
rises with similar kinetics to that of mV̇O2 (e.g. Barker et al., 2008; Grassi et al., 
1996; Krustrup et al., 2009; Rossiter et al., 2002; Figure 2.10). However, few 
studies have simultaneously and invasively measured the dynamics of mV̇O2 
and pulmonary V̇O2 at the onset of exercise in humans. Krustrup et al. (2009) 
were the first to investigate the transit time for blood flow from the contracting 
muscles to reach the lungs following the onset of knee-extensor exercise 
performed above and below the GET and, thereby, the contribution from the 
contracting muscles to pulmonary V̇O2. The primary finding of this study was 
that the phase II τ for pulmonary V̇O2 reflected the kinetics of mV̇O2 at the on-
transient to both exercise above and below the GET (see Figure 2.10). There 
was also no difference between the amplitude for mV̇O2 and pulmonary V̇O2 
suggesting other tissues are contributing a minimal amount to pulmonary V̇O2 
during this mode of exercise.  
Whilst this type of research is not ethical or feasible in children, attempts have 
been made to characterise the kinetics of pulmonary V̇O2 against the fall in 
muscle [PCr], taken as a surrogate measure of mV̇O2 (Meyer et al., 1988). In 
healthy adults, Rossiter and colleagues (1999) demonstrated a close kinetic 
coupling between the fall in [PCr], and rise in phase II of the pulmonary V̇O2 
response at the onset of prone knee-extensor exercise (see Figure 2.11) using 
31Phosphorous magnetic resonance spectroscopy (31P-MRS). Since the signal 
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from children during knee extensor exercise was deemed insufficient to 
compare with the pulmonary V̇O2 response to knee-extensor exercise, Barker et 
al. (2008) subsequently compared the pulmonary V̇O2 response during upright 
cycling with the kinetics of muscle [PCr] during prone CWR quadriceps 
exercise. This study confirmed that the kinetic changes in muscle [PCr] are 
closely coupled (to within ±4 s) with the phase II pulmonary V̇O2 response at 
both the onset and offset of exercise. Thus indirectly suggesting that phase II of 
the V̇ O2 response in children provides an indirect measurement of m V̇ O2 
kinetics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A 
B 
Figure 2.10. Muscle and pulmonary oxygen uptake (mV̇O2 (○ white circles) and 
V̇ O2 (● black circles), respectively) response to knee-extensor exercise 
performed below (A) and above (B) the gas exchange threshold. The 
pulmonary V̇O2 data have been time aligned to the mV̇O2 data by moving the 
data back by the time equal to the time delay of phase I-II of the pulmonary V̇O2 
response. Image taken from Krustrup et al. (2009) with permission.   
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A standard exponential equation has been used to characterise this rise in V̇O2 
measured at the pulmonary level (Figure 2.8b) at the onset of CWR exercise 
(Equation 2.5):  
V̇O2 (t) = V̇O2 baseline + Δ V̇O2 A  · (1 – e 
– (t –TD)/τ)                          Equation 2.5. 
 
where V̇O2 (t), Δ V̇O2 A, TD, and τ represent the value of V̇O2 at a given time (t), 
the V̇ O2 prior to the onset of exercise, the amplitude change in V̇ O2 from 
baseline to its asymptote, time delay, and the time constant of the response, 
respectively.  
 
The mathematically modelled time constant (τ; time taken to achieve 63% of the 
response amplitude) of the phase II region of the pulmonary V̇O2 response at 
exercise onset is of particular interest, since it is considered to be an important 
Figure 2.11. Schematic of the pulmonary oxygen uptake (V̇O2; ● black circles) 
and muscle phosphocreatine ([PCr]; ○ white circles) responses at the onset of 
moderate intensity constant work rate exercise in an example participant. Note 
that the time aligned and modelled pulmonary V̇O2 response closely represents 
the kinetics of [PCr]. Taken from Rossiter et al. (1999) with permission.  
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determinant of the O2 deficit (see Figure 2.10). The phase II V̇O2 τ during upright 
cycling is approximately 20-30 s in healthy children and young adults and 
reaches a steady state (phase III) with an O2 cost of approximately 10 mL·min
-
1·W-1 (e.g., Breese et al., 2012; Koga et al., 1999), however higher V̇O2 gain 
values have been reported in children (Armon et al., 1990) as well as faster 
phase II τ  compared with adults (see Barker et al., 2010 for a review).  
Although Figure 2.8b depicts the three recognised phases of the pulmonary V̇O2 
response at the onset of moderate intensity CWR exercise (Whipp et al., 1982; 
Whipp & Ward, 1992), the response becomes more complex when more 
intense exercise is performed (Poole & Jones, 2012; Rossiter, 2011; see 
Figures 2.11 and 2.12). A steady-state V̇ O2 is achieved during moderate 
intensity exercise, indicating an adequate matching of V̇O2 to the muscle ATP 
turnover rate. However, during exercise performed above the LT, or its non-
invasive equivalent the GET, V̇O2 can increase to higher values than would be 
predicted based on the work rate, potentially even driving V̇O2 towards V̇O2peak.   
Several schemas have been developed to provide a frame of reference for 
investigating V̇O2 kinetics, within discrete exercise intensity domains that are 
demarcated by specific physiological parameters (Figures 2.12 and 2.13). In the 
majority of adult studies (see Figure 2.11), the moderate domain is defined as 
all work rates that fall below LT, or its non-invasive equivalent the GET or 
ventilatory threshold. The heavy domain is exercise performed above the LT, 
whereas severe intensity exercise is demarcated by critical power (CP), which 
represents the asymptote of the hyperbolic relationship between work rate and 
time to exhaustion (Poole et al., 1988). 
 
  
95 
 
 
 
 
 
 
 
 
 
 
 
 
Whilst the above boundaries (Figure 2.12) have been used to demarcate the 
intensity domains by Jones and colleagues over recent years, a slightly 
modified schema has also been outlined (see Figure 2.13). The primary 
difference with the schema presented in Figure 2.13 is evident with the 
terminology for workrates above CP. Whilst the schematic used by Jones and 
colleagues refers to these intensities as ‘severe’ and ‘extreme’, Whipp and 
colleagues term these ‘very heavy’ and ‘severe’. Within this thesis, the 
terminology presented in Figure 2.13 has been used, since this schema 
represents the majority of studies in paediatric exercise science.  
The delayed and elevated V̇O2 that is seen during exercise above the GET has 
been termed the V̇O2 ‘slow-component’. The slow-component is of practical and 
Figure 2.12. Schematic of the pulmonary oxygen uptake (V̇O2) response 
during constant work rate moderate (below the LT), heavy (above the LT) 
and severe intensity exercise (above CP). Note that the V̇ O2 response 
occurring at exercise onset (phase I) has been omitted. LT, lactate threshold; 
CP, critical power. Adapted from Jones & Poole (2005) with permission.  
LT 
CP 
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functional importance, since it is linked to the progressive loss of muscle 
homeostasis  (Burnley & Jones, 2007; Jones et al., 2010; Rossiter et al., 2002) 
and muscle contractile efficiency (Barclay et al., 1996; Krustrup, 2004; Woledge 
et al., 1998). During exercise performed above CP, the V̇O2 slow-component 
elevates V̇O2 to V̇O2max. The V̇O2 slow-component is therefore related to the 
muscle fatigue process and a reduction in exercise tolerance.  
 
 
 
 
 
 
 
 
 
 
The functional V̇ O2 gain of phase II is also reportedly reduced when the 
imposed work rate exceeds CP (Wilkerson et al., 2004). For work rates above 
the GET, the development of the V̇ O2 slow-component during exercise 
increases the O2 cost of exercise to ~12-14 mL·min
-1·W-1 (impaired efficiency) 
and reflects the fatigue processes occurring within the contracting mycoytes 
(Jones et al., 2011). The higher the work rate is above CP, the lower the 
magnitude of the V̇O2 slow-component, such that at work rates close to V̇O2max 
 
Figure 2.13. Schematic of the boundaries of the different domains, demarcated 
by specific parameters of physiological function (red lines) and the typical 
pulmonary oxygen uptake (V̇O2) response within these domains (solid and dashed 
black lines). V̇O2peak, peak oxygen uptake; MLSS, maximum lactate steady-state; 
CP, critical power; LT, lactate threshold. Image adapted from Armstrong & Barker 
(2009) with permission.  
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the V̇O2 kinetic response follows a single-exponential function until exhaustion 
occurs, with the participant reaching their V̇O2max (Özyener et al., 2001). 
Characterising the kinetics of phase II of the V̇O2 response and the magnitude 
of the V̇O2 slow-component can therefore be particularly insightful when trying to 
understand the adequacy of oxidative metabolism and mechanistic basis of 
fatigue and exercise (in)tolerance in both health and disease. However, the 
impact that exercise intensity has on the V̇O2 kinetic response to exercise 
requires careful consideration when investigating the effect of diseases, such as 
CF. For example, the prescription of a single absolute work rate is likely to 
render patients with CF exercise at a higher percentage of their aerobic fitness 
than their healthy counterparts, as V̇O2peak is reduced in this patient group (e.g. 
Moser et al., 2000). Equally, the prescription of a work rate relative to a 
percentage of V̇O2max is flawed, as although the GET appears to be preserved in 
CF when normalised to V̇O2max (Thin et al., 2002; Hebestreit et al., 2005) there 
is a large variability in the position of the GET relative to V̇O2peak across patients 
with CF and their healthy peers. Consequently, the use of an absolute work rate 
or work rate prescribed relative to V̇ O2peak will likely result in participants 
exercising across the moderate to heavy intensity domains. This practice will 
alter the pattern of the V̇O2 kinetic response (Figure 2.9) and confound any 
interpretation of the influence of CF disease upon the dynamics of V̇O2.    
An additional issue in paediatric studies is the prescription of exercise 
intensities above the LT, due to the characteristically low absolute differences in 
pulmonary V̇O2 measured between the LT and V̇O2peak. This reduces the range 
of work rates available to prescribe exercise within the heavy or very heavy 
intensity domains. Furthermore, the CP boundary delineating the heavy and 
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very heavy domains cannot routinely be assessed in children and adolescents 
and requirs several testing sessions (Barker et al. 2012). Consequently, the 
‘delta’ (∆) concept should be utilised to prescribe work rates as a percentage 
difference between the LT/GET and V̇ O2peak (Armstrong & Barker, 2009). 
Typically, ∆ 40% is used to prescribe heavy intensity exercise and ∆ 60-70% is 
used for very heavy intensity exercise. Prescribing exercise within equivalent 
intensity domains is essential in order to derive valid physiological inferences 
regarding the influence that CF disease may have upon skeletal muscle 
oxidative metabolism.  
Dysfunction can occur at any step of the O2 transport and utilisation pathway, 
as typically found in disease (e.g. Spencer et al., 2013), causes a slowing of the 
V̇O2 kinetic response at the onset of exercise. For a given metabolic rate, 
slowed V̇O2 kinetics mandate a greater O2 deficit, increased requirement for 
substrate level phosphorylation (e.g., muscle [PCr] breakdown, anaerobic 
glycolysis) and the accumulation of fatigue inducing metabolites (e.g., inorganic 
phosphate (Pi), hydrogen ions), which can impair patients’ ability to tolerate 
exercise (Poole & Jones, 2012; Rossiter, 2011). The functional V̇O2 gain and 
magnitude of the V̇O2 slow-component can also provide information regarding 
aerobic exercise efficiency and the fatigue process(es), respectively. For that 
reason, measuring the V̇O2 kinetic response at the onset of exercise and during 
recovery in patients with CF can provide valuable insight into the mechanism(s) 
regulating muscle energetics and exercise tolerance.  
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2.6 Current evidence of aerobic exercise (dys)function in cystic fibrosis  
2.6.1 Incremental CPET 
In addition to the common clinical symptoms characterising CF (see sections 
1.1. and 2.1), early studies show that patients also present with reduced peak 
exercise performance upon testing (e.g. Almajed & Lands, 2012; Cerny et al., 
1982; Cropp et al., 1982; Godfrey & Mearns, 1971; Hjeltnes et al., 1984; Klijn et 
al., 2003; Moser et al., 2000; Shah et al., 1998). The first studies to document 
the cardiorespiratory exercise response in people with CF were begun over 40 
years ago (Cerny et al., 1982; Cropp et al., 1982; Godfrey & Mearns, 1971). 
Although more detailed investigations trying to ascertain the factor(s) 
contributing to exercise dysfunction in this group started over a decade later 
(e.g. Regnis et al., 1996), much remains to be elucidated regarding the extent 
and cause(s) of exercise limitation in people with CF. Particularly, there is a 
need to further characterise the extent of aerobic exercise (dys)function in 
children and adolescents with mild-to-moderate CF disease. The current 
knowledge regarding how CF impacts parameters from an incremental maximal 
CPET, primarily the key parameters of aerobic exercise function (Whipp et al., 
1981; Section 2.4.1) is outlined below.  
 
2.6.1.1  Peak ?̇?O2 
Godfrey and Mearns (1971) provided the first detailed overview of the 
physiological response of patients with CF (n = 41, 24 male, 5-21 y) at rest and 
during exercise. The authors employed the same Godfrey protocol that they had 
previously applied to the study of healthy children (Godfrey & Davies, 1970), 
which involved progressive increases in work rate each minute. The ability to 
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exercise was related to disease severity, with Wpeak significantly lower in more 
severe CF. In the mildest severity group, Wpeak was within the normal range. 
Hjeltnes and colleagues (1984) also provided early suggestions that V̇O2peak 
may be lower in CF than healthy male adolescents (15-17 y), however a large 
variation was observed with values ranging from 40-125% (mean 79%) 
predicted.  
Since this early work, several authors have sought to characterise aerobic 
fitness of people with CF, with the majority of studies adopting the Godfrey 
protocol. Specific focus has been on V̇O2peak or V̇O2max, due to the clinical utility 
described in sections 1.2 and 2.5.1. In general, patients with CF were 
traditionally considered to present with a lower V̇O2peak than their healthy peers 
upon exercise testing; however there are equivocal data in the literature.  
Shah et al. (1998) compared 17 individuals with CF (9 males, 25 ± 10 y, FEV1 
62 ± 21% predicted) and 17 age- and gender-matched controls (7 males, 25 ± 8 
y, FEV1 112 ± 15% predicted) during a CPET whereby work rate increased by 
30 W every 30s. Body mass normalised V̇O2peak was significantly lower in CF 
than controls (24.6 ± 6.0 vs. 35.5 ± 8.5 mL·kg-1·min-1, respectively). Savi and 
colleagues (2015) recently compared 30 adults with mild-to-moderate CF (33.3 
± 9.0 y, FEV1 71 ± 19% predicted) with 15 healthy controls (29 ± 5 y, FEV1 109 
± 11% predicted). They reported both a lower absolute (1.91 ± 0.47 vs. 2.66 ± 
0.77 L·min-1) and relative (28.7 ± 5.0 vs. 35.9 ± 5.0 mL·kg-1·min-1) V̇O2peak in CF, 
differences which remained when age, gender, BMI and FEV1 were corrected 
for. Perpati et al. (2010) also recorded a reduced V̇O2peak (29.12 ± 7.02 vs. 
35.54 ± 7.31 mL·kg-1·min-1) in older individuals with CF (9 male, 21 ±  11 y, 77 ±  
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33% predicted) compared with healthy controls (3 male, 29 ±  4 y, 104 ±  16% 
predicted), in line with findings in more severe CF disease (Poulio et al., 2001).   
From a paediatric perspective, Moser et al. (2000), using an exhaustive 
incremental cycling protocol (10 W·min-1), compared 22 paediatric patients with 
CF (8 males, 10.3 ± 0.7 y) and 54 healthy controls (17 males, 9.3 ± 0.1 y). As 
hypothesised, both absolute (0.96 ± 0.81 L·min-1 vs. 1.47 ± 0.54 L·min-1) and 
relative (31 vs. 45 mL·kg-1·min-1) V̇O2peak were significantly lower in CF than 
controls, respectively. Keochkerian et al. (2008) also reported significantly 
reduced body mass normalised V̇O2peak in CF versus healthy boys (34.7 ± 8.4 
vs. 49.2 ± 4.0 mL·kg-1·min-1, respectively). More recently, Bongers and 
colleagues (Bongers et al., 2012; Bongers et al., 2014) have also reported a 
reduced V̇O2peak ) in two groups of adolescents with CF compared with healthy 
controls using the Godfrey protocol, even following bronchodilation with 
salbutamol (Bongers et al., 2014).  
There are, however, some conflicting reports, suggesting V̇ O2peak is similar 
between individuals with CF and healthy controls. For example, Hebestreit et al. 
(2005) reported similar V̇O2peak in a relatively young CF cohort (n = 18, 11 
males, 15.8 ± 6.1 y, FEV1 71.5 ± 19.5% predicted) compared to their respective 
controls (n = 15, 8 males, 17.8 7.0 y, FEV1 101.0 ± 12.2% predicted). What 
should be noted is that this patient group ranged from 9 to 33 y of age and the 
mode of exercise was semi-supine rather than upright cycling. There is, 
therefore, a need to further investigate the impact of age- and disease severity 
upon aerobic fitness in CF, particularly since the V̇O2peak in the CF cohort was 
subtly higher than the controls in this study (38.5 ± 7.1 vs. 37.9 ± 5.0 mL·kg-
1·min-1). However, a recent study by Wells et al. (2011) also reported a similar 
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V̇O2peak  in 20 adolescents with CF (10 male) using the Godfrey protocol, 
compared with healthy controls (44.2 ± 10.9 vs. 44.7 ± 11.6 mL·kg-1·min-1) with 
similar habitual physical activity patterns. This raises the question as to whether 
V̇O2peak can be maintained at ‘normal’ levels in young people with CF if physical 
activity levels are the same as their healthy peers.  
Whilst the previously outlined validity considerations regarding the Godfrey 
protocol should be acknowledged, another factor that should be considered is 
the normalisation of V̇ O2peak to body composition, specifically FFM. Since 
patients with CF were traditionally malnourished and nutritional status is a 
principle concern, normalising for whole body mass may result in undetectable 
changes in aerobic fitness. In adolescents with CF (14.5 (10-22) y, FEV1 77.5 
(45-123)% predicted), Wideman et al. (2009) observed that absolute (1.33 
(0.43-2.37) vs. 2.09 (1.15-3.96) L·min-1) and body mass normalised (30.6 (8.5-
45.2) vs. 40.6 (29.0-64.5) mL·kg-1·min-1) V̇O2peak were significantly reduced in 
CF compared with their healthy peers (13.8 (10-19) y, FEV1 91.0 (70-110)% 
predicted). Several studies conducted by Stevens and colleagues have also 
demonstrated both reduced body mass normalised and FFM normalised V̇O2peak 
in young people with CF compared with their healthy peers (Stevens et al., 
2009; Stevens et al., 2011).  In a comparison of maximal CPET responses in 16 
young patients with CF (6 males, 13.1 ± 3.9 y, FEV1 89.9 ± 18.9% predicted) 
compared with 15 healthy controls (6 males, 14 ± 3 y, FEV1 105.5 ± 9.8% 
predicted), Fielding et al. (2015) reported no significant differences observed in 
V̇O2peak (1.5  ±0.7 vs. 1.8 ± 0.7 L·min
-1), work rate (119 ± 52 vs. 150 ± 54 W) or 
HR (175 ± 10 vs. 184 ± 15 b·min-1) in CF versus controls, using the Godfrey 
protocol. Similarly, when normalised for body mass, no differences were 
evident. Conversely, differences in both Wpeak and V̇O2peak were observed when 
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normalised for FFM (43.5 ± 7.7 vs. 50.6 ± 7.4 mL·kg-1·min-1), in a CF group who 
had a significantly lower fat-mass than their healthy peers (8.3 ± 2.6 vs. 11.3 ± 
5.0 kg, respectively).  
Although Fielding et al. (2015) represents one of the first attempts to normalise 
V̇O2max to dual-energy X-ray absorptiometry (DEXA) derived FFM, this finding 
corresponds with previous reports in young patients with CF that have not 
normalised V̇O2peak to FFM. For example, Poore et al. (2013) recently reported 
similar absolute (1.44 ± 0.68 vs. 1.81 ± 0.71 L·min-1) and body mass normalised 
(32.8 6.2 vs. 36.6 ± 8.6 ml·kg-1·min-1) V̇O2peak values in 15 young people with CF 
(5 males, 12.6 ± 3.4 y, 87.7 ± 22.3% predicted) and 15 healthy matched 
controls (6 males, 13.6 ± 2.7 y, 104.5 ± 11.8% predicted) using the Godfrey 
protocol.  
The extent of impairment may also depend on disease severity. In a study by de 
Meer et al. (1999), absolute and FFM normalised V̇O2peak were reduced in 
patients with moderate CF disease (n = 15, 9 males; 14.8 ± 1.9 y, FEV1 56 ± 
12% predicted) compared with healthy controls (n = 13, 8 males, 15.2 ± 1.9 y, 
FEV1 111 ± 12% predicted; 47 ± 7 vs. 61 ± 7 mL·kg
-1·min-1), however this was 
not the case in patients with milder CF disease (n = 13, 8 males, 15.3 ± 1.8 y, 
FEV1 100 ± 11% predicted; 57 ± 7 vs. 61 ± 7 mL·kg
-1·min-1).   
Since previous studies have largely utilised the Godfrey protocol, confirmation 
of the extent of any reduction in V̇O2peak using a valid and robust protocol is 
needed. There is also a need to examine specific effects on younger patients, 
with milder CF, who are habitually active, to explore the impact of CF where 
sedentariness and deconditioning may well play less of a role, particularly since 
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V̇O2peak typically falls approximately 5–8% per year in this patient group (Pianosi 
et al., 2005).   
 
2.6.1.2  GET  
The GET, VT and AT can all be used to broadly reflect the time at which the LT 
occurs, however within this thesis, the GET will be taken to reflect the non-
invasive equivalent of the LT. The onset of the GET also provides additional 
information regarding an individual’s aerobic fitness status, with an earlier 
occurrence indicative of poorer fitness. It has been suggested that an 
occurrence of this threshold < 50% of predicted V̇ O2max is associated with 
deconditioning (Urquart & Vendrusculo, 2015). Promisingly, over recent years 
authors are presenting both submaximal and maximal parameters of aerobic 
function; however available GET data are still relatively scarce.  
In a study by Groen and colleagues (2010), there was no significant difference 
in the VT expressed as a percentage of V̇O2peak in young people with CF 
compared to healthy controls (59.7 ± 14.2 vs. 64.2 ± 8.91%). In a recent study 
by Savi et al. (2015), comparing 30 adults with mild-to-moderate CF (33 ± 3 y, 
FEV1 50-90% predicted) with 15 healthy controls (FEV1 ≥ 80% predicted), the 
GET was shown to occur at a similar work rate (80 ± 35 vs. 88 ± 25 W) and 
corresponding V̇O2 (1.19 ± 0.33 vs. 1.37 ± 0.31 L·min
-1) in CF and their healthy 
controls, using the V-slope method of determination. This was also seen when 
data were expressed as a percentage of predicted V̇O2peak although this was not 
measured. Interestingly, Fielding et al. (2015) also reported a similar 
percentage of V̇O2peak for the occurrence of the GET in paediatric patients with 
CF compared with their healthy counterparts (60 ± 7 vs. 62 ± 7% of V̇O2peak, 
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respectively). The data in this study correspond with earlier findings in two 
groups of adolescents with mild-to-moderate CF compared with healthy controls 
that there is no difference in the occurrence of the GET relative to V̇O2peak (67.3 
± 8.8 vs. 67.2 ± 7.7% of V̇O2peak (Bongers et al., 2012) and 58.0 ± 9.0 vs. 55.0 ± 
9.0% of V̇O2peak (Bongers et al., 2014), respectively).  
However, Stevens et al. (2011) observed significant differences in the work rate 
(69 ± 32 vs. 102 ±  53 W) and body mass normalised V̇O2 (19 ±  4 vs. 26 ± 8 
mL·kg-1·min-1) at the GET in paediatric patients with mild-to-moderate CF. 
Unfortunately, data expressed as a percentage of V̇O2peak or Wpeak were not 
provided. The disparity between these studies may well be due to different 
levels of methodological rigour when identifying the GET. Issues in idenfification 
have previously been raised. Thin et al. (2002) presented their absolute GET 
data in healthy control participants (1.79 ± 0.51 L·min-1) and those with mild 
(1.20 ± 0.56 L·min-1), moderate (1.00 ± 0.22 L·min-1) and severe CF (0.74 ± 
0.25 L·min-1) and noted that a VT was only identified in ~ 50% of their patient 
group. However, other studies have not had the same problem. For example, 
Hebestreit and colleagues (2005) observed no difference in a mixed cohort of 
paediatric and adult patients (67.5 ± 7.6 vs. 65.7 ± 10.5% of V̇O2peak).  
As outlined recently by Visschers and colleagues (2014), there is no real 
consensus regarding the most accurate method to determine the GET in 
individuals with chronic diseases, such as CF, which may play some part in the 
limited presentation of this parameter within the literature. However, it has been 
demonstrated that the GET can be used to obtain an unbiased estimated of the 
LT which is reproducible (Thin et al., 2002). Furthermore, the V-slope method, 
ventilatory equivalents and investigating the PETO2 response can identify the 
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GET at comparable V̇O2 and work rate values and are equally reproducible 
(Visschers et al., 2014). There is, however, a need to confirm the influence of 
mild-to-moderate CF on the GET using rigourous identification procedures.  
 
2.6.1.3  ?̇?O2 gain 
As outlined in section 2.4.1, the slope of the regression of V̇O2 against work rate 
obtained from an incremental exercise test to exhaustion can provide further 
insight into aerobic (dys)function, which is independent of effort. This measure 
provides an index of aerobic exercise efficiency (O2 cost of exercise) (Neder et 
al., 2001) and has been shown to provide a sensitive parameter of abnormal 
muscle O2 delivery-to-utilisation during exercise (Gimenes et al., 2011; Hansen 
et al., 1987; Jones et al., 1998; Meyer et al., 1998; Neder et al., 2001). A 
reduced ability to increase V̇O2 with work rate indicates an increased reliance on 
anaerobic glycolysis during exercise. However, as with the GET, the number of 
studies reporting values for the V̇O2 gain in individuals with CF is limited.   
Fielding and colleagues (2015) reported that the V̇O2 gain was significantly 
lower in paediatric patients with CF compared with healthy controls (8.4 ± 3 
mL·min-1·W-1 vs. 10.1 ± 1.4 mL·min-1·W-1, respectively), a finding in agreement 
with earlier observations (Moser et al., 2000).  If a lower V̇ O2 gain is 
characteristic of children and adolescents with CF, this would indicate a 
reduced metabolic capacity to increase V̇O2 in accordance with an increasing 
work rate. This however needs further confirmation, since there is debate 
regarding how CF impacts this parameter (e.g. Groen et al., 2010). It would be 
expected that if young patients with CF have impairment in O2 transport and O2 
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utilisation during exhaustive, incremental exercise, then the V̇O2 gain would be 
shallower than their healthy peers.  
Using an incremental cycling test, Groen et al. (2010) did not find a significant 
difference between adolescents with CF and healthy controls (10.1 ± 1.3 vs. 9.2 
± 1.0 mL·min-1·W-1), despite a difference being observed when healthy young 
people were compared with another clinical group (juvenile dermatomyositis). 
Although not significant (p = 0.08) the authors noted that values tended to be 
higher in CF than controls. Savi et al. (2015) also reported no difference 
between CF and healthy adults. Higher values have also previously been 
presented. de Meer and colleagues (1999) reported higher values for patients 
with mild (19.2 ± 2.3 mL·min-1·W-1) and moderate (18.2 ± 2.0 mL·min-1·W-1) CF, 
compared with their healthy peers (16.3 ± 2.6 mL·min-1·W-1), however even the 
healthy values are higher than would be expected. 
It has been proposed that the existing disparity within the literature regarding 
the influence of CF disease upon the V̇O2 gain may result from the difference in 
disease severity investigated and methods utilised to determine the V̇O2 gain, 
specifically whether data was included up to or including data above the GET 
(Fielding et al., 2015). All of these previous studies have included data from the 
onset of exercise, which may skew the calculated slope of the response, since it 
is recommended that the initial 2 min be removed to account for any influence 
of the V̇ O2 MRT. Furthermore, it has been suggested that since the V̇ O2 
response above the GET is not always linear, it should possibly be excluded 
from calculations of the V̇O2 gain (Boone & Bourgois, 2012) or the V̇O2 gain 
could be determined for the regions above and below the GET. To date, 
Fielding et al. (2015) present the only data concerning the V̇O2 gain calculated 
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using only the linear data points as recommended by Boone and Bourgois 
(2012).  
 
2.6.1.4  ?̇?O2 MRT 
The MRT marks the intersection point between the baseline V̇ O2 and a 
backward extrapolation of the linear portion of the V̇O2 response. The kinetic 
adjustment of V̇O2 at the onset of ramp incremental exercise is fundamentally 
similar to the MRT measured at the onset of CWR exercise, representing O2 
utilisation by the muscle at the onset of exercise. However, this parameter has 
remained unused within much of the literature investigating aerobic exercise 
(dys)function in patients with CF. Specifically, data is limited to a single study by 
Fielding et al. (2015). This study represented one of the first attempts to use the 
V̇ O2 MRT to investigate the adequacy of the V̇ O2 kinetic response during 
incremental exercise in CF. As hypothesised, Fielding et al. (2015) observed a 
significant slowing of the V̇O2 MRT in CF compared with healthy matched 
controls (36.1 ± 15.1 vs. 25.0 ± 12.4 s, respectively). Furthermore, the V̇O2 MRT 
was inversely related to pulmonary function (FEV1/FVC), indicating that better 
pulmonary function may be associated with faster V̇O2 kinetics in children and 
adolescents with CF during incremental exercise.  
 
2.6.2 Pulmonary ?̇?O2 kinetics 
As outlined in section 2.5.2, assessing the kinetics of the V̇O2 response to an 
altered work rate can also provide valuable insight into the integrated capacity 
of the O2 transport and utilisation pathways to support the increased rate of ATP 
turnover in the contracting myocytes (see Figure 2.6). Although the V̇O2 kinetic 
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response is now relatively well documented in healthy children (Armstrong & 
Barker, 2009), evidence of the influence of CF upon this response is scarce. 
Although the V̇O2 MRT has recently been used to suggest a slowing of the V̇O2 
kinetic response during incremental exercise in individuals with CF (Fielding et 
al., 2015; see section 2.6.1), there is limited data concerning the mathematically 
modelled V̇O2 response within strict intensity domains in this patient group. 
Moreover, that which has been conducted comprises a number of 
methodological issues which must be considered.  
In the first study to investigate the V̇O2 kinetic response in CF, Braggion and 
colleagues (1989) investigated the profile of 10 young people with mild CF 
(11.1-15.3 y; FEV1 77 ± 22% predicted) and 10 healthy age-matched controls 
(12.2-15.2 y) during 6 min cycling at an intensity equivalent to 1.7 W·kg-1. The 
kinetics of V̇O2 at the onset and end of the exercise transition were recorded 
and a monoexponential fit was applied. Although no difference was observed 
between the groups, a number of methodological issues comprised this study. 
Specifically, only a single exercise transition was employed to quantify the V̇O2 
response and the modelling procedure used did not enable phase II of the 
response to be isolated which, as previously outlined, is crucial to infer mV̇O2 
dynamics. Additionally, no consideration was given to standardising the 
exercise intensity domain within and between the groups which, as outlined in 
section 2.5.2., may render patients with CF exercising at a higher percentage of 
their aerobic fitness than their healthy counterparts. Barker et al. (2004) also 
found similar τ in patients with CF and healthy controls, when fitting a single 
monoexponential model to the entire phase I and phase II V̇O2 response.  
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There are, however, contrasting reports regarding the influence of CF disease 
upon the kinetics of V̇ O2 at the onset of exercise. Massin et al. (2000) 
investigated the V̇O2 and HR kinetics of paediatric and adult patients with CF (n 
= 20, 10 males; 5-28 y; FEV1 25-99% predicted). Instead of employing a CWR 
exercise challenge, participants undertook a pseudo-random binary sequence 
(PRBS) exercise task. PRBS involves random transitioning between two work 
rates within the aerobic range and has been validated in healthy children and 
adolescents and those with cardiac problems (Massin et al., 1998), with the 
reproducibility for CF patients also reported (Kusenbach et al., 1999). This 
protocol was employed since the authors deemed it more indicative of ADLs. 
CF patients were divided into 3 groups, dependent on disease severity 
assessed using the Shwachman Score (SS) (A, n = 7, 5-28 y, SS 85-90; B, n = 
6, 5-24 y, SS, 70-80; C, n = 7, 5-24 y, SS, 30-65). In line with Braggion and 
colleagues’ (1989) findings in patients with mild CF, the V̇O2 kinetics of patients 
in group A were not significantly prolonged. However, a reduced V̇O2peak, V̇O2 
amplitude and V̇O2 ‘lag time’ were observed in the CF patients in groups B and 
C and correlated with both FEV1 and the SS.  It should, however, be 
acknowledged that PRBS exercise protocols again prohibit the isolation of the 
different phases of the V̇ O2 kinetic response, do not involve any explicit 
mathematical modelling of the kinetic parameters and encompass changes in 
V̇O2 during the recovery period. Furthermore, since a wide age group were 
pooled together it is difficult to separate the effects of age and disease on the 
V̇O2 kinetic response. Kusenbach et al. (1999) provided further support to the 
observations made by Massin and colleagues (2000), reporting slower V̇O2 
kinetics in 9 individuals with CF (5 male, 13-31 y, FEV1 42-88% predicted) 
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compared with 13 healthy controls (8 male, 9-29 y, FEV1 84-143% predicted) 
during submaximal PBRS cycling exercise.  
To provide further clarity regarding the V̇O2 kinetic response characterising 
individuals with CF, Hebestreit et al. (2005) sought to investigate the V̇ O2 
kinetics in a group of patients (FEV1 37-98% predicted, 9.8-33.8 y) compared 
with their healthy counterparts (age 9.9-30.8 y). A two stage protocol was 
employed, consisting of semi-supine cycling at 20 W for 2 min, followed by 3 
min cycling at a work rate corresponding to 1.4 W·kg-1 or 1.3 W·kg-1 for males 
and females, respectively. This protocol was repeated 2-4 times to improve the 
signal-to-noise ratio of the V̇ O2 kinetic response (Whipp et al., 1981). 
Interestingly, Hebestreit et al. (2005) observed a significantly prolonged phase II 
V̇O2 τ in the CF group compared with the healthy controls (36.8 ± 1.8 vs. 26.4 ± 
9.1 s), with no difference in the O2 cost of exercise (10.9 ± 1.8 vs. 10.2 ± 1.6 
mL·min-1·W-1). However, several methodological issues potentially confound the 
interpretation of this study. 
Although Hebestreit and colleagues provided the first attempt to isolate the 
phase II region of the response and apply an appropriate mathematical model 
to the data, the prescribed work rate was not classified within a particular 
exercise intensity domain (see Figures 2.12 and 2.13). As rationalised in section 
2.5.2, equating exercise intensity is crucial in the study of V̇ O2 kinetics, 
particularly when the substantial inter-individual variability in the occurrence of 
the LT as a percentage of V̇O2max in children and adolescents is considered 
(Reybrouck et al., 1985). Not prescribing exercise intensity within strict domains 
therefore increases the possibility that participants both between and within the 
groups may have been exercising across the moderate and heavy intensity 
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domains. Secondly, 2-4 repetitions of the exercise protocol were completed on 
the same day with only 10 min recovery. This raises the possibility that a 
‘priming’ effect may have occurred on the V̇O2 kinetic response (Burnley et al., 
2006), which is likely to be more influential in individuals with slower V̇ O2 
kinetics (Gurd et al., 2005). Furthermore, the exercise mode was semi-supine 
rather than upright cycling, which may have reduced muscle O2 delivery during 
exercise, due to the absence of the gravitational assist to muscle blood flow, 
and slowed the V̇O2 kinetic response (Jones & Burnley, 2005; Jones et al., 
2006; Koga et al., 1999; MacDonald et al., 1998). Finally, Hebestreit and 
colleagues pooled together a wide age group, who will likely span the disease 
severity spectrum, which has been shown to potentially influence the V̇O2 kinetic 
response (Massin et al., 2000).  
In further support of an impact of age and disease severity on the V̇O2 kinetic 
response, Armeniakou et al. (2015) recently reported prolonged V̇O2 kinetics 
during submaximal exercise in adults with CF (V̇O2 τ: 42.3 ± 21.5 s) compared 
with their healthy counterparts (V̇O2 τ: 29.3 ± 6.4 s). Furthermore, in line with 
Massin et al’s (2000) observations, the phase II V̇O2 τ was associated with 
disease severity, as indicated by the SS, suggesting that this clinical index may 
provide a useful, independent predictor of the phase II V̇O2 τ in adults with CF 
(R2 = 0.72, P = 0.001).  
In addition to documenting the V̇O2 on-kinetics, the recovery kinetics of V̇O2 is 
also important, since they can provide an effort independent insight into skeletal 
muscle oxidative capacity (Paganini et al., 1997). Pouliou et al. (2001) explored 
the influence of CF on the V̇O2 recovery kinetics of 18 patients (9 male, 23 ± 13 
y, FEV1 23-128% predicted) versus 11 healthy controls (3 male, 29 ± 4 y) 
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following an exhaustive treadmill CPET. The recovery of V̇O2, as quantified 
using a linear slope function to characterise the rapid exponential-like phase 
during the first minute of recovery following the V̇O2max test, to be significantly 
slower in CF. Interestingly, in agreement with previous observations concerning 
the phase II τ at the onset of exercise (Armeniakou et al., 2015), Pouliou and 
colleagues (2001) also showed an association between the recovery of V̇O2 and 
the SS (r = 0.81, P < 0.001), which again remained the only predictor after 
accounting for confounding variables ( V̇ O2max and FEV1) in a multivariate 
analysis. More recently, Perpati et al. (2010) extended these findings from 
treadmill exercise, demonstrating prolonged V̇O2 recovery kinetics in adults with 
CF during cycling exercise, again indicated by the first degree slope of V̇O2 
during the first minute of recovery following an exhaustive incremental CPET.  
Similar results have also been reported in a more homogenous sample of 
patients with chronic chest diseases (70% CF, FEV1 82 ± 23% predicted, age 
12.7 ± 3.1 y) compared with healthy controls (age 13.2 ± 3.3 y; Stevens et al., 
2009). In Stevens et al’s (2009) study, children and adolescents with chronic 
chest disease were shown to be characterised by a slower V̇ O2 recovery 
following a V̇O2max test, which correlated with V̇O2max (r = -0.39, p = 0.04), when 
compared with their healthy peers.  Furthermore, in CF patients only, the speed 
of V̇O2 recovery was again associated with the SS (r = -0.63, p = < 0.01), 
supporting earlier observations in older patients (Perpati et al., 2010; Pouliou et 
al., 2001).  
There is therefore a need to clarify the impact of CF on the kinetics of V̇O2 in a 
cohort of children and adolescents with mild-to-moderate disease. Specifically, 
since almost all chronic diseases that involve one or more of the respiratory, 
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cardiovascular and/or muscular systems have the potential to slow the V̇O2 
kinetic response, confirmation of the impact of mild-to-moderate CF on the 
dynamics of V̇O2 during exercise within defined intensity domains and using 
accurate mathematical modelling is warranted. Moreover, the V̇ O2 kinetic 
response during exercise performed above the GET has not formally been 
documented. Although Hebestreit et al. (2005) reported that their study was 
investigating the V̇ O2 response during moderate intensity cycling, some 
participants may well have been exercising above the GET and some below. 
Consequently, the V̇O2 response of people with CF above and below the GET 
requires investigation. Given earlier suggestions that the kinetics of V̇O2 may be 
related to V̇ O2max (an independent predictor of prognosis in CF), further 
characterisation of the response may also be of prognostic utility. There is, 
therefore, a need for experimentally robust studies to elucidate how CF disease 
modulates the V̇O2 kinetic profile.  
There is some, but limited, evidence to support a contribution from a rate-
limiting step in the O2 cascade from the alveoli to the mitochondria. Massin et 
al. (2000) suggested that O2 delivery, indicated by insufficient SV, plays a role 
in the altered V̇O2 kinetics that reportedly characterise patients with CF. This 
was further postulated by Hebestreit et al. (2005), however this was inferred 
from a correlation between the phase II V̇O2 τ and SpO2 and this study was not 
designed to detect abnormalities in muscle metabolism during exercise. Any 
conditions that impair muscle O2 delivery have the potential to reduce the speed 
of the V̇O2 kinetic response. However, until physiological information regarding 
the oxygenation kinetics within the contracting muscles and the balance 
between O2 delivery and utilisation within the microvasculature of skeletal 
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muscle are determined in conjunction with pulmonary V̇O2 kinetics, this cannot 
be confirmed.  
 
2.7   Additional techniques to assess exercise (dys)function in patients 
with CF  
In addition to traditional measurements made via assessments of pulmonary 
gas exchange and ventilation, several other techniques enable insight into 
central (O2 delivery) and peripheral function (O2 extraction and utilisation) and 
have gained popularity over recent years (see Figure 2.14). For example, 
thoracic electrical bioimpedance cardiography and NIRS now enable valuable 
insight into cardiac function and central O2 delivery and localised fractional O2 
extraction within exercising muscle, which was previously not viable in children 
and adolescents given their invasiveness. These techniques are outlined below.  
 
 
 
Figure 2.14. Schematic representation of simultaneous measures of 
pulmonary oxygen uptake (V̇O2), cardiac output (?̇?) and muscle oxygenation 
(∆HbMbO2) and deoxygenation (∆HHbMb) during cycling exercise (A) and 
the local region of muscle interrogated by near-infrared spectroscopy (NIRS) 
(B). Image taken from Lai et al. (2009) with permission.  
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2.7.1 Near-infrared spectroscopy 
NIRS provides a non-invasive method to examine the oxygenation status at the 
skeletal muscle level, at rest and during exercise. This is particularly useful in 
paediatric research, given that many of the other methods to investigate 
changes in muscle blood flow, O2 delivery and muscle metabolism are not 
feasible given their invasiveness and cost (e.g. muscle biopsy, tissue O2 
microelectrodes, nicotinamide adenine dinucleotide analysis from exposed 
tissue surfaces, myoglobin O2 saturation by spectrophotometric analysis). 
Whilst 31P-MRS has shown promise in paediatric studies (e.g. Barker & 
Armstrong, 2010; Willcocks et al., 2010a; Willcocks et al., 2010b; Willcocks et 
al., 2014), this technique focuses on muscle metabolism, is incredibly costly and 
limited by the exercise tasks that can be performed and location of the testing 
environment. NIRS, however, is non-invasive, portable, relatively cheap and 
enables continuous, real-time measures to be made, thereby providing 
measurements of dynamic changes in tissue oxygenation in vivo.  
NIRS is based on the relative ease with which near-infrared light passes 
through biological tissues, including bone, skin and muscle. The amount of light 
recovered after illuminating the tissue depends on the degree of scattering in 
the tissue and the amount of absorption by the chromophores in the tissue. 
Only three molecules are known to affect near-infrared light absorption during 
changes in tissue tension, haemoglobin, myoglobin and cytochrome c oxidase 
(Boushel & Piantadosi, 2000). When evaluating changes within skeletal muscle 
tissue, measures of tissue oxygenation are based on the fractional reflection 
and refraction of near-infrared light by haemoglobin in the microvasculature and 
myoglobin in the muscle. Each of these measures are dependent on whether 
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these compounds are bound to O2. During exercise, this provides insight into 
the fractional extraction of O2 in the working muscles.  
Whilst early NIRS devices used single-distance continuous-wave light source-
detector pairs (McCully & Hamaoka, 2000), more recent models which comprise 
multi-channel or imaging devices enable measurements of wider areas of 
interrogation (Queresima et al., 2001; Yamamoto et al., 2001) and have made it 
possible to image regional differences in skeletal muscle oxygenation and 
metabolism in different muscle locations (Hamaoka et al., 2011; see Figure 
2.15).  The development of portable NIRS devices has also meant that 
measurements can be made more freely during movement (Shiga et al., 1995). 
For example, a wireless continuous-wave NIRS system, small in size, was 
developed by Artinis Medical Systems (which will be used within this thesis) to 
measure muscle oxygenation.  
 
 
 
 
 
 
 
 
 
Figure 2.15. Example data depicting the muscle oxygenation response at the m. 
rectus femoris and m. vastus lateralis during and after isometric knee-extension 
exercise, as assessed using a multi-channel near-infrared spectroscopy (NIRS) 
device. Image taken from Hamaoka et al. (2011) with permission.  
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In intact skeletal muscle, NIRS allows semi-quantitative measurements of 
haemoglobin plus myoglobin oxygenation (tissue O2 stores) and the 
haemoglobin volume to be made (Boushel & Piantadosi, 2000). Specifically, 
NIRS has primarily been used to assess dynamic changes in the status of 
tissue oxyhaemoglobin (HbO2), deoxy-haemoglobin (HHb) and total blood 
(haemoglobin) volume in brain and muscle tissue. However, the levels of 
muscle oxygen measured by NIRS are only understood to be a result of the 
dynamic balance between muscle O2 delivery and consumption (Ding et al., 
2001). From the parameters of the response, the investigator can draw 
conclusions about the balance of O2 delivery and utilisation, but NIRS cannot 
distinguish between these two factors. The NIRS-derived [HHb] signal therefore 
provides a measure of estimated skeletal muscle microvascular O2 extraction at 
the periphery (e.g. DeLorey et al., 2003; Ferreira et al, 2007; Grassi et al., 2003) 
and, thus, the ratio of local muscle O2 utilisation to microvascular blood flow. 
NIRS may therefore be useful for understanding muscle oxidative metabolism 
and alterations caused by changes in aerobic fitness status and/or disease 
progression in CF.  
The profile of the [HHb] signal has been used to describe O2 extraction 
dynamics during ramp exercise, which in turn permits inferences regarding 
blood flow within the microcirculation of exercising muscle during this type of 
exercise (e.g. Boone et al., 2009; DiMenna et al., 2010; Ferreira et al., 2007; 
McNarry et al., 2011; McNarry et al., 2015). Although pulmonary V̇O2 is known 
to increase linearly with increasing work rate, following an initial time lag, 
muscle ∆[HHb] has been shown to increase in a nonlinear manner (see Figure 
2.16). The ∆[HHb] response to incremental ramp cycling exercise is typically 
described using a sigmoidal model (e.g. Boone et al, 2009; DiMenna et al., 
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2010; Ferreira et al., 2007; McNarry et al., 2011; McNarry et al., 2015), although 
a bi-linear model is favoured by some (Murias et al., 2013a; Murias et al. 
2013b). This response has been well characterised using a sigmoidal (S-
shaped) function relative to wrk rate and V̇O2 in healthy individuals ranging from 
children to the elderly during ramp cycling exercise.  
During steady-state exercise, muscle blood flow increases in proportion to 
muscle V̇O2, with a positive intercept on the y-axis (blood flow) that is fibre type 
dependent (Ferreira et al., 2007). According to the Fick principle, this 
relationship mandates a hyperbolic increase in fractional O2 extraction with 
increasing muscle V̇O2 and, by extension, work rate. However, using NIRS-
derived [HHb] data as a surrogate for microvascular O2 extraction, the 
consensus from the literature suggests that a sigmoidal model is better fit to 
[HHb] data during upright ramp incremental cycling exercise to exhaustion (e.g., 
Boone et al., 2009; Boone et al., 2010; DiMenna et al., 2010; Ferreira et al., 
2007; McNarry et al., 2011; McNarry et al., 2015). Analysis of the Δ[HHb] 
adjustment during incremental exercise provides information regarding the 
matching of muscle O2 delivery and extraction during non-steady-state exercise 
covering a wide range of exercise intensities.  
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This sigmoidal response has been characterised with three distinct regions; an 
initial region, slope region and, finally, the plateau region (see Figure 2.16). 
Assuming the normal linear increase in V̇O2 with incremental work rate, the 
blunted [HHb] rise within the initial region has been interpreted as evidence that 
muscle blood flow increases faster that muscle V̇O2 during the initial 2 min of 
exercise (Ferreira et al., 2007). Conversely, the slope region is characterised by 
a markedly steeper response, which indicates a greater reliance on fractional 
O2 extraction as higher work rates are reached. Finally, in most healthy 
individuals, a plateau occurs, implying an inability for O2 extraction to increase 
further and implies a linear muscle blood flow to V̇O2 relationship, until the point 
of exhaustion (Ferreira et al., 2007).  
Ferreira et al. (2007) developed computer simulations to assess the sigmoidal 
[HHb] response and advanced a model whereby the slope and plateau regions 
provide information that could be useful for assessing localised blood flow within 
Figure 2.16. Schematic representation of the three phases of the 
deoxygenated haemoglobin concentration ([HHb]) sigmoidal response that 
has been characterised with three distinct regions. Image taken from DiMenna 
et al. (2010).  
  
121 
 
exercising skeletal muscle and detecting early stages of dysfunction during 
routine clinical exercise testing. Specifically, Ferreira et al. (2007) suggested 
that disease-related changes in microvascular function might shift the sigmoid 
to the left, whereas exercise training and pharmacological treatment that 
improves vascular function might shift the sigmoid to the right.  
To date, there is no evidence concerning the influence of CF disease upon the 
dynamics of [HHb] during ramp incremental exercise to exhaustion. Considering 
the hypothesis proposed by Ferreira and colleagues (2007), it may be expected 
that since CF causes a reduction in aerobic fitness (e.g. Bongers et al., 2012; 
Bongers et al., 2014; Moser et al., 2000; Wideman et al., 2009), then this may 
causes a leftward shift of the [HHb] sigmoid. In support of this, Boone et al. 
(2009) found a rightward shift of the [HHb] response in healthy adults who are 
trained compared with less well trained counterparts (see Figure 2.17). Boone 
et al. (2009) demonstrated a rightward shift in the NIRS-derived [HHb] sigmoidal 
response, measured at the m. vastus lateralis, in healthy trained cyclists (n = 
10) compared with healthy physically active students (n = 11). When normalised 
to the total amplitude of the [HHb] response, the work rate corresponding to 
50% of the ∆[HHb] amplitude (c/d) was the only parameter that differed between 
healthy trained versus untrained adults, indicating altered O2 extraction 
dynamics as a function of aerobic fitness status.  This finding was further 
supported more recently in a much larger (n = 64) sample of participants 
(Boone et al., 2016). 
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The reproducibility of NIRS in children has been documented (Leclair et al., 
2010) and over recent years studies have begun to utilise NIRS to investigate 
muscle oxygenation of healthy children during ramp incremental exercise 
(McNarry et al., 2011; McNarry et al., 2015). In support of the findings in adults, 
a rightward shift of the [HHb] sigmoid has been observed in trained versus 
untrained girls (McNarry et al. 2011; see Figure 2.18). Furthermore, more 
recently McNarry and colleagues (2015) provided the largest dataset to date (n 
= 51; 9.9 ± 0.6 y, 31 boys) concerning the typical muscle [HHb] response of 
healthy children during exercise. This study sought to characterise the ∆[HHb] 
dynamics in healthy boys and girls during exhaustvie incrememntal exercise 
Figure 2.17. Deoxygenated haemoglobin concentration ([HHb]) plus myoglobin 
concentration response as a function of relative work rate in trained (cyclists) 
and physically active (PA) students during ramp incremental cycling exercise. 
This data demonstrates a rightward shift of the sigmoidal [HHb] response as a 
result of training. Image taken from Boone et al. (2009) with permission.  
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and whether the reduced V̇O2max in girls compared to boys was related to 
altered muscle [HHb] dynamics, as evidenced by an accelerated ∆[HHb] 
response. This study demonstrated that the reduced aerobic fitness observed in 
girls is partly due to gender-specific changes in muscle fractional O2 extraction 
dynamics during ramp incremental cycling exercise. 
 
 
 
 
 
 
 
 
 
 
 
 
However, in contrast to the findings regarding training status, recent evidence 
comparing older (70 ± 3 y) and younger (25 ± 5 y) adults only observed 
alterations in muscle [HHb] dynamics when the data was expressed relative to 
absolute work rate. The authors did not observe any significant age-related 
differences in the ∆[HHb] dynamics when expressed as a function of 
percentage Wpeak, despite a reduced V̇O2max in the older participant group (30 
Figure 2.18. Deoxygenated haemoglobin concentration ([HHb]) plus myoglobin 
concentration response as a function of relative work rate (WR) for a 
representative trained (● shaded circles) and untrained (○ open circles) girl during 
ramp incremental cycling exercise. This data demonstrates a rightward shift of the 
sigmoidal [HHb] response as a result of training, indicating a better matching of O2 
delivery-to-O2 utilisation and the muscle level. Image taken from McNarry et al. 
(2011) with permission.  
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vs. 49 mL·kg-1·min-1) (Gravelle et al., 2012; see Figure 2.19). When the 
response during CWR exercise was investigated, however, differences in the 
dynamics of ∆[HHb] between the groups during the on-transient to moderate 
intensity exercise (80% of the LT) were evident.  
 
 
 
 
 
 
 
 
 
 
 
Although the HHb profile during ramp exercise has been used to describe the 
effect of body position (DiMenna et al., 2010), trained status (e.g. Boone et al., 
2009; McNarry et al., 2011), gender (McNarry et al., 2015) and ageing (e.g. 
Gravelle et al., 2012; McNarry et al., 2011), there is scare evidence concerning 
clinical perturbations that might be expected to shift the [HHb] sigmoid leftward. 
Although NIRS has recently been employed within clinical populations (e.g., 
Habers et al., 2012; MacDonald et al., 2012), no research has assessed the 
Figure 2.19. Sigmoid models of normalised changes in deoxygenated 
haemoglobin concentration ([HHb]) plus myoglobin concentration 
(percentage of peak amplitude) as a function of relative (percentage peak) 
work rate for young adults (YA) versus older adults (OA). Image taken from 
Gravelle et al. (2012) with permission.  
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influence of clinical perturbations on the sigmoid function of the Δ[HHb] 
response.  
 
From a clinical perspective, NIRS has been used in a variety of populations. 
NIRS, in combination with 31P-MRS has also been used to determine 
mitochondrial function and the degree of ischaemia in patients with type II 
diabetes mellitus and peripheral vascular disease (Malagoni et al., 2010). NIRS 
has also been used to investigate the effect of bronchodilators (Berton et al., 
2010) and O2 administration (Siquera et al., 2010; Vogiatzis et al., 2009) in 
patients with chronic obstructive pulmonary disease (Rondelli et al., 2009) and 
the response to pharmacological treatment (Sperandio et al., 2009) exercise 
rehabilitation in patients with chronic heart failure (Gerovasili et al., 2009). 
Whilst NIRS has been used in combination with pulmonary V̇O2 measurement to 
explore exercise limitation in patients with metabolic myopathies (Grassi et al., 
2007; Grassi et al., 2009), paraplegia (Muraki et al., 2007), type II diabetes 
(Bauer et al., 2007; Pedersen et al., 2009) and trapezius myalgia (Andersen et 
al., 2010), it has yet to be applied to people with CF.  
Alterations within the O2 delivery-to-O2 utilisation relationship would be 
expected to shift the Δ[HHb] sigmoid and, as previously outlined, a leftward shift 
has been hypothesised for chronically diseased individuals (Ferreira et al., 
2007). An inadequate adjustment of muscle blood flow, specifically 
microvascular blood flow, would require increased O2 extraction to meet the 
muscle O2 requirement for mitochondrial oxidative ATP production. Thus, if O2 
delivery is compromised in children and adolescents with CF during CPET, a 
more rapid extraction of O2 at the periphery would be required, thereby shifting 
the sigmoid to the left compared with a healthy response. Assessing the 
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dynamics of [HHb] relative to the kinetics of pulmonary V̇ O2 during CWR 
exercise is also warranted. However, to date only a single study has utilised 
NIRS in the assessment of individuals with CF (Erickson et al., 2015). NIRS 
was used to measure the recovery rate of muscle O2 consumption of the m. 
vastus lateralis following 15 s of electrical stimulation (4 Hz) and subsequent 
repeated transient arterial occlusions, observing a reduction in maximal muscle 
V̇O2 in CF versus their healthy counterparts.  
 
2.7.1 Thoracic electrical bioimpedance cardiography  
Thoracic electrical bioimpedance cardiography provides a non-invasive, 
portable, relatively low cost tool, which requires little technical expertise to 
operate and, thus, is well suited for use in paediatric groups. Thoracic electrical 
bioimpedance cardiography allows the non-invasive estimation of changes in ?̇?, 
SV and HR at rest and during exercise. ?̇? can be measured by passing high 
frequency, small alternating current through the chest (Warburton et al., 1999). 
Changes in electrical impedance, caused by pulsatile changes in aortic blood 
flow, are measured by recording electrodes placed in specific locations on the 
body. It is assumed that changes in thoracic impedance during systole are 
related to SV. The PhysioFlow device does not require the measurement of 
baseline impedance, which is affected by hydration status, blood resistivity, and 
distance between electrodes. This technique has been shown to provide similar 
results to direct measures of cardiac function during rest and exercise, including 
maximal exercise (Charloux et al., 2000; Richard et al., 2001).   
Several studies have sought to validate thoracic electrical bioimpedance 
cardiography against other methods of assessing changes in cardiac indices 
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during exercise. Moore et al. (1992) compared thoracic electrical bioimpedance 
cardiography (Biomed NCCOM-3) derived ?̇? to that measured using the indirect 
Fick method (CO2 rebreathing technique) in 11 healthy males at rest and during 
three steady-state intensities (60 W, 120 W and 180 W) of cycling exercise. The 
?̇? derived using both methods correlated with changes in V̇O2, with a higher 
correlation for ?̇?  by the rebreathing technique (r = 0.94) than for thoracic 
impedance cardiography (r = 0.88).  These results were interpreted to show that 
thoracic electrical bioimpedance cardiography provides a valid tool for the 
assessment of ?̇? during low and moderate intensity cycling exercise in healthy 
adults.  
Pianosi (1996) sought to investigate the validity of this technique (ICG-M401 
impedance cardiograph) versus the CO2 rebreathing technique in paediatric 
participants. The accuracy of this technique to monitor changes in ?̇?  was 
assessed in 30 healthy children during two intensities of CWR cycling exercise 
(0.5 and 1.5 W·kg-1). Given that 80% of the impedance cardiography values 
were within ±20% of those derived using CO2 rebreathing, it was concluded that 
this technique provides an accurate estimate of ?̇?  in healthy children during 
exercise. Furthermore, using a large sample of healthy young people (n = 115; 
7-19 y), changes in ?̇?  and SV (normalised to body surface area (BSA) and 
expressed as the stroke volume index (SVI)) were measured during an 
incremental cycling test to exhaustion, in conjunction with changes in V̇ O2 
measured at the mouth (Pianosi, 2004). When ?̇? was regressed against V̇O2, as 
expected, ?̇?  increased linearly with V̇O2 in all participants, with the majority 
demonstrating a gentle, progressive increase in SV in line with work rate. It was 
concluded that thoracic impedance cardiography has the capacity to accurately 
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measure changes in ?̇?  during exercise and provides a useful clinical and 
research tool in paediatric cardiology and paediatric exercise physiology.  
Following validation of thoracic electrical bioimpedance cardiography in healthy 
young people, Pianosi (1997) sought to assess the accuracy of this technique in 
21 young people with CF (FEV1 77 ± 21% predicted), compared with CO2 
rebreathing with sampling of capillary blood gases, during the same two 
exercise intensities employed in their earlier work in healthy young people (0.5 
and 1.5 W·kg-1).  In this group, 83% of impedance cardiography values were 
within ±20% of those measured using CO2 rebreathing. It was concluded that 
this device also provides rapid, accurate and non-invasive measurements in 
children with CF. 
 
The reproducibility of using thoracic electrical bioimpedance analysis to 
determine ?̇? during maximal CPET has been evaluated in children (Welsman et 
al., 2005). Welsman and colleagues investigated the reproducibility of the 
PhysioFlow device to determine changes in SV and ?̇? in 10-11 year olds during 
maximal ramp incremental cycling exercise. The PhysioFlow device was shown 
to allow non-invasive, beat-by-beat determination of ?̇? and SV, which is feasible 
for measurements during maximal exercise in children. TEs across three trials, 
each separated by one week, were 9.3% and 9.3% for ?̇? and SV, respectively. 
The reproducibility statistics demonstrated that, at maximal exercise, this 
technique falls between Doppler echocardiography (5% variation) and the CO2 
rebreathing technique (12% variation).  
Despite the demonstrated utility of this method to assess the cardiac function of 
young people with CF during exercise, its application has been limited. Pianosi 
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and Pelech (1996) did employ this technique to characterise changes in ?̇? and 
SV in 18 patients spanning the spectrum of mild-to-moderate to severe CF 
disease (FEV1 28-80%) compared with 16 healthy matched control participants. 
Again, ?̇? was measured during 3 intensities of cycling, with a similar exercising 
?̇? reported for both the CF and healthy groups. However, interestingly, SV was 
reportedly lower in the CF group, particularly those with poorer lung function 
(FEV1 ≤ 55% predicted). Although further analyses demonstrated body 
compostion and being underweight was also known to play a role, SV was still 
lower than controls in well-nourished patients with CF with better pulmonay 
function (FEV1 56-80% predicted). Since this finding was consistent across the 
spectrum of pulmonary limitation, even in the absence of malnutrition, another 
mechanism(s) causing a suppressed exercising SV in CF is speculated. 
However, this observation requires further investigation during the range of 
exercise intensities up to V̇O2max. Furthermore, no studies have investigated 
cardiac indices using thoracic electrical bioimpedance cardiography 
simultaneously with both V̇O2 and NIRS-derived muscle oxygenation.  
 
2.8 Mechanistic basis of aerobic exercise (dys)function in CF  
Debate remains regarding the mechanism(s) responsible for impaired aerobic 
exercise function in patients with CF. Several reviews have been published on 
the topic in recent years (e.g., Hulzebos et al., 2015; Rand & Prasad, 2012; 
Williams et al., 2014). In a recent article concerning the utility and interpretation 
of CPET in CF, Urquart & Vendrusculo (2015) provided a suggested flow-chart 
to interpret CPET results in individuals with CF (Figure 2.20). However, this 
schematic outlined ventilatory limitation, deconditioning, submaximal effort and 
‘other’ as the possible factor(s) that may impair aerobic fitness status in this 
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patient group. There has been much debate regarding what these ‘other’ factors 
are.  
A review by Rand and Prasad (2012) outlined a number of factors that likely 
contribute to reduce aerobic exercise function in patients with CF, including 
pulmonary function, nutritional status, muscle (dys)function, genotype, habitual 
physical activity (and the impact gender has upon this), and psychosocial 
influences. Exercise capacity has also recently been associated with chronic 
infection and inflammatory status (van de Weert-van Leeuwen et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
Typically, the fundamental causes of exercise limitation in pulmonary disease 
are dyspnoea and leg discomfort (Ferrazza et al., 2009). Although progressive 
lung disease is the major manifestation of CF, the relationship between 
Figure 2.20. Suggested schematic of the interpretation of data from a 
cardiopulmonary exercise test in patients with cystic fibrosis. Image taken 
from Urquart & Vendrusculo (2015) with permission.  
  
131 
 
pulmonary function and peak exercise performance is weak (e.g., Klijn et al., 
2003; Shah et al., 1988) and, as previously outlined, pulmonary dysfunction and 
ventilatory abnormalities do not appear to principally modulate the altered 
aerobic exercise function characterising children and adolescents with mild-to-
moderate CF. In patients with mild-to-moderate pulmonary disease, non-
pulmonary factors such as low muscle mass, impaired skeletal muscle function, 
and centrally mediated O2 delivery, seem to predominate in limiting exercise 
capacity (Moorcroft et al., 2005; Regnis et al., 1996).  
 
2.8.1 Genotype 
It is not clear whether genotype per se plays a role in the extent of exercise 
(dys)function in young patients with CF. There is evidence supporting a 
significant relationship between the class of the second CFTR mutation and 
aerobic capacity, anaerobic power and BMI in adolescent patients (~11-17 y) 
with CF who were heterozygous for the F508del mutation (Selvadurai et al., 
2002). Selvadurai et al. (2002) also reported that a second CFTR mutation 
belonging to either class I or II was associated with reduced aerobic fitness 
status, anaerobic power and a lower BMI and SS. Conversely, class III, IV and 
V mutations were associated with higher levels of aerobic fitness, anaerobic 
power, an increased BMI and less severe disease. Although Selvadurai et al. 
(2002) observed no significant relationship between pulmonary function and 
genotype, a more recent study (McBride et al., 2010) observed relationships 
between reduced pulmonary function and malnutrition and exercise 
performance, but no relationship with F508del status.  
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2.8.2 Ventilatory Function 
Although impaired aerobic fitness in adults with CF appears to be multifactorial, 
V̇O2peak has been associated with the magnitude of the ventilatory response 
during exercise (Pastré et al., 2014). Specifically, in patients with severe airway 
obstruction (FEV1 < 50% predicted), multivariate analysis revealed FEV1 to be a 
significant predictor of exercise capacity, whereas V̇ E/ V̇ CO2 ratio at peak 
exercise was the major determinant of exercise limitation in patients with mild-
to-moderate disease (FEV1 > 50% of predicted).  
High ventilatory dead space ratio (VD/VT) values during exercise have also been 
reported in patients with CF (Bongers et al., 2014; Cerney et al., 1982; Coates 
et al., 1988; Thin et al., 2004; Wilkens et al., 2010). This, in combination with 
the trend for higher PETCO2 in patients with CF, indicates abnormal alveolar 
dead space ventilation (Wilkens et al., 2010), which might explain the higher V̇E 
values at rest and during submaximal exercise that have been reported in 
patients with mild-to-moderate CF disease.  
Prevalence of dynamic hyperinflation in adults with mild-to-moderate CF is high 
and is associated with poorer pulmonary function and exercise tolerance, and 
increased exertional dyspnoea (Stevens et al., 2013). Due to continuous airflow 
obstruction, as reflected by a decreased FEV1 and dynamic hyperinflation, 
adolescents with CF have been found to develop a rapid, shallow breathing 
pattern at rest (Hart et al., 2002) and during exercise (Keochkerian et al., 2005). 
This can be accompanied with a decreased ventilatory capacity at V̇ O2peak 
(Keochkerian et al., 2008). This exaggerated ventilatory response with a rapid 
shallow breathing pattern at rest (Hart et al., 2002) and during exercise 
(Keochkerian et al., 2008) in adolescents with mild-to-moderate CF could be 
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due to increased V̇CO2 increasing ventilation during exercise. However, two 
recent studies investigating young patients with milder CF disease did not 
observe any differences in the ventilatory response and/or this rapid shallow 
breathing pattern during exercise (Borel et al., 2014; Bongers et al., 2014). 
Although there is some evidence that children and adolescents with static 
hyperinflation at rest (residual volume to total lung capacity ratio > 30%) seem 
to be more prone to a ventilatory limitation during exercise (Sovtic et al., 2013; 
Werkman et al., 2011). Contrasting data has shown that the presence of static 
hyperinflation in adolescents with CF does not strongly influence ventilatory 
constraints during exercise and that static hyperinflation is only a slightly 
stronger predictor of Wpeak and V̇O2peak than airflow obstruction (Werkman et al., 
2011).    
Furthermore, Bongers et al. (2014) reported no differences in the breathing 
pattern of young patients with mild CF (FEV1 78.6 ± 17.3% of predicted) 
compared with healthy controls (14.3 ± 1.4 y) during a maximal CPET. 
However, they did observe increased V̇E at rest and a trend towards lower V̇E 
values at maximal exercise. The estimated VD/VT ratio and V̇E/work rate ratio 
were also significantly elevated throughout CPET. Although this increased 
V̇E/work rate implies an exaggerated ventilatory response, Bongers et al. (2014) 
importantly documented that this ventilatory response was adequate for CO2 
exhalation in paediatric patients with mild-to-moderate CF. This was inferred 
from a similar V̇ E/ V̇ CO2-slope, increased RER at submaximal exercise 
intensities, and the ability to maintain PETCO2 values within normal ranges 
throughout the range of exercise intensities that span an exhaustive CPET.  
  
134 
 
Although Hart et al. (2002) and Keochkerian et al. (2008) reported abnormal 
breathing pattern in patients with relatively low pulmonary function, the recent 
work in paediatric patients with milder airway obstruction (Borel et al., 2014; 
Bongers et al., 2014) suggests that signs of pulmonary insufficiency do not 
typically characterise children and adolescents with mild CF disease. Although 
the ventilatory response in young patients with mild-to-moderate CF appears to 
be adequate, patients still present with significantly reduced V̇ O2peak (e.g., 
Almajed & Lands, 2012; Bongers et al., 2014; Rand & Prasad, 2012), a 
reduction which reportedly falls approximately 5–8% per year (Pianosi et al., 
2005). As such, understanding the other factors that impair aerobic exercise 
function in this patient group is important.  
 
2.8.3 Cardiac Function 
From a central perspective, early studies indicate impaired cardiac function 
(Benson et al., 1984; Ionescu et al., 2001; Marcotte et al., 1986; Pianosi & 
Pelech, 1996). More recently, an inability to augment SV during exercise has 
also been reported in CF (Rosenthal et al., 2009), which is likely to reduce 
central O2 delivery. Early research suggested that a decreased SV in 
malnourished individuals with CF was possibly caused by both right and left 
ventricular dysfunction during stress (Marcotte et al., 1986), without clinical 
signs or symptoms (Benson et al., 1984). However, this SV was indirectly 
measured using the Fick equation, which cannot clearly differentiate between 
right or left ventricular dysfunction.  
Further research has sought to characterise ventricular function in this patient 
group. Of the earlier research, CF patients with normal left ventricular ejection 
fraction at rest showed compromised ejection fraction during exercise (Benson 
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et al., 1984; Chipps et al., 1979). Although earlier suggestions indicated that left 
ventricular dysfunction appears to be rare in CF, even in the most severe 
pulmonary disease (Fraser et al., 1999; Hirschfield et al., 1979; Panidis et al., 
1985; Vizza et al., 1998), there was some evidence of increased right 
ventricular wall thickness and dimensions and abnormal systolic time intervals 
(Gewitz et al., 1977; Hirschfield et al., 1979; Rosenthal et al., 1976), with post-
mortem data reporting right ventricular hypertrophy in 70% of the children with 
CF in a study by Marcotte and colleagues (1986). However, since imaging the 
right hand side of the heart presents a greater challenge, much of the research 
to date has focused on left ventricular function. 
Furthermore, an abnormal right ventricular ejection fraction has been reported 
using radionuclide angiography (Chipps et al., 1979) and others have shown 
marked right ventricular dilation and flattening or compression of the ventricular 
septum in the majority of patients with advanced CF and clinical evidence of 
right-sided heart failure (Jacobstein et al., 1981). More recently, the presence of 
significant right ventricular systolic and diastolic dysfunction in the setting of 
consistent tachycardia and increased ?̇? was evidenced in 103 UK based adults 
with severe CF disease, using two-dimensional and Doppler echocardiography 
(Florea et al., 2000) and, again, no specific left ventricular abnormalities were 
detected. Decreased septal and lateral strain rates have also been observed in 
patients with CF and were found to negatively correlate with the severity of 
pulmonary impairment (Labombarda et al., 2011). 
However, it has been suggested that abnormal right ventricular ejection fraction 
is only found in patients with severe CF disease (Matthay et al., 1980) and that 
right and left ventricular systolic function are well preserved in patients with 
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moderately severe CF (Florea et al., 2000; Panidis et al., 1985). Reports that 
right-ventricular abnormalities in CF may be caused by pulmonary hypertension 
offer some support to this (Eckles et al., 2003; Ionescu et al., 2001; Ozcelik et 
al., 2013). There is also evidence that in adults with severe but stable CF, left 
and right ventricular function is well maintained in the absence of significant 
coronary artery disease (Fraser et al., 1999). However, pulmonary hypertension 
develops in a significant proportion of older patients and is strongly related to O2 
status, independent of pulmonary function; and subclinical pulmonary 
hypertension is associated with increased mortality (Fraser et al., 1999). It has 
been suggested that right ventricular hypertrophy may be a precursor to 
ventricular failure in CF; however this appears to be delayed until the terminal 
stages of the condition.  
Few studies to date have documented the cardiac (dys)function of patients with 
CF during exercise. Pianosi and Pelech (1996) measured ?̇? using the indirect 
Fick method with blood sampling in patients with CF (FEV1 28-80% predicted) 
compared with healthy controls, during three intensities of cycling exercise. This 
study documented that patients with mild-to-moderate CF presented with a 
significantly lower SV, particularly those with poorer pulmonary function (FEV1 ≤ 
55% predicted). However, the CF group were still able to maintain adequate ?̇? 
during low-to-moderate intensity exercise, through a compensatory increase in 
HR above that of their healthy peers. However, there was an effect of body 
weight and malnourishment on SV, although well-nourished patients with poor 
pulmonary function also had a reduced SV. As such, there is a need to examine 
the scaling of SV data, normalising for body size using BSA or FFM, and 
whether exercising differences are still evident. Several other factors have been 
proposed to contribute to changes in ?̇?  in CF, including training status, 
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elevations in pulmonary vascular resistance caused by dynamic hyperinflation 
during exercise (Wright et al., 1983), reduction in the size of the pulmonary bed 
because of increased arteriolar wall thickness and reduced arterial density 
(Ryland & Reid, 1975), and myocardial fibrosis (Oppenheimer & Esterly, 1973). 
Since there may be some issues with the indirect Fick method in this patient 
group (Pianosi & Hochman, 1996), alternative assessment methods such as 
thoracic bioimpedance cardiography warrant further investigation. 
Massin et al. (2000) investigated the HR kinetics of 20 severely ill patients with 
CF (10 male, 5-28 y, FEV1 < 55% predicted) during PBRS exercise. Extending 
the observations by Pianosi et al. (1996), Massin and colleagues (2000) 
reported slower HR kinetics in severely ill adults with CF compared with healthy 
matched controls, which were attributed to an earlier occurrence of vagal 
withdrawal during low exercise intensities in CF, with significantly impaired SV. 
However, in the healthier patients, a higher HR was observed, which concurs 
with the findings by Pianosi and Pelech (1996).  
More recently, reduced exercising SV has also been inferred in patients with CF 
using respiratory mass spectroscopy (Rosenthal et al., 2009). Whilst it has been 
proposed that patients with CF can achieve apparently “normal” ?̇?  in the 
presence of a lower exercising SV, through elevated HR (Ionescu et al., 2001; 
Lands et al., 1992), more recent findings suggest that this may only be viable at 
lower intensities of exercise. Rosenthal et al. (2009) documented a reduced (~ 
24%) estimated SV at maximal exercise in young patients with CF, although this 
was coupled with a similar HR response to healthy individuals.  
Due to the presence of pulmonary disease, it is not clear whether these 
observed changes in ventricular function are simply the result of chronic 
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pulmonary dysfunction, or are a direct impact of CFTR dysfunction in the heart 
itself. However, CFTR has been found in ventricular myocytes of various 
mammalian species, including mice, rats, swine, simians, and humans (Duan et 
al., 1999; Gao et al., 2007; Tilly et al., 1996; Warth et al., 1996). CFTR may also 
play a role in the resting membrane potential and regulating the action potential 
duration, as well as minimising the depolarisation effect of Ca2+ entry upon β–
adrenergic stimulation (Duan, 2013). An ex vivo study on isolated perfused 
hearts of CFTR-knockout mice also suggests that CFTR is involved in 
mediating ischemic preconditioning (Chen et al., 2004). Additionally, CFTR was 
found to be down-regulated in patients with heart failure (Solbach et al., 2008). 
In a recent study on isolated neonatal myocytes, Sellers et al. (2010) observed 
decreased contraction rate and increased Ca2+ uptake via the L-type Ca2+ 
channels in the presence of a CFTR inhibitor. Furthermore, increased 
ventricular pressure and decreased contractile reserve were observed in 
response to β–adrenergic stimulation in adult CFTR knockout mice (Sellers et 
al., 2013). Furthermore, changes in myocardial wall thickness and left 
ventricular chamber size have also been documented (Sellers et al., 2013). 
However, it was unclear whether these changes can be directly attributed to 
altered myocyte contractility due to CFTR disruption in the myocytes, or 
whether these changes in cardiac function are due to systemic loss of CFTR 
and are secondary to CF complications.   
To investigate this question further, Jiang et al. (2015) recently investigated 
cardiac function of mice with cardiomyocyte-specific or global knockout of 
CFTR, both at rest and under β–stimulation by MRI in vivo, in addition to in vitro 
measures of myocyte contractility and Ca2+ transients. This study demonstrated 
that CFTR dysfunction, as evident in CF, leads to increased myocardial 
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contractility at rest, which may trigger myocardial remodelling in patients with 
CF, which is independent of pulmonary disease. Despite these observed in vivo 
changes, there were no differences in myocyte contractility and Ca2+ transients. 
Sellers and colleagues (2010) previously reported increased peak left 
ventricular pressure and pressure rate at both systole and diastole in CF mice, 
also suggesting increased myocardial contractility in vivo (Warth et al., 1996). 
Furthermore, they also observed decreased aortic diameter and increased 
aortic stiffness by echocardiography, which was further supported by Jiang et 
al. (2015). The observed increase in myocardial contractility in vivo can be an 
adaptation to the increased afterload in order to maintain normal ?̇?. However, 
the mechanisms leading to aortic constriction and stiffness need further 
investigation.  
Jiang et al. (2015) demonstrated that CFTR disruption leads to increased left-
ventricular regional function at baseline, as well as slightly attenuated response 
to β–adrenergic stimulation in young CFTR knockout mice, in the absence of 
pulmonary infection and exacerbation. These observations show that 
chronically elevated myocardial contractility at baseline may render the hearts 
of patients with CF more susceptible to untoward remodelling processes that 
will eventually lead to abnormal left ventricular function that is independent of 
pulmonary disease, which is supported by the recent observations of early signs 
of cardiac disease in relatively healthy, young patients with CF (Giacchi et al., 
2015).  
In a recent study utilising Doppler-echocardiography in adult (n  = CF) and 
paediatric (n  = 30) patients with CF, Giacchi et al. (2015) demonstrated that 
early signs of potential heart impairment, represented by an increase of 
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pulmonary blood pressure, are already evidence in young people with CF. 
Furthermore, in adults with CF, the systolic function of the right ventricle may 
also be impaired. The authors suggested that these cardiac abnormalities may 
progressively develop as a consequence of chronic inflammation, caused by the 
degeneration of pulmonary function. 
 
2.8.4 Skeletal Muscle Function 
Compared with healthy controls, reduced peripheral muscle strength has been 
reported in people with CF (de Meer et al., 1999; Dunnink et al., 2009; Hussey 
et al., 2002; Sahlberg et al, 2005; Troosters et al., 2009; Vallier et al., 2011), 
which has been associated with BMI, pulmonary function and inflammatory 
status (Troosters et al., 2009). However this does not appear to be an 
independent predictor of respiratory or peripheral muscle strength (Dufresne et 
al., 2009). Furthermore, more recently, it was demonstrated that reductions in 
peripheral muscle strength were still present when data was normalised to lean 
muscle mass (de Meer et al., 1999; Hussey et al., 2002), found to be of 
contractile origin (Vallier et al., 2011), suggesting that skeletal muscle quality 
(e.g. the intrinsic force-generating ability) is altered in CF.  
From a respiratory muscle perspective, inspiratory muscle strength has been 
found to be well preserved (Enright et al., 2007) or even higher (Dunnink et al., 
2009) in adults with CF compared with their healthy peers, potentially due to an 
increased work of breathing (Dunnink et al., 2009). There is evidence, however, 
that reduced FFM is related to a loss in inspiratory muscle strength (Enright et 
al., 2007) and some studies have reported reduced inspiratory muscle strength 
in CF (Keochkerian et al., 2005; Lands et al., 1992). Although inspiratory 
muscle endurance may be reduced in CF and has been associated with 
  
141 
 
dyspnoea, recent evidence suggests that inspiratory muscle strength is 
independent of maximal exercise capacity (Leroy et al., 2011).  
Moser et al. (2000) hypothesised that the exercise impairment in CF is 
principally due to a reduced overall muscle mass rather than an abnormality in 
muscle metabolism. However, reductions in V̇ O2peak in young CF patients 
compared with healthy controls could not solely be explained by a specific 
reduction in muscle size. Specifically, reductions in V̇O2peak were still evident 
when data was normalised to muscle CSA. Consequently, Moser et al. (2000) 
suggested that impaired O2 delivery and/or an intrinsic skeletal muscle 
abnormality may be responsible for impairing aerobic exercise function in CF. 
Whilst the potential mechanisms of altered cardiac function in this patient group 
are covered in section 2.7.3. Several studies have also proposed that the 
oxidative efficiency of skeletal muscle in individuals with CF may be reduced. 
The principle factors that could influence the efficiency of oxidative 
phosphorylation and, thus, the rise in pulmonary V̇O2 (and thereby mV̇O2) at the 
onset of exercise include the transport and delivery of O2 to the mitochondria, 
the provision of necessary substrate into the electron transfer chain and/or 
feedback control linked to the rise in adenosine diphosphate (ADP) and Pi 
released from ATP hydrolysis at the myofibrils. Any of these mechanisms may 
delay the matching of oxidative ATP resynthesis to the rate of ATP turnover 
occurring with the myocyte.   
An area of particular interest over recent years has been the capacity of CF 
skeletal muscle to extract and utilise O2. Furthermore there is some evidence to 
support impaired delivery of O2 in children and adolescents with CF, it has been 
hypothesised that patients would therefore present with a compensatory 
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increase in O2 extraction at the periphery (Ferreira et al., 2007). However, 
Rosenthal et al. (2009) observed no such response in a study that utilised 
respiratory mass spectroscopy. Although Rosenthal et al. (2009) could not 
determine the cause of impaired O2 extraction and/or utilisation in CF skeletal 
muscle, because no direct peripheral measurements were made, it was 
suggested that muscle metabolic issues resulting from chronic bronchial sepsis 
may contribute. However, further confirmation of this response is warranted 
because inferences at the skeletal muscle level were based upon indirect, 
interlinked mathematical calculations. Furthermore, although Shah et al. (1997) 
demonstrated faster HR recovery kinetics (73 ± 6 vs. 86 ± 8 s) and improved 
supramaximal exercise performance in patients with CF following supplemental 
O2 compared with room air, data from patients with less severe CF have 
reported that inhaling hyperoxic gas does not improve either V̇O2peak (Nixon et 
al., 1990) or V̇O2 kinetics (Kusenbach et al., 1999). 
Slower post-exercise muscle [PCr] recovery kinetics, measured using 31P-MRS, 
have recently been documented in the m. vastus lateralis of patients with CF 
(Wells et al., 2011). What was unique to the study by Wells and colleagues 
(2011) was that they sought to ascertain whether the metabolic abnormalities 
that reportedly characterise patients with CF are specific to this condition or, 
rather, are a consequence of chronic respiratory disease in general. 
Consequently, they investigated twenty patients with CF (FEV1: 92.9 ± 12.7% 
predicted, age 15.1 ± 1.5 y) and two age-, gender- and habitual activity-
matched control groups; healthy controls (FEV1 94.4 ± 6.6% predicted, age 15.2 
± 1.4 y) and a non-CF respiratory disease control group [primary ciliary 
dyskinesia (PCD); FEV1 91.8 ± 9.5% predicted, age 13.8 ± 2.3 y]. In line with 
earlier findings in the forearm muscle (de Meer et al., 1995), Wells et al. (2011) 
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reported abnormalities at rest (lower resting [ATP]) and during short bouts of 
high-intensity exercise (increased end-exercise pH) in patients with CF. 
Interestingly, this response was not observed in the respiratory disease control 
group or healthy controls, although both PCD and CF patient groups 
demonstrated slower [PCr] recovery time constants. This study therefore 
showed that whilst there are non-specific effects of chronic respiratory disease 
on skeletal muscle oxidative function in young people, there appear to be some 
CF-specific abnormalities of skeletal muscle metabolism.  
Wells and colleagues (2011) also characterised the efficiency of oxidative 
exercise function in the skeletal muscle of the forearm during exercise in 
patients with CF (n = 8, 12-17 y) compared with healthy individuals (8-36 y). 
Intracellular pH and concentrations of phosphate compounds were measured 
during four steady states of submaximal exercise using 31P-MRS. This study 
reported that the efficiency of oxidative ATP synthesis of forearm muscle was 
19-25% lower in patients with CF compared with healthy controls. Although de 
Meer et al. (1995) concluded that an intrinsic role of CFTR to cause abnormal 
oxidative phosphorylation in CF skeletal muscle was unlikely, this protein has 
since been expressed within both murine (Fiedler et al., 1992) and human 
(Lamhonwah et al., 2010) skeletal muscle, as outlined in section 2.1, making a 
role conceivable (Lamhonwah et al. 2010).  
More recently, reduced local muscle oxidative capacity has also been inferred 
from NIRS-derived [HHb] recovery of m. vastus lateralis O2 consumption 
following 15 s of electrical stimulation and subsequent repeated transient 
arterial occlusions (Erickson et al., 2015). NIRS was used to measure the 
recovery rate of mV̇O2 after 15 s of electrical stimulation (4 Hz) and repeated 
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transient arterial occlusions. Maximal mV̇O2 was reduced in patients with CF 
(1.82 ± 0.4 L·min−1) compared with control subjects (2.13 ± 0.5 L·min−1, P = 
0.04). A significant inverse relationship between age and maximal mV̇O2 was 
observed in patients with CF (r = −0.676, p = 0.011) but not in control 
participants (r = −0.291, p = 0.274), indicating that patients with CF exhibit a 
reduction in skeletal muscle oxidative capacity compared with healthy controls. 
The authors concluded that this reduced skeletal muscle oxidative capacity is 
accelerated by age and may contribute to exercise (dys)function in patients with 
CF. 
More recently, Werkman et al. (2015) provided the first study that combined 
NIRS and 31P-MRS techniques to investigate skeletal muscle oxygenation and 
metabolism during exercise in 10 paediatric patients with CF with class I-III 
mutations (5 males, 13.8 ± 1.3 y, FEV1 92.8 ± 14.6% predicted) versus 10 
healthy controls (5 males, 13.7 ± 1.1 y, FEV1 90.3 ± 13.4% predicted). Using 
supine cycling exercise, with the upper body set to an approximately 40 degree 
angle, participants performed a step incremental (0.3 kg·min-1 for males and 0.2 
kg·min-1 for females) cycling test to exhaustion. However, contrary to previous 
suggestions, Werkman and colleagues did not observe a relationship between 
exercise capacity and skeletal muscle oxidative metabolism. More specifically, 
no significant differences in FFM normalised V̇O2peak were seen between CF and 
controls. Furthermore, no differences in 31P-MRS derived [PCr] recovery or 
[HHb] dynamics were observed, in contrast with previous suggestions (de Meer 
et al., 1995; Wells et al., 2011).  
It has been proposed that deficient sarcoplasmic reticulum CFTR Cl- channels 
(Lamhonwah et al., 2010) could perturb electrochemical gradient, leading to 
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Ca2+ homeostasis dysregulation which could alter excitation-contraction 
coupling. Since this may contribute to increase fatiguabiliy and reduce 
functional capacity in patients with CF, Gruet et al. (2015) recently sought to 
determine whether adult patients with mild-to-moderate CF present with altered 
skeletal muscle contractility and greater muscle fatigue during exercise. 
Patients performed quadriceps neuromuscular evaluation using single and 
paired femoral nerve magnetic stimulations and electromyographic (EMG) and 
mechanical parameters were measured during voluntary and magnetically-
evoked contractions at rest, during and after a fatiguing isometric task. 
Quadriceps muscle CSA was also determined using MRI. In contrast with 
previous suggestions, Gruet et al. (2015) observed similar skeletal muscle 
endurance and fatiguability in patients with CF and their healthy counterparts, 
which is in line with earlier reports (Vallier et al., 2011).  
As such, the precise cause(s) of an intramuscular impairment in skeletal muscle 
oxidative metabolism in people with CF requires further investigation, although 
several other factors have been proposed. Reduced antioxidant capacity, 
arising from systemic inflammation and/or oxidative damage, may lower 
mitochondrial efficiency (Wells et al., 2011). However, it may also be a 
consequence of the CFTR genetic mutation. As outlined in section 2.1, CFTR is 
expressed in skeletal muscle cells (Lamhonwah et al., 2010) and there are a 
number of structural and functional changes in the skeletal muscle of individuals 
with CF (de Meer et al., 1995; Wells et al., 2011; Lamhonwah et al., 2010). 
Furthermore, in vitro study of leucocyte mitochondria in patients with CF 
demonstrates that properties of complex I of the respiratory chain are 
significantly altered (Dechecci et al., 1988) and the absence of CFTR from 
skeletal muscle has been shown to dysregulate Ca2+ homeostasis, augment 
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inflammatory or atrophic gene expression signatures and increase diaphragm 
weakness (Divangahi et al., 2009).   
 
2.9 Summary  
 
Since the preservation of aerobic fitness and pulmonary function are important 
for the prognosis and QoL of patients with CF, it is important to understand the 
factors responsible for impairment. This chapter has critiqued current evidence 
regarding aerobic exercise (dys)function characterising children and 
adolescents with mild-to-moderate CF. However, it has highlighted a need to 
clarify the extent of impairment to the key parameters of aerobic exercise 
function in this patient group. For this to be possible, there is a need to first 
develop a valid and reproducible CPET protocol to study the physiological 
responses of young people with CF during exercise that spans the intensity 
domains, to the point of exhaustion. Chapter 2 has also identified the need for 
further research investigating the pulmonary V̇ O2 response during CWR 
exercise of different intensities, demarcated by the GET. According to the Fick 
principle, the rate of adjustment in V̇O2 is dictated by O2 delivery and utilisation 
mechanisms (Figure 2.6), however debate remains regarding the role of 
respiratory and cardiovascular (dys)function and/or intrinsic muscle 
abnormalities to impair the response in children and adolescents with CF. The 
body’s upper limit for V̇O2 is determined by the maximal ?̇?, arterial O2 content, 
fractional distribution of ?̇?  to the exercising muscles, and the ability of the 
skeletal muscle to extract O2 (Wasserman et al., 2004). Therefore simultaneous 
measurements at the central (cardiorespiratory) and peripheral (skeletal 
muscle) levels are needed to further understand the dynamic matching of O2 
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delivery-to-O2 utilisation in this patient group during exercise and how this 
modulates aerobic exercise (dys)function. There is therefore a need for 
research that utilises additional techniques available, such as NIRS and 
thoracic electrical bioimpedance cardiography.  
 
2.10  Thesis Objectives 
 Study 1 (Chapter 4) will develop a valid CPET protocol for use in 
paediatric patients with CF. Specifically it will 1) determine whether 
traditional criteria used to verify V̇O2max in children and adolescents 
with CF are valid and, 2) investigate the utility of Smax verification as 
an alternative method to confirm V̇O2max in children and adolescents 
with mild-to-moderate CF; 
 
 Study 2 (Chapter 5) will determine the reproducibity of the key 
parameters of aerobic exercise function derived from CPET in 
children and adolescents with mild-to-moderate CF over the short- 
(48 h) and clinically relevant medium-term (4-6 weeks); 
 
 Study 3 (Chapter 6) will investigate the influence of mild-to-moderate 
CF on aerobic exercise function during exhaustive ramp incremental 
cycling exercise. Specifically it will investigate 1) any impairment to 
key parameters of aerobic exercise function and 2) determine 
whether central and/or peripheral factor(s) modulate any changes in 
aerobic exercise function; 
 
 Study 4 (Chapter 7) will demonstrate the application of a valid and 
reproducible CPET protocol as an outcome tool within clinical 
  
148 
 
interventions. Specifically, it will investigate changes in aerobic 
exercise function during 12 weeks treatment with Ivacaftor using a 
case-based design; 
 
 Study 5 (Chapter 8) will investigate the influence of mild-to-moderate 
CF on aerobic exercise function during CWR exercise. Specifically, it 
will 1) determine any changes in the kinetics of pulmonary V̇O2 and 
skeletal muscle [HHb] at the onset of moderate and very heavy 
intensity cycling exercise and 2) determine the contribution of central 
and/or peripheral factor(s) to modulate the pulmonary V̇O2 kinetic 
response in children and adolescents with mild-to-moderate CF 
during moderate and very heavy cycling exercise.  
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CHAPTER THREE 
General Methods 
 
3.1 Scientific review and ethics approval  
All study protocols were assessed by an independent scientific reviewer from 
the Research and Development Unit at the Royal Devon and Exeter NHS 
Foundation Trust Hospital (RD&E) (Appendix A). Ethics approval for all work 
involving patients with CF was obtained from the Local NHS Research Ethics 
Committees (Appendices B, D, G-I) and experimental procedures for the 
healthy control participants in Chapter 6 were approved by the University of 
Exeter Sport and Health Sciences Ethics Committee (Appendix E).  
3.2 Funding 
All studies were supported by small grants obtained from the Research and 
Development department at the RD&E (Appendix C).  
3.3 Study Participants 
Children and adolescents (7-18 y) with CF were recruited from paediatric CF 
outpatient clinics at the RD&E. The lower age limit was raised to 10 y of age for 
Chapter 8 to ensure that participants could adhere to the requirements of the 
investigation. Prior to any invitation to participate, patients’ suitability was 
assessed by their primary respiratory consultant and the research team using 
clinical information extracted from routine hospital appointments. Suitable 
patients were then invited to participate, via their parent(s)/guardian(s). The 
method of recruitment was voluntary participation through the RD&E. All 
procedures were explained to patients and their parent(s)/guardian(s) and 
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supportive written information detailing the exact procedures of each respective 
study were provided. Potential participants were then contacted 48 hours later 
via telephone. All participants were informed that voluntary withdrawal was 
possible at any time. For Chapters 6 and 8, healthy age- and gender-matched 
controls were recruited from the local area. No group presented with any 
contraindications to exhaustive exercise. 
All participants and their parent(s)/guardian(s) were provided with supportive 
written documentation in appropriate language (Appendix D), which was 
substantiated with verbal explanation of the protocol during the familiarisation 
session. Fully informed written assent (participants < 16 y) and consent was 
obtained from participants and their parent(s)/guardian(s), respectively 
(Appendices G-I). Patients between the ages of 16-18 y were deemed capable 
of providing consent and, therefore, asked to provide consent in addition to their 
parent(s)/guardian(s).   
3.4   Participant inclusion and exclusion criteria 
3.4.1  Cystic fibrosis patients 
Males and females diagnosed with CF were invited to participate if their 
pulmonary function and disease profile were considered stable. Specifically, 
pulmonary function (FEV1) was within 10% of their best in the preceding 2 
months and there was no increase in other clinical symptoms or weight loss in 
the 2 weeks prior to testing. Diagnosis of CF was based on clinical features and 
was supported by an abnormal sweat test (sweat Cl- > 60 mmol·L-1 > 100 mg 
sweat) and, where possible, diagnostic genotyping. All CF maintenance 
medications and therapies were continued throughout each study and were 
documented. It was also desirable that patients were regularly participating in 
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physical activity, as recommended as part of the standard clinical care 
guidelines, although no formal assessment of physical activity status was made 
due to adherence issues. Participants were also required to be able to 
understand and cooperate with each study protocol. Patients were excluded if 
they had any non-pulmonary conditions that may impair exercise ability, such as 
musculoskeletal disorders and cardiovascular disease or if they were unable to 
understand or cooperate with the study protocol. Exclusion at familiarisation 
could also occur due to the onset of an acute infection, issues regarding 
understanding or cooperating with the study protocol, or the participant and/or 
their parent(s)/guardian(s) no longer wished to participate.  
The clinical profile and disease severity of the young patients with CF were 
recorded upon enrolment into each experimental study. Information included CF 
genotype, resting SpO2, BMI, physical activity level (none, school sports, or 
extracurricular), physical chest examination findings (evidence of clubbing, 
crackling, wheeze, or hyperinflation), nutritional status and pancreatic 
sufficiency, chest radiographic findings, pathogens in sputum in the last year 
(any evidence of Pseudomonas Aeruginosa in accordance with the Leeds 
criteria (Lee et al., 2003), or other regular pathogens), smoking, medical 
imaging and DEXA, assessment of liver function and glycaemic control, current 
treatments and IVABs in the past year, renal function, bone chemistry, dietetic 
review and any airway clearance methods routinely used. The SS was also 
used to score general disease profile, scoring four aspects of the disease profile 
(general activity, physical examination, nutritional status, and chest radiographic 
findings), with a total of 100 points representing a perfect score of health. The 
Northern Score provided evidence of radiographic chest findings, with a 
maximum score of 20 being the most severe.  
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3.4.2  Healthy control participants 
Healthy males and females were recruited as matched controls for each 
participant with CF. In addition to being age- and gender-matched, the control 
group were required to have no diagnosis of any respiratory condition or any 
non-pulmonary condition that may impair exercise ability, no contraindications 
to performing exhaustive exercise, be regularly participating in physical activity 
and be able to understand and cooperate with the study protocol. Healthy 
controls were excluded if they had any pulmonary conditions, any non-
pulmonary conditions that may impair exercise ability, such as musculoskeletal 
disorders (active arthritis, joint or muscle disease) and cardiovascular disease 
(congenital heart disease or cardiomyopathy), they presented with co-
morbidities to performing they required exercise, were unable to understand or 
cooperate with the study protocol due to learning difficulties or otherwise. 
Controls were also excuded at familiarisation if there was the onset of any 
infection, any of the above exclusion criteria were met, or the child and/or their 
parent/guardian was not willing to participate any further.   
 
3.5  Age 
Decimal age was calculated, to the nearest 0.1 year, as the difference between 
the date of birth and the date of the first testing session for each experimental 
study.  
3.6  Pubertal maturity 
Pubertal maturity was measured in accordance with the secondary sex 
characteristics outlined by Tanner (1962), with stage 1 representing pre-
pubertal, stages 2, 3 and 4 circum-pubertal, and stage 5 post-pubertal. 
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Drawings of male and female pubic hair development (Morris & Udry, 1980) 
made from photographs by Tanner (1975) were used, in conjunction with a 
written description for each of the 5 stages of male and female pubic hair 
development underneath each drawing. This measure was self-assessed at 
home following the last visit for each respective investigation (Appendix J) and 
was returned to the research team in a sealed envelope. This method has been 
shown to be valid and reproducible (Chan et al., 2008; Morris & Udry, 1980; 
Taylor et al., 2001; Norris & Richter, 2005; Schmitz et al., 2004).  
3.7 Anthropometry  
All anthropometric measurements were made during the familiarisation session 
for each study. Measurements were taken by the same researcher throughout, 
with participants wearing shorts and t-shirt/vest and with their footwear 
removed.  
3.7.1  Body mass 
Body mass was measured to the nearest 0.1 kg using electronic weighing 
scales (Seca 220; Vogel & Halke, Hamburg, Germany), with footwear removed.  
3.7.2  Stature 
Stature was measured to the nearest 1 cm using a stadiometer (Seca 220; 
Vogel & Halke, Hamburg, Germany). With footwear removed, participants were 
instructed to stand upright with their heels against the stadiometer and feet 
together. Gentle pressure was applied to the mastoid process, whilst 
participants were instructed to stand up straight and look forward.  
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3.7.3  Body mass index 
Body mass index was calculated using the following equation:  
BMI = body mass (kg) / stature (m2)                               Equation 3.1. 
 
3.7.4  Skinfold measurements 
Skinfold measurements were taken on the right hand side of the body using 
spring loaded callipers (Harpenden; British Indicators, Burgess Hill, UK) with 
another adult present. Triplicate measurements were taken at the bicep, tricep, 
subscapular and suprailiac regions. Skinfolds were held between the thumb and 
forefinger for ~ 2 s prior to the measurement being recorded, to the nearest 0.1 
mm. Repeat measurements were separated by at least 1 min, to minimise 
skinfold compression. The median or triplicate measures at each site was then 
calculated and used to determine the sum of skinfolds (SSkF). Measurements 
were taken in accordance with recommended guidelines (Eston et al., 2009).  
The measurements obtained at the tricep and subscapular regions were then 
used to determine FFM using pubertal stage and gender specific equations 
(Slaughter et al., 1988; see Equations 3.2-3.6). This method has been shown to 
be suitable for use in paediatric patients with CF (Wells et al., 2008): 
Body fat percentage for pre-pubertal males: 
Body fat percentage = 1.21 (triceps + subscapular) – 0.008 (triceps + 
subscapular)2 – 1.7 
 
Equation 3.2 
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Body fat percentage for circum-pubertal males: 
Body fat percentage = 1.21 (triceps + subscapular) – 0.008 (triceps + 
subscapular)2 – 3.4 
 
Equation 3.3 
 
Body fat percentage for post-pubertal males: 
Body fat percentage = 1.21 (triceps + subscapular) – 0.008 (triceps + 
subscapular)2 – 5.5 
 
Equation 3.4 
 
Body fat percentage for all females: 
Body fat percentage = 1.33 (triceps + subscapular) – 0.013 (triceps + 
subscapular)2 – 2.5 
 
Equation 3.5 
 
FFM was then calculated as follows;  
 
FFM = body mass – (percentage body fat x body mass) / 100 
 
Equation 3.6 
                                  
3.8   Pulmonary function 
Forced vital capacity (FVC), FEV1 and peak expiratory flow (PEF) were 
assessed using flow-volume loop spirometry (Micromedical Microloop 3535, 
Numed, Sheffield, UK), with participants seated. All spirometric pulmonary 
function assessments were performed in line with recommendations by the 
British Thoracic Society (BTS, 1994) and with verbal encouragement provided 
during all manoeuvres. The best of three consistent (< 5% variability) 
exhalations was documented and expressed as a percentage of predicted using 
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appropriate reference data for young Caucasians (Stanojevic et al., 2009). 
Values were deemed technically and clinically ‘acceptable’ if the reported 
values did not exceed the next greatest by > 5%.  
Participants were instructed to place their lips tightly around the antibacterial 
mouthpiece. Following three initial resting breaths, they were directed to 
breathe in as deeply as possible, and then to ‘blow out’ into the equipment as 
hard and as fast as possible until no further air could be exhaled. A minimum of 
three ‘acceptable’ manoeuvres were performed, with a minimum rest period of 
30 s between attempts, to minimise respiratory fatigue.  
3.9  Infection control and patient safety during exercise  
In line with standard clinical practice, segregation was ensured during 
recruitment discussions at outpatient clinics and throughout any subsequent 
visits relating to all research studies presented herein. All equipment was 
cleaned using appropriate bacteriocidal wipes and sterilised following each use 
and the testing environment was cleaned following each participant and the 
room ventilated for > 4 hours.  
Participants were monitored throughout exercise for any significant 
development of symptoms, such as severe discomfort or dyspnoea. Fingertip 
SpO2 was also monitored on a beat-by-beat basis via pulse oximetery (NONIN, 
Avant 4000, NONIN Medical Inc.), at rest, throughout exercise and recovery. 
Supplemental O2 was available if cases of severe hypoxemia presented, 
however this was not warranted in any of the presented 6 investigations. 
Medical personnel were aware when testing was taking place and could be 
contacted in the event of any adverse symptoms during or following exercise. If 
patients did experience severe or persistent symptoms during testing, a 
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respiratory clinician would have provided a medical examination, however this 
was not needed during any of the testing. 
 
3.10   Familiarisation session 
All participants were required to attend a preliminary familiarisation visit prior to 
involvement in the research studies. The aim of this session was to obtain fully 
informed written consent and assent (depending on participant’s age), to 
familiarise participants and their parents/guardians with the equipment, 
experimental procedures and the testing environment. For Chapter 8, this visit 
was also used to obtain information necessary to set the exercise intensities for 
the subsequent visits.  
During this visit, the principal investigator talked through the information sheet 
and study protocol again, to ensure that all parties were clear about the study 
requirements. Following this, consent to participate was obtained. 
Anthropometric data (see section 3.7) and resting pulmonary function (see 
section 3.8) were then recorded. Next, participants were familiarised with 
exercising on a cycle ergometer and maintaining a constant cadence both 
against a constant and incremental work rate. Appropriate adjustments were 
made to the ergometer seat, handlebar and pedal cranks for each participant 
and recorded for subsequent visits (see section 3.11).  
3.11  Exercise testing 
All testing of patients with CF was conducted within temporary exercise 
laboratories established at the RD&E. Healthy age- and gender matched control 
participants were tested at the Children’s Health and Exercise Research Centre 
at the University of Exeter. All repeat testing in the same participants was 
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performed at the same time of day (± 2 h). Participants were instructed to arrive 
in a rested and hydrated state, > 2 h postprandial and having refrained from 
consuming caffeine for > 2 h.  
 
3.12   Maximal cardiopulmonary exercise testing 
3.12.1  Equipment  
All exercise testing was performed on a cycle ergometer (Lode Excalibur or 
Lode Corival, Groningen, The Netherlands; Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
3.12.2  Protocol 
In all studies comprising this thesis, CPET involved a combined ramp 
incremental and supramaximal test to exhaustion (see Figure 3.2). For the initial 
ramp protocol, the ramp rate (10-25 W·min-1) was individually targeted to each 
participant to produce test durations of 8-12 min, based on information 
concerning the participant’s physical activity and clinical status and their 
familisation on the cycle ergometer. Following a 3 min warm-up, cycling at 20 
Figure 3.1. The equipment used during all exercise testing which comprises 
this thesis.  Consent was provided to include these photographs within this 
thesis. (Consent for photography and publication was obtained from all of 
these participants and their parent(s/guardian(s)).  
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W, work rate was increased. A cadence of 70-80 rpm was maintained 
throughout. Volitional exhaustion was defined as a drop in cadence ≥ 10 rpm for 
5 consecutive seconds, despite strong verbal encouragement. Five min active 
recovery, cycling at 20 W, and then 10 min passive seated recovery then 
followed. The Smax test was then performed. Smax consisted of 3 min warm-up, 
cycling at 20 W, followed by a ‘step’ transition to a CWR equivalent to 110% 
Wpeak output achieved during the preceding ramp test. Upon exhaustion from 
the Smax, 5 min active recovery (20 W) was undertaken (Figure 3.2).  
 
 
 
 
 
 
 
 
 
 
 
 
3.13   CWR exercise testing 
3.13.1  Equipment 
In Chapter 8, CWR exercise was performed on the same equipment as 
previously outlined for CPET.   
 
 
 
Figure 3.2. An example pulmonary oxygen uptake ( V̇O2) response during the 
combined ramp incremental and supramaximal cardiopulmonary exercise testing 
protocol used to determine V̇O2max.      
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3.13.2  CWR Testing Protocol 
For Chapter 8, participants attended the laboratory on four subsequent 
occasions at a similar time of day to complete ‘step’ change CWR exercise tests 
within the MOD and VH intensity domains (Figure 3.3). All CWR tests consisted 
of 6 min of pedalling at 10 W, followed by an instantaneous transition in power 
output, intended to elicit a V̇O2 amplitude corresponding to 90% of the GET and 
Δ60% (60% of the difference between the GET and V̇O2max) for MOD and VH 
intensity exercise, respectively, following correction for the V̇O2 lag time (Whipp 
et al., 1981).  
 
This equated to MOD work rates of 58 ± 24 W and 73 ± 35 W for CF and CON, 
respectively. During VH exercise CF and CON worked at 121 ± 43 W vs. 150 ± 
64 W, respectively. A cadence within the range of 70-80 rpm was maintained 
during all exercise and MOD and VH exercise. Part 1 and part 2 were separated 
by 30 min seated and 10 min active recovery (total 40 min), in order to remove 
any priming influence of the preceding exercise. Although at least 45 min is 
reportedly needed in healthy adults to eliminate a priming effect of prior heavy 
exercise on the subsequent V̇O2 response (Burnley et al., 2006), 40 min was the 
90% GET 90% GET 90% GET 
∆60% 
4  4  6  6  6
  
6  
30  
MOD VH MOD MOD 
6  6  6  Active  
reecovery 
 
Figure 3.3. Schematic illustration of the exercise testing protocol. 
MOD, moderate-intensity exercise (90% GET); VH, very heavy-
intensity exercise (∆60%).    
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cut-off time due to time restraints on the testing facility and patient time. Each 
visit was separated by 48-72 hours.   
 
Isolating and characterising an acceptable estimation of m V̇ O2 kinetics is 
complicated in young people, due to the inherently low pulmonary V̇ O2 
amplitude and larger inter-breath fluctuations, resulting in V̇O2 dynamics with 
low signal-to-noise properties (Armstrong & Barker, 2009; Potter et al., 1999). 
Previous work in healthy young people has demonstrated that averaging 4-10 
step transitions can yield 95% confidence intervals in the phase II V̇O2 τ within 
approximately 5% (Barker et al., 2008; Fawkner et al., 2002). Therefore, in 
Chapter 8 four transitions were completed for all conditions to improve the 
signal-to-noise.  
 
3.14    Measurement of pulmonary gas exchange  
A metabolic gas analyser (Metalyzer 3B Cortex, Biophysik, Leipzig, Germany; 
Figure 3.1) was used to measure V̇ O2, V̇ CO2, V̇ E, V̇ E/ V̇ O2 and V̇ E/ V̇ CO2, 
respectively. Prior to each test, the metabolic cart was calibrated using gases of 
known concentration (15.0% O2 and 5.0% CO2) and a 3 L calibration syringe 
(Hans Rudolph, Kansas City, MO) was used to calibrate the turbine volume 
transducer. Furthermore, prior to each test, the analyser recorded ambient air 
temperature and pressure. Breath-by-breath changes in pulmonary gas 
exchange and ventilation were measured at rest and throughout exercise. It is 
acknowledged that there are differences between all commercially available gas 
analysis systems in the method of capture and measurements process. As 
such, the same system was used throughout all testing. Furthermore, when 
appropriately calibrated the accuracy of measuring volume and gas fractions 
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are 2% and 0.1%, respectively and the reproducibility of the Metalyzer 3B 
system has previously been documented in healthy subjects (Meyer et al., 
2001), with a marginally smaller variability than the Metamax 3B system. Intra-
class correlation coefficients of 0.98, 0.98 and 0.97 have been documented for 
V̇O2, V̇CO2 and V̇E, respectively, when using the Metalyser 3B.  
 
3.15    Measurement of cardiac parameters 
Cardiac parameters were non-invasively measured on a beat-by-beat basis 
using thoracic bioelectric impedance cardiography (PhysioFlow, PF-05, 
Manatec Biomedical, Paris, France; Figure 3.1). This technique uses a high-
frequency (75 kHz) and low-magnitude (1.8 mA) current across the thorax, to 
enable changes in thoracic impedance during the cardiac cycle to be recorded. 
?̇? was determined in accordance with Equation 3.7:  
?̇? = fc   x   SVi   x   BSA                        Equation 3.7. 
where fc was HR based on the measurement of the R-R interval as determined 
by the ECG first derivative dECG/dt, BSA was body surface area (BSA) 
calculated using the Haycock equation (Haycock et al., 1978; see Equation 3.8) 
and SVi was the stroke volume index (SVI).  
BSA = 0.024265   x   body mass0.5378   x   stature 0.3964         Equation 3.8. 
To establish the thoracic impedance signal, electrodes (Blue Sensor R; Ambu, 
Ballerup, Denmark) were positioned on the forehead and base of the neck 
above the supraclavicular fossa, and two were positioned on the xiphoid 
process. Another set of two electrodes was used to determine a single 
electrocardiograph signal at the V1 and V6 positions. This pattern of electrode 
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placement adheres to recommendations for paediatric practice (Welsman et al., 
2005). All skin sites were cleaned prior to electrode contact.  
 
Prior to testing and following 10 min of seated rest, the device was 
autocalibrated in accordance with the manufacturer’s guidelines. Blood 
pressure was determined manually using a sphygmomanometer and 
stethoscope with the participant seated and relaxed on the cycle ergometer. 
The participant’s mean resting blood pressure, age, stature and body mass 
were then entered into the software. Autocalibration then established the basic 
impedance waveforms over 30 cardiac cycles. This technique has previously 
been validated in children with CF (Pianosi et al., 1997). Impedance 
cardiography measures of ?̇?  at two exercise intensities (0.5 and 1.5 W·kg-1) 
were compared to ?̇?  derived using the indirect Fick method, involving CO2 
rebreathing with sampling of capillary blood gases. Thoracic bioelectrical 
impedance cardiography derived values were reportedly within ± 20% of values 
measured using the indirect Fick method. Regarding the reproducibility of this 
device, coefficients of variation of 9.3% have been reported in healthy children 
for both ?̇? and SV at peak exercise during ramp incremental exercise testing 
(Welsman et al., 2005). It has also been documented that this technique is 
relatively insensitive to minor changes in electrode placement (Tan et al., 2006).    
 
3.16  Measurement of muscle oxygenation  
In Chapters 6-8, muscle oxygenation status was non-invasively assessed from 
the HHb dynamics of the m. vastus lateralis using NIRS (Portamon, Artinis 
Medical Systems). This system has previously been used in children (e.g. 
McNarry et al., 2011; McNarry et al., 2014) and consists of an emission probe, 
with three light sources emitting two wavelengths of light (760 and 850 nm) and 
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a photon detector. The intensity of incident and transmitted light was recorded 
continuously at 10 Hz and used to estimate [HHb]. Evidence was recently 
provided to demonstrate that the kinetics of the NIRS-derived deoxygenation 
signal in the superficial and deeper muscle regions provides an index of local 
O2 extraction kinetics within the intramuscular microcirculation during exercise, 
rather than intramyocyte myoglobin (Koga et al., 2012). As such, changes in the 
deoxygenation signal should be taken to indicate changes in local muscle O2 
extraction. The wireless emitter-detector unit was placed over the m. vastus 
lateralis, midway between the greater trochanter and lateral epicondyle of the 
femur. The area of interrogation was initially cleaned and shaved and, following 
marking of the placement area, the device was secured with tape (KinesioTex®) 
and a dark elastic bandage, to minimise extraneous light interference with the 
near-infrared signal. The Portamon device has been reported to produce 
acceptable reproducibility estimates (Shadgan et al., 2009).  
 
3.17  Measurement of blood lactate concentration 
In Chapter 4, a fingertip capillary blood sample (~5 µL) was taken within 30 s of 
volitional exhaustion from the incremental ramp test and analysed for the 
concentration of whole blood lactate (La[B]) using a portable device (Lactate Pro, 
Arkray, Japan). This device has been shown to strongly correlate (r = 0.99) with 
lactate determined using the YSI device (YSI 1500, Yellow Springs Instruments, 
Australia) (Medbø et al. 2000; Pyne et al., 2000).  
 
 
 
 
 
3.18  Measurement of SpO2 
Transcutaneous SpO2 was non-invasively measured at the fingertip using pulse 
oximetry (NONIN, Avant 4000, NONIN Medical Inc., USA).  
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3.19  Measurement of effort and dyspnoea 
Subjective ratings of perceived exertion (RPE) and dyspnoea (RPD) were 
determined upon exhaustion using the pictorial children’s effort rating table (P-
CERT) (Lamb et al., 2000) and the 0-10 category ratio (CR-10) scale (Borg, 
1982; Appendix M), respectively. Prior to each study, participants were 
thoroughly familiarised with all rating scales during their habituation session. 
The P-CERT (Appendix L) was used throughout, since the scale best depicts 
incremental exercise.  
3.20  Determination of the key parameters of aerobic function  
3.20.1  Determination of ?̇?O2max 
In study 1, the presence of a V̇O2 plateau was determined using methodology 
that have been previously employed in a paediatric population (Barker et al., 
2011; Day et al., 2003). Concisely, a linear regression was plotted over the 
‘linear’ portion of the V̇O2 response. The V̇O2 profile at exhaustion was then 
characterised by extrapolating this linear regression function to exhaustion and 
isolating the final 60 s of data, to examine the residuals against the extrapolated 
line (see Figure 3.4). A negative residual indicated a deceleration in V̇O2 against 
power output and was considered a ‘plateau’ when the magnitude of the 
residuals was ≥ 5% of the projected V̇O2 (i.e. V̇O2 was ≤ 95% of the projected 
V̇O2). A positive residual ≥ 5% of the projected V̇O2 represented acceleration 
and positive or negative residuals < 5% of the peak power output projected V̇O2 
were categorised as linear responses (Barker et al., 2011).  
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Secondary verification criteria (V̇O2 at an RER > 1.00 (Gulmans et al., 1997; 
Klijn et al., 2003), 1.10 (Moser et al., 2000), a HR of 180 b∙min-1 (Gulmans et al., 
1997; Klijn et al., 2003) and 95% age-predicted HRmax (Stevens et al., 2009; 
Stevens et al., 2011)) were taken from key studies implementing CPET within 
patients with CF, whilst La[B] ≥ 6 mmol∙L
-1 is often utilised in paediatric 
physiology. Subsequently, the highest 15 s averaged V̇O2 obtained during the 
ramp and Smax tests was taken to represent V̇O2max.  
Scaling of physiological data is particularly important in paediatric groups, in 
order to create a ‘size free’ parameter that controls for any influence of 
maturation (Baxter-Jones et al., 2005). Whilst allometry, regression and 
traditional ratio standard methods are available, in all chapters comprising this 
Figure 3.4. Example profile determination of pulmonary oxygen uptake (V̇O2) 
plateau. In this case, the response was -3.7% which was classified as a linear 
V̇O2 response upon exhaustion.    
A 
B 
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thesis, a log-linear allometric model yielded a scaling component close to unity 
for FFM, meaning the ratio standard method for normalising V̇ O2max was 
appropriate. This traditional method involves expressing physiological 
measurements as a ratio standard, adjusting the function for body size (i.e., 
expressing V̇O2max relative to body mass).  
 
3.20.2  Determination of the GET 
Purpose built software was used to identify the GET (LabVIEW, National 
Instruments, Newbury, UK; Figure 3.5). The first 60 s of data following the onset 
of the ramp forcing function and data following the respiratory compensation 
point (RCP) were removed. A plot of V̇CO2 against V̇O2 was then produced 
(Figure 3.5a). The GET was identified as the intersection point between the two 
regression lines, i.e. a disproportionate increase in V̇CO2 relative to V̇O2, in 
accordance with the V-slope method (Beaver et al., 1986). The GET was then 
visually confirmed using the ventilatory equivalents for V̇ O2 and V̇ CO2 of 
observation of the PETCO2 response (Wasserman et al., 2004; see Figure 3.5b). 
The GET was independently identified by two experienced researchers and 
expressed both in absolute terms and as a percentage of V̇O2max. As mentioned 
earlier, both of these methods are appropriate for use in children with CF 
(Visschers et al., 2015). 
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3.20.3  Determination of the ?̇?O2 gain 
The functional V̇O2 gain (ΔV̇O2/ΔWR) was determined through regression of the 
linear portion of the V̇O2 response versus power output. The linear portion of the 
A 
B 
Figure 3.5. Example dataset from a paediatric patient with cystic fibrosis in the 
purpose built software (LabVIEW, National Instruments, Newbury, UK) used to 
identifiy the gas exchange threshold (GET).  Following averaging of the data and 
removal of the respiratory compensation point, Panel A shows the inflection point 
identified by the software in a plot of expired carbon dioxide ( V̇ CO2) against 
pulmonary oxygen uptake (V̇O2). This intersection point between the two regression 
lines marks a disproportionate increase in V̇CO2 relative to V̇O2, in accordance with 
the V-slope method (Beaver et al., 1986).  Panel B then demonstrates the 
subsequent identification and confirmation of this point using the ventilatory 
equivalents for V̇O2 and V̇CO2 (Wasserman et al., 2004).   
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test was determined by removing the first 120 s and final 120-180 s of the test, 
depending on test duration. The decision was verified by visual observation of 
the data by two trained researchers.  
3.20.4  Determination of the ?̇?O2 MRT 
The V̇O2 MRT was determined by backward extrapolating the linear function of 
the V̇O2 response as a function of time to the point where this line intersected 
baseline V̇O2 (Figure 3.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
3.21  Determination of the OUES 
The OUES for the entire exercise duration (OUES100) and up to the GET 
(OUESGET) were derived from the slope of the linear function between V̇O2 
(mL∙min-1) and log V̇E (L∙min
-1) (Baba et al., 1996).  
 
Figure 3.6. Example identification of the pulmonary oxygen uptake ( V̇ O2) mean 
response time (MRT) in a paediatric patient with cystic fibrosis. In this case, the derived 
MRT was 55 s. The black solid line represents the backward extrapolation of the 
regression line fitted through the linear portion of the V̇O2 response.   
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3.22  Determination of ventilatory drive 
The V̇E/V̇CO2–slope (ventilatory drive) was calculated using linear regression of 
the ∆V̇E/∆V̇CO2 response during the entire ramp test (Tabet et al., 2003). 
 
3.23  Determination of the  O2 pulse 
The O2 pulse ( V̇ O2/HRpeak) was determined using the following standard 
equation:  
V̇O2/HRpeak (mL∙beat
-1) = V̇O2 (L∙min
-1) x 1000 mL / HR (beats∙min-1)        
Equation 3.9 
 
3.24  Determination of the arterial-venous O2 content difference 
The arterial-venous O2 content difference [C(a- v̅ )O2] was estimated via 
rearrangement of the Fick equation (Equation 3.10):  
C(a-v̅)O2  =  V̇O2   /  ?̇?                                                              Equation 3.10  
 
3.25  Analysis of muscle oxygenation response during ramp incremental 
exercise 
For studies 3 and 4, muscle [HHb] data were interpolated to 1 s intervals and 
averaged to 15 s time bins for the entire test duration. Responses were then 
normalised to the total amplitude of the response (% ∆[HHb]), such that 0% 
represented steady-state values observed during the period of baseline cycling 
and 100% represented the highest average (i.e., ∆[HHb]peak) (Boone et al., 
2009; Gravelle et al., 2012). The response was then expressed as a function of 
absolute and relative Wpeak and V̇O2max. Although other research groups report a 
bilinear fit of [HHb] data during ramp incremental exercise (Spencer et al., 
2012), preliminary statistical analyses (GraphPad Prism; GraphPad Software, 
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San Diego, CA) revealed that a sigmoid function provided a superior fit to the 
[HHb] response when compared with bilinear or hyperbolic curve fitting 
procedures. The ∆[HHb] response to incremental ramp cycling exercise was 
therefore described using a sigmoidal model (Equation 3.11) in line with 
previous studies (Boone et al., 2009; Ferreira et al., 2007; McNarry et al., 2011), 
as follows: 
 
y = f0 + A / (1 + e 
–(c+dx))             Equation 3.11 
 
where f0 represents baseline [HHb], A represents the amplitude of the response, 
d represents the slope of the sigmoid, c represents the constant that is 
dependent on d, and c/d represents the value corresponding to 50% of the total 
amplitude, respectively. 
 
 
 
3.26  Analysis of ?̇?O2 kinetic response during CWR exercise  
In studies 5 and 6, breath-by-breath changes in V̇O2 for each exercise bout 
were analysed using methodology previously utilised in paediatric studies (e.g. 
Barker et al., 2014; Barker et al., 2010; Breese et al., 2012; Fawkner & 
Armstrong, 2004a). Data for each exercise transition was initially examined for 
fluctuations that were > 3 standard deviations (SD) from a local moving mean 
and any errant breaths were excluded. Subsequently, the four repeat transitions 
for both MOD and VH intensity conditions were linearly interpolated to 1 s data, 
time aligned to the onset of exercise (i.e., t = 0 s) and ensemble averaged to 
improve the signal-to-noise ratio (Figure 3.7).  
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The 1 s averaged V̇O2 response for the MOD and VH intensity conditions for 
each participant were then baseline corrected, by subtracting the mean V̇O2 
between -60 and -5 s from the exercise response. To remove the influence of 
the cardiodynamic phase (phase I) on the analysis of the V̇ O2 response, 
following visual inspection of V̇O2 versus time, the first 21 ± 3 s and 17 ± 4 s of 
Figure 3.7. Example profile of the pulmonary oxygen uptake ( V̇ O2) kinetic 
response of a paediatric patient with cystic fibrosis. Panels A and B represent the 
V̇O2 kinetic response to 4 averaged transitions during moderate intensity exercise. 
Note that averaging to 5-s intervals, as demonstrated in Panel B, improves the 
signal-to-noise ratio from Panel A and, therefore, the confidence associated with 
the derived kinetic parameters. The red line denotes the monoexponential fit and 
the black trace denotes the residuals of the response.   
A 
B 
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the MOD data and the first 19 ± 5 s and 16 ± 2 s for the VH response were 
omitted in CF and heathy participants, respectively. For moderate intensity 
exercise, the phase II portion of the V̇O2 response (5 s averaged data) was then 
characterised using Equation 3.12 (GraphPad Prism; GraphPad Software, San 
Diego, CA): 
 
V̇O2 (t) = Δ V̇O2 A  · (1 – e 
– (t –TD)/τ)                          Equation 3.12 
 
where V̇O2 (t), Δ V̇O2 A, TD, and τ represent the value of V̇O2 at a given time (t), 
the amplitude change in V̇O2 from baseline to its asymptote, time delay, and the 
time constant of the response, respectively.  
For very heavy intensity exercise, it was necessary to account for the V̇O2 slow-
component. In line with previous recommendations (Rossiter et al., 2002), the 
fitting window was constrained to exclude all data following the visually 
determined onset of the slow-component, the onset of which was determined 
using a purpose written computer program (LabVIEW, version 6.1; National 
Instruments, Newbury, UK); see Figure 3.8. A non-linear equation was initially fit 
up to the first 60 s of exercise and then increased iteratively by 1 s until it 
encompassed the entire exercise bout (Rossiter et al., 2011). The estimated 
V̇O2 τ for each fitting window was plotted against time to visually identify the 
point at which the V̇O2 slow-component began, which was defined as the point 
at which a plateau in the estimated phase II τ was followed by a consistent and 
progressive increase (Fawkner & Armstrong, 2004b; Rossiter et al., 2001), as 
shown in Figure 3.8. The phase II parameter estimates from Equation 3.12 were 
then resolved by least-squares nonlinear regression (GraphPad Prism; 
GraphPad Software, San Diego, CA).  
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The magnitude of the V̇O2 slow-component was determined as the difference 
between the mean of the final 30 s of VH intensity exercise and the phase II 
asymptote. The V̇O2 slow-component amplitude was expressed both in absolute 
terms and relative to end-exercise V̇O2. To provide a description of the overall 
kinetic response for both intensities of exercise, the MRT was also derived, by 
constraining the TD in Equation 3.12 to 0 s and fitting from exercise onset to 6 
min. The functional gain of the phase II V̇O2 response was also determined for 
both MOD and VH intensities, by dividing the asymptotic phase II V̇O2 amplitude 
by the change in work rate above baseline. The end-exercise V̇O2 gain was 
calculated in a similar manner.   
Figure 3.8.  Example visual identification of the V̇O2 slow-component during 
very heavy intensity cycling exercise in a paediatric patient with cystic 
fibrosis. The vertical green line denotes the onset of the slow component, 
defined as the point at which a plateau in the estimated phase II τ was 
followed by a consistent and progressive increase (~120 seconds in this 
case). 
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An example profile for the pulmonary V̇O2 response of a child with CF during 
MOD and VH intensity cycling is provided in Figure 3.9: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.27  Analysis of muscle oxygenation during CWR exercise 
As with ramp incremental exercise, NIRS data was collected at 10 Hz during 
CWR exercise. Data were subsequently interpolated to 1 s intervals and 
expressed as a change, in arbitrary units (a.u.), from baseline. Subsequently, 
[HHb] profiles were averaged into 5 s time bins, time aligned to the onset of the 
exercise, and ensemble averaged to yield a single response for both exercise 
Figure 3.9. Example profile of the pulmonary oxygen uptake (V̇O2) kinetic 
response of a female paediatric patient (13.8 y; 1.47 m; 41.5 kg; 
∆F508/2186delA) with cystic fibrosis during moderate (●) and very heavy (○) 
intensity cycling exercise. The vertical dotted lines represent the different 
phases (I, II and III) of the V̇O2 kinetic response. Notice that during moderate 
intensity exercise, following phase II (~120 s), the V̇O2 response has attained 
a steady-state. In contrast, during very heavy exercise, following phase II 
(~120 s), a steady-state is not achieved due to the emergence of a V̇O2 slow-
component, which increases the O2 cost of exercise towards V̇O2max, which in 
in this patient was 1.68 L·min-1. Figure taken from Williams et al. (2014).  
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intensities. The dynamics (fast and slow-component phases) of the [HHb] 
response for moderate and very heavy intensity exercise were then modelled in 
a similar manner to the methods outlined above for V̇O2, with slight modification. 
Since the [HHb] response increases with exponential-like properties following a 
short delay, data were modelled in line with the methods outlined by DeLorey et 
al. (2003). The time at which the exponential-like increase in [HHb] occurred 
was determined as a 1 SD increase above baseline and, following the removal 
of the data preceding this exponential-like increase, Equation 3.12 was applied 
to resolve the [HHb] TD and τ. For both MOD and VH, the presence of a slow-
component was identified using the methods outlined above for V̇O2. When a 
slow-component was present, the fitting window was constrained to the time of 
onset. The overall [HHb] MRT was also determined as the sum of the TD and τ 
over the fast component of the response.  
 
 
3.28 Analysis of the cardiac response during CWR exercise 
In studies 5 and 6, beat-by-beat changes in HR, SV and ?̇?  were linearly 
interpolated on a second-by-second basis, time aligned to the onset of exercise 
and ensemble averaged to yield a single averaged file for each participant for 
both moderate and very heavy intensity exercise. Additionally, the C(a-v̅)O2 was 
estimated via rearrangement of the Fick equation [C(a- v̅ )O2 = V̇ O2/  ?̇? ] and 
averaged as above. In line with existing recommendations (Dewey et al., 2008), 
SV and ?̇? were normalised to FFM to determine the SVI and CI. Initial log-linear 
allometric modelling deemed that the ratio standard method was an appropriate 
method of scaling for cardiac parameters, since the derived scaling component 
was close to unity for FFM. To provide a description of the changes in HR, SV, 
?̇?and C(a-v̅)O2 during both MOD and VH intensity exercise, data were averaged 
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to 30 s time bins. To provide an index of muscle O2 availability, the increase in 
?̇? relative to V̇O2 (?̇?/V̇O2) was also determined at 30 s intervals during MOD and 
VH intensity exercise.  
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CHAPTER FOUR 
A Protocol to Determine Valid ?̇?O2max in Young Cystic Fibrosis 
Patients 
 
This experimental study has been disseminated as follows: 
 
Publication: Saynor, Z. L., Barker, A. R., Oades, P. J., Williams, C. A. (2013). 
A protocol to determine valid V̇O2max in young cystic fibrosis patients. J Sci Med 
Sport, 16(6), 539-544.  
Published Abstract: Saynor, Z. L., Barker, A. R., Oades, P.J., Williams, C. A. 
(2011). A protocol to determine valid V̇O2max in young cystic fibrosis patients: 
recommendations for clinical practice: J Cyst Fibros, 11(Suppl. 1):  S99.  
Oral Presentation: Saynor, Z. L., Barker, A. R., Oades, P. J. & Williams, C. A. 
(2011). Reliability and validity of maximal cardiopulmonary exercise testing in 
children and adolescents with cystic fibrosis. The XXVIIth International ‘Children 
and Exercise’ Symposium of the European Group of Pediatric Work Physiology, 
Mawgan Porth, UK. 
Poster Presentation: Saynor, Z L., Barker, A. R., Oades P. J. & Williams, C. 
A. (2012). A protocol to determine V̇O2max in young patients with cystic fibrosis: 
Recommendations for clinical practice. The 35th European Cystic Fibrosis 
Society Conference, Dublin, Ireland.  
 
 
 
4.1 Introduction  
Exercise testing is a valuable investigative tool in young people with chronic 
diseases, such as CF. Although lung function traditionally measures disease 
severity, it cannot accurately predict exercise capacity (Nixon et al., 1992; 
Stevens et al., 2010). Current standards for CF management therefore 
recommend at least annual exercise testing (Day et al., 2003), however current 
provision is unsatisfactory (Barker et al., 2004; Stevens et al. 2010). CPET, 
incorporating measurement of pulmonary gas exchange, provides the most 
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precise measure of exercise capacity ( V̇ O2max) in mild-to-moderate CF. 
Furthermore, V̇ O2max holds suggested value in prognostic stratification of 
patients (Nixon et al., 1992).  
  
V̇O2max represents the integrated capacity of the pulmonary, cardiovascular and 
muscular systems to uptake and utilise O2 during intense exercise and is 
traditionally identified by a V̇O2 plateau upon exhaustion despite an increasing 
work rate (Rowland et al., 1993). Since only a minority of young people display 
this response (Astorino et al., 2009; Barker et al., 2004; Rowland et al., 1993), 
the term V̇O2peak is commonly used, defined as the highest V̇O2 attained during 
an exhaustive test (Barker et al., 2011). To verify a ‘maximal effort’, reliance 
therefore falls upon secondary criteria, encompassing subjective indicators of 
effort (sweating, facial flushing, hyperpnoea) and objective secondary criteria 
(HR, RER and/or La[B]). Unfortunately, most previous studies in CF have not 
specified their verification criteria. In those which have, there is some disparity, 
with objective criteria including RER > 1.00 (Gulmans et al., 1997; Klijn et al., 
2003) and > 1.10 (Nixon et al., 1992) and HR criteria of 180 b·min-1 (Gulmans et 
al., 1997; Klijn et al., 2003) and 95% of age-predicted maximum (Stevens et al., 
2009; Stevens et al., 2011). Such criteria are dependent on arbitrary values 
which often underestimate ‘true’ V̇O2max and have thus been deemed invalid for 
healthy children (Barker  et al., 2011) and young spina bifida patients (de Groot 
et al., 2009). It is conceivable that secondary criteria are equally unsuitable for 
young CF patients. Documenting a valid V̇O2max is crucial to the clinical utility of 
CPET within CF. Accepting submaximal values could distort clinical 
interpretation and underestimate patients’ prognosis, influencing decisions 
regarding clinical intervention and/or exercise prescription.   
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It is important that new conceptual advances within exercise physiology 
continue to be incorporated within clinical practice. A procedure termed the 
‘verification phase’, where CPET is followed by an individualised supramaximal 
‘step’ test to exhaustion, can ensure the valid determination of V̇O2max in healthy 
children (Barker et al., 2011), sedentary adults (Astorino et al., 2009), active 
middle-aged and older adults (Dalleck et al., 2012; Rossiter et al., 2006) and 
adolescent spina bifida patients (de Groot et al., 2009). Supramaximal exercise 
denotes exercise above the highest peak power achieved during a preceding 
exhaustive CPET. While Smax has been safely implemented in paediatric spina 
bifida patients (de Groot et al., 2009) and patients with chronic heart failure 
(Bowen et al., 2011), the utility, safety and feasibility for young CF patients is 
unknown. This study aimed to establish the validity of CPET derived V̇O2max and 
the utility of Smax to provide a robust measure of V̇O2max in young CF patients. 
We hypothesised that: 1) traditional verification criteria would significantly 
underestimate ‘true’ V̇O2max; and 2) the V̇O2max obtained during a traditional 
incremental ramp test would not significantly differ to that from a subsequent 
Smax verification test, thus providing a valid measure of V̇O2max.  
 
4.2 Methods 
4.3.1 Participants, anthropometry and pulmonary function 
Fourteen young patients (Table 4.1) with mild-to-moderate CF, regularly 
partaking in physical activity as is suggested by clinical disease management 
guidelines, participated in this study. Inclusion criteria comprised a diagnosis of 
CF based on clinical features, an abnormal sweat test (sweat Cl- > 60 mmol·L-1 
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/ 100 mg sweat) and genotyping. Stable pulmonary function within 10% of best 
in the preceding 6 months and no symptomatic increase or weight loss within 2 
weeks was mandatory. Unstable non-pulmonary comorbidities and/or acute 
infection warranted exclusion. Disease severity was graded using the SS as 
part of patients’ annual clinical review (Table 4.1). Ethics approval was granted 
by the South West NHS Research Ethics Committee and informed written 
consent and assent obtained from parents/guardians and patients, respectively. 
Body mass was measured to the nearest 0.1 kg and stature to the nearest 0.01 
m. Pulmonary function, assessed via spirometry (MicroMedical MicroLoop 
3535), determined FVC and FEV1 (Table 4.1). Pubertal staging was self-
assessed (boys ≥ 10 y and girls ≥ 8 y) according to pubic hair classification 
(Tanner et al., 1962) (Table 4.1) following testing.  
 
4.3.2 Exercise protocol 
Exercise was performed on cycle ergometers [Lode Excalibur, Groningen, The 
Netherlands; Lode (paediatric)]. Following 3 min warm-up (20 W), patients 
completed an incremental ramp test, whereby resistance increased at a 
predetermined rate (10-25 W∙min-1), ensuring ~ 8-12 min test durations. 
Patients maintained ~ 70-80 rpm until volitional exhaustion, defined as a drop in 
cadence > 10 rpm for 5 consecutive seconds despite strong verbal 
encouragement. Wpeak was recorded upon exhaustion. Five minutes warm-
down (20 W) and 10 min seated recovery followed. Smax was subsequently 
undertaken, whereby 3 min cycling (20 W) preceded a ‘step’ transition to a 
CWR equivalent to 110% of Wpeak. This work rate was maintained until 
exhaustion, followed by 5 min recovery (20 W).  
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TABLES 
Table 4.1. Patients’ baseline anthropometric and clinical data.  
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Patient 
(Gender) 
Pubertal 
maturity 
Age  
(y) 
Stature 
(m) 
Body 
mass (kg) 
BMI 
(kg·m2) 
CFTR genotype C. 
P
S
Aa 
SS North-
ern  
scoreb 
FVC 
[% predicted (L)] 
FEV1 
[% predicted (L)] 
1 (M) 3 13.4 164.9 62.1 23.1 ∆ F508 /∆F508 I 85 4 127  (4.58) 120  (4.07) 
2 (M) 4 16.7 177.0 85.0 29.4 ∆ F508 /∆F508 F 87 4 112  (4.95) 87  (3.60) 
3 (M) 4 13.4 167.9 69.7 24.1 ∆ F508/P67L F 80 3 101  (3.57) 112  (3.04) 
4 (F) 1 7.6 123.6 24.0 16.1 ∆ F508 /621+IG     T F 89 3 112  (1.62) 108 (1.43) 
5 (M) 4 9.9 141.2 41.8 21.1 ∆ F508 /∆F508 C 85 4 106  (2.47) 93  (2.04) 
6 (M) 2 11.2 141.9 44.8 22.8 ∆ F508 /∆F508 F 79 5 96  (2.23) 65  (1.39) 
7 (M) 3 13.9 174.6 89.8 28.1 ∆ F508 /∆F508 I 82 4 123  (5.11) 97  (3.84) 
8 (F) 1 12.2 135.0 32.5 18.1 ∆ F508 / 2184delA N 81 3 125  (2.19) 101  (1.95) 
9 (M) 1 11.1 149.5 32.1 14.4 ∆ F508 /∆F508 I 67 6 79  (2.19) 67  (1.71) 
10 (M) 2 16.1 151.6 44.1 19.3 ∆ F508 /∆F508 F 75 3 93 (2.69) 69 (1.83) 
11 (M) 2 14.9 170.3 56.7 19.5 ∆ F508 / G55ID C 82 6 115  (4.55) 110 (4.06) 
12 (M) 1 7.8 135.1 43.6 25.0 ∆ F508 /∆F508 N 91 2 112  (2.40) 108  (1.92) 
13 (F) 2 16.6 166.0 65.0 25.0 ∆ F508 /∆F508 F 88 3 99  (3.46) 85 (2.95) 
14 (F) 4 18.4 172.0 58.0 20.2 ∆ F508 /∆F508 I 81 3 85  (3.53) 82 (2.98) 
Mean 
(SD) 
[range] 
2 
(1) 
[1-4] 
13.1 
(3.32) 
[7.57-
18.4] 
1.5 
(0.17) 
[1.23-
1.74] 
55.5 
(19.3) 
[24.4-
87.9] 
21.9 
(4.31) 
[14.4-
29.4] 
- 
- 
- 
- 
- 
- 
82 
(6) 
[67-91] 
4 
(1) 
[2-6] 
104; 3.30  
(15; 1.2) 
[79-127; 1.62-5.11] 
92; 2.66 
(18; 1.0) 
[65-120; 1.39-
4.07] 
Values are means ± SD, with the range also displayed where suitable, unless otherwise stated. BMI, body mass index; CFTR, cystic fibrosis transmembrane conductance regulator; C. 
PSA, chronic Pseudomonas aeruginosa infection; I, intermittent; F, free; C, chronic; N, never; SS, Shwachman score - scoring 4 separate aspects of the disease profile; general activity; 
physical examination; nutritional status; and chest radiographic findings, using the most recent clinical review information. A total of 100 points represents a perfect score of health; FVC, 
forced vital capacity; FEV1, forced expiratory volume in 1 s. 
a
 According to Leeds Criteria, “chronic”, >50% of the preceding 12 months were P. aeruginosa culture positive; “intermittent”, 
≤50% of the preceding 12 months were P. aeruginosa culture positive; “never”, no growth of P. aeruginosa for the previous 12 months, having previously been P. aeruginosa culture 
positive; “free”, P. aeruginosa has never been cultured. 
b
 Provides evidence of radiographic chest findings. Maximum score is 20, with 20 being the most severe.  
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4.3.3 Exercise test measurements 
Gas analysers were calibrated using gases of known concentration, and the turbine 
volume transducer using a 3 L calibration syringe (Hans Rudolph, Kansas City, MO). 
Breath-by-breath pulmonary gas exchange and ventilation (Metalyzer 3B Cortex, 
Biophysik, Leipzig, Germany; Metasoft v.3.9.7) were measured using a face mask 
and, following 1 s interpolation, averaged to 15 s time bins which was subsequently 
used for all parameters. When appropriately calibrated the accuracy of measuring 
volume and gas fractions are 2% and 0.1%, respectively. The highest 15 s stationary 
average represented V̇O2peak. 
 
HR was determined at 5 s intervals (PhysioFlow, PF-05, Manatec Biomedical, Paris, 
France) and HRpeak taken as the highest 15 s mean value. SpO2 was determined on 
a beat-by-beat basis via pulse oximetry (Avant 4000, NONIN Medical Inc., USA). A 
fingertip capillary blood sample (~5 µL) was taken within 30 s of exhaustion following 
the ramp and analysed for La[B] (Lactate Pro, Arkray, Japan). Subjective ratings of 
RPE and RPD were recorded upon exhaustion using the P-CERT (Lamb et al., 
2000) and the CR-10 scale (Borg, 1982), respectively. 
 
4.3.4 Data analysis 
The presence of a V̇ O2 plateau was determined using methodology more 
comprehensively described elsewhere (Chapter 3; Day et al., 2003; Rossiter et al., 
2006). Briefly, analysis requires a linear regression over the ‘linear’ portion of the V̇O2 
response. The V̇ O2 profile at exhaustion was subsequently characterised by 
extrapolating this linear regression function to exhaustion and isolating the final 60 s 
of data to examine the residuals against the extrapolated line. A negative residual 
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indicated a deceleration in V̇O2 against power output and was considered a ‘plateau’ 
when the magnitude of the residuals was ≥ 5% of the projected V̇O2 (i.e. V̇O2 was ≤ 
95% of the projected V̇O2). A positive residual ≥ 5% of the projected V̇O2 represented 
acceleration and positive or negative residuals < 5% of the Wpeak projected V̇O2 were 
categorised as a linear responses (Ruf et al., 2010). Secondary verification criteria 
(V̇O2 at an RER of 1.00 (Gulmans et al., 1997; Klijn et al., 2003) and 1.10 (Moser et 
al., 2000), a HR of 180 b∙min-1 (Gulmans et al., 1997; Klijn et al., 2003) and 95% 
age-predicted HRmax (Stevens et al., 2009; Stevens et al., 2011)) were selected 
within the current study based on their use within CF patients, whilst La[B] ≥ 6 
mmol∙L-1 is often utilised in paediatric studies. 
 
4.3.5 Statistics 
Data are expressed as means and standard deviations unless otherwise stated and 
significance set at p < 0.05. Paired samples t-tests determined mean differences 
between ramp and Smax V̇O2peak. Linear regression and Bland and Altman limits of 
agreement analysis (Bland & Altman, 1999) (mean bias and 95% confidence limits 
[95% CL]) examined the agreement between ramp and Smax V̇O2peak. A greater than 
9% increase was considered a ‘meaningful’ change between ramp and Smax derived 
V̇O2peak  (see section 2.4.5 for further details). This value is considered the typical 
within-subject short-term variation of V̇O2max in paediatric CF patients, established 
using unpublished data from within our laboratory. Analyses were performed using 
SPSS v.18.0 (Chicago, Illinois, USA) and GraphPad Prism (GraphPad Software Inc., 
San Diego, California, USA). 
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4.3 Results 
Mean ramp test duration was 9 min 27 s ± 3 min 16 s, resulting in a Wpeak of 174 ± 
84 W. Mean V̇O2peak was 1.83 ± 0.78 L·min
-1 (34.23 ± 6.57 mL∙kg-1∙min-1). Ramp 
V̇ O2peak was not significantly different to the V̇ O2peak predicted by the linear 
extrapolation of the V̇O2-power output relationship (1.83 ± 0.84 L·min
-1; p = 0.99). 
Mean goodness of fit (R2) for the linear function was 0.84 ± 0.19.  Analysis of 
patients’ V̇O2-power output profiles revealed a single plateau upon exhaustion, with 
13 patients characterised by a linear V̇O2 response (Table 4.2). The mean ‘gain’ 
(ΔV̇O2/ΔWR) of patients’ V̇O2 response to the ramp test was 7.81 ± 1.57 mL∙min
-1∙W-
1. 
 
All patients satisfied the RER > 1.00 and >1.10 criteria (Table 4.2). However, the V̇O2 
at a RER of 1.00 (0.99 ± 0.47 L·min-1) was lower than that recorded at exhaustion 
(1.83 ± 0.78 L·min-1; p < 0.001), representing only 54% of V̇O2peak. Similarly, the V̇O2 
at RER of 1.10 (1.36 ± 0.59 L·min-1; p < 0.001) were lower than V̇ O2 upon 
exhaustion, representing only 74% of V̇ O2peak. Bland and Altman analysis 
demonstrated the RER of 1.00 and 1.10 criteria to underestimate V̇O2max by a mean 
bias of –1.10 L·min-1 (95% CL: -1.68 to -0.01 L·min-1, Figure 4.1a) and -0.47 L·min-1 
(95% CL: -1.02 to 0.08 L·min-1, Figure 4.1b), respectively. Mean La[B] following the 
ramp was 9.5 ± 13.1 mmol∙L-1 (n = 13). Ten patients satisfied the ≥ 6 mmol∙L-1 
criteria (Table 4.2).   
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Table 4.2. Ramp test responses in relation to traditional verification criteria. 
Patient Gender Age 
(y) 
Ramp 
V̇O2peak 
(L∙min-1) 
V̇O2 
plateau 
V̇O2 at 
RER 
>1.00 
(L∙min-1) 
V̇O2 at 
RER  
>1.10 
(L∙min-1) 
V̇O2 at 
180 
b∙min-1 
(L∙min-1) 
V̇O2 at 95% age-
predicted HR 
(L∙min-1)  
La[B] ≥ 6 
mmol∙L-1 
1 M 13.4 2.32 No 0.96 1.58 - - Yes 
2 M 16.7 3.78 Yes 2.30 3.09 2.76 N/A Yes 
3 M 13.4 2.05 No 0.79 1.23 1.94 N/A Yes 
4 F 7.6 0.84 No 0.47 0.73 N/A N/A DNC 
5 M 9.9 1.39 No 0.73 1.08 1.39 N/A No 
6 M 11.2 1.74 No 1.12 1.42 1.50 1.50 Yes 
7 M 13.9 2.16 No 1.25 1.53 - - Yes 
8 F 12.2 1.18 No 0.83 1.06 1.11 N/A Yes 
9 M 11.1 1.03 No 0.71 0.94 N/A N/A No 
10 M 16.1 1.72 No 0.96 1.45 1.45 1.37 Yes 
11 M 14.9 2.65 No 1.50 1.89 2.40 2.28 Yes 
12 M 7.8 1.11 No 0.83 0.79 1.02 N/A No 
13 F 16.6 2.16 No 0.75 1.32 2.16 N/A Yes 
14 F 18.4 1.49 No 0.71 0.96 N/A N/A Yes 
 
DNC, did not consent to blood sampling for assessment of end-exercise blood lactate concentration (La[B]); N/A, not achieved; - , Loss of PhysioFlow data. 
V̇O2peak, peak oxygen uptake; RER, respiratory exchange ratio; HR, heart rate (n = 12); La[B], blood lactate concentration; ramp; incremental ramp test.
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Figure 4.1. Bland and Altman plots for the secondary criteria typically used during 
CPET of young CF patients. Plots show the mean bias (floating dotted line) and 95% 
confidence limits (floating dashed lines) for the oxygen uptake (V̇O2) recorded at an 
RER of ≥ 1.00 (A), an RER of ≥ 1.10 and (B) a heart rate of 180 beats·min-1 (C) 
compared with the actual V̇O2 recorded at exhaustion from the traditional ramp test 
in absolute terms (top row) and as a percentage of the difference (bottom row).  
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Due to data loss, HR is presented for 12 patients with a HRpeak of 188 ± 12 b·min
-1. 
Nine patients satisfied achieved 180 b·min-1 (Table 4.2), whilst 3 attained 95% age-
predicted maximum (equating to 196 ± 2 b∙min-1; Table 4.2). In those patients 
satisfying the HR criteria, V̇O2 at 180 b·min
-1 (1.75 ± 0.60 L·min-1) and 95% of their 
age-predicted maximum (1.72 ± 0.50 L·min-1) was lower than that recorded upon 
exhaustion (1.98 ± 0.84 and 2.04 ± 0.53 L·min-1, respectively), representing 88% and 
84% of V̇O2peak, respectively. Bland and Altman analysis revealed 180 b·min
-1 and 
95% age-predicted maximum criteria to underestimate V̇O2max by a mean bias of -
0.23 L·min-1 (95% CL: -0.85 to 0.39 L·min-1; Figure 4.1c) and -0.32 L·min-1 (95% CL: 
-0.46 to -0.18 L·min-1), respectively. 
 
Mean Smax duration was 1 min 23 s ± 0 min 20 s and elicited a similar V̇O2peak to the 
ramp, despite exercising at a higher power output (191 ± 93 W, Table 4.3). Bland 
Altman analysis for ramp and Smax V̇O2peak revealed a mean bias of -0.00 L·min
-1 
(95% CL: -0.46 to 0.46 L·min-1) or 1.0% (95% CL: -22.5% to 24.5%). No significant 
differences were observed for HRpeak, end-exercise SpO2, RPE or RPD during ramp 
and Smax testing (Table 4.4).  
 
Smax increased V̇O2peak above ramp V̇O2peak in 7 patients (50%) (Table 4.4; Figure 
4.2), 3 (21%) of which were deemed clinically important rises (i.e. > 9 % change). 
Based on this criterion, Smax confirmed a valid V̇O2max in 11/14 (79%) patients and 
identified 3 (21%) cases where a ‘true’ V̇O2max was not obtained, with an average V̇O2 
increase of 20.3 ± 15.7% or 0.33 ± 0.21 L·min-1. No significant relationship existed 
between Smax duration and the difference between the ramp and Smax V̇O2peak (r = 
0.29; p = 0.32).    
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Table 4.3. Decision to accept  V̇O2peak using a combined ramp and Smax exercise 
test. 
 
Patient 
(Gender) 
Age (y) Ramp 
V̇O2peak 
(L·min
-1
) 
Smax 
V̇O2peak 
(L·min
-1
) 
∆ 
Change 
(L·min-1) 
% 
Change 
True V̇O2max 
obtained? 
1 (M) 13.4 2.32 2.01 -0.31 -13.4 Yes (ramp) 
2 (M) 16.7 3.78 3.35 -0.43 -8.5 Yes (ramp) 
3 (M) 13.4 2.05 2.31 +0.26 +12.7 No 
4 (F) 7.6 0.84 0.89 +0.05 +6.0 Yes (Smax) 
5 (M) 9.9 1.39 1.41 +0.02 +1.4 Yes (Smax) 
6 (M) 11.2 1.74 1.57 -0.17 -9.8 Yes (ramp) 
7 (M) 13.9 2.16 1.99 -0.17 -7.9 Yes (ramp) 
8 (F) 12.2 1.18 1.11 -0.07 -5.9 Yes (ramp) 
9 (M) 11.1 1.03 1.10 +0.07 +6.8 Yes (Smax) 
10 (M)  16.1 1.72 1.89 +0.17 +9.9 No 
11 (M) 14.9 2.65 2.47 -0.18 -6.8 Yes (ramp) 
12 (M) 7.8 1.11 1.11 0 0 Yes (either) 
13 (F) 16.6 2.16 2.20 +0.04 +1.9 Yes (Smax) 
14 (F) 18.4 1.49 2.06 +0.57 +38.3 No 
 
V̇O2max, maximal oxygen uptake; ramp; incremental ramp test; Smax, supramaximal 
exercise   test. 
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Table 4.4. Peak physiological responses during the ramp and Smax tests. 
 
 
 
Variable Ramp Smax p-
value 
V̇O2peak (L∙min
-1) 1.83 ± 0.78  [0.84-3.77] 1.83 ± 0.69  [0.89-3.46] 0.98 
V̇O2peak (mL∙kg
-1∙min-1) 34.23 ± 6.57  [25.23-
47.54] 
34.46 ± 5.65  [23.32-
44.42] 
0.83 
RERpeak 1.29 ± 0.10  [1.15-1.49] 1.23 ± 0.12  [0.99-1.34] 0.07 
HRpeak (b∙min
-1, n=12) 188 ± 12  [170-208] 183 ± 13  [158-201] 0.08 
SpO2 (%) 96 ± 2   [90-99] 95 ± 3   [90-98] 0.19 
RPE 8 ± 2   [5-10] 8 ± 3   [4-10] 0.37 
RPD 6 ± 2   [2-10] 7 ± 3   [4-10] 0.26 
 
Values are means ± SD, with the range also displayed in parenthesis unless otherwise stated. 
V̇O2peak, peak oxygen uptake; RERpeak, peak respiratory exchange ratio; HRpeak, peak heart rate; SpO2, 
end-exercise arterial oxygen saturation; RPE, end-exercise rating of perceived exertion; RPD, end-
exercise rating of perceived dyspnoea; ramp; incremental ramp test; Smax, supramaximal exercise 
test.  
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Figure 4.2. The agreement between the peak oxygen uptake (V̇O2peak) recorded at 
exhaustion during ramp and Smax testing. Plots show the mean bias (floating dotted 
line) and 95% confidence limits (floating dashed lines) for the V̇O2 recorded at 
exhaustion during ramp and Smax exercise in absolute terms (A) and as a percentage 
of the difference (B), according to Bland and Altman (1986).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4 Discussion  
This study sought to establish the validity of traditional V̇O2max verification criteria and 
establish the utility of Smax in young CF patients. Results revealed four principle 
findings: 1) a V̇O2 plateau is rarely observed upon exhaustion; 2) adherence to 
secondary traditional criteria underreports V̇O2max; 3) in most cases (78.6%), Smax did 
not increase V̇O2peak thus confirming a valid V̇O2max; and 4) Smax verification identified 
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those whose initial CPET V̇O2peak was not a ‘true’ maximum. These findings have 
significant implications for the assessment and interpretation of CPET in young CF 
patients in both a clinical and research setting.  
 
In this study only one V̇O2 plateau was documented upon exhaustion during CPET. 
While this is the first study to document the V̇O2 profile of young CF patients during 
ramp exercise, Werkman et al. (2011) recorded a plateau in 5 of 16 adolescents with 
CF during step exercise to exhaustion. However, the latter study employed a fixed 
V̇O2 plateau criterion (< 2.1 mL·kg
-1·min-1), which was originally developed on adults 
during a discontinuous running protocol consisting of steady-state stages (Taylor et 
al., 1955) and is unlikely to account for the altered O2 cost of exercise reported in 
young CF patients (Moser et al., 2000). This was accounted for in our study, using 
an extrapolated linear function from each participant’s V̇O2-power output profile prior 
to exhaustion. Our findings indicate that young CF patients rarely satisfy the 
conventional criteria of a V̇O2 plateau during CPET.  
 
Secondary criteria have therefore been adopted to verify V̇O2max in young people, 
however they often underreport V̇O2max or reject a ‘true’ measure within healthy 
children (Barker et al., 2011; Rowland et al., 1993). Such criteria may be equally 
unsuitable for clinical paediatric populations. The present investigation confirms this 
notion. Achieving an RER > 1.00 was the least robust criterion, underestimating on 
average by 46% (Figure 4.1a). Achieving a RER > 1.10, 180 b·min-1 (Figure 4.1c) 
and 95% of age-predicted HRmax underestimated V̇O2max by an average of 26%, 12% 
and 16%, respectively. Although HR criteria appear more robust, their use is limited 
as five patients (36%) failed to achieve a HR of 180 b·min-1, and eleven (79%) failed 
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to achieve 95% of their age-predicted HRmax, one of whom exhibited a V̇O2 plateau. 
Given the emerging evidence base to reject secondary criteria in healthy children 
(Barker et al., 2011; Rowland et al., 1993) and adults (Poole et al., 2008) and now 
young CF patients, their use as a verification tool is limited and should be 
discontinued.  
 
Smax verification ensures that if the V̇O2peak obtained during a CPET is ‘truly’ maximal, 
then performing exercise above Wpeak from a preceding ramp test should not elicit a 
further increase in V̇ O2, thus satisfying the primary plateau criterion. Limited 
application of Smax in clinical populations is plausible, as poor exercise tolerance and 
slow V̇O2 kinetics (Hebestreit et al., 2005) may preclude the attainment of V̇O2max. 
The present study has demonstrated, however, that Smax can verify V̇ O2max in 
individuals with CF. Additionally, mean Smax duration was 85 ± 26 s, which is 
comparable with healthy children (91 ± 26 s) exercising at 105% Wpeak (Barker et al., 
2011). No adverse incidents were encountered, substantiating previous reports that 
exercise testing is safe in mild-to-moderate CF (Ruf et al., 2010).  
 
Although mean Smax V̇O2peak was comparable with traditional ramp testing, Smax 
elicited meaningful rises in 3 of 14 (21%) cases (range 9.9-38.3%; Figure 4.2), 
findings comparable to young spina bifida (de Groot et al., 2009) [5 of 20 (33%)] and 
adult chronic heart failure (21%) patients (Bowen et al., 2011). In healthy children, 
Smax increased V̇O2peak (potentially negligible) in only 1 of 13 cases (8%) (Barker et 
al., 2011). These findings support the use of Smax as a safe and powerful tool in CF 
patients to validate V̇O2max measurement.  
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Werkman et al. (2011) recently examined the feasibility of a SRT to verify V̇O2max in 
adolescent CF patients. The authors concluded that V̇O2peak from traditional CPET 
reflected ‘true’ V̇O2max. Although, not discussed by these authors, it is clear that 4 of 
their 13 patients experienced a potentially meaningful rise in V̇O2 during the SRT 
(see Figure 2), which is comparable to the Smax increase in V̇O2peak herein. This 
supports the present findings that Smax confirmation is an essential addition to 
traditional CPET to confirm a ‘true’ V̇O2max in young patients with CF.  
 
Individual patient data is of interest to the clinician, in that those with the greatest 
increase in V̇ O2max resulting from Smax were patients about whom there were 
treatment adherence concerns (e.g. patients 3 and 14). Conversely, those with lower 
Smax V̇O2peak versus the ramp were typically physically active and more accomplished 
in sporting activities (e.g. patients 1 and 6). Although patients 3 and 14 possessed 
slightly lower V̇O2peak scores when expressed relative to body mass, their lower 
fitness are unlikely solely attributable to more severe disease, since superior fitness 
was recorded for a number of patients with lower scores on all aspects of the 
disease profile (Table 4.1). Their scores likely represent poor motivation during 
CPET which may be indicative of motivation in other aspects of their disease 
management.  
 
Combining a traditional ramp CPET with a Smax test permits the identification of a 
valid V̇O2max. This protocol can be safely and effectively undertaken within a single 
laboratory visit and offers clear guidelines and a superior validation of V̇O2max than 
current methods. To utilise V̇O2max in prognostic stratification (Nixon et al., 1992), it is 
essential that ‘true’ measurements are obtained. Accepting submaximal or rejecting 
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‘true’ values could distort clinical application and interpretation of CPET. Since 
healthy adults do not always demonstrate a V̇O2 plateau, Smax may be useful for 
adult CF patients. However, as more severe disease is associated with aging in CF, 
the safety and tolerance of Smax in older patients warrants investigation. Whether a 
further Smax test, at a higher percentage of Wpeak, could verify V̇O2max in the cases 
where V̇ O2peak increased significantly is also unknown, although utility of a 
subsequent, more intense verification test to verify V̇O2max has been demonstrated in 
healthy adults (Scharhag-Rosenberger et al., 2011). From a practical viewpoint, Smax 
verification is straightforward to implement as the imposed power output is calculated 
from ramp test Wpeak on an individual basis and, clinically, may minimise the costs 
associated with re-tests when the validity of test results is questionable.  
 
4.5 Conclusion 
In conclusion, Smax verification is a safe and well-tolerated tool to determine valid 
V̇O2max in paediatric patients with CF. Although the present uptake of CPET is poor 
within the clinical management of young people with mild-to-moderate CF (Barker et 
al., 2004; Stevens et al., 2010), the ECFS Exercise Working Group have recently 
recognised such testing as the method of choice when assessing aerobic fitness in 
this patient population. Consequently, it is recommended that Smax verification 
replace traditional criteria for confirming a ‘true’ V̇O2max measurement in young CF 
patients with mild-to-moderate disease.  
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4.6 Practical implications 
 Aerobic fitness (V̇O2max) measurement can help predict survival in CF.    
 Criteria commonly used to confirm V̇O2max tend to underreport ‘true’ fitness. 
Conversely, a Smax exercise test can confirm ‘true’ measurements.  
 Underreporting V̇ O2max could result in incorrect interpretation of patients’ 
fitness, prognosis and/or the influence of a therapeutic intervention.  
 It is recommended that Smax be adopted when performing CPET on young CF 
patients in the clinical or research environments.   
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CHAPTER FIVE 
Reproducibility of Maximal Cardiopulmonary Exercise Testing for 
Young Cystic Fibrosis Patients 
 
This experimental study has been disseminated as follows: 
 
Publication: Saynor, Z. L., Barker, A. R., Oades, P. J., Williams, C. A. (2013). 
Reproducibility of maximal cardiopulmonary exercise testing for young cystic fibrosis 
patients.  J Cyst Fibros, 12(6), 644-650.  
Published Abstract: Williams, C. A., Saynor, Z. L., Barker, A. R., Oades, P.J. 
(2011). The reliability of maximal cardiopulmonary exercise testing for young cystic 
fibrosis patients. J Cyst Fibros, 11(Suppl. 1), S35.  
Oral Presentation: Saynor, Z. L., Barker, A. R., Oades, P. J. & Williams, C. A. 
(2011). Reliability and validity of maximal cardiopulmonary exercise testing in 
children and adolescents with cystic fibrosis. The XXVIIth International ‘Children and 
Exercise’ Symposium of the European Group of Pediatric Work Physiology, Mawgan 
Porth, UK. 
Verbal Presentation: Williams, C. A., Saynor Z. L., Barker, A. R. & Oades, P. J. 
(2012). The reliability of maximal cardiopulmonary exercise testing for young cystic 
fibrosis patients. The 35th European Cystic Fibrosis Society Conference, Dublin, 
Ireland. 
 
Poster Presentation: Saynor, Z. L., Barker, A. R., Oades, P. J. & Williams, C. A. 
(2012). The reproducibility of maximal cardiopulmonary exercise testing for young 
cystic fibrosis patients. The 1st European Workshop on Paediatric Clinical Exercise 
testing, Utrecht, The Netherlands.  
 
 
 
5.1  Introduction 
A maximal CPET is considered the ‘gold-standard’ method for evaluating aerobic 
fitness (V̇O2max) in patients with mild-to-moderate CF. The ECFS Exercise Working 
Group recently promoted CPET as the exercise testing method of choice for this 
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patient group. Moreover, the ECFS Clinical Trials Network Standardisation 
Committee has called for assessment of the validity, reproducibility and feasibility of 
outcome measures utilised in CF and advocated research into the most appropriate 
exercise test for paediatric patients (Bradley et al., 2012). 
 
Recently, our research group presented a combined incremental and Smax 
verification CPET protocol, which is superior at determining valid V̇O2max in young CF 
patients compared to a ramp only protocol (Chapter 4; Saynor et al., 2013a). V̇O2max 
is currently the principle outcome from a CPET, as it has been shown to be an 
independent predictor of CF patient mortality (Nixon et al., 1992). However, a more 
comprehensive evaluation of patients’ cardiorespiratory fitness may be gained from 
CPET, through the quantification of submaximal parameters of aerobic (LT, the 
kinetics of V̇O2 and work efficiency) and ventilatory ( V̇E/V̇CO2 -slope and OUES 
(Baba et al., 1996)) function. Submaximal outcomes may be especially useful in the 
clinical environment, as patients may not be able or willing to provide a maximal 
effort.  
 
Unfortunately, insufficient data exists regarding the reproducibility of CPET in CF 
patients and that which does exist has utilised testing protocols which cannot verify a 
‘true’ maximal effort (e.g., Kent et al., 2012; McKone et al., 1999). Moreover, the only 
paediatric study to address this issue (Kent et al., 2012) did not measure V̇O2max. 
Quantifying reproducibility enables researchers and clinicians to understand the 
variation associated with outcome measures (Hopkins, 2000) and to determine 
meaningful changes (Atkinson & Nevill, 1998). Consequently, inferences regarding 
therapeutic interventions or disease-related changes in CPET derived parameters 
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cannot currently be discerned with certainty in these patients. Therefore, this study 
sought to establish the short- (48 h) and medium-term (4-6 weeks) reproducibility of 
maximal and submaximal indicators of cardiorespiratory fitness using our recently 
validated CPET protocol.  
 
5.2  Methods 
5.2.1   Participants, anthropometry and pulmonary function 
Thirteen young patients (Table 5.1) with mild-to-moderate CF were recruited from 
outpatient CF clinics at the RD&E. Inclusion criteria comprised a CF diagnosis based 
on clinical features, sweat Cl- > 60 mmol·L-1 / 100 mg and genotyping. Stable 
pulmonary function within 10% of best in the preceding 6 months and no increase in 
symptoms or weight loss 2 weeks prior to testing was obligatory. Unstable non-
pulmonary comorbidities or acute infections warranted exclusion. Disease severity 
was graded using the SS (Schwachman et al., 1958) and routine clinical 
measurements obtained as part of patients’ annual review by their multidisciplinary 
CF clinical care team (Table 5.1). Ethics approval was granted by the South West 
NHS Research Ethics Committee and written informed consent and assent obtained 
from parents/guardians and patients, respectively. Patients arrived at the laboratory 
in a rested state, at least 2 h post-prandial and having refrained from caffeine for > 2 
h. All patients were instructed to continue maintenance medications as usual 
throughout the duration of their study involvement.  
 
Body mass (Seca 220; Vogel & Halke, Hamburg, Germany) and stature (Seca 220; 
Vogel & Halke, Hamburg, Germany) were measured to the nearest 0.1 kg and 0.01 
m, respectively, at each visit. Skinfolds were measured to the nearest 1 mm on the 
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right-hand side of the body at the biceps brachii, tricep, subscapula and suprailiac 
regions (Harpenden; British Indicators, Burgess Hill, UK). FVC and FEV1 were also 
assessed at each visit to the laboratory, using flow-volume loop spirometry 
(MicroMedical MicroLoop 3535, Numed, Sheffield, UK). The best of three consistent 
exhalations (< 5% variability) was recorded, in accordance with the British Thoracic 
Society (1994) guidelines. All pulmonary function measurements were expressed as 
a percentage predicted normal, using appropriate reference data (Quanjer et al., 
1993). 
 
Table 5.1. Patients’ baseline anthropometric and pulmonary function data upon 
initiation into the study (n = 13; 4 females). 
 
Variable Value (mean ± SD)  Range 
Age (y) 12.81 ± 3.26 7.57-18.44 
Stature (m)  1.53 ± 0.16 1.23-1.74 
Body mass (kg) 50.89 ± 17.26 24.35-83.50 
BMI (kg·m2) 21.18 ± 3.86 14.19-28.24 
SSkF (mm) 43 ± 13 24-67 
Gender m = 9, f = 4 - 
CFTR genotype: 
Homozygote ∆F508  
∆F508/P67L 
∆F508/ 621+IG       T 
∆F508/ 2184delA 
∆F508/ G55ID 
- 
9 
1 
1 
1 
1 
- 
- 
- 
- 
- 
- 
Chronic P. Aeruginosa infection a “chronic,” n = 2; 
“intermittent,” n = 4 
“free,” n = 5 
“never,” n = 2 
Shwachman score 82 ± 6 67-91 
Northern score b 4 ± 1 2-6 
FVC [ % predicted (L)] 103.5 ± 15.0 (3.3 ± 1.2) 79.0-127.0 (1.6-5.1) 
FEV1 [% predicted (L)] 91.7 ± 17.8 (2.7 ± 1.0) 65.0-120.0 (1.4-4.1) 
Values are means ± SD, with the range also displayed where suitable, unless otherwise stated. 
BMI, body mass index; SSkF, sum of skinfolds; CFTR, cystic fibrosis transmembrane conductance 
regulator; P. Aeruginosa; Pseudomonas Aeruginosa; Shwachman score - scoring 4 separate aspects 
of the disease profile; general activity; physical examination; nutritional status; and chest radiographic 
findings, using the most recent clinical review information. A total of 100 points represents a perfect 
score of health; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; 
a
 According to 
Leeds Criteria, “chronic”, >50% of the preceding 12 months were P. aeruginosa culture positive; 
“intermittent”, ≤50% of the preceding 12 months were P. aeruginosa culture positive; “never”, no 
growth of P. aeruginosa for the previous 12 months, having previously been P. aeruginosa culture 
positive; “free”, P. aeruginosa has never been cultured.  
b
 Provides evidence of radiographic chest 
findings. Maximum score is 20, with 20 being the most severe.  
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5.2.2   Exercise testing protocol   
Following familiarisation, exercise was performed on a cycle ergometer (Lode 
Excalibur or Lode Corival, Groningen, The Netherlands). The experimental protocol 
was identical to our previous study (Chapter 4 - Saynor et al., 2013a), using a 
combined ramp-incremental and Smax verification protocol. Following 3 min warm-up 
(20 W), patients completed an incremental ramp cycling test, whereby resistance 
increased at a predetermined rate (10-25 W·min-1). Ramp rate was dependent on 
patients’ age, height and fitness level, to elicit ~ 8-12 min test durations. Patients 
maintained ~ 70-80 rpm until volitional exhaustion, defined as a drop in cadence > 
10 rpm for 5 consecutive s despite strong verbal encouragement. Five minutes 
active (20 W cycling) and 10 min passive seated recovery followed. Smax verification 
of V̇O2max was then performed, whereby a 3 min warm-up (20 W) preceded a ‘step’ 
transition to a CWR equivalent to 110% Wpeak. This work rate was maintained until 
voluntary exhaustion. Five minutes active recovery (20 W cycling) completed the 
CPET.  
 
Following test one (T1), all procedures were repeated 48 h (short-term; T2) and 4-6 
weeks (medium-term; T3) later, at a similar time of day. Medium-term clinical stability 
was monitored T1-T3, with disease considered unstable if a pulmonary exacerbation 
developed, a change in pulmonary medications was required, chest signs on 
physical examination altered, or a ≥ 10% decline in pulmonary function was 
recorded.   
 
 
 
  
204 
 
5.2.3   Exercise testing measurements 
Gas analysis. Prior to each test, the metabolic cart (Metalyzer 3B Cortex, Biophysik, 
Leipzig, Germany) was calibrated using gases of known concentration, and the 
turbine volume transducer using a 3 L calibration syringe (Hans Rudolph, Kansas 
City, MO). Breath-by-breath pulmonary gas exchange and ventilation were 
measured and averaged to 15 s time bins.  The highest 15 s stationary average V̇O2 
from the ramp and Smax protocols was then taken to represent V̇O2max (Chapter 4; 
Saynor et al., 2013).  
Submaximal gas exchange parameters. The LT was non-invasively identified using 
the GET (Beaver et al., 1986) and confirmed through visual inspection of the 
ventilatory equivalents for V̇O2 and V̇CO2 (Wasserman, 1984). The V̇O2 MRT was 
determined using the time from the onset of the ramp test to the intersection point 
between the baseline V̇O2 and a backwards extrapolation of the slope of V̇O2 as a 
function of time. The V̇O2 ‘gain’ (ΔV̇O2/ΔWR) was determined by regression of the 
‘linear’ portion of the V̇O2 response against power output. The OUES for the entire 
exercise duration (OUES100) and up to the GET (OUESGET) were derived from the 
slope of the linear function between V̇O2 (mL∙min
-1) and log V̇E (L∙min
-1) (Baba et al., 
1996). The V̇E/V̇CO2–slope (ventilatory drive) was calculated using linear regression 
during the entire CPET (Tabet et al., 2003).  
 
Additional measures: HR was determined every 5 s (PhysioFlow, PF-05, Manatec 
Biomedical, Paris, France), with the highest 15 s value taken as HRpeak. Fingertip 
SpO2 was measured on a beat-by-beat basis via pulse oximetry (NONIN, Avant 
4000, NONIN Medical Inc., USA). Subjective ratings of RPE and RPD were recorded 
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upon exhaustion using the P-CERT and CR-10 scales, respectively, the 
methodology for which is described elsewhere (Chapter 3; Saynor et al., 2013). 
 
5.2.4   Data analysis and statistics  
Data are expressed as means and standard deviations unless otherwise stated. 
Reproducibility was assessed using a downloadable spreadsheet (Hopkins, 2000). 
Following initial analyses to ensure distribution normality and heteroscedasticity, 
paired samples t-tests examined differences between tests with significance set at p 
< 0.05. Change in the mean, intraclass correlation coefficients (ICCs), absolute TE 
and TE expressed as a percentage of the coefficient of variation (TECV%), were 
calculated (with 90% confidence limits) for short- (T1-T2) and medium-term (T1-T3) 
pairwise comparisons.  
 
5.3  Results 
One patient was lost to follow-up at T3, due to reasons unrelated to the study. Table 
5.1 summarises patients’ (n = 13) baseline physical characteristics. Clinical stability 
was defined by symptoms, changes in patients’ treatment, spirometric variables and 
body mass over the course of the study (T1-T3). All patients remained clinically stable 
and with no change in symptoms, treatment, body mass [50.89 (17.26) vs. 50.98 
(17.17) kg; p = 0.63], BMI [21.23 (7.79) vs. 21.18 (7.61) kg·m2; p = 0.97] or 
pulmonary function [FVC: 3.12 (1.08) vs. 3.03 (1.04) L; p = 0.10; FEV1: 2.53 (0.88) 
vs. 2.48 (0.87) L; p = 0.10]. Stability predated T1 (i.e. recruitment) and was 
maintained beyond T3.  
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Maximal and submaximal physiological responses from the CPET are presented in 
Table 5.2. Short- (T1-T2) and medium-term (T1-T3) reproducibility data from CPET 
derived measures are presented in Tables 5.3 and 5.4 respectively. The 
reproducibility for V̇O2max is presented in Figure 5.1. The GET and OUESGET were 
identifiable in all patients at T1 and 12 (92%) patients at T2 and T3. MRT was 
detected in 11 (85%) patients from T1-T3. 
 
When compared with this combined approach (ramp and Smax), V̇O2max obtained 
using the traditional ramp only method was significantly lower at both T2 [1.76 (0.56) 
vs. 1.63 (0.52) L·min-1; p = 0.01] and T3 [1.69 (0.55) vs. 1.62 (0.54) L·min
-1; p = 
0.07], with a trend towards significance at T1 [1.77 (0.57 vs. 1.68 (0.56) L·min
-1; p = 
0.07], as has been previously demonstrated (Chapter 4; Saynor et al., 2013a). 
Moreover, V̇O2max using the combined approach was also associated with smaller 
error over both the short- [TE: 0.15 (0.12-0.23) vs. 0.23 (0.17-0.38) L·min-1; TECV%: 
9.3 (6.9-14.3) vs. 13.5 (9.5-23.3) %] and medium-term [TE: 0.16 (0.12-0.25) vs. 0.19 
(0.14-0.32) L·min-1; TECV%: 13.3 (9.9-20.9) vs. 15.5 (10.9-26.9) %] when compared 
with a ramp test in isolation. 
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Table 5.2. Patients’ physiological responses to CPET during the three visits. 
 
 
Variable n Test 1  Test 2  Test 3  
Maximal exercise 
parameters 
- - - - 
V̇O2max (L∙min
-1) 13 1.77 (0.57) 1.76 (0.56) 1.68 (0.55) 
HRpeak (b∙min
-1) 11 190 (12) 186 (14) 186 (19) 
SpO2 (%) 13 95 (3) 96 (1) 96 (3) 
RPE 13 9 (2) 9 (2) 9 (1) 
RPD 13 7 (3) 6 (3) 8 (3) 
Ramp peak power output 
(W) 
13 157 (55) 148 (62) 145 (65) 
Submaximal parameters - - - - 
GET (L∙min-1) 12 1.00 (0.22) 0.93 (0.21) 1.05 (0.29) 
MRT (s) 11 42 (15) 65 (17) 54 (26) 
V̇O2 gain (mL·min
-1·W-1)  12 8.01 (1.36) 8.11 (1.22) 7.73 (2.64) 
OUES100 (mL·min
-1·logL-1) 12 803 (227) 789 (181) 799 (218) 
OUESGET (mL·min
-1·logL-
1) 
12 797 (223) 730 (188) 756 (389) 
V̇E/V̇CO2-slope 12 34.13 (4.51) 33.26 (3.25) 32.14 (5.39) 
V̇E/V̇O2 at the GET 12 28.57 (5.45) 28.63 (3.84) 28.09 (4.58) 
V̇E/V̇CO2 at the GET  12 28.07 (3.96) 29.15 (5.43) 27.95 (5.51) 
 
Values are means ± SD, with the range also displayed unless otherwise stated. V̇O2max, maximal 
oxygen uptake; HRpeak, peak heart rate; SpO2, end-exercise arterial oxygen saturation; RPE, end-
exercise rating of perceived exertion; RPD, end-exercise rating of perceived dyspnoea; ramp; 
incremental ramp test; GET, non-invasive estimate of the lactate threshold which was verified by the 
ventilatory threshold; MRT, mean response time; V̇O2 gain, oxygen cost of exercise; OUES100, oxygen 
uptake efficiency slope for the entire duration of the ramp test; OUESGET, OUES to the GET; V̇E/V̇CO2-
slope, ventilatory drive; V̇ E/ V̇ O2, ventilatory equivalent for oxygen uptake; V̇ E/ V̇ CO2, ventilatory 
equivalent for carbon dioxide.    
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Figure 5.1. Line of identity plot for pulmonary oxygen uptake (V̇O2max) over 
both the short- [48 h (5.1a)] and medium-term [4-6 weeks (5.1b)]. 
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Table 5.3. Short-term (48 h) test-retest reproducibility (T1-T2) of CPET derived measures.  
 
 
Values are reported as means (95% confidence intervals). TE, typical error; TECV%, TE expressed as a percentage of the coefficient of variation; ICC, intra-
class correlation coefficient. See table 2 for list of abbreviations for exercise outcomes.   
Variable n Change 
in the 
mean 
p-
value 
TE TECV% ICC      p-
value 
Lung function - - - - - - - 
FVC (L) 13 0.01 0.79 0.08 (0.05-0.11) 3.1 (2.3-4.7) 1.00 < 0.01 
FEV1 (L) 13 -0.02 0.48 0.07 (0.06-0.11) 2.7 (2.0-4.1) 0.99 < 0.01 
        
Maximal exercise 
parameters 
- - - - - - - 
V̇O2max (L∙min
-1) 13 -0.01 0.91 0.15 (0.12-0.23) 9.3 (6.9-14.3) 0.94 < 0.01 
HRpeak (b∙min
-1) 11 -4 0.14 6 (4-9) 3.2 (2.3-5.1) 0.83 < 0.01 
SpO2 (%) 13 1 0.42 2 (2-3) 2.2 (1.7-3.4) 0.03 0.91 
RPE 13 0.1 0.72 0.5 (0.4-0.8) 7.8 (5.8-12.0) 0.91 < 0.01 
RPD 13 -1.3 0.09 1.7 (1.3-2.6) 63.7 (45.1-111.0) 0.60 0.05 
Ramp peak power output (W) 13 -9 0.11 14 (11.21) 21.6 (16.0-34.6) 0.95 < 0.01 
        
Submaximal parameters - - - - - - - 
GET (L∙min-1)  12 -0.06 0.17 0.11 (0.08-0.16) 11.2 (8.2-17.8) 0.80 < 0.01 
MRT (s)  11 23 <0.01 14 (10-22) 37.8 (26.8-66.7) 0.32 0.39 
V̇O2 gain (mL·min
-1·W-1) 12 0.10 0.84 1.18 (0.84-2.01) 17.4 (12.0-31.2) 0.18 0.62 
OUES100  (mL·min
-1·logL-1) 12 -14.12 0.74 100.85 (75.41-156.39) 12.0 (8.9-19.2) 0.79 < 0.01 
OUESGET ( mL·min
-1·logL-1) 12 -67.20 0.23 127.89 (95.63-198.31) 17.9 (13.1-39.1) 0.66 0.03 
V̇E/V̇CO2-slope 12 -0.88 0.42 2.54 (1.90-3.94) 7.8 (5.8-12.3) 0.63 0.03 
V̇E/V̇O2 at the GET 12 0.06 0.96 3.19 (2.38-4.94) 10.2 (7.5-16.2) 0.59 0.05 
V̇E/V̇CO2 at the GET 12 1.09 0.32 2.57 (1.92-3.99) 8.8 (6.5-14.0) 0.75 0.01 
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Table 5.4. Medium-term (4-6 weeks) test-retest reproducibility (T1-T3) of CPET derived measures. 
 
Values are reported as means (95% confidence intervals). TE, typical error; TECV%, TE expressed as a percentage of the coefficient of variation; ICC, intra-
class correlation coefficient. See table 2 for list of abbreviations for exercise outcomes. 
Variable n Change 
in the 
mean 
p-
value 
TE TECV% ICC    p-value 
Lung function - - - - - - - 
FVC (L) 13 -0.08 0.09 0.11 (0.08-0.16) 3.4 (2.6-5.2) 0.99 < 0.01 
FEV1 (L) 13 -0.07 0.07 0.08 (0.06-0.12) 3.4 (2.5-5.1) 0.99 < 0.01 
        
Maximal  exercise 
parameters 
- - - - - - - 
V̇O2max (L∙min
-1) 13 -0.09 0.21 0.16 (0.12-0.25) 13.3 (9.9-20.9) 0.93 < 0.01 
HRpeak (b∙min
-1) 11 -5 0.49 14 (10-22) 7.8 (5.7-12.7) 0.30 0.38 
SpO2 (%) 13 1 0.60 3 (2-5) 3.1 (2.2-5.2) -0.28 0.40 
RPE 13 0.3 0.22 0.6 (0.5-0.9) 7.6 (5.7-11.8) 0.85 < 0.01 
RPD 13 0.3 0.68 1.9 (1.4-2.8) 38.5 (27.9-63.8) 0.47 0.13 
Ramp peak power output (W) 13 -12 0.05 14 (11-22) 19.8 (14.7-31.6) 0.95 < 0.01 
        
Submaximal parameters - - - - - - - 
GET (L∙min-1) 12 0.05 0.40 0.14 (0.11-0.22) 16.8 (12.3-27.2) 0.74 0.01 
MRT (s) 11 12 0.26 24 (18-38) 89.4 (60.3-176.7) -0.33 0.31 
V̇O2 gain (mL·min
-1·W-1) 12 -0.28 0.72 1.85 (1.31-3.15) 24.5 (16.8-45.0) 0.24 0.40 
OUES100  (mL·min
-1·logL-1) 12 -4.29 0.92 107.28 (80.21-166.35) 15.3 (11.3-24.7) 0.80 < 0.01 
OUESGET ( mL·min
-1·logL-1) 12 -40.69 0.61 188.78 (141.15-292.73) 45.4 (32.3-78.6) 0.69 0.01 
V̇E/V̇CO2-slope 12 -2.00 0.32 4.66 (3.49-7.23) 17.7 (12.9-28.7) 0.13 0.71 
V̇E/V̇O2 at the GET 12 -0.47 0.72 3.13 (2.34-4.86) 10.1 (7.4-16.0) 0.66 0.03 
V̇E/V̇CO2 at the GET 12 -0.12 0.90 2.38 (1.78-3.69) 9.4 (6.9-14.9) 0.79 < 0.01 
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5.4  Discussion 
The principle finding of this study was that CPET was reproducible when determining 
V̇ O2max [short-term (T1-T2) ICC: 0.94; medium-term (T1-T3) ICC: 0.93], with no 
significant learning effect and short- and medium-term TEs of 150 mL (Δ 9%) and 
160 mL (Δ 13.3%). Of the additional maximal parameters, HR (3.2%, 7.8%), SpO2 
(2.2%, 3.1%) and RPE (7.8%, 7.6%) appear to hold acceptable short- and medium-
term reproducibility, respectively. Submaximal measures were identifiable in most 
cases, with the V̇E/V̇CO2-slope (7.8%), V̇E/V̇CO2 at the GET (8.8%), V̇E/V̇O2 at the 
GET (10.2%), the GET (11.2%) and OUES100 (12.0%) demonstrating promising 
reproducibility over 48 h. However, an increased TEcv% was observed for 
submaximal parameters at 4-6 weeks, with three (V̇O2 gain, OUESGET, V̇O2 MRT) 
TEs increasing above 20% (24.5%, 45.4%, 89.0%, respectively). Excluding the latter 
two variables (OUESGET and V̇O2 MRT), good short- and medium-term agreement 
was observed for all measures, highlighting the potential for CPET outcomes to be 
used to monitor disease progression and/or the effect of therapeutic interventions. 
 
Our data contribute significantly to the literature because the reproducibility of V̇O2max 
has not been established in CF using a valid protocol. Reproducibility over time is 
crucial when evaluating the efficacy of treatments (e.g. antimicrobials, mucolytics 
and gene mutation targeted therapies) which may accrue over weeks or months, as 
well as monitoring exercise training interventions (4-6 weeks). To our knowledge, 
only one study has examined the reproducibility of Smax verified (treadmill) V̇O2peak in 
a paediatric clinical population (de Groot et al., 2011), reporting an 8.2% (100 mL) 
variation in young spina bifida patients over a 2 week period. Using a solitary 
traditional ramp test, variations of 6.9% (McKone et al., 1999) and 8.5% (Gruet et al., 
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2010) have been reported over 4 weeks in CF adults for V̇O2peak. The reproducibility 
estimate for V̇O2max in the present study is therefore similar (9.3% and 13.3%) to 
these earlier studies (Gruet et al., 2010; McKone et al., 1999) and confirms CPET as 
a reproducible assessment tool. Whilst the compromised validity of performing 
traditional ramp tests, such as the popular Gofrey protocol, in isolation has 
previously been demonstrated (Chapter 4; Saynor et al., 2013a) and substantiated 
herein, the present study in paediatric CF patients also highlights a larger within-
subject variation in V̇O2max over both the short- (13.5 vs. 9.3 %) and medium-term 
(15.5 vs. 13.3 %) when compared with the combined ramp and Smax approach. Only 
one study has previously investigated CPET reproducibility in CF children (Kent et 
al., 2012), but is limited due to methodological concerns. Firstly, only three outcome 
measures (Wpeak, SpO2 and HR) were obtained, offering limited interpretation of 
aerobic fitness. Moreover, an intermittent sprint cycle test preceded the ramp test, 
which likely caused fatigue and may explain, in part, their short mean ramp test 
duration (~ 4 min).  
 
Outcome measures which can assess patients’ ability to perform at intensities similar 
to ADLs are also important. Submaximal measures hold specific value when 
maximal exercise performance is limited by ventilatory capacity and/or effort (Baba 
et al., 1996; Barker et al., 2011). Furthermore, the GET can improve independent of 
V̇O2max (Casaburi et al., 1991; Wasserman, 1984) and facilitates the identification of 
individualised exercise intensities within specific intensity domains (i.e. at a %GET or 
%Δ) for young CF patients (e.g. Stevens et al., 2011). The present study employed a 
cluster of measures and two independent observers to identify the GET in 12 of 13 
(92%) patients for all tests, with TE of 11.2% (or 110 mL) and 16.8% (or 140 mL) 
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over the short- and medium-term, respectively. Using similar methodology, our 
laboratory has previously reported a similar GET detection rate (100%) in healthy 
children, with a reproducibility estimate of ~ 8% (Fawkner et al., 2002). The present 
findings challenge previous reports suggesting difficulties in non-invasively detecting 
the GET and ventilatory threshold in patients with chronic respiratory disease and 
airflow limitation (e.g. Sexauer et al., 2003), likely due to the mild disease severity 
and subsequently normal ventilatory drive of our patients. The V̇ O2 gain was 
associated with reasonable TEs of 17.4% and 24.5% over the short- and medium-
term, respectively. The V̇O2 MRT was associated with considerably greater short- 
(37.8%) and medium-term (89.4%) variation. These submaximal measures, 
especially the MRT, may therefore be less useful than the GET.  
 
Ventilatory efficiency is best described by relating V̇O2 and V̇CO2 dynamics to V̇E 
(Arena et al., 2012). The V̇E-V̇O2 relationship is optimally described through the 
OUES (Arena et al., 2012), which is theoretically resistant to early test termination 
and intra- and inter-observed variability (Akkerman et al., 2010). In the current study, 
OUES100 was detectable in all tests and the OUESGET detectable in all patients at T1 
and 92% at T2 and T3. Short- and medium-term TEs of 12.0% and 15.3% were 
associated with the OUES100, compared with 8.3% documented in adult CF patients 
over a 4 week period (Gruet et al., 2010). Similar variations of 7.8% and 17.7% were 
documented for the V̇ E/ V̇CO2-slope in the present study. As the OUESGET was 
associated with increased short- (17.9%) and medium-term (45.4%) error and lower 
detection rate compared to the OUES100, the OUES100 appears a more robust 
outcome measure.  
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The present study provides the reproducibility for maximal and submaximal 
parameters over the short- and medium-term. Our data denote that V̇O2max changes 
exceeding 9% (150 mL) and 13% (160 mL) may indicate a change attributable to 
therapeutic intervention or disease progression over the short- and medium-term, 
respectively. The TE must, however, be considered relative to an established 
smallest worthwhile change (SWC), to estimate how many participants are needed 
to observe a ‘meaningful’ effect (Atkinson & Nevill, 1998; Hopkins, 2000; de Vet et 
al., 2006). 
 
Using Hopkins’ formula (Hopkins, 2000) for the estimation of sample size [n = 8 
(CV2/d2)], CV and d can be substituted for TE and SWC, respectively. While the 
present study has documented the CV, the value of d is uncertain for CPET 
outcomes in CF. Cox and Elkins (2011) recently raised concerns regarding how 
‘clinically worthwhile’ exercise training interventions are for patients with CF, given 
that the SWC for outcome measures had yet to be established. However, the mean 
annual rate of V̇O2max decline could, for example, be used to determine the SWC in 
V̇O2max, since it reportedly predicts CF patient survival (Pianosi et al., 2005). Using 
Pianosi and colleagues’ annual V̇O2max decline and the fitness of our similarly aged 
patients, an increase of ~ 6% in V̇O2max relative to baseline fitness would be required 
to prevent a meaningful drop in prognostic stratification. Using 6% as the SWC and a 
13.3% TE, 5 patients would be required to detect a change in V̇O2max from a 4-6 
week intervention that would be considered meaningful and clinically worthwhile. 
 
Determining the extent to which changes in outcome measurements relate to a given 
reference measure is essential to the clinical utility of CPET. Responsiveness to 
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intervention has been conceptually described as a signal-to-noise ratio (Atkinson & 
Nevill, 1998; de Vet et al., 2006; Hopkins, 2000), whereby the TE represents the 
‘noise’ and any intervention-induced effect, the ‘signal’. Data concerning V̇ O2max 
responsiveness within CF are sparse (Selvadurai et al., 2002). Of the available 
evidence, studies have reported training-related improvements in V̇O2max ranging 
from ~ 10-20% (e.g. Hebstreit et al., 2010; Hulzebos et al., 2010; Selvadurai et al., 
2002). Using our established long-term TE, the aerobic training improvement could 
be considered meaningful with a signal-to-noise ratio of ~ 1.5:1.0 for an ~ 20% 
improvement, but questionable, with a signal to noise ratio of ~ 0.8:1.0 for a 10% 
improvement. Unfortunately, the signal-to-noise ratio for most parameters is 
unknown. If future intervention studies provided more comprehensive CPET data, 
this would permit more informed data interpretation, as researchers could select 
measurements with higher signal-to-noise ratios, whilst also considering their 
sensitivity.  
 
Standardising CPET procedures will enable a larger empirical database of CF 
patients to accumulate and, longitudinally, enhance our understanding of the link 
between physiological dysfunction during exercise and patients’ prognostic 
stratification. Whilst V̇O2peak possesses recognised prognostic value (Nixon et al., 
1992), the V̇ E/ V̇ CO2-slope and OUES have demonstrated superior prognostic 
information in other clinical populations (e.g. Arena et al., 2012; Kasikcioglu et al., 
2009) and warrant investigation in CF, particularly given that although patients 
remained clinically stable throughout the present study, increased medium-term 
noise was associated with submaximal parameters. This may indicate value in 
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detecting subtle clinical changes, which current clinical assessments cannot. CPET 
to assess therapeutic interventions also requires investigation.  
 
5.5  Conclusion 
In conclusion, V̇O2max was reproducible over 48 h (Δ150 mL; Δ9.3%) and 4-6 weeks 
(Δ160 mL; Δ13.3%). Supplementary maximal and submaximal parameters should be 
incorporated to comprehensively assess aerobic exercise function. The present 
study provides a reproducible CPET protocol for young patients with mild-to-
moderate CF and will inform sample size and power calculations when planning 
interventional studies that use cardiorespiratory fitness as an endpoint.  
 
5.6    Practical implications 
 Maximal CPET is a reproducible clinical assessment tool that can be used to 
assess changes in aerobic exercise function in children and adolescents with 
mild-to-moderate CF.  
 A change > Δ150 mL or Δ9.3% over a 48 h period would indicate a clinically 
meaningful change in disease progression or in response to a therapeutic 
intervention. 
 A change > Δ 160 mL or Δ 13.3% over a 4-6 week period would indicate a 
clinically meaningful change in disease progression or in response to a 
therapeutic intervention. 
 The TE values presented in this study will enable the patient sample size for 
future interventional studies to be determined.  
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CHAPTER SIX 
Impaired Aerobic Function in Young Patients with Cystic Fibrosis 
during Ramp Exercise 
 
This experimental study has been disseminated as follows: 
 
Publication: Saynor, Z. L., Barker, A. R., Oades, P. J., Williams, C. A. (2014). 
Impaired aerobic function in patients with cystic fibrosis during ramp exercise. Med 
Sci Sports Exerc, 46(12), 2271-2278.  
Poster Presentation: Saynor, Z. L., Barker, A. R., Oades, P. J. & Williams, C. A. 
(2012). The influence of cystic fibrosis disease on the cardiopulmonary response to 
incremental ramp cycle exercise. The 1st European Workshop on Paediatric Clinical 
Exercise testing, Utrecht, The Netherlands.  
 
Poster Presentation: Saynor, Z. L., Barker, A. R., Oades, P. J. & Williams, C. A. 
(2013). Exercise limitation in paediatric patients with mild-to-moderate cystic fibrosis. 
The University of Exeter Medical School Medical and Health Research Showcase, 
Exeter, UK.  
 
Oral presentation: Williams, C. A., Saynor, Z. L., Oades, P. J. & Barker, A. R. 
(2013). Cardiopulmonary and muscle oxygenation responses during ramp exercise 
in young cystic fibrosis patients. Symposium of the European Group of Pediatric 
Work Physiology, Portugal. 
 
 
6.1  Introduction 
CF is a complex multiorgan genetic disease, expressed as a disruption in the CFTR 
protein. In conjunction with its clinical presentation, reduced aerobic fitness (typically 
determined as V̇O2max), is commonly observed in both adult (Freeman et al., 1993) 
and paediatric patients (Ionescu et al., 2001). Reduced aerobic fitness is of clinical 
relevance in patients with CF, given its association with longevity (Nixon et al., 1992; 
Pianosi et al., 2005), QoL (de Jong et al., 1997) and risk of hospitalisation (Pérez et 
  
 218 
al., 2013). Key parameters of aerobic exercise function (i.e., V̇O2max, V̇O2 gain, GET, 
and V̇ O2 MRT) (Whipp et al., 1981) have not, however, been comprehensively 
documented in CF. Moreover, no previous studies have used a valid protocol 
(Chapter 4; Saynor et al., 2013a) to obtain a ‘true’ measure of V̇ O2max in this 
population. Identifying the limiting factor(s) impairing aerobic function in CF will 
facilitate the development of more effective strategies to improve longevity and QoL 
in this aging patient population. 
 
Because the body’s upper limit for V̇O2 use is determined by the maximal ?̇?, arterial 
V̇O2 content, fractional distribution of ?̇? to the exercising muscles, and the ability of 
the skeletal muscle to extract O2 (Wasserman et al., 2004), simultaneous 
measurements at the central (cardiorespiratory) and peripheral (skeletal muscle) 
levels are required to understand the dynamic matching of O2 delivery-to-O2 
utilisation during exercise. Previous studies in CF have, however, largely neglected 
this complex interaction and based inferences on investigations of isolated organ 
systems (e.g. divangahi et al., 2009; Ionescu et al., 2001; Lands et al., 1992;).  
 
As a result, debate remains regarding the relative importance of central and 
peripheral mechanisms to explain the reduced V̇ O2max in patients with mild-to-
moderate CF. Expression of CFTR in the human skeletal muscle (Lamhonwah et al., 
2010) suggests an intrinsic myocyte metabolic abnormality, which may be specific to 
CF (e.g. de Meer et al., 1995; Divangahi et al., 2009) or a consequence of chronic 
respiratory disease (Rosenthal et al., 2009; Wells et al., 2011). In addition, there is 
evidence to support a central limitation to exercise through a reduction in SV 
(Pianosi & Pelech, 1996) and, presumably, muscle O2 delivery (Rosenthal et al., 
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2009), in paediatric patients with CF. Although a compensatory increase in muscle 
O2 extraction may be expected to occur in the presence of reduced muscle O2 
delivery, this was not observed in a previous study (Rosenthal et al., 2009). 
However, further confirmation of this response is warranted because inferences at 
the skeletal muscle level were based upon indirect, interlinked mathematical 
calculations.  
 
To further understand how disease pathophysiology alters the O2 delivery-to-O2 
utilisation relationship during exercise, NIRS can provide valuable, non-invasive 
insight into peripheral O2 extraction. Specifically, the profile of the [HHb] signal has 
been used to describe O2 extraction dynamics during ramp exercise, which in turn 
permit inferences regarding blood flow within the microcirculation of exercising 
muscle (Boone et al., 2009; Ferreira et al., 2007; McNarry et al. 2011; Murias et al., 
2013a; Murias et al., 2013b). Although the [HHb] profile during ramp exercise has 
been used to describe the effect of trained status (Boone et al., 2009; McNarry et al., 
2011) and ageing (Gravelle et al., 2012; McNarry et al., 2011), there are no data 
documenting the influence of disease on the [HHb] response to exhaustive 
incremental exercise. If the supply of blood to the active muscle during exercise is 
impaired in CF, as would be indirectly inferred from previous reports of a reduced SV 
(Pianosi & Pelech, 1996), an increased rate of fractional O2 extraction for a given 
V̇O2 would be expected (Ferreira et al., 2007).  
 
The purpose of the present study was twofold; 1) to characterise the four key 
parameters of aerobic function in paediatric patients with mild-to-moderate CF and 2) 
to characterise the dynamic adjustment of NIRS-derived leg muscle [HHb] during 
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ramp exercise. It was hypothesised that: 1) aerobic exercise function would be 
impaired in CF, as evidenced by a reduced V̇ O2max, slower V̇ O2 MRT, earlier 
occurrence of the GET and shallower V̇O2 gain and, furthermore, that 2) patients with 
CF would be characterised by more rapid [HHb] dynamics during ramp exercise (i.e., 
leftward shift), which will correlate with impaired parameters of aerobic function.   
 
6.2  Methods 
6.2.1   Participants, anthropometry and pulmonary function   
Ten young patients (9 males (Table 6.1)) with stable mild-to-moderate CF disease 
(CF) regularly partaking in school and/or extracurricular physical activity were 
recruited from outpatient clinics at the Royal Devon and Exeter NHS Foundation 
Trust Hospital. CF inclusion and exclusion criteria are detailed elsewhere (Saynor et 
al., 2013a). Ten healthy age- and gender- matched control participants (CON) were 
recruited from the local area (Table 6.1). Neither group presented with any 
contraindications to exhaustive exercise, and CON were free from any pulmonary 
conditions. Ethics approval was granted by the South West NHS Research Ethics 
Committee. Informed written consent and assent were obtained from 
parents/guardians and patients, respectively. Details concerning the CF patients’ 
disease severity and clinical profile were obtained by their clinician (Table 6.2). All 
CF maintenance medications were continued as usual throughout the study.  
 
Body mass (Seca 220; Vogel & Halke, Hamburg, Germany) and stature (Seca 220; 
Vogel & Halke, Hamburg, Germany) were measured to the nearest 0.01 kg and 0.01 
m, respectively. Pubertal maturity was determined using Tanner staging (Tanner, 
1962). Skinfolds measured to the nearest 1 mm on the right-hand side of the body at 
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the tricep and subscapula regions (Harpenden; British Indicators, Burgess Hill, UK) 
and were used to estimate FFM (Slaughter et al., 1988). FVC and FEV1 were 
assessed using flow-volume loop spirometry (MicroMedical MicroLoop 3535, 
Numed, Sheffield, UK). The best of three consistent (< 5% variability) exhalations 
was documented and expressed as a percentage of predicted using appropriate 
reference data (Stanojevic et al., 2009).  
 
Table 6.1. Baseline anthropometric and pulmonary function data for young CF 
patients (n = 10, 1 female) and healthy age- and gender-matched controls. 
 
Variable CF 
(Mean ± SD) 
CON  
(Mean ± SD) 
Change,  
90% CL 
Inference 
(in CF) 
ES 
      
Age (y) 
 
12.7 ± 2.8 12.5 ± 2.8 0.2, ±2.2 Unclear  0.07 
Stature (m) 
 
1.53 ± 0.15 1.58 ± 0.19 -0.05, 
±0.14 
Unclear -0.25 
Body mass 
(kg) 
 
53.2 ± 20.0 50.5 ± 17.4 2.7, ± 14.6 Unclear  0.14 
BMI (kg·m2) 
 
22.0 ± 4.6 19.5 ± 2.7 2.4, ±3.0 Likely higher   
0.60 
BSA (m2) 
 
1.51 ± 0.35 1.48 ± 0.35 0.03, ±0.27 Unclear   
0.08 
FFM (kg) 
 
42.0 ± 14.6 41.3 ± 14.0 0.6, ±11.1 Unclear  
0.04 
FVC (L) 
 
3.36 ± 1.30  
 
3.69 ± 1.33 -0.33, 
±1.03 
Unclear -
0.24 
FVC ( % 
predicted  
(range)) 
102 ± 14 
(79-123) 
106 ± 10 
(92-125) 
-4, ±10 Unclear -
0.28 
 
FEV1 (L) 
 
 
2.69 ± 1.12 
 
3.18 ± 1.18 
 
-0.49, 
±0.89 
 
Unclear 
 
-
0.41 
FEV1  
(% predicted 
(range)) 
97 ± 22 
(66-127) 
107 ± 10 
(96-129) 
-10, ±14 Likely lower -
0.55 
 
Values are means ± SD. ES; Effect size; CI, confidence intervals; BMI, body mass index; FFM, fat-
free mass (calculated using the equation of Slaughter et al. (1988); FVC, forced vital capacity; FEV1, 
forced expiratory volume in 1 s. N.B. Parameters of pulmonary function are expressed as a 
percentage predicted normal using appropriate reference data (Stanojevic et al., 2009).  
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Table 6.2. Baseline clinical characteristics for the young CF patients (n = 10, 1 
female).  
Variable Value (mean ± SD) Range 
CFTR genotype: 
Homozygote ∆F508 (Class I mutation) 
∆F508/ 2184delA (Class II Mutation) 
∆F508/ G55ID (Class III mutation) 
- 
8 
1 
1 
- 
- 
- 
- 
Chronic P. Aeruginosa infection a “chronic,” n = 2; 
“intermittent,” n = 3 
“free,” n = 3 
“never,” n = 2 
Shwachman score 81 ± 7 67-91 
Northern score b 4 ± 1 2-6 
Pancreatic insufficient n = 10  
CF-related diabetes n = 3 - 
CF-related liver disease 
IVABs (days in last year) 
n = 3 
10 ± 15 
- 
0-42 
 
Values are means ± SD, unless otherwise stated. 
CFTR, cystic fibrosis transmembrane conductance regulator; P. Aeruginosa; Pseudomonas 
Aeruginosa; Shwachman score - scoring 4 separate aspects of the disease profile; general activity; 
physical examination; nutritional status; and chest radiographic findings, using the most recent clinical 
review information. A total of 100 points represents a perfect score of health; IVABs, intravenous 
antibiotics; 
a
According to Leeds Criteria, “chronic”, >50% of the preceding 12 months were P. 
aeruginosa culture positive; “intermittent”, ≤50% of the preceding 12 months were P. aeruginosa 
culture positive; “never”, no growth of P. aeruginosa for the previous 12 months, having previously 
been P. aeruginosa culture positive; “free”, P. aeruginosa has never been cultured.   
b
 Provides evidence of radiographic chest findings. Maximum score is 20, with 20 being the most 
severe.  
 
 
6.2.2   Exercise testing protocol   
Participants arrived to the laboratory in a rested state, ≥ 2 h postprandial and having 
refrained from caffeine for ≥ 2 h. A maximal CPET was performed on a cycle 
ergometer (Lode Excalibur or Lode Corival, Groningen, The Netherlands) using a 
single session, combined ramp incremental and Smax CPET protocol, which has 
been validated in healthy children (Barker et al., 2011) and children and adolescents 
with CF (Chapter 4 - Saynor et al., 2013a). This protocol, the reproducibility of which 
has recently been documented in young CF patients (Chapter 5; Saynor et al., 
2013b), involved an exhaustive ramp incremental (10-25 W∙min-1) cycling test with a 
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subsequent Smax (110% Wpeak) test to exhaustion to verify V̇O2max. After a 3 min 
warm-up period (20 W cycling), participants completed the incremental ramp test 
while cycling at a cadence of approximately 70-80 rpm until volitional exhaustion, 
defined as a drop in cadence ≥ 10 rpm for five consecutive seconds, despite strong 
verbal encouragement. Five minutes active recovery (20 W cycling) and 10 min 
passive seated recovery then preceded the Smax verification test, which involved a 3 
min warm-up (20 W cycling) before a ‘step’ transition to a CWR equivalent to 110% 
Wpeak. Upon voluntary exhaustion, 5 min active recovery (20 W cycling) completed 
the CPET assessment.  
 
6.2.3   Exercise testing measurements 
Before each test, the metabolic cart (Metalyzer 3B Cortex, Biophysik, Leipzig, 
Germany) was calibrated using gases of known concentration and a 3 L calibration 
syringe (Hans Rudolph, Kansas City, MO) was used to calibrate the turbine volume 
transducer. Breath-by-breath changes in pulmonary gas exchange and ventilation 
were measured and averaged to 15 s time bins, with the highest 15 s stationary 
average from the ramp or Smax tests representing V̇O2max.  
 
6.2.4   Data analysis   
The GET in absolute terms and expressed as a percentage of V̇O2max was non-
invasively identified and confirmed through visual identification of the ventilatory 
equivalents for V̇O2 and V̇CO2. The V̇O2 MRT was determined using the time from the 
onset of ramp exercise to the intersection point between baseline V̇ O2 and a 
backward extrapolation of the slope of V̇O2 as a function of time (Wasserman et al., 
2004). Regression of the linear portion of the V̇O2 response versus power output was 
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used to determine the functional V̇O2 gain (∆V̇O2/∆WR). Equation 6.1 was used to 
determine the O2 pulse (V̇O2/HRpeak).  
 
V̇O2/HRpeak (mL∙b
-1) = V̇O2 (L∙min
-1) x 1000 mL / HR (b∙min-1)               Equation 6.1. 
 
Near-infrared spectroscopy 
HHb dynamics from the m. vastus lateralis were noninvasively measured using NIRS 
(Portamon, Artinis Medical Systems). This system has previously been used in 
children (McNarry et al., 2011) and consists of an emission probe, with three light 
sources emitting two wavelengths of light (760 and 850 nm) and a photon detector. 
The intensity of incident and transmitted light was recorded continuously at 10 Hz 
and used to estimate [HHb]. Since the NIRS-derived [HHb] signal does encompass 
contribution from intramyocyte myoglobin and does not solely reflect the 
microcirculatory compartment [vascular (Hb) deoxygenation] (Koga et al., 2012), the 
changes in muscle [HHb] should be considered to represent [Hb+Mb]. The wireless 
emitter-detector unit was placed over the m. vastus lateralis, midway between the 
greater trochanter and lateral epicondyle of the femur. The area of interrogation was 
initially cleaned and shaved and, after marking of the placement area, the device 
was secured with tape (KinesioTex®) and a dark elastic bandage, to minimise 
extraneous light interference with the near-infrared signal.  
 
Additional measures 
HR was measured on a beat-by-beat basis using the ECG-derived R-R interval 
(PhysioFlow, PF-05, Manatec Biomedical, Paris, France). Fingertip SpO2 was 
recorded via pulse oximetry (NONIN, Avant 4000, NONIN Medical Inc., USA). 
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Subjective ratings of RPE and RPD were determined upon exhaustion using the P-
CERT and CR-10 scales, respectively, the methodology for which is described 
elsewhere.   
 
HHb modelling procedures  
Muscle [HHb] data were interpolated to 1 s intervals and averaged data (15 s) for the 
entire test were subsequently normalised to the total amplitude of the response 
(%∆[HHb]), such that 0% represented steady-state values observed during the 
period of baseline (20 W) cycling and 100% represented the highest average (i.e., 
∆[HHb]peak) (Boone et al., 2009; Gravelle et al., 2012). The response was then 
expressed as a function of absolute and relative Wpeak and V̇O2max. Preliminary 
statistical analyses (GraphPad Prism, GraphPad Software, San Diego, CA) revealed 
that the sigmoid provided a superior fit to the [HHb] response when compared with 
bilinear or hyperbolic curve fitting procedures. The ∆[HHb] response to incremental 
ramp cycling exercise was therefore described using a sigmoidal model (Equation 
6.2) in line with previous studies (Boone et al., 2009; Ferreira et al., 2007; McNarry 
et al., 2011) as follows: 
 
y = f0 + A / (1 + e 
–(c+dx))         Equation 6.2. 
 
where f0 represents baseline [HHb], A the amplitude of the response, d the slope of 
the sigmoid, c the constant that is dependent on d and c/d the value corresponding 
to 50% of the total amplitude, respectively. 
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6.2.5   Statistical analysis 
Log-linear allometric models were used to adjust V̇O2max for body size. The log-linear 
allometric model yielded a scaling exponent close to unity for FFM (b = 1.03), 
meaning the ratio standard method for normalising V̇O2max was deemed appropriate. 
Data are expressed as means and standard deviations unless otherwise stated. 
Independent samples t-tests (SPSS v19.0, Chicago, USA) derived p-values for 
subsequent inferential analyses. Inferential statistics, using 90% confidence intervals 
(CI) and the effect size (ES), were used to derive magnitude-based inferences 
regarding the true value of the observed effect statistic (Hopkins et al., 2009). 
Facilitated by a published Microsoft Excel® spreadsheet (Hopkins, 2007), any 
influence of CF on parameters of the [HHb] response and maximal and submaximal 
CPET parameters was calculated, using a 90% CI and the ES. Using a smallest 
worthwhile ES change of 0.2 (Cohen, 1988) and the 90% CI, the likelihood that the 
observed effect was beneficial (e.g. higher V̇O2max, faster MRT), trivial or harmful 
(e.g. lower V̇O2max, slower MRT) was reported. The qualitative terms used to inform 
these decisions were: < 0.5%, ‘most unlikely’; 0.5-5%, ‘very unlikely’; 5-25%, 
‘unlikely’; 25-75%, ‘possibly’; 75-95%, ‘likely’; 95-99.5%, ‘very likely’; > 99.5%, ‘most 
likely’. An effect was deemed trivial when the majority (> 50%) of the 90% CI resided 
between beneficial and harmful. Conversely, an effect was deemed unclear when 
the likelihood of a beneficial and harmful effect was > 5%.  
 
Hopkins’ published spreadsheet (Hopkins, 2007) was also used to determine the 
90% CI for Pearson’s correlation coefficients to explore the relationship between key 
parameters of aerobic exercise function (i.e., V̇O2max, V̇O2 gain, MRT and the GET) 
and mechanistically linked parameters of muscle O2 extraction (e.g., d and c/d of the 
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[HHb] response) and O2 delivery (e.g., end-exercise SpO2 and O2 pulse) in CF. 
Cohen’s thresholds (Cohen, 1988) for small (0.1), moderate (0.3), large (0.5) and 
very large (0.7) relationships describe the magnitude of correlations.  
 
6.3  Results 
Table 6.1 presents participants’ baseline physical characteristics, with Table 6.2 
detailing the clinical profile of the patients with CF. BMI was likely higher, whereas 
FEV1 (% predicted) was likely lower in CF than CON. Pubertal maturity of both 
groups was as follows: pre-pubertal (n in CF = 3; n in CON = 1), circum-pubertal (n 
in CF = 7; n in CON = 8) and post-pubertal (n in CF = 0; n in CON = 1).  
 
Maximal and submaximal CPET parameters are presented in Table 6.3. All 
participants completed CPET without any adverse events. Ramp PPO was possibly 
lower in CF and likely lower when expressed relative to body mass. As expected, CF 
presented with very likely reduced V̇O2max, when normalised for both body mass and 
FFM. Furthermore, the V̇O2 gain was very likely lower and the V̇O2 MRT was likely 
slowed in CF. The RPD upon exhaustion was most likely higher in CF, respectively.  
 
Parameter estimates for normalised muscle [HHb] as a function of absolute and 
percentage Wpeak (%Wpeak) and V̇O2max (%V̇O2max) are compared in Table 6.4, and 
the Δ[HHb]-work rate profile for two representative CF and CON matched pairs are 
shown in Figure 6.1. Any effect of the reduced aerobic fitness in patients with CF 
upon the slope (d) of the Δ[HHb]-work rate response was mechanistically unclear 
when expressed either as a function of absolute and percentage Wpeak or absolute 
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and percentage V̇O2max. Furthermore, the effect of CF upon the absolute and relative 
work rate and V̇O2 corresponding to 50% [HHb] amplitude (c/d) was mechanistically 
unclear.  
 
  
 229 
 
Table 6.3. Maximal and submaximal physiologic responses of young patients with CF and healthy age- and gender-matched 
controls to ramp incremental cycle exercise.  
Variable CF 
(Mean ± SD) 
CON 
(Mean ± SD) 
Change, 90% CI Inference 
(in CF) 
ES 
Maximal exercise parameters - - - - - 
Absolute V̇O2max (L∙min
-1) 1.93 ± 0.84 2.21 ± 0.79 -0.29, ±0.63 Unclear -0.34 
Relative V̇O2max (mL∙kg
-1∙min-1) 
V̇O2max/FFM (mL∙kg
-1∙min-1) 
36.3 ±  7.6 
45.5 ± 9.1 
43.9 ± 5.2 
53.5 ± 6.4 
-7.6, ±5.1 
-7.9, ±6.1 
Very likely lower  
Very likely lower 
-1.11 
-0.96 
V̇Emax (L∙min
-1) 84.27  ± 33.07 99.31 ± 39.95 -15.04, ±28.53 Unclear  -0.39 
Breathing reserve (%) 20.4 ± 19.9 12.4 ± 16.2 8.0, ±14.1 Unclear 0.42 
HRmax (b∙min
-1) 192 ± 11 190 ± 13 2, ±10 Unclear 0.18 
V̇O2/HRmax (mL·b
-1) 9.78 ± 4.71 11.01 ± 3.39 -1.23, ±3.41 Unclear -0.28 
SpO2 (%) 95 ± 2 97 ± 1 -3, ±1 Most likely lower  -1.63 
Ramp Wpeak (W) 176 ± 94 205 ± 82 -30, ±69 Possibly lower -0.32 
Relative ramp Wpeak (W·kg
-1) 3 ± 1 4 ± 1 -0.7, ±0.5 Likely lower -0.84 
RPE 9 ± 2 10 ± 1 -1, ±1 Unclear -0.35 
RPD 9 ± 2 6 ± 2 3, ±2 Most likely higher 1.46 
Submaximal exercise  - - - - - 
V̇O2 at the GET (L∙min
-1) 1.13 ± 0.41 1.20 ±  0.30  -0.07, ±0.28 Unclear -0.20 
GET% (% of V̇O2max) 61.3 ± 10.2 56.7 ± 8.4 4.6, ±7.3 Unclear 0.47 
MRT (s) 49 ± 21 38 ± 11 11, ±13 Likely slower 0.63 
ΔV̇O2/ΔWR (mL∙min
-1∙W-1) 7.62 ± 1.67 9.05 ± 1.17 -1.44, ±1.12 Very likely lower  -0.95 
Values are means ± SD. RPE, RPD and SpO2 were measured at the end of exercise. ΔV̇O2/ΔWR, oxygen cost of exercise (efficiency); GET, non-invasive 
estimate of the lactate threshold which was verified by the ventilatory threshold; GET%, GET expressed as a percentage of V̇O2max; MVV, maximal voluntary 
ventilation; V̇ O2max, maximal oxygen uptake; MVV, maximal voluntary ventilation;  V̇ O2/HRmax, maximal oxygen pulse;  V̇ Emax, maximal minute 
ventilation;  V̇ O2/HRmax, maximal oxygen pulse;  V̇ E/ V̇ CO2-slope, ventilatory drive.
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Figure 6.1. Sigmoid models of normalised muscle deoxygenation (% ∆[HHb]) during 
ramp incremental exercise as a function of percentage peak oxygen uptake for two 
representative young patients with CF (●, black circles) of the leftward and rightward 
response patterns and their healthy age- and gender-matched control participants 
(dashed line; ○, white circles).  
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Correlational analyses within the CF group revealed small relationships between 
patients’ V̇O2max and their [HHb] c/d, expressed as a function of %Wpeak (r = 0.14, 
±0.58) and %V̇O2max (r = - 0.21, ±0.57), respectively. With the exception of the very 
large relationship between V̇ O2 gain and [HHb] c/d %Wpeak (r = 0.70, ±0.36), 
relationships between V̇O2 gain and [HHb] c/d %V̇O2max and the GET and MRT with 
[HHb] c/d %Wpeak and % V̇ O2max were all small. A moderate relationship was 
observed between V̇O2max and end-exercise SpO2 (r = 0.33, ±0.51) in CF (Figure 
6.2), however this was small (r = 0.20, ±0.54) in the healthy control group. The 
relationship between V̇O2max and O2 pulse was large in CF (r = 0.58, ±0.41; Figure 
6.2) and CON (r = 0.98, ±0.00). Similarly, the relationships between V̇O2 gain and 
end-exercise SpO2 and O2 pulse were moderate (r = 0.40, ±0.49) and large (r = 0.65, 
±0.37), respectively in CF, however these were small in CON (r = -0.15, ±0.54 and r 
= 0.1, ±0.58, respectively). Very large relationships were also evident between the 
GET and end-exercise SpO2 (r = -0.88, ±0.16) and O2 pulse (r = 0.98, ±0.03) in CF. 
The relationship between the GET and O2 pulse was very large in CON (r = 0.92, 
±0.12); however that with SpO2 was small (r = 0.1, ±0.55). A moderate relationship (r 
= 0.39, ±0.49) was also evident between the V̇O2 gain and MRT in CF, however this 
was small in CON (r = 0.01, ±0.55). 
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Table 6.4. Parameter estimates for normalised muscle deoxygenation (∆[HHb]) as a function of absolute and percentage peak 
work rate during ramp incremental cycling and the absolute and normalised ratio of [HHb]-to-pulmonary oxygen uptake above and 
below the gas exchange threshold and at exhaustion. 
 
Variable Parameter 
expressed 
function of 
CF (n = 9) 
(Mean ± SD) 
CON (n = 9) 
(Mean ± SD) 
Change, 
90% CI 
Inference 
(in CF) 
ES 
A (%) Wpeak 100.1 ± 18.0 96.1 ± 8.1 4.0, ±11.8 Unclear 0.27 
d (%·W-1) Wpeak 0.1 ± 0.1 0.1 ± 0.0 0.0, ±0.1 Unclear 0.40 
c/d (W) Wpeak 98 ± 52 112 ± 54 -14, ±44 Unclear  -0.25 
A (%) % Wpeak 100.0 ± 17.8 96.1 ± 8.1 3.9, ±11.7 Unclear 0.26 
d (%·%Wpeak
-1) %Wpeak 0.1 ± 0.1 0.1 ± 0.0 0.0, ±0.0 Unclear 0.16 
c/d (%Wpeak) % Wpeak 47.1 ± 17.8 47.7 ±  9.1 -0.7, ±12.0 Unclear -0.04 
A (%) V̇O2max 88.2 ± 10.2 93.6 ± 6.8 -5.4, ±7.2 Likely lower -0.59 
d (%·L-1) V̇O2max 13.3 ± 16.4 6.9 ± 4.3 6.3, ±10.4 Unclear 0.48 
c/d  (L) V̇O2max 1.27 ± 0.51 1.36 ± 0.52 -0.10, ±0.43 Unclear -0.18 
A (%) %V̇O2max 91.6 ± 9.0 93.5 ± 6.8 -1.9, ±6.6 Unclear -0.23 
d (%·%max
-1) %V̇O2max 0.2 ± 0.1 0.1 ± 0.0 0.0, ±0.1 Unclear 0.38 
c/d (%max) %V̇O2max 66.9 ± 8.5 63.6 ± 5.7 3.3, ±6.0 Unclear 0.43 
 
 
Values are means ± SD unless otherwise stated. 
Because of technical issues, [HHb] data are presented for nine matched pairs.  
A, amplitude of the change in the deoxygenated haemoglobin (Δ[HHb]) response; c, constant that is dependent upon d and where c/d x-value corresponding 
to 50% A, respectively; d, slope of sigmoid.  
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Figure 6.2. The relationship between maximal oxygen uptake (V̇O2max) and changes in end-exercise arterial oxygen saturation 
(SpO2) and the maximal oxygen pulse in young patients with cystic fibrosis.  
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6.4  Discussion 
This is the first study to examine the influence of mild-to-moderate CF on the aerobic 
function and dynamic adjustments in localised muscle (vastus lateralis) fractional 
oxygen extraction (∆[HHb]) in paediatric patients during ramp incremental cycling 
exercise.  As expected, CF patients were characterised by impaired aerobic exercise 
function, as displayed by a very likely reduced body mass or FFM normalised 
V̇O2max, a very likely lower V̇O2 gain, and likely slower V̇O2 MRT. Contrary to the 
experimental hypothesis, however, this reduced aerobic fitness status did not have a 
clear effect upon the dynamics of the ∆[HHb] during ramp incremental exercise. 
Specifically, no clear shift in c/d of the [HHb] response was evident when expressed 
relative to percentage Wpeak or V̇O2max and relationships with the key parameters of 
aerobic exercise function were small. Indicators of central O2 delivery were, 
however, altered by CF. Specifically, end-exercise SpO2 was most likely lower and 
correlated with V̇ O2max in the CF group only. Thus, these data show that the 
observed changes in the aerobic exercise function of paediatric patients with CF 
during incremental ramp cycling are likely related to alterations in muscle O2 
delivery, with no compensatory adjustment to the dynamics of muscle O2 extraction 
within the microcirculation.   
This study is unique for a number of reasons. It is the first to use a validated protocol 
(Chapter 4 - Saynor et al., 2013a) to document ‘true’ V̇O2max in young patients with 
CF. Consistent with earlier reports (Keochkerian et al., 2008), V̇O2max in patients with 
CF was very likely lower than that of CON in this study when normalised for both 
body mass and FFM. But importantly, the present results are robust because this is 
the first to include a Smax V̇O2max verification phase (Chapter 4; Saynor et al., 2013a) 
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within the CPET protocol, thereby removing the issue of previous studies, where 
aerobic fitness status may have been underrepresented because of invalid 
verification criteria (Chapter 4; Saynor et al., 2013a).  
 
Secondly, this study presents, for the first time, the four key parameters of aerobic 
function (Whipp et al., 1981), allowing a comprehensive assessment of aerobic 
fitness in this patient group. Of the additional key parameters, patients with CF 
presented with a very likely reduced V̇O2 gain and a likely slowed V̇O2 MRT, with no 
clear effect on the GET. While slower pulmonary V̇ O2 kinetics have been 
documented in patients with CF during constant-load, moderate intensity cycling 
(Hebestreit et al., 2005), the present study extends these findings to the V̇ O2 
response at the onset of ramp incremental cycling. Although no clear influence upon 
the GET was evident, the functional gain during the moderate-intensity region of 
ramp exercise was very likely lower in CF, reflecting either an apparently greater 
skeletal muscle efficiency or impaired muscle O2 consumption. Shallower ∆V̇O2/∆WR 
slopes during exercise have previously been reported in patients with CF (Moser et 
al., 2000), congenital heart disease (Groen et al., 2010) and juvenile 
dermatomyositis (Groen et al., 2010). However, steeper ∆V̇O2/∆WR responses have 
also been observed in young patients with CF (Groen et al., 2010). It would be 
misleading to interpret the reduced ∆V̇O2/∆WR in the present findings as enhanced 
aerobic efficiency, particularly given the impairment in other parameters of aerobic 
function (i.e., V̇O2max and MRT). Given the moderate relationship between the V̇O2 
gain and MRT in CF, the lower ∆V̇O2/∆WR slope may be related to the slower 
pulmonary V̇ O2 kinetics, such that the rise in V̇ O2 was not sufficiently rapid to 
respond to the work rate increments during the CPET. 
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To our knowledge, this study is the first to report the ∆[HHb] dynamics during ramp 
exercise in paediatric patients with CF. While pulmonary V̇O2 increased linearly with 
increasing work rate following an initial time lag, muscle ∆[HHb] (reflecting the ratio 
of muscle blood flow to muscle O2 utilisation (Table 6.4; Figure 6.1) increased in a 
nonlinear manner. This response was well characterised using a sigmoid function 
relative to work rate and V̇O2 in both groups in the current study, which is consistent 
with previous reports in children and young and old adults during ramp incremental 
cycling exercise (Boone et al., 2009; Gravelle et al., 2012; McNarry et al., 2011).  
 
Contrary to the study hypothesis, the ∆[HHb] dynamics during ramp exercise were 
similar between CF and CON in the present study. That is, no clear effect of CF 
upon either the absolute and relative work rate and V̇O2 corresponding to 50% 
∆[HHb] amplitude was observed. This is despite previous reports that aerobic fitness 
status has an effect upon the dynamic balance between O2 supply and demand and, 
consequently, the sigmoidal pattern of ∆[HHb] (Boone et al., 2009; McNarry et al., 
201). Boone et al. (2009) previously demonstrated that a higher aerobic fitness is 
associated with a rightward shift of the [HHb] sigmoidal response (relative to %Wpeak) 
in healthy adults and that the response correlated with parameters of aerobic fitness 
(i.e., V̇O2max and the GET). The purported mechanism for this rightward shift in the 
[HHb] response was attributed to a higher oxidative capacity and/or altered muscle 
fiber distribution. The rate of fractional oxygen extraction has been shown to be 
influenced by training status and enhanced O2 delivery in trained versus untrained 
healthy girls (McNarry et al., 2011). Because V̇O2max was meaningfully reduced in 
patients with CF in the present study, a more rapid increase in ∆[HHb] during ramp 
exercise would be expected. However, a previous study (Gravelle et al., 2012) 
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comparing older (approximately 70 y) and younger (approximately 25 y) healthy 
adults, which observed alterations when expressed relative to absolute power 
output, did not observe any age-related differences in ∆[HHb] response dynamics 
when expressed as a function of %Wpeak, despite a reduced V̇O2max in the older 
participants (30 vs. 49 mL·kg-1·min-1).  
 
Some caution may, however, be applied when considering the present findings to 
suggest that there are no differences between the ∆[HHb] response of healthy and 
CF children and adolescents. Inter-patient differences (Figure 6.1) in the Δ[HHb] 
response suggest that the interpretation that the rate of muscle O2 extraction is 
unaltered by CF may be too simplistic. When the distribution of the 90% CI for the 
effect of CF on the ∆HHb c/d was expressed relative to percentage V̇O2max, the 
majority of the 90% CI distribution favoured a reduced rate of extraction (leftward 
shift: 9%; trivial: 22%; rightward shift: 69%). The unclear statistical outcome is, 
therefore, likely to reflect the large inter-patient variability present for this outcome 
(see Figure 6.1). Indeed, inter-patients differences are not improbable given the 
complex nature and varied clinical presentation of CF disease, meaning further 
comment on the responses shown in Figure 6.1 may be of clinical interest. Patient A, 
who has a left shift on the ∆[HHb] response, is a physically mature boy with few 
complications and excellent pulmonary function. In contrast, patient B (also male), 
whose ∆[HHb] response is shifted to the right has poorer pulmonary function, a 
worse chest x-ray score, nutritional concerns, and complications including CF-related 
liver disease and impaired glucose tolerance. This is reflected in patient B having 
received 28 dys of intravenous antibiotics, which signifies treatment intensification, 
within the preceding year. However, despite patient B’s poorer clinical profile, his 
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V̇O2max is markedly higher than that of patient A (49.4 vs. 32.6 mL·kg
-1·min-1), which 
may have played a role in causing the rightward shift in the ∆[HHb] response 
dynamics. However, it should be noted that we only found a small relationship 
between V̇O2max and [HHb] c/d in the present study.    
 
Interestingly, the present findings of unaltered [HHb] response dynamics for the CF 
group in the present study are in line with a previous report by Rosenthal et al. 
(2009), who observed similar O2 extraction dynamics during exercise in young 
patients with CF and their healthy counterparts, despite presenting with impaired 
aerobic function. When considered in reference to the Fick equation, these data 
therefore suggest that the impaired aerobic exercise function characterising young 
patients with CF is caused by a reduction in O2 delivery. Altered cardiac function 
(Benson et al., 1984; Ionescu et al., 2001; Pianosi & Pelech, 1996) and an inability to 
augment SV during exercise (Rosenthal et al., 2009), which are likely to reduce 
central O2 delivery, have previously been documented in patients with CF, and the 
most likely lower SpO2 in the present study provides further support. Although it has 
been propositioned that patients with CF can achieve apparently “normal” ?̇? in the 
presence of reduced SV during exercise, through elevated HR (Ionescu et al., 2001; 
Lands et al., 1992), this compensation only seems viable at submaximal exercise 
intensities, as both CF and CON had similar HR responses at maximal exercise in 
the present study. In accordance with this findings, a reduced (approximately 24%) 
estimated SV (derived using respiratory mass spectroscopy) at maximal exercise in 
young patients with CF coupled with a similar HR response to healthy controls has 
previously been documented (Rosenthal et al., 2009).  
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Although it has been hypothesised that patients limited by O2 delivery during 
exercise would present with a compensatory increase in O2 extraction at the local 
level (Ferreira et al., 2007), both this study and the previous study by Rosenthal et 
al. (2009), using respiratory mass spectroscopy, observed no augmentation of O2 
extraction in the face of inadequate O2 delivery during exercise (Rosenthal et al., 
2009). Although the previous authors could not determine the cause of this because 
no direct peripheral measurements were made, it was suggested that muscle 
metabolic issues resulting from chronic bronchial sepsis may contribute. Importantly, 
the present study utilising NIRS corroborates the observations of Rosenthal et al. 
(2009) using a more direct measurement technique.  
 
The relationships between parameters of aerobic exercise function and mechanistic 
parameters indicative of O2 delivery and extraction further emphasise the importance 
of O2 delivery in explaining the impaired aerobic function in young patients with CF. 
Although the relationships between key parameters of aerobic exercise function and 
the rate of peripheral fractional O2 extraction were small, stronger relationships with 
parameters of O2 delivery were evident. Furthermore, while SpO2 did not correlate 
with FFM normalised V̇O2max in healthy controls, a moderate correlation with end-
exercise SpO2 was observed in patients with CF, along with a large relationship 
between V̇O2max and the O2 pulse. The relationships between V̇O2 gain and end-
exercise SpO2 and O2 pulse were also moderate and large, respectively. Similarly, 
very large relationships were evident between the GET and end-exercise SpO2 and 
O2 pulse.  
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There are several limitations of NIRS, which must be acknowledged. First, 
measurements are restricted to a specific area of interrogation over a, in this case, 
single heterogenous and superficial muscle, which may not represent whole body 
skeletal muscle blood flow responses. However, the muscle deoxygenation response 
measured in the superficial and deeper muscle fibres using NIRS has been shown to 
reflect muscle oxygenation as measured using phosphorous quenching derived 
microvascular O2 partial pressure within the same region of muscle (Koga et al., 
2012). Although inter-site variation in the [HHb] response cannot be directly rectified, 
the device was secured to the same anatomical region for all participants to 
eradicate inter-individual regional differences within the m. vastus lateralis. Although 
the influence of adipose tissue at the area of interrogation was not directly 
determined, in line with recommendations, responses were standardised to the total 
[HHb] amplitude to provide a physiologic normalisation (Boone et al., 2009). Finally, 
the generalisability of these findings should be viewed in light of the small sample of 
Northern European patients with CF recruited for this study.  
 
6.5  Conclusion 
To conclude, this was the first study to examine the influence of mild-to-moderate CF 
on key parameters of aerobic function in paediatric patients. As expected, paediatric 
patients with CF presented with impaired aerobic exercise function compared with 
that of their healthy counterparts. Specifically, V̇O2max and the V̇O2 gain were very 
likely reduced and the MRT likely slowed. However, in contrast to the study 
hypothesis, NIRS derived [HHb] dynamics during ramp incremental cycling exercise 
were similar between CF and CON. The present findings support the notion of 
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centrally mediated O2 delivery principally limiting the aerobic exercise function of 
young patients with CF during ramp incremental cycling exercise. 
 
 
6.6    Practical implications 
 Aerobic fitness (V̇O2max) measurement can help predict survival in CF.    
 Even relatively well, habitually active children and adolescents with mild-to-
moderate CF present with impaired aerobic exercise function compared with 
their healthy peers.  
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CHAPTER SEVEN 
The Effect of Ivacaftor in Adolescents with Cystic Fibrosis (G551D 
mutation): An Exercise Physiology Perspective 
 
 
This experimental study has been disseminated as follows: 
 
Publication: Saynor, Z. L., Barker, A. R., Oades, P. J., Williams, C. A. (2014). The 
effect of ivacaftor in children with cystic fibrosis (G551D mutation): an exercise 
physiology perspective. Ped Phys Ther, 26(4), 454-461.  
 
 
7.1  Introduction 
CF is caused by mutations in the gene encoding the CFTR protein. Traditional 
therapies focus on alleviating manifestations secondary to CFTR dysfunction. A new 
oral treatment (Ivacaftor, Vertex Pharmaceuticals, Boston, Massachusetts) has been 
licensed specifically for those with the G551D-CFTR mutation. Ivacaftor, a CFTR 
“potentiator”, increases the open time of activated CFTR at the cell surface, restoring 
Cl--transport activity of the G551D-CFTR protein (van Goor et al., 2009).  
 
To date, sustained improvements in QoL, incidence of pulmonary exacerbations, 
respiratory symptoms, pulmonary function, body mass, and biomarkers of CFTR 
activity (sweat Cl- and nasal potential difference) have been reported following 
treatment with Ivacaftor in patients that are heterozygous for the G551D mutation 
with mild-to-moderately impaired pulmonary function, without substantial adverse 
effects (Accurso et al., 2010; Davies et al., 2013; McKone et al., 2012; Ramsey et 
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al., 2011). More recently, administration of Ivacaftor has also revealed clinical 
improvements in severely ill patients (Hebestreit et al., 2013) and a G551D 
homozygote (Harrison et al., 2013).  
 
Although common clinical assessments such as spirometry and body mass provide 
key endpoints for the evaluation of new CF treatments, their sensitivity to detect 
change in early disease has been questioned (Welsh, 2010). Furthermore, 
measurements of lung function cannot accurately predict patients’ exercise capacity. 
Aerobic fitness (V̇O2max) is of particular clinical importance in patients with CF given 
its association with longevity (Nixon et al., 1992; Pianosi et al., 2005), QoL (de Jong 
et al., 1997) and reduced risk of hospitalisation (Pérez et al., 2014). However, 
exercise testing as an outcome in both physical therapy practice and therapeutic 
trials remains in its infancy (Bell & Morris, 2010). Understanding how the clinical 
alterations evident following pharmacological or physical therapy treatment translate 
to changes in patients’ physical function is important.   
 
Only 1 previous study investigating the effects of Ivacaftor has incorporated an 
exercise testing measure (Harrison et al., 2013), documenting a 292% (+ 410 m) 
improvement from baseline in the distance achieved during the 6MWT in a female 
adult (G551D homozygote) following 12 months of treatment. Although tests such as 
this are common practice within physical therapy for individuals with CF, a number of 
methodological issues accompany these crude tests, which must be considered 
when used in this context. First, these tests are often subjective and submaximal in 
nature and fail to quantify physiologically a maximal effort. Second, the derived 
parameters are limited to HR and SpO2, which are often not presented and do not 
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provide physiological data to support the mechanism(s) responsible for any observed 
change.  
 
Maximal CPET, incorporating measurement of gas exchange and ventilation, 
provides the most precise measurement of aerobic fitness. Much of the value of 
CPET resides in its capacity to describe the integrated function of the pulmonary, 
cardiovascular and muscular systems during exercise. Moreover, in addition to 
V̇O2max, additional key parameters of aerobic exercise function can also be obtained, 
such as the O2 cost of exercise (exercise efficiency) (Whipp et al., 1981). In 
response to the ECFS Clinical Trials Network Standardisation Committee’s call to 
assess the validity, reproducibility and feasibility of outcome measures to be used in 
CF, a valid protocol for use with young patients with CF was recently presented 
(Chapter 4 -Saynor et al., 2013a). Furthermore, the TEs associated with the derived 
outcome measures have since been presented (Chapter 5 - Saynor et al., 2013b), 
enabling meaningful change from therapeutic or physical therapy interventions to 
now be ascertained. However, to our knowledge there are no reports of effect of 
Ivacaftor on patients’ aerobic fitness assessed using the reference standard CPET.  
 
The purpose of this report was to provide novel data from CPET in 2 teenage 
patients with CF (∆F508/G551D) treated with Ivacaftor to demonstrate (1) the effects 
of Ivacaftor on aerobic exercise function and (2) the possible factor(s) modulating 
this response. By answering these questions, the report will provide novel data on 
the utility and feasibility of CPET as a clinical outcome measure.  
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7.2  Methods 
7.2.1   Participants, anthropometry and pulmonary function 
Case A: A 14 y old female climbing enthusiast had presented with neonatal 
meconium ileus requiring bowel resection. She suffered a complicated clinical 
course, with early Pseudomonal and then Stenotrophomonal respiratory infections, 
allergic bronchopulmonary aspergillosis, and more recently Mycobacterium 
abscessus infection that could not be eradicated. Despite preserved pulmonary 
function (FEV1 92% predicted), thoracic HRCT detailed extensive bronchiectasis and 
consolidation in right middle and lingual lobes (Figure 7.1a). BMI was 20.3 kg·m2 (> 
50th centile). Sweat Cl- measured 104 mmol·L-1 pre-treatment. Routine maintenance 
medications included the following: pancrelipase (10, 000 and 40, 000 in various 
combinations with meals and snacks), vitamin E (200 units alternate days), vitamin A 
and D gel (1 daily), ursodeoxycholic acid (450 mg twice daily), polyethylene glycol 
solution (1 sachet daily), azithromycin (500 mg daily), doxycycline (100 mg once 
daily), meropenem (nebuliser 250 mg twice daily), dornase alpha (nebuliser 2.5 mg 
once daily), hypertonic saline (7% nebulised [4 ml] once or twice daily with physical 
therapy), beclomethasone (200 μg twice daily via spacer), salbutamol (2-4 puffs 
when required for wheezing), and amphotericin (nebulised 20 mg alternate days, 
nonliposomal formulation).    
 
Case B: An active 16 y old male presented at the age of 16 months with recurrent 
respiratory infections and failure to thrive. He has suffered recurrent Pseudomonal 
infections from an early age but has remained well with aggressive treatments (FEV1 
108% predicted). Thoracic HRCT showed widespread bronchiectatic changes but 
without significant consolidation (Figure 7.1b). BMI was 19.7 kg·m2 (50th centile). 
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Sweat Cl- measured 107 mmol·L-1 pre-treatment. Routine maintenance medications 
included the following: pancrelipase (10, 000 and 40, 000 in various combinations 
with meals and snacks), vitamin A and D gel caps (3 daily), vitamin E (200 units 
daily), vitamin K (10 mg daily), Fortisip Compact nutritional supplement (with Creon 2 
daily), colomycin (nebulised 2 mega units mixed with gentamicin 80 mg twice daily), 
dornase alpha (nebulised 2.5 mg once daily), flucloxacillin (500 mg twice daily). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1. High-resolution computed tomography images for case A and 
case B pretreatment with orally administered ivacaftor. Case A 
microbiology: Mycobacterium abscessus, Stenotrophomas maltophilia, 
allergic bronchopulmonary aspergillosis in remission. Case B 
microbiology: Intermittent Pseudomonas Aeruginosa and previous 
Achromobacter xylosoxidans.  
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Body mass (Seca 220; Vogel & Halke, Hamburg, Germany) and stature (Seca 220; 
Vogel & Halke, Hamburg, Germany) were measured to the nearest 0.01 kg and 0.01 
m, respectively. FEV1 and FVC were assessed using spirometry (MicroMedical 
MicroLoop 3535). The best of three consistent (< 5% variability) exhalations was 
documented and expressed as a percentage of predicted reference data (Stanojevic 
et al., 2009). 
  
7.2.2   Description of Intervention 
The main goal of this intervention was to assess the influence of orally administered 
Ivacaftor treatment (150 mg 12 hourly) on CPET-derived measures of aerobic 
exercise function in 2 young patients with CF in conjunction with common clinical 
outcome measures. To monitor the effects of treatment, the 2 teenage patients, both 
compound heterozygotes (G551D/ΔF508), underwent routine clinical assessments 
for a period of 20 weeks.  
 
In addition to this, CPET was performed before and after (6 and 12 weeks) initiating 
orally administered Ivacaftor treatment to assess whether any change in aerobic 
exercise function was evident and, if so, the physiological factor(s) responsible for 
this. These time points for reassessment were implemented to enable comparison of 
intervention-induced changes with the TEs of the CPET measurements established 
in this patient population over this time period to identify clinically meaningful 
changes (Chapter 5; Saynor et al., 2013b). The patients continued their normal 
maintenance medications as required and continued with their typical physical 
activity and nutritional intake patterns. Additional measurements of central (O2 
  
248 
  
delivery) and peripheral (O2 extraction / utilisation) factors that can influence V̇O2max 
were also obtained to understand the mechanism(s) responsible for any change.  
 
7.2.3   Exercise testing protocol 
Participants were instructed to arrive at the exercise laboratory in a rested state, > 2 
h postprandial and having refrained from caffeine for > 2 h. Following thorough 
familiarisation with the equipment and requirements of the visit, a maximal CPET 
was performed on a cycle ergometer [Lode Excalibur or Lode Corival, Groningen, 
The Netherlands]. A single-session protocol, encompassing a ramp incremental test 
(10-25 W·min-1) and a Smax (110% Wpeak) verification phase that has been validated 
in this patient population (Chapter 4; Saynor et al., 2013a) was used. Following a 3 
min warm-up (20 W cycling), the incremental ramp test was completed until 
exhaustion whilst pedalling between 70 to 80 rpm. Exhaustion was defined as a drop 
in pedal speed of more than 10 rpm for 5 consecutive seconds, despite strong verbal 
encouragement. Participants then completed 5 min active recovery (20 W cycling) 
and 10 min passive seated recovery before completing the Smax verification test. Smax 
involved a 3 min warm-up (20 W cycling), an exhaustive ‘step’ transition to a CWR 
equivalent to 110% Wpeak from the ramp test, followed by 5 min active recovery (20 
W cycling).  
 
7.2.4   Exercise testing measurements 
Pulmonary gas analysis. Prior to each exercise test, a metabolic cart (Metalyzer 3B 
Cortex, Biophysik, Leipzig, Germany) was calibrated using gases of known 
concentration, and the turbine volume transducer using a 3 L calibration syringe 
(Hans Rudolph, Kansas City, MO). Breath-by-breath pulmonary gas exchange and 
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ventilation were measured and averaged to 15 s time bins.  The highest 15 s 
stationary average V̇O2 from the combined ramp and Smax exercise tests was taken 
to represent V̇ O2max, a safe and appropriate V̇ O2max verification criterion in this 
population (Chapter 4 - Saynor et al., 2013a). The primary outcome measure, given 
its clinical important in CF, was V̇O2max. However, additional submaximal parameters 
of aerobic fitness were also derived. The LT was noninvasively identified using the 
GET (Beaver et al., 1986) and confirmed through visual inspection of the ventilatory 
equivalents for V̇O2 and V̇CO2. The V̇O2 gain (ΔV̇O2/ΔWR), a measure of exercise 
efficiency, was determined by regression of the linear portion of the V̇O2 response 
against power output.  
 
Additional mechanistic measures: Thoracic bioelectrical impedance cardiography 
(PhysioFlow, PF-05, Manatec Biomedical, Paris, France), which has been validated 
in CF (Pianosi, 1997), was used to noninvasively measure beat-by-beat HR, SV and 
?̇?, which was subsequently averaged to 15 s time intervals. C(a-?̅?)O2, a measure of 
O2 extraction, was estimated via rearrangement of the Fick equation:  
(C(a-?̅?)O2)  =  
V̇O2
?̇?
 
SpO2 at the fingertip was measured on a beat-by-beat basis via pulse oximetry 
(NONIN, Avant 4000, NONIN Medical Inc., USA). Subjective ratings of RPE and 
RPD were recorded upon exhaustion using methodology described elsewhere 
(Chapters 4 and 5; Saynor et al., 2013a; Saynor et al., 2013b). All procedures and 
protocol were approved by the institutional ethics committee and informed parental 
consent and participant assent were obtained prior to the commencement of the 
study.  
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7.3  Results 
The 2 patients’ clinical and exercise characteristics at baseline and in response to 12 
weeks of treatment with Ivacaftor are presented in Table 7.1. Figure 7.2 presents the 
percentage change in BMI, FEV1 and V̇O2max during 12 weeks of treatment. BMI and 
FEV1 were then monitored during follow-up to week 20. The magnitude of change in 
these measurements is presented in relation to the established TE of measurement 
using these procedures over a 4-6 week period. All exercise testing was well 
tolerated with no adverse events, and all tests satisfied the criteria for the provision 
of a maximal effort. However, case B reported to his 12 week CPET feeling fatigued.  
 
Case A 
This patient experienced 2 successive URTIs (weeks 3 and 10) during treatment. 
Despite this, her pulmonary function and body mass were maintained when she 
would typically deteriorate. Following the first 6 weeks of treatment, her weight had 
increased from 48.5 kg to 50.5 kg, while predicted FEV1 increased from 92% to 96%. 
A fall in her sweat Cl- (104 to 21 mmol·L-1) was noted at this time point. Following 6 
weeks of treatment her body mass normalised V̇O2max had increased by 6.4% from 
baseline, which was not considered a clinically a meaningful improvement since it 
resides within the TE of this measurement (Chapter 5; Saynor et al., 2013b). End-
exercise SpO2 upon exhaustion increased from 92% to 96%. Because of a 
combination of leg fatigue (9 out of 10) and dyspnoea (rating of 7 out of 10) CPET 
was terminated.  
 
At the 12 week assessment, subjectively she reported feeling better and more 
“energetic” and was slightly more productive with airway clearance physiotherapy. 
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Her FEV1 (%predicted) and body mass showed moderate though convincing 
increases (+ 4.7% relative and + 1.7 kg, respectively). A small increase in sweat Cl- 
(21 to 35 mmol·L-1) was evident. Although there was minimal influence upon Wpeak, 
subjective ratings of exertion and dyspnoea or the additional submaximal parameters 
of aerobic exercise function (GET and V̇O2 gain) at this time point, her body mass 
normalised V̇ O2max had increased by 30.3% from pre-treatment baseline. This 
substantial increase was deemed clinically meaningful since the change over this 6 
week period exceeded the TE (13.3%) of measurement established over this 
duration (Chapter 5 - Saynor et al., 2013b). Furthermore, end-exercise SpO2 had 
improved to 98% from 95% pre-treatment. By this point, her Wpeak had also 
increased by 9.0% (12 W) and her rating of dyspnoea had improved from 7 to 5. 
Little change was detected in the submaximal parameters of aerobic exercise 
function.  
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Figure 7.2. Percentage change from baseline in body mass index, 
forced expiratory volume in 1 second (percentage predicted (Stanojevic 
et al., 2009)) and body mass normalised maximal oxygen uptake 
(V̇O2max) in 2 patients with cystic fibrosis patients (CF) with the G551D-
CFTR mutation [A (14 y female; ● black circles) and B (16 y male; ○ 
white circles)] at the start of Ivacaftor (day 0) and following 6, 12 and 20 
weeks of treatment. Exercise testing was not performed at 20 weeks 
and the magnitude of change is presented in relation to the typical error 
of measurements in young patients with CF over a 4 to 6 week period 
(Saynor et al., 2013b).   
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Table 7.1. The clinical and exercise-based response of 2 paediatric cystic fibrosis 
patients (A, 14 y female; B, 16 y male) with the ∆F508/G551D mutation to  6 and 12 
weeks of oral Ivacaftor treatment.  
 
 
Values are means ± SD, with the range also displayed unless otherwise stated. %predicted, 
percentage predicted (Stanojevic et al., 2009);  
 
Variable Case A 
Pre-
Ivacaftor 
Case A 
6 weeks 
post 
Case A 
12 weeks 
post  
Case B 
Pre-
Ivacaftor 
Case B 
6 weeks 
post 
Case B 
12 weeks  
post 
Clinical outcomes - - - - - - 
FEV1  
[L∙min-1 (%predicted)] 
2.53 (92) 2.62 (96) 2.65 (97) 4.19 
(108) 
4.33 
(112) 
4.65 (120) 
FVC  
[L∙min-1 (%predicted)] 
3.20 
(100) 
3.36 
(105) 
3.32 (107) 4.86 
(104) 
4.59 (98) 4.98 (106) 
FEF25-75  
[L∙min-1 (%predicted)] 
2.29 (66) 2.38 (67) 2.52 (71) 4.77 
(106) 
5.08 
(113) 
5.41 (120) 
Sweat Cl- concentration 
(mmol∙L-1) 
104 
- 
21 
- 
35 
- 
107 
- 
58 
- 
43 
- 
Body mass (kg) 48.5 50.5 50.2 58.3 58.3 58.8 
Stature (cm) 154.8 155.0 155.0 172.0 172.0 172.2 
Maximal exercise  
parameters 
- - - - - - 
Absolute V̇O2max (L∙min
-1 
) 1.45  1.60  1.95 2.59  2.60 2.44 
Relative V̇O2max  
(mL∙kg-1∙min-1) 
29.42 
- 
31.30 
- 
38.33 
- 
44.20 
- 
45.72 
- 
41.93 
- 
HRmax (b∙min
-1) 205 202 202 198 195 175 
SVmax (mL) 52.4 56.2 60.3 83.9 89.2 104.2 
Q̇max (L∙min
-1) 10.6 10.8 11.6 19.0 15.5 18.2 
a-V̇O2 diff. (mL∙min
-
1∙100mL) 
13.7 14.8 16.8 13.6 16.8 13.4 
Lowest SpO2 (%) 92 96 98 96 96 98 
RPE 10 9 9 9 9 9 
RPD 7 6 5 7 7 9 
Ramp peak power output 
(W) 
136 129 148 220 225 240 
Submaximal  
parameters 
- - - - - -              
V̇O2 at the GET (L∙min
-1) 0.87 0.85 0.87 1.32 1.28 1.09                                             
%GET (% of V̇O2max) 60.12 52.99 44.55 51.05 54.78 44.72                             
∆V̇O2/∆WR (mL·min
-1·W-1)  7.20 8.00 7.40 9.32 8.46 6.52 
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Of the factors which can affect case A’s V̇O2max, a change was observed in both 
central (O2 delivery) and peripheral (O2 extraction) indices. With regard to O2 
delivery, a slight reduction in HR was evident at weeks 6 and 12 (205 b∙min-1 to 202 
b∙min-1 at both tests). However, since SV was increased at both time points [52 
mL∙b-1 to 56 (+ 7%) and 60 (+ 15%) mL∙b-1], ?̇? was improved as a consequence 
[10.6 L·min-1 to 10.8 and 11.6 L·min-1 (+ 2% and + 9%, respectively)]. Arterial O2 
desaturation upon exhaustion was also reduced during the 12 weeks of treatment, 
with SpO2 rising from 92% to 96% and 98% at weeks 6 and 12, respectively.  
Estimated O2 extraction (C(a-?̅?)O2) was also increased at both week 6 [+ 1 mL·min
-
1·100mL (+ 8%) and week 12 [+ 3 mL·min-1·100mL (+ 23%)]. This change in 
physiological function detected through CPET following 12 weeks of treatment 
preceded the later rise detected in FEV1 (+ 19% from baseline) following 20 weeks 
(Figure 7.2). Her body mass also increased further to 52.4 kg (+ 3.9 kg from 
baseline) at this stage.  
 
Case B 
This patient was clinically well throughout treatment and body mass and pulmonary 
function remained stable. Following 6 weeks of treatment, his weight remained 
stable at 58.3 kg while lung function (FEV1) improved from 108% to 112% predicted. 
A notable fall in sweat Cl- (107 to 58 mmol·L-1) was also evident in this patient at this 
time point. A modest improvement in his body mass normalised V̇O2max from baseline 
was evident (+ 3.4%); however, this was not considered clinical meaningful. End-
exercise SpO2 was unchanged at 96% and CPET was terminated because of both 
leg fatigue (RPE of 9) and dyspnoea (RPD of 7). 
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Following 12 weeks of treatment, he reported feeling clinically well; however he was 
tired because of heavy school and football workloads over the preceding weeks. In a 
patient who has difficulty maintaining weight, he had gained 0.5 kg by week 12. FEV1 
had also increased from 108% predicted at baseline to 120% predicted and sweat 
chloride concentration has reduced further to 43 mmol∙L-1. Although Wpeak increased 
by 9% from baseline (20 W) and SpO2 at exhaustion had improved from 96% to 
98%, his body mass normalised V̇ O2max was marginally reduced (- 5.1% from 
baseline) as were the submaximal indicators of aerobic fitness. However, this should 
not be considered a true impairment of aerobic exercise function as it is within the 
TE of these measurements (Chapter 5 - Saynor et al., 2013b). While his perceived 
dyspnoea upon exhaustion was higher (7-9), RPE remained stable at 9. 
 
Although modest improvement was observed in his systemic O2 delivery (?̇?  and 
SpO2), this appeared to fluctuate around baseline. Maximal ?̇? was 19.0 L·min
-1 at 
baseline and then 15.5 and 18.2 L·min-1 following 6 and 12 weeks of treatment, 
respectively. HR and SV remained relatively stable at week 6 (- 3 b·min-1 and + 5 
mL·b-1, respectively). However, at 12 weeks his SV was increased to 104 mL·b-1 and 
maximal HR was substantially lower at 175 b·min-1, meaning ?̇? was not particularly 
influenced. Furthermore, following increased extraction at 6 weeks (+ 3 mL·min-
1·100mL), this was near baseline by week 12 (- 0.2 mL·min-1·100mL). No clinically 
significant change in SpO2 was observed. Continued clinical monitoring to week 20 
then revealed a steady increase in body mass to gain 3.2 kg from baseline and 
increase the relative change from baseline in FEV1% predicted to 6.7%.  
 
 
  
256 
  
7.4  Discussion 
The aim of this case report was to describe the effects of orally administered 
Ivacaftor on the aerobic exercise function and clinical profile of 2 teenage patients 
with CF (A, 14 y old female; B, 16 y old male) who were heterozygous for the G551D 
mutation. Furthermore, this report aimed to demonstrate the utility of CPET as a 
clinical outcome measure. Following 12 weeks of treatment with Ivacaftor, both 
patients showed substantial improvements in sweat Cl-. Despite case A experiencing 
2 successive URTIs, pulmonary function and body mass were maintained when she 
would typically deteriorate. Case B was clinically well throughout treatment, with his 
body weight and lung function stable throughout. Following 12 weeks of treatment, 
no meaningful change was observed in V̇O2max in case B. In case A, however, V̇O2max 
increased by 30.3%, which should be considered clinically meaningful because it is 
20% greater than the 4 to 6 week TE associated with this measurement. This 
improvement resulted from both enhanced muscle O2 delivery and muscle O2 
extraction. 
 
There could be numerous explanations for the varied response observed between 
these patients. Firstly, at outset, both patients presented with mildly impaired 
pulmonary function. However, case A’s pulmonary function was a little lower, 
evidence of active underlying infection with M. Abscessus was present and thoracic 
HRCT identified more severe lung damage with patchy parenchymal inflammatory 
changes. Although established lung damage cannot directly be rectified, this patient 
may well have had more to gain from this new, transformational treatment. In an 
earlier Ivacaftor clinical trial cohort (Ramsey et al., 2011), improvements in sweat Cl- 
and FEV1 were seen to plateau after 2 weeks. Because case B’s pulmonary function 
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at baseline was higher than the patients in this initial study by Ramsey et al. (2011), 
this may explain why a plateau was observed in his response.  
 
Conceivably, an individual ceiling effect for V̇O2max improvements may exist, whereby 
relatively fit patients have less to gain in the absence of exercise training, and that 
case B’s original fitness status resided around this threshold. As such, case A’s 
V̇O2max normalised to body mass was lower than case B at baseline, of which gender 
difference may be a factor. An impact of overreaching or chronic fatigue in case B 
also cannot be excluded. Although a higher Wpeak was documented, this patient 
reported to the exercise laboratory for his week 12 CPET feeling tired, due to school 
and football workloads. His lower maximal HR (~ 20 b·min-1) compared with his 
previous CPETs may support this. Interestingly, this reduced response has 
previously been observed in this patient when he previously performed 2 CPETs 
over a short-term period. This stresses the importance of CPET standardisation 
when interpreting “true” physiological changes in results. Although measures of O2 
delivery, extraction and minimum SpO2 in this patient all fluctuated around baseline, 
without meaningful change, SV was elevated following 12 weeks. However, given 
that maximal HR was lower, his resulting ?̇? was not increased.   
 
To our knowledge, the only existing evidence of Ivacaftor’s effect upon aerobic 
fitness was demonstrated in a 19 y old G551D homozygote with poor pulmonary 
function using the 6MWT [292% (+ 410 m) improvement from baseline) (Harrison et 
al., 2013). However, in contrast to this study, the shuttle walk assessment by 
Harrison et al. (2013) was undertaken following 12 months of treatment. However, 
although only presented graphically, the authors’ figure indicates that exercise 
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testing was also performed at approximately 2 and 10 weeks. Interestingly, the 
majority of the patient’s improvement in aerobic fitness occurred within the time 
period spanning these 2 time points (approximately + 225 m (week 2) and + 310 m 
(week 10) from baseline, respectively). Only further longitudinal study would confirm 
the inter-patient variability observed within the present case report and determine 
whether Ivacaftor could sustain patients’ aerobic fitness following initial 
improvements. However, data from the Harrison et al. (2013) study are promising, 
presenting a modest but steady improvement from approximately 10 weeks to 52 
weeks of treatment. Of additional interest is the relatively fixed status of the 
submaximal indices of aerobic function (GET and V̇O2 gain) in contrast to the acute 
improvement in V̇O2max. Whether these parameters respond over a longer duration 
warrants further exploration.  
 
The data from this study are clinically useful for a number of reasons. Firstly, they 
provide novel data regarding the mechanisms by which Ivacaftor may enhance 
patients’ physiological function during exercise. The magnitude of change in case A 
was particularly impressive given that 1) she was in a state of URTI during the 
majority of her treatment, 2) improvements cannot simply be attributable to a 
learning effect or initial submaximal effort, because both patients were thoroughly 
familiarised with the protocol that encompasses a verification phase to confirm “true” 
V̇O2max (Chapter 5; Saynor et al., 2013a); and 3) no exercise training intervention 
was undertaken outside the patients’ typical physical activity routine. 
 
Sparse data exists concerning the magnitude of change in V̇O2max of young patients 
with CF following pharmacological or exercise interventions. To date, only 1 previous 
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study has demonstrated a meaningful improvement in V̇O2max in young patients with 
CF and this was following an intense 6 week period of exercise training. Hulzebos et 
al. (2011) reported a “meaningful” improvement (19%), following a high-intensity 
cycling exercise training programme. This training intervention resulted in an 
indication of enhanced O2 delivery to the active muscle tissue, evidenced by the O2 
pulse. It was suggested that O2 extraction was also influenced; however, only data 
for the V̇ O2 gain was presented, which provides a measure of submaximal O2 
consumption and exercise efficiency.   
 
An additional important purpose of the present report was to demonstrate the utility 
of CPET to make inferences regarding therapeutic interventions or disease-related 
changes. Although case A reported feeling better and more “energetic” at week 12, 
no clinical improvement was detected using standard spirometric indices until week 
20. However, CPET did document substantial improvement in her physiological 
function. The fact that her V̇O2max improvement was out of proportion with early 
pulmonary function changes, although the latter did pick up during extended follow-
up, demonstrated the capacity of this integrated testing to detected subtle changes in 
patients that are relatively well earlier than common clinical outcomes. Furthermore, 
although more common clinical exercise tests are often cost-effective and easily 
conducted, a CPET can provide a wealth of mechanistic information that cannot be 
derived from standard clinical assessments or crude exercise tests such as shuttle 
walk or step protocols. In addition, although such tests can be used to estimate 
V̇O2max, they are likely to underestimate aerobic fitness and cannot truly verify a 
maximal effort. Owing to its merits, the ECFS Exercise Working Group recently 
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promoted CPET as the exercise testing method of choice where possible for this 
patient group. 
 
Aerobic fitness is an important clinical parameter in CF and should become an 
important outcome within the physiotherapy assessment of patients. Although the 
present report focused on the utility of CPET to assess the response to Ivacaftor, 
more common practices such as IVABs and physical therapy interventions warrant 
detailed assessment. For example, the present patient reporting feeling more 
energised is a common response during treatment with IVABs, particularly electively. 
However, patients must often continue treatment until a change in pulmonary 
function is observed. CPET may provide a more sensitive outcome measure to 
detect subtle changes earlier.   
 
It is acknowledged that case study data are limited in their generalisability to the 
wider patient population. Furthermore, the follow-up time was relatively short and it 
would have been of interest to have performed CPET at week 20. In addition, no 
measurements of habitual physical activity were obtained to see whether improved 
exercise capacity translated into increased levels or intensity of physical activity.  
 
Given the ongoing change in stance from the ECFS regarding the clinical relevance 
of CPET in CF, it is likely that this will become a routine assessment method over the 
coming years. If more physical therapists involved in the management and treatment 
of this condition can adopt this form of testing, this would be of great benefit. It is 
hoped that this study demonstrates how insightful and relatively straightforward 
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CPET is and will encourage more physical therapists to adopt it in clinical practice 
and as an investigative tool.  
 
7.5  Conclusion 
These cases demonstrate that not only does Ivacaftor have a substantial beneficial 
effect on the sweat Cl- of patients with CF and the G551D mutation, but clinically 
meaningful improvement in aerobic fitness can also be observed in the absence of 
exercise training. These changes manifest earlier than current clinical outcomes and 
result from both improved muscle O2 delivery and extraction during exercise. 
However, a fitness threshold may exist whereby patients who are relatively fit 
experience less or no improvement. Importantly, this case review highlights that 
CPET can provide an additional important clinical outcome measure to assess 
functional change and with this the mechanism(s) responsible for change. CPET can 
detect substantial changes in aerobic fitness, which may occur independently from 
adaptations in pulmonary function, as was evidenced in 1 of the present patients. To 
objectively quantify the influence of pharmacological or physiotherapy interventions 
on patients’ physiological function, the use of CPET is encouraged. CPET should be 
included within future, long-term research demonstrating its utility within 
physiotherapy practice, pharmacological and/or exercise interventions.   
 
7.6    Practical implications 
 Aerobic fitness (V̇O2max) measurement can help predict survival in CF.    
 Ivacfator may be able to significantly improve V̇O2max in young patients with 
mild-to-moderate CF and the G551D mutation in the absence of exercise 
training. 
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 Ivacfator may improve both cardiac function, which will improve the delivery of 
O2, and also the abilty of skeletal muscles to extract and use O2 during 
exercise. 
  CPET should be included within future, long-term research demonstrating its 
utility within clinical practice, pharmacological or exercise interventions.   
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CHAPTER EIGHT 
Impaired Pulmonary O2 Uptake Kinetics in Young Patients with 
Cystic Fibrosis depend on Exercise Intensity 
 
This experimental study has been disseminated as follows: 
 
Publication: Saynor, Z. L., Barker, A. R., Oades, P.J., Williams, C. A. (Accepted for 
Publication May 2016).Impaired pulmonary O2 uptake kinetics in cystic fibrosis 
depend on exercise intensity. Medicine and Science in Sports and Exerc.  
Poster Presentation: Williams, C.A., Saynor, Z. L., Oades, P. J., Barker, A.R. 
(2013). Oxygen uptake kinetics during cycling in healthy and cystic fibrosis children. 
The British Association of Sport and Exercise Sciences conference, Preston, UK.  
 
Poster Presentation: Saynor, Z. L., Barker, A. R., Oades, P. J. & Williams, C. A. 
(2013). Exercise limitation in paediatric patients with mild-to-moderate cystic fibrosis. 
The University of Exeter Medical School Medical and Health Research Showcase, 
Exeter, UK.  
 
Oral Presentation: Saynor, Z. L., Oades, P. J., Barker, A.R., Williams, C. A. (2015). 
Pulmonary oxygen uptake kinetics of young cystic fibrosis children patients are 
slowed during very heavy but not moderate intensity exercise. 11th Australasian 
Cystic Fibrosis Conference, Sydney, Australia.  
 
 
 
8.1  Introduction 
V̇O2max is clinically important in patients with CF, given associations with prognosis 
(Pianosi et al., 2005), risk of hospitalisation (Pérez et al., 2014) and health-related 
QoL (de Jong et al., 1997). V̇O2max by definition does not, however, represent the 
rate at which aerobic energy transfer adapts to the changing metabolic demands 
facing O2 transport and utilisation during everyday life. In contrast, assessing the 
dynamic adjustment in pulmonary V̇O2 [τ for the primary component (phase II)] at the 
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onset of exercise provides a non-invasive insight into mV̇O2 dynamics (Krustrup et 
al., 2009) and the breakdown of muscle [PCr] (Barker et al., 2008; Rossiter et al., 
2002). Consequently, this parameter can provide insight into the factor(s) mediating 
muscle metabolic function and the integration of the respiratory, cardiovascular and 
muscular systems can also be characterised. Although the V̇O2 kinetic response and 
mechanism(s) regulating the rate of rise are relatively well documented in healthy 
children, there is limited evidence in young people with CF. 
 
Slower V̇O2 kinetics have been reported in children and adolescents with CF during 
incremental (Fielding et al., 2015; Saynor et al., 2014), PRBS (Kusenbach et al., 
1999) and CWR exercise (Armeniakou et al., 2015; Hebestreit et al., 2005). 
However, in contrast a similar response to healthy controls has also been 
documented in young people with CF (11-15 y) during intense exercise (Braggion et 
al., 1989). Methodological issues may explain these disparities. Firstly, during 
incremental and PRBS exercise the phase II portion of the V̇O2 response was not 
isolated, which is critical to reflect the kinetics of mV̇O2 (Krustrup et al., 2009). 
Secondly, the CWR exercise study by Hebestreit and colleagues (2005) did not 
prescribe work rate within physiologically defined exercise intensity domains, semi-
recumbent cycling was used which may negate muscle O2 delivery during exercise, 
and a mixed age group of 10-33 y, which would comprise a range of pulmonary 
function characteristics, were tested (Hebestreit et al., 2005).  
 
According to the Fick principle, the rate of adjustment in V̇O2 is dictated by O2 
delivery and utilisation mechanisms. Although the Fick equation has been used to 
provide mechanistic interpretation during incremental exhaustive exercise in CF (e.g. 
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Chapter 7; Saynor et al., 2014), few studies have applied this to understand how CF 
modifies the V̇O2 kinetic response to CWR exercise (Williams et al., 2014). Slower 
V̇O2 kinetics in young patients with CF have been linked to inadequate O2 delivery 
(Hebestreit et al., 2005), inferred from SpO2. Although young patients with CF may 
present with early signs of cardiovascular abnormalities (Giacchi et al., 2015; Poore 
et al., 2013; Tousson et al., 1998), impaired skeletal muscle oxidative capacity in CF 
has also been shown (de Meer et al., 1995; Erickson et al., 2015; Rosenthal et al. 
2009; Saynor et al., 2014a (Chapter 6); Wells et al., 2011). However, contrasting 
data has reported no differences in skeletal muscle oxidative function in children and 
adolescents with CF compared with their healthy peers (Werkman et al., 2015). The 
NIRS-derived muscle deoxygenation (∆[HHb]) signal provides insight into the ratio of 
local muscle O2 delivery to muscle O2 utilisation. Thus, changes in muscle HHb are 
considered to represent changes in muscle O2 extraction dynamics during exercise 
(e.g. Ferreira et al., 2007). Although it has been hypothesised that a more rapid 
increase in muscle HHb dynamics would be evident in the face of reduced central or 
muscle O2 delivery (Ferreira et al., 2007), as evidenced in Chapter 6, children and 
adolescents with CF do not appear able to compensate by increasing muscle O2 
extraction during exhaustive ramp incremental exercise (Rosenthal et al., 2009; 
Saynor et al., 2014). This raises questions regarding the capacity of CF skeletal 
muscle to increase muscle O2 extraction during exercise, but this has yet to be 
evaluated alongside pulmonary V̇O2 kinetics during CWR cycling exercise.  
 
Consequently, this study aimed to characterise the pulmonary V̇O2 kinetic response 
of children and adolescents with mild-to-moderate CF at the onset of MOD and VH 
intensity exercise. It was hypothesised that: 1) a longer phase II V̇O2 τ at the onset of 
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MOD and VH exercise would be evident in CF; 2) slower ?̇? (inferred from the CI) and 
more rapid [HHb] kinetics would be evident in CF during MOD and VH exercise; and 
3) slower V̇ O2 kinetics would relate to reduced ?̇?  and altered muscle ∆[HHb] 
dynamics in the CF group.  
 
8.2  Methods 
8.2.1   Participants, anthropometry and pulmonary function   
Seven young people with stable, mild-to-moderate CF (Tables 8.1 and 8.2) and 7 
controls (CON) (Table 8.2) participated. Inclusion and exclusion criteria are detailed 
in Chapter 3. Neither group presented with any contraindications to exercise. Ethics 
approval was granted by the South West NHS Research Ethics Committee. Informed 
written consent was obtained from parent(s)/guardian(s) and participants. 
Participants attended the laboratory five times over a 2 week period, at a similar time 
of day and separated by 24-48 h. Participants were advised to arrive rested and 
hydrated, > 2 h postprandial and having refrained from caffeine for > 2 h.  
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Table 8.1. Baseline clinical characteristics for the young CF patients upon initiation 
into the study.  
Variable Value (mean ± SD) Range 
CFTR genotype: 
Homozygote ∆F508  
∆F508/ 2184delA 
∆F508/ G55ID 
 
4 
1 
1 
 
 
 
 
∆F508/ P67L 1  
Chronic P. Aeruginosa infection a “chronic,” n = 1; 
“intermittent,” n = 2 
“free,” n = 3 
“never,” n = 1 
Shwachman score 85 ± 5 80-90 
Northern score b 4 ± 1 3-6 
Pancreatic insufficient n = 7  
CF-related diabetes n = 1  
CF-related liver disease 
IVABs (days in last year) 
n = 1 
11 ± 9 
 
0-24 
 
Values are means ± SD, with the range also displayed where suitable, unless otherwise stated. 
CFTR, cystic fibrosis transmembrane conductance regulator; P. Aeruginosa; Pseudomonas 
Aeruginosa; Shwachman score - scoring 4 separate aspects of the disease profile; general activity; 
physical examination; nutritional status; and chest radiographic findings, using the most recent clinical 
review information. A total of 100 points represents a perfect score of health; IVABs, intravenous 
antibiotics; 
a
According to Leeds Criteria, “chronic”, > 50% of the preceding 12 months were P. 
aeruginosa culture positive; “intermittent”, ≤50% of the preceding 12 months were P. aeruginosa 
culture positive; “never”, no growth of P. aeruginosa for the previous 12 months, having previously 
been P. aeruginosa culture positive; “free”, P. aeruginosa has never been cultured.  
b
 Provides 
evidence of radiographic chest findings. Maximum score is 20, with 20 being the most severe.  
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Table 8.2. Baseline anthropometric, pulmonary function and maximal 
cardiopulmonary exercise testing data for young patients and healthy age- and 
gender-matched control participants upon initiation into the study.  
 
Values are means ± SD unless otherwise stated. M, males; F, females; BMI, body mass index; FVC, 
forced vital capacity; FEV1, forced expiratory volume in 1 s; CPET, cardiopulmonary exercise testing; 
V̇O2max, maximal oxygen uptake; FFM, fat-free mass; GET, gas exchange threshold; MRT, mean 
response time; Wpeak, peak work rate; TTE, time to exhaustion; Smax, supramaximal verification phase; 
SpO2%, arterial oxygen saturation.  
a
According to Stanojevic et al. (2009). 
 
Variable CF 
Mean ± SD 
CON 
Mean ± SD 
p-value ES (d) 
Gender 5 M, 2 F 5 M, 2 F - - 
Age (y) 13.5 ± 2.80 13.6 ± 2.40 0.93 -0.04 
Stature (m)  1.61 ± 0.20 1.62 ± 0.17 0.92 -0.05 
Body mass (kg) 60.7 ± 22.8 52.4 ± 17.8 0.46 0.38 
BMI (kg·m2) 22.6 ± 4.5 19.4 ± 2.9 0.14 0.79 
FFM (kg) 49.5 ± 19.9 40.1 ± 12.5 0.30 0.54 
FVC (L) 3.91 ± 1.29 4.08 ± 1.50 0.82 -0.12 
FVC ( % predicted
a) 106 ± 10 107 ± 17 0.82 -0.11 
FEV1 (L) 3.27 ± 1.00 3.59 ± 1.26 0.61 -0.26 
FEV1 (% predicted
a) 102 ± 6 110 ± 12 0.17 -0.72 
 
CPET parameters 
- - - - 
V̇O2max (L·min
-1) 2.08 ± 0.74 2.51 ± 0.91 0.34 -0.49 
V̇O2max  (mL·kg
-1·min-1) 34.30 ± 8.88 47.75 ± 3.56 < 0.01* -1.79 
V̇O2max/FFM (mL·kg
-1·min-1) 51.87 ± 
34.90 
65.52 ± 24.65 0.42 -0.42 
V̇O2 at the GET (L·min
-1) 1.09 ± 0.31 1.38 ± 0.48 0.20 -0.67 
GET% (% of V̇O2max ) 53.7 ± 6.4 55.2 ± 3.3 0.57 -0.28 
Ramp Wpeak (W) 162 ± 61 208 ± 86 0.27 -0.58 
Ramp TTE (s) 546 ± 111 729 ± 113   0.01* -1.52 
SpO2% (%) 95 ± 3 98 ± 1   0.04* -1.23 
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8.2.2   Exercise testing protocol   
Following anthropometric and pulmonary function measurements, the combined 
ramp incremental and Smax CPET that was established in Chapters 4 and 5 was 
used to determine V̇O2max and the GET (Saynor et al., 2013a; Saynor et al., 2013b). 
All exercise was performed on a cycle ergometer (Lode, Groningen, The 
Netherlands).  
 
Participants completed MOD and VH CWR exercise tests, comprising 6 min 
unloaded pedalling (10 W), followed by transitions to elicit V̇ O2 amplitudes 
corresponding to 90% GET and Δ60% (60% of the difference between the GET and 
V̇O2max) for 6 min. This equated to MOD work rates of 58 ± 24 W and 73 ± 35 W for 
CF and CON, respectively. During VH, CF and CON cycled at 121 ± 43 W and 150 ± 
64 W, respectively. Thirty minutes rest separated the MOD and VH transitions.  
 
8.2.3   Exercise testing measurements 
Body mass (Seca 220; Vogel & Halke, Hamburg, Germany) and stature (Seca 220; 
Vogel & Halke, Hamburg, Germany) were measured to the nearest 0.01 kg and 0.01 
m. Skinfold measurements (Harpenden; British Indicators, Burgess Hill, UK) were 
used to estimate percentage body fat (Slaughter et al., 1988). FVC and FEV1 were 
assessed using spirometry (Micromedical Microloop 3535, Numed, Sheffield, UK), 
and expressed as a percentage predicted (Stanojevic et al., 2009).  
 
Breath-by-breath changes in gas exchange and ventilation were determined using a 
metabolic cart (Metalyzer 3B Cortex, Biophysik, Leipzig, Germany), which was 
calibrated each test using gases of known concentration and a 3 L syringe (Hans 
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Rudolph, Kansas City, MO). Fingertip SpO2 was measured using pulse oximetry 
(NONIN, Avant 4000, NONIN Medical Inc., USA). A near-infrared spectrometer 
(Portamon, Artinis Medical Systems) was used to non-invasively measure [HHb] at 
the m. vastus lateralis. Details regarding this system and the site 
preparation/placement are provided earlier in this thesis (Chapters 2 and 3). Beat-by-
beat changes in HR, SV and ?̇?  were measured using thoracic bioelectrical 
impedance cardiography (PhysioFlow, PF-05, Manatec Biomedical, Paris, France), 
further details of which are provided in Chapters 2 and 3.   
 
8.2.4   Data analysis   
CPET parameters of aerobic function. As validated in Chapter 4, the highest 15 s 
averaged V̇O2 from the ramp and Smax tests was taken to represent V̇O2max (Saynor 
et al., 2013) and was normalised to FFM using the ratio standard method. The GET 
was identified using the V-slope method (Beaver et al., 1986) and confirmed through 
visual inspection of the ventilatory equivalents for V̇O2 and V̇CO2.  
 
Pulmonary ?̇?O2 kinetics. Breath-by-breath changes in V̇O2 were analysed using 
methodology previously described by our laboratory (Barker et al., 2010; Breese et 
al., 2012). The four repeat transitions for both MOD and VH were linearly 
interpolated to 1 s, time aligned to exercise onset (i.e., t = 0 s) and ensemble 
averaged. The 1 s averaged V̇O2 response for the MOD and VH conditions for each 
participant were then baseline corrected, by subtracting the mean V̇O2 between -60 
and -5 s from the exercise response. The duration of phase I was visually assessed 
to account for the cardiodynamic contribution to the V̇O2 kinetic response. The first 
21 ± 3 s and 17 ± 4 s of the MOD data and the first 19 ± 5 s and 16 ± 2 s for VH were 
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omitted in CF and CON participants, respectively. The phase II portion of the 
V̇ O2 response was then characterised using Equation 2.5 (GraphPad Prism; 
GraphPad Software, San Diego, CA), where V̇O2 (t), Δ V̇O2 A, TD, and τ represent the 
value of V̇O2 at a given time (t), the amplitude change in V̇O2 from baseline to its 
asymptote, time delay, and the time constant of the response, respectively.  
 
The MRT was derived to describe the overall kinetics during both intensities of 
exercise, by constraining the TD in Equation 1 to 0 s and fitting from exercise onset 
to 6 min. The functional gain of phase II was determined by dividing the phase II V̇O2 
amplitude by the change in work rate above baseline. End-exercise V̇O2 gain was 
calculated in a similar manner. For VH exercise, the V̇O2 slow-component onset and 
amplitude were determined in line with previous work from our laboratory (Barker et 
al., 2010; Breese et al., 2010). The V̇O2 slow-component was expressed in both 
absolute terms and relative to end-exercise V̇O2. 
Muscle oxygenation. NIRS data were collected at 10 Hz, interpolated to 1 s 
intervals and expressed as a change, in arbitrary units (a.u.), from baseline. 
Subsequently, [HHb] profiles were 5 s averaged, time aligned to exercise onset and 
ensemble averaged to yield a single response. The dynamics of [HHb] were 
modelled in a similar manner to V̇O2, with slight modification as detailed in Chapter 3 
(Barker et al., 2010).  
 
Heart rate, stroke volume, cardiac output and C(a-?̅?)O2. Beat-by-beat changes in 
HR, SV and ?̇? were linearly interpolated to 1 s, time aligned and ensemble averaged 
to 30 s. The C(a-v̅)O2 was estimated via rearrangement of the Fick equation [C(a-v̅)O2 = 
V̇O2/ ?̇? ]. SV and ?̇?  were normalised to FFM (Dewey et al., 2008) using the ratio 
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standard method, to determine the CI and SVI. The ?̇?/V̇O2 ratio was used to provide 
an index of muscle O2 availability relative to metabolic rate.  
 
 8.2.5   Statistical analysis 
Independent samples t-tests examined mean differences between CF and CON. 
Additionally, ES (d) statistics determined the magnitude of the effect, using a pooled 
SD. The magnitude of the difference between variables of interest were explored 
using ES thresholds of trivial (< 0.2), small (> 0.2), moderate (> 0.5), large (> 0.8), 
and very large (> 1.0) (Cohen, 1992). Changes in HR, SV, 𝑄 ̇ and C(a-v̅)O2 were 
analysed using mixed model ANOVA. Significant interactions were followed up using 
independent samples t-tests. Pearson’s correlation coefficients assessed 
relationships between V̇O2 kinetics and mechanistic parameters of O2 delivery and 
utilisation. Statistical analyses were performed using SPSS (version 19.0, SPSS, 
Chicago, IL), with the null-hypothesis rejected at alpha level of 0.05.  
 
8.3  Results 
Maximal cardiopulmonary exercise testing: Descriptive characteristics and CPET 
data are presented in Table 8.2. There were no differences in body size and 
composition and pulmonary function between CF and CON. V̇O2max was reduced in 
CF compared with CON when normalised using body mass but not FFM.   
 
Pulmonary ?̇?O2 kinetics: The V̇O2 responses during MOD and VH are presented in 
Figure 8.1 and the kinetic parameters in Table 8.3. There was no significant 
difference in baseline V̇O2 between the groups for either MOD or VH exercise (Table 
8.3). For MOD, CF had no influence on either the phase II τ, TD or MRT. However, 
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the phase II V̇O2 gain was lower in CF. During VH, the V̇O2 MRT and phase II τ were 
slower in CF. The phase II TD, amplitude and gain and end-exercise V̇O2 were not 
altered in CF. A V̇O2 slow-component manifested in all VH responses, however the 
amplitude was similar between CF and CON.  
 
Muscle oxygenation kinetics: The group mean data for [HHb] and the 
corresponding kinetic parameters are shown in Figure 8.2 and Table 8.4, 
respectively. The [HHb] response of one CF patient (male, 10 y, ∆F508 homozygote) 
did not display exponential characteristics and was, in addition to their healthy 
control, excluded from [HHb] analyses. There was no difference between CF and 
CON for any of the [HHb] kinetic parameters during MOD or VH exercise. 
 
Heart rate, stroke volume index, cardiac index and C(a-?̅?)O2:  Group mean HR, 
CI, SVI and C(a-v̅)O2 dynamics are presented in Figure 8.3. No significant time by 
disease state interaction effect for SVI was evident during either MOD (p = 0.09) or 
VH (p = 0.27). During VH there was a significant interaction between time and 
disease state for HR (p = < 0.01), with follow-up comparisons identifying a higher HR 
in CF at 30 s (p < 0.05). There was a significant main effect for disease state (p = 
0.01) for CI to be lower in CF during MOD but not VH (p > 0.05). There was a time 
by disease state interaction (p = 0.03) for C(a-v)O2 during VH (Figure 8.3), with 
extraction significantly reduced in CF at 30 s (p = 0.02) and a trend towards reduced 
values at 0 s (p = 0.07), 60 s (p = 0.05) and 120 s (p = 0.07). ?̇?/V̇O2 was not different 
between the groups for either intensity (p > 0.05).  
 
Relationships between ?̇?O2 kinetics and mechanistic parameters: During MOD, 
the phase II V̇O2 τ significantly correlated with ∆[HHb] (r = 0.84; p = 0.04) in CF, 
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whilst the MOD V̇O2 MRT correlated with ∆SVI in CON (r = -0.81; p = 0.03). During 
VH, the ∆C(a-v̅)O2 significantly correlated with the phase II V̇O2 τ (r = -0.85; p = 0.02) 
and MRT (r = -0.79; p = 0.03) in CF. Furthermore, ∆?̇?/∆V̇O2 (r = 0.78; p = 0.04) 
significantly correlated with the phase II V̇O2 τ in CF during VH exercise.     
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        Table 8.3. Pulmonary oxygen uptake kinetics in CF and CON during MOD and VH exercise.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable CF 
Mean ± SD 
CON 
Mean ± SD 
 
p-value ES (d) 
Moderate intensity exercise 
 
Baseline V̇O2 (L·min
-1) 0.62 ± 0.13 0.68 ± 0.16 0.47 -0.38 
Phase II V̇O2  τ (s) 25.2 ± 6.7 26.1 ± 8.4 0.84 -0.11 
Phase II V̇O2  TD (s) 21.7 ± 7.3 14.8 ± 7.1 0.10  0.90 
Phase II V̇O2 amplitude (L·min
-1) 0.42 ± 0.20 0.64 ± 0.34 0.16 -0.76 
Phase II V̇O2 gain (mL·min
-1·W-1) 8.6 ± 1.3 10.4 ± 1.4   0.03* -1.21 
V̇O2 mean response time (s) 44.6 ± 8.0 41.6 ± 8.9 0.52 0.33 
 
Very heavy intensity exercise 
 
Baseline V̇O2 (L·min
-1) 0.68 ± 0.15 0.76 ± 0.19 0.37 -0.46 
Phase II V̇O2  τ (s) 37.5 ± 10.8 25.1 ± 6.5 0.02* 1.28 
Phase II V̇O2 TD (s) 14.7 ± 6.1 14.6 ± 3.0 0.96 0.03 
Phase II V̇O2  amplitude (L·min
-1) 0.97 ± 0.34 1.26 ± 0.54 0.25 -0.60 
Phase II  V̇O2 gain (mL·min
-1·W-1) 8.9 ± 0.8 9.2 ± 1.2 0.51 -0.34 
V̇O2 slow-component onset (s) 144 ± 29 117 ± 21 0.07 0.99 
V̇O2 slow-component amplitude (L·min
-
1)   
0.19 ± 0.15 0.16 ± 0.13 0.74 0.17 
V̇O2 slow-component relative amplitude 
(%) 
9.0 ± 6.3 6.7 ± 3.8 0.43 0.40 
End-exercise V̇O2 (L·min
-1) 1.83 ± 0.59 2.18 ± 0.83 0.38 -0.46 
End-exercise V̇O2  gain (mL·min
-1·W-1) 9.9 ± 1.3 10.3 ± 0.9 0.56 -0.30 
V̇O2 mean response time (s) 74.6 ± 19.4 51.6 ± 8.3 0.01* 1.40 
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Table 8.4. Muscle oxygenation kinetics of young CF patients and healthy control participants at the onset of moderate and very 
heavy intensity cycling exercise.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Four participants per group, two healthy controls presented with a monoexponential response and their matched patients were 
subsequently also removed from the slow-component analyses; b three per group, two healthy controls presented with a 
monoexponential response and one CF patient had an abnormal negative response following the slow-component onset, therefore 
their matched patients were subsequently also removed from the slow-component analyses; c one CF patient presented with a 
monoexponential response and her healthy match was subsequently also removed from the slow-component analyse analyses.    
Variable CF (Mean ± SD) CON (Mean) ± 
SD 
p-value   ES 
(d) 
 
Moderate intensity exercise 
Baseline [HHb] (a.u.) -0.01 ± 0.08 0.01 ± 0.03 0.74 -0.17 
Phase II [HHb] τ (s) 12.5 ± 8.8 9.0 ± 5.0 0.42 0.44 
Phase II [HHb] TD (s) 14.8 ± 3.3 11.9 ± 5.6 0.30 0.57 
[HHb] mean response time (s) 27.3 ± 7.6 20.9 ± 2.2 0.08 0.99 
Phase II [HHb] amplitude (a.u.) 1.63 ± 1.73 2.76 ± 1.75 0.29 -0.60 
[HHb] slow-component onset (s) a 104 ± 19 103 ± 30 0.95 0.04 
[HHb] slow-component amplitude (a.u.) b 0.30 ± 0.58 0.51 ± 0.50 0.43 -0.33 
[HHb] slow-component relative amplitude (%) b 11.37 ± 6.90 18.10 ± 5.27 0.25 -0.86 
End-exercise [HHb] (a.u.) 1.99 ± 2.12 3.12 ± 1.91 0.35 -0.52 
Very heavy intensity exercise 
Baseline [HHb] (a.u.) 0.00 ± 0.03 0.02 ± 0.03 0.60 0.29 
Phase II [HHb] τ (s) 13.0 ± 12.4 9.4 ± 3.9 0.51 0.34 
Phase II [HHb] TD (s) 11.3 ± 2.7 9.9 ± 2.7 0.41 0.46 
[HHb] mean response time (s) 24.2 ± 11.9 19.3 ± 1.8 0.34 0.49 
Phase II [HHb] amplitude (a.u.) 4.11 ± 4.70 6.20 ± 3.07 0.39 -0.48 
[HHb] slow-component onset (s) c  151.0 ± 73.4 96.0 ± 29.03 0.18 0.84 
[HHb] slow-component amplitude (a.u.) c 1.15 ± 0.65 1.69 ± 0.48 0.17 -0.85 
[HHb] slow-component relative amplitude (%) c 26.5 ± 13.6 21.6 ± 6.2 0.49 0.40 
End-exercise [HHb] (a.u.) 5.13 ± 5.12 7.81 ± 3.43 0.31 -0.56 
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Figure 8.1. Mean pulmonary oxygen uptake (V̇O2) profile for cystic fibrosis (○ white circles) versus healthy (● black circles) children 
and adolescents during moderate (A, C) and very heavy (B, D) intensity cycling exercise. Figures C and D provide the normalised 
to end-exercise so that the differences in the phase II region of the V̇O2 response can be observed. The vertical dotted line 
illustrates the onset of exercise from a 10 W baseline. Data are presented as 5 s averages.  
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Figure 8.2. Mean muscle deoxygenation ([HHb]) profile for cystic fibrosis (○ white circles) and healthy (● black circles) young 
people during moderate (A,C) and very heavy (B,D) intensity cycling exercise. Figures C and D provide the normalised to end-
exercise so that the differences in the phase II region of the [HHb] response can be observed The vertical dotted line denotes the 
onset of exercise from a 10 W baseline. Data are presented as 5 s averages.  
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Figure 8.3. Group mean heart rate (A), fat-free mass (FFM) normalised stroke volume (B), 
FFM normalised cardiac output (C) and FFM normalised arterial-venous O2 content 
difference [C(a-v)O2] (D) dynamics of young cystic fibrosis patients (○ white circles) and 
healthy age- and gender-matched controls (● black circles) during moderate (1) and very 
heavy (2) intensity cycling exercise. The vertical dotted line denotes the onset of exercise 
from a 10 W baseline. Data are mean and SD and 30 s averages. * denotes P < 0.05, i.e. 
significant mean difference between CF patients and healthy controls, whilst + denotes a 
statistical trend (p = 0.07). 
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8.4  Discussion 
This is the first study to examine the dynamics of V̇O2 in children and adolescents 
with mild-to-moderate CF at the onset of MOD and VH intensity cycling exercise, 
relative to adjustments in central O2 delivery and localised muscle (m. vastus 
lateralis) O2 extraction. The novel findings from this study were that 1) pulmonary 
V̇O2 kinetics were slowed in CF during VH but not MOD; 2) there was no differences 
in muscle [HHb] kinetics between CF and CON during MOD and VH exercise; 3) 
during VH exercise only, C(a-v̅)O2 was reduced in CF within the initial 60 s of exercise 
onset, and 4) the change in C(a-v̅)O2 during VH exercise was significantly correlated 
with the phase II V̇O2 τ and MRT in CF. Collectively, these findings support the notion 
that impaired muscle oxidative metabolism in young CF patients is dependent on the 
intensity of exercise and principally limited by muscular factors, which limit the 
extraction and utilisation of O2 during VH exercise  
 
Contrary to our hypothesis, neither the phase II or overall V̇O2 kinetics were slowed 
during MOD intensity cycling in young people with CF. This is consistent with early 
observations in similarly aged patients (11.1-15.3 y) with mild airway obstruction 
during 6 min cycling at 1.7 W·kg-1 (Braggion et al., 1989). In contrast, two studies 
have documented slower V̇ O2 dynamics during exercise in patients with CF 
(Hebestreit et al., 2005; Kusenbach et al., 1999), however methodological issues 
may explain this disparity. Kusenbach et al. (1999) employed PRBS exercise which 
fails to isolate phase II of the V̇O2 response. Although Hebestreit et al. (2005) utilised 
CWR exercise and isolated phase II, work rate was not prescribed within 
physiologically defined intensity domains. This meant that patients were likely to be 
exercising across the MOD-severe intensity domains which, if the intensity was 
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above the GET, would be consistent with our present findings of slowed V̇O2 kinetics 
during exercise performed above the GET. Hebestreit and colleagues (2005) also 
used semi-supine exercise, which may reduce muscle perfusion and slow V̇ O2 
dynamics (Koga et al., 1999). Finally, the combination of adult and paediatric 
patients (10-33 y) could have contributed to slow V̇O2 kinetics, since slower phase II 
kinetics were recently documented in adults with more advanced CF (22 ± 4 y) 
during submaximal cycling (Armeniakou et al., 2015). 
 
An interesting finding in this study was that the influence of CF on oxidative muscle 
metabolism appears to be exercise intensity dependent. This is based on the finding 
that the phase II V̇O2 τ and MRT were slowed only during VH exercise and the ES 
was very large (> 1.0). This is of clinical importance, since slower V̇ O2 kinetic 
response will incur a greater O2 deficit and a greater degree of substrate-level 
phosphorylation (increased lactic acid and [PCr] breakdown) and the accumulation of 
fatigue-inducing metabolites (e.g., Pi and H
+ ions), which may impair exercise 
tolerance, especially during VH exercise, in young people with CF. An exercise 
intensity dependence to the impaired oxidative metabolism in CF corresponds with 
earlier observations in adolescent patients during a 90 s high-intensity exercise 
challenge, but not shorter duration or less intense exercise (Wells et al., 2011). This 
may reflect the greater physiological challenge to mitochondrial aerobic metabolism 
elicited by higher intensities of exercise. 
 
The longer phase II V̇O2 τ of patients with CF (10-33 y; FEV1: 37-98% predicted) has 
previously been linked to inadequate O2 delivery, inferred by a significant 
relationship with SpO2 (Hebestreit et al., 2005). In the current study, bulk blood flow 
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(?̇?), as inferred using the CI, was not profoundly altered during either MOD or VH 
exercise in CF. Furthermore, V̇O2 kinetics were not mechanistically linked to the CI 
and SVI dynamics in this group of patients, despite previous reports that early signs 
of cardiac dysfunction may present in paediatric patients with CF (Giacchi et al., 
2015; Saynor et al., 2014a – Chapter 6). Although CFTR is involved in the regulation 
of cardiomyocyte contraction (Sellers et al., 2010) and gene mutation targeted 
therapies have been shown to increase SV in adolescents with CF (Saynor et al., 
2014b – Chapter 7), the current study suggests that central O2 delivery does not 
principally limit V̇O2 kinetics in young CF patients. This is further supported by 
research demonstrating that elevating SpO2 through the inspiration of hyperoxic gas 
does not improve the kinetics of V̇O2 in patients with CF (Kusenbach et al., 1999). 
However, it must be acknowledged that only central indices of O2 delivery, which are 
relatively poor indicators of O2 delivery at the local muscle level during exercise 
(Murias et al., 2013), were obtained in these studies.  
 
However, considering the findings in the present study, the impaired V̇O2 kinetics 
during VH exercise herein were related to the capacity of skeletal muscle to extract 
and utilise O2. For the first time, this study investigated the [HHb] dynamics of young 
CF patients during CWR exercise, with similar kinetics observed between the 
groups. If muscle O2 availability was limiting oxidative metabolism in CF, a 
compensatory acceleration in the rate of O2 extraction would be expected (Ferreira 
et al., 2007). This was not observed in the present study and this finding 
corresponds with earlier studies during incremental exercise using both NIRS 
(Saynor et al., 2014a – Chapter 6) and respiratory mass spectroscopy (Rosenthal et 
al., 2009). Whilst this finding shows that the rate of O2 extraction taking place was 
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not different in CF, [HHb] does not reflect the amount of O2 extraction taking place. 
This can be physiologically interpreted from the C(a-v̅)O2 parameter.  
 
Interestingly, we observed a significant reduction in C(a-v̅)O2 in CF during the early 
stages of VH exercise (see Figure 8.3D), which corresponds with the timing of the 
phase II portion of the V̇O2 response. Furthermore, ∆C(a-v̅)O2 significantly correlated 
with the phase II V̇O2 τ and MRT during VH in CF only. These findings suggest that 
the amount of muscle O2 extraction and utilisation is impaired in this patient group 
near the onset of exercise and is mechanistically linked to the dynamics of V̇O2. 
These findings support previous speculations regarding a peripheral limitation 
slowing V̇O2 kinetics in patients with CF (Hebestreit et al., 2005). This O2 extraction 
and utilisation impairment may be explained by structural and functional changes in 
skeletal muscle that are evident in CF (de Meer et al., 1995; Lamhonwah et al., 
2010; Wells et al., 2011). Although a recent study has provided conflicting data 
(Werkman et al., 2015), slower post-exercise [PCr] recovery kinetics, measured 
using 31Phosporous magnetic resonance spectroscopy, suggest impaired muscle 
oxidative capacity in both the  m. vastus lateralis and forearm muscle (de Meer et al., 
1995; Wells et al., 2011). More recently, reduced local muscle oxidative capacity was 
inferred from the recovery of m. vastus lateralis O2 consumption following 15 s of 
electrical stimulation and subsequent repeated transient arterial occlusions (Erickson 
et al., 2015). Evidence of CF-specific muscle metabolic abnormalities (lower [ATP] 
and [ATP]:[PCr] at rest and significantly higher end-exercise pH values) (Wells et al., 
2011) also support the present suggestions regarding a muscular abnormality in this 
patient group.   
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The cause(s) of an intramuscular impairment in CF are currently unknown, although 
several factors have been proposed. Reduced antioxidant capacity, arising from 
systemic inflammation and/or oxidative damage, may lower mitochondrial efficiency 
(Wells et al., 2011). However, it may also be a consequence of the CFTR genetic 
mutation. CFTR is expressed in skeletal muscle cells (Lamhonwah et al., 2010) and 
in vitro study of leucocyte mitochondria in patients with CF demonstrates that 
properties of complex I of the respiratory chain are significantly altered (Dechecci et 
al., 1988). Furthermore, absence of CFTR from skeletal muscle has been shown to 
dysregulate Ca2+ homeostasis, augment inflammatory or atrophic gene expression 
signatures and increase diaphragm weakness (Divangahi et al., 2009). Conversely, 
improving CFTR (dys)function using Ivacaftor shows potential to improve aerobic 
exercise function in adolescents with CF (Saynor et al., 2014b – Chapter 7). 
However, the impact of impaired vascular function on the ability of people with CF to 
deliver O2 locally for extraction also requires further investigation, given recent 
evidence that vascular endothelial (dys)function is associated with a poorer V̇O2max in 
young people with CF (Poore et al., 2013) association with V̇O2max in this patient 
group.  
 
Whilst the present study provides the first robust investigation of the V̇O2 kinetic 
response in young CF patients, there are a number of limitations inherent to the 
employed measurement techniques. The considerations regarding NIRS exercise 
measurements in this population have been outlined in greater detail in Chapters 2, 
3 and 6 of this thesis and elsewhere (Saynor et al., 2014a). However, these include 
a restricted, heterogenous and superficial area of interrogation and possible inter-site 
variation in [HHb]. To minimise these limitations, the NIRS device was secured to the 
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same anatomical region of all participants to eradicate inter-individual regional 
differences within the m. vastus lateralis and [HHb] responses were standardised to 
the total [HHb] amplitude to provide a physiologic normalisation (Boone et al., 2009). 
Although the utilised thoracic impedance cardiography device has been validated in 
CF patients (Pianosi, 1997), this technique provides a non-invasive estimate of SV 
and   more detailed echocardiography indices of ventricular function, in addition to 
further measurements of vascular endothelial function would be insightful. Further, 
since CFTR is expressed in human vasculature and vascular endothelial dysfunction 
has been related to V̇O2max in young CF patients (Poore et al., 2013), contribution to 
altered V̇O2 kinetics warrants further investigation. Finally, since muscle fibre type 
composition and recruitment were not measured herein, discrepancies in fibre type 
composition and recruitment strategies between the groups cannot be excluded.  
 
These findings help us to further understand how young people with CF respond to 
the increased metabolic demand during activities of daily living and fatiguing 
exercise. Whilst children and adolescents with mild-to-moderate CF appear to 
respond in a similar manner to their healthy counterparts during MOD exercise, the 
slowed V̇O2 kinetics at the onset of exercise above the GET may well be linked to 
reduced exercise tolerance, which should be considered by the exercise practitioner 
when considering exercise prescription strategies for this patient group. Promisingly, 
identifying the rate limiting determinant(s) of pulmonary V̇O2 kinetics in individuals 
with CF may provide viable targets for intervention.  
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8.5  Conclusion 
To conclude, this study demonstrates that the V̇O2 kinetics of paediatric patients with 
CF are slowed during VH but not MOD intensity cycling exercise. Impaired skeletal 
muscle oxidative metabolism in this patient group is intensity dependent and appears 
to be mechanistically linked to an intrinsic intramuscular impairment which limits O2 
extraction and utilisation. Identifying the rate limiting determinant(s) of pulmonary 
V̇O2 kinetics in individuals with CF may provide viable targets for intervention in the 
future.  
 
8.6    Practical implications 
 Pulmonary V̇O2 kinetics may reflect better the demands of daily activities. 
 Young people with mild-to-moderate CF appear able to maintain normal 
oxidative muscle function during moderate intensity exercise performed below 
the GET. 
 Skeletal muscle oxidative metabolism is impaired during higher intensities of 
exercise and may lead to an earlier onset of fatigue than their healthy peers.  
 This impairment appears to be caused by an abnormality within the exercising 
muscle, preventing it from extracting and using O2 as well as healthy young 
people.  
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CHAPTER NINE 
Summary, Conclusions, Recommendations and Directions for 
Future Research 
 
 
9.1 Summary of experimental chapters 
The primary objective of this thesis was to further our understanding concerning both 
the assessment and interpretation of aerobic exercise (dys)function in paediatric 
patients with CF. Specifically, the studies addressed the following:  
1. Investigate the validity of V̇O2max and the utility of Smax verification in young 
patients with CF (Chapter 4);  
2. Establish the reproducibility of CPET in young patients with CF (Chapter 5);  
3. Investigate the influence of CF on the aerobic exercise function of young 
patients during ramp incremental exercise to exhaustion (Chapter 6);  
4. Use a case study design to explore the effect of a CFTR potentiator on the 
aerobic exercise (dys)function of young patients with CF (G551D mutation) 
(Chapter 7); 
5. Determine whether mild-to-moderate CF slows the V̇ O2 kinetics of young 
patients with CF at the onset of moderate and very heavy intensity exercise 
and whether this is mechanistically linked to O2 delivery and/or utilisation 
(Chapter 8);  
The experimental chapters in this thesis provide a significant contribution to the 
literature in this area and offer important information to develop exercise testing 
guidelines and viable targets for therapeutic intervention. This chapter will briefly 
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summarise the primary findings of each of the experimental chapters and their 
contribution. Following this, the overall experimental findings and their impact to this 
field of research will be synthesised. Finally, experimental considerations and 
recommendations for future research will conclude this thesis.  
9.1.1 Chapter 4 
The purpose of this study was to compare the validity of a traditional ramp 
incremental CPET protocol to determine V̇O2max, with secondary verification criteria, 
versus the utility of Smax verification in paediatric patients with mild-to-moderate CF. 
At the time of this investigation, no study had explored this concept in this patient 
group. The strengths of this study included 1) the use of commonly used secondary 
verification criteria from the CF exercise literature; 2) the use of a Smax verification 
phase to provide evidence of how well patients tolerate this intensity of exercise and 
whether this provides a valid measure of  V̇O2max.  
In this study, only one patient exhibited a V̇O2 plateau upon exhaustion during an 
isolated single ramp test. This low prevalence is in line with evidence presented by 
Werkman and colleagues (2011). These findings highlight that the use of the 
traditional primary plateau criteria to confirm V̇O2max is not suitable in paediatric 
patients with CF, which is in line with recommendations for healthy young people 
(Barker et al., 2011). What this study also demonstrates is that the use of other 
traditional secondary verification criteria, such as HR and RER, will significantly 
underreport V̇O2max in paediatric patients with CF. Therefore, this study demonstrated 
that the previously reported low V̇O2peak values in young people with CF, that were 
determined using secondary verification criteria, warrant further investigation to 
determine the true extent of any impairment. What this study also demonstrated, 
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however, is that a Smax verification phase provides a useful alternative that can 
confirm whether a ‘true’ V̇O2max is achieved or not, with a combined ramp and Smax 
protocol identifying a meaningful (> 9%) increase (9.9 – 38.3%) in V̇O2peak in 3 of 14 
cases in the present study. Clinically, if used as part of the annual review, a 
misleading value such as this would lead to incorrect interpretation of the data (i.e. a 
patient’s health and physiological function is declining when it is not) and, possibly, 
result in unnecessary clinical intervention that is aimed at improving V̇O2max. This 
finding extends earlier observations in healthy children and adolescents (Barker et 
al., 2011) and those with spina bifida (de Groot et al., 2009), which advocate that 
Smax verification testing should be used to verify V̇O2max during CPET of paediatric 
groups.  
Whilst current clinical exercise testing protocols, such as shuttle and step tests, are 
limited in their capacity to ensure a maximal effort and the scope of physiological 
interpretation they convey, this study also raised concerns regarding the validity of 
current CPET protocols. The present findings highlight that CPET results should be 
interpreted with caution when traditional verification criteria are used, particularly in 
the clinical environment where clinical management strategies may be changed in 
response and it is recommended that Smax verification be included when an 
incremental test is performed. At present, this protocol has not been incorporated 
into clinical management guidelines; however the recent ECFS consensus statement 
marks an improvement with the recommendation for clinical CPET in this patient 
group (Hebestreit et al., 2015).  
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9.1.2 Chapter 5 
In order to implement CPET as a clinical assessment tool, it is necessary to 
determine the TE in key parameters of aerobic exercise (dys)function in this patient 
group over relevant time periods, e.g. the short-term or the duration of routine clinical 
interventions, such as IVABs (~ 4-6 weeks). Having established a valid protocol in 
Chapter 4, the purpose of Chapter 5 was to determine the reproducibility of this 
CPET protocol in young patients with CF over both the short- (48 h) and medium-
term (4-6 weeks). This is a pertinent question given that reductions in V̇O2peak over 
time are clinically relevant and previously suggested to be around 5-8% per year. 
Furthermore, it is vital to assess the true magnitude of improvement caused by any 
clinical or exercise-related intervention. It is therefore important to identify the typical 
reproducibility of aerobic fitness status over time given the cyclic nature of CF 
exacerbations.   
The strengths of this study include; 1) the implementation of a valid CPET protocol to 
determine V̇O2max, in addition to other key parameters of aerobic exercise function; 2) 
the assessment across clinically relevant time periods; 3) presentation of all of the 
key parameters of aerobic exercise function (Whipp et al., 1981; Whipp et al., 1982) 
in addition to other physiologically useful parameters, such as SpO2 and HR.  
Data from this study demonstrated that V̇O2max can be repeatedly determined, with 
no learning effect, in young patients with CF over both the short- (48 h; 9.3% TECV%) 
and medium-term (4-6 weeks; 13.3% TECV%). It is important to note that all patients 
were thoroughly familiarised with the testing protocol and environment in order to 
achieve these TEs and this should be a key consideration in research and clinical 
practice alike. A greater variance was, however, evident over a longer period of time 
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(4-6 weeks). Importantly, this study also revealed that a combined ramp and Smax 
protocol also demonstrated improved reproducibility over both the short- (TECV%: 9.3 
(6.9-14.3) vs. 13.5 (9.5-23.3)%) and medium-term (TECV%: 13.3 (9.9-20.9) vs. 15.5 
(10.9-26.9)%) when compared with traditional CPET protocols.  
Prior to this study, the reproducibility of CPET had not been established in young 
patients with CF using a valid protocol (Kent et al., 2012; McKone et al., 1999). 
Although submaximal parameters were identifiable in most cases, some should be 
approached with caution (e.g. the V̇O2 MRT) when being used to monitor disease 
progression and/or the effect of therapeutic interventions given their increased 
variability. Taken together, this study established limits of variability to determine 
clinically meaningful changes over the short- and medium-term for CPET outcomes 
in young patients with CF, using a superior testing protocol to those currently 
employed. This application was subsequently demonstrated in experimental 
Chapters 6 and 7. From a clinical impact perspective, the outcomes of the studies 
presented in Chapters 5 and 6, have resulted in the RD&E adopting the protocol to 
use in a clinical setting as part of patients’ annual clinical review. More recently, 
these protocols have also been embedded within the annual review of paediatric and 
adult patients with CF (> 400 patients) and non-CF bronchiectasis patients under the 
clinical management of the Southampton General Hospital and Queen Alexandra 
Hospital (Portsmouth) and hopefully marks a change in the UK, whereby more CF 
clinics will adopt this form of exercise testing.  
 
9.1.3 Chapter 6 
Following the development of valid and reproducible CPET methodology in Chapters 
4 and 5, the objective of Chapter 6 was to provide a comprehensive overview of the 
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physiological response of young patients with CF during ramp incremental cycling 
exercise. As outlined in section 2.6.1., maximal aerobic fitness is reportedly reduced 
in young people with CF in addition to abnormalities in other key parameters of 
aerobic exercise function. Given the protocol issues outlined in Chapters 4 and 5, 
there was a need to present an accurate reflection of the response of this patient 
group during this type of exercise.    
The novelty of this study includes: 1) the use of a valid and reproducible CPET 
protocol for which the TEs are known; 2) the comprehensive simultaneous 
evaluation of breath-by-breath changes in V̇O2, muscle deoxygenation ([HHb]) and 
thoracic bioimpedance cardiography derived HR, SV, and ?̇?  during exercise; 3) 
appropriate sigmoidal mathematical modelling of the [HHb] data during ramp 
incremental cycling exercise to provide insight into the matching between O2 delivery 
and utilisation; 4) investigation of the relationships between these mechanistically 
important parameters of O2 delivery and extraction and the parameters of aerobic 
exercise function derived from the CPET. 
This study demonstrated that, even when a valid and reproducible CPET protocol is 
used, FFM normalised V̇O2max is reduced in relatively well children and adolescents 
with mild-to-moderate CF compared with their healthy counterparts. Despite previous 
debate, the V̇O2 gain was reduced and the V̇O2 MRT was slower in CF. These 
findings suggest that the key parameters of aerobic function are impaired in 
paediatric patients with CF during ramp exercise. This study also investigated the 
mechanism(s) responsible for the observed changes in aerobic exercise function in 
this patient group. From a central perspective, in contrast, some parameters of 
central O2 delivery were altered in CF; specifically, end-exercise SpO2 was reduced 
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and there were moderate-strong relationships with parameters of aerobic exercise 
function.  
Finally, this study was the first to examine the influence of mild-to-moderate CF on 
the dynamic adjustments in localised skeletal muscle (vastus lateralis) fractional O2 
extraction in paediatric patients during exercise. Although it has been hypothesised 
that O2 extraction at peripheral skeletal muscle is accelerated during exercise when 
the delivery of O2 is inadequate, this study demonstrated that this is not the case is 
young people with CF during exhaustive incremental cycling exercise. Specially, the 
dynamics of [HHb] were not altered compared to healthy controls, with only a weak 
relationship evident with key parameters of aerobic function.  
 
Collectively, these findings support the notion that central O2 delivery is the principle 
modulator of aerobic function in paediatric patients with CF during exhaustive ramp 
incremental cycling exercise. The inadequacy of CF skeletal muscle to compensate 
for inadequate O2 delivery also raises questions regarding whether there is a 
reduced ability of CF skeletal muscle to extract O2. This proposition does 
complement previous suggestions that the oxidative capacity of skeletal muscle in 
CF may be impaired (de Meer et al., 1995; Erickson et al., 2015; Moser et al., 2000; 
Rosenthal et al., 2009).  
 
9.1.4 Chapter 7 
The purpose of Chapter 7 was to evaluate, for the first time, the effects of 12 weeks 
treatment with an orally administered CFTR potentiator (Ivacaftor) on the aerobic 
exercise function of two teenage patients with CF (G551D mutation). Using a case 
study design, the CPET methodology established in Chapters 4 and 5 was used to 
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examine whether the impairments documented in Chapter 6 can be reversed by this 
ground-breaking new pharmacological treatments. It has been proposed that both 
altered cardiac function and skeletal muscle oxidative function may contribute to 
impair aerobic exercise function in patients with CF. As outlined in section 2.1, 
evidence of CFTR expression on cardiac and skeletal muscle tissue is now available 
(Duan et al., 1999; Gao et al., 2007; Lamhonwah et al., 2010; Tilly et al., 1996; 
Warth et al., 1996). Since Ivacaftor has been shown to restore CFTR function in 
patients with the G551D mutation, this intervention should provide some insight into 
the role of dysfunctional CFTR to the aerobic exercise function of patients with CF.  
Whilst this study adopted a case study approach, due to the prevalence of this CFTR 
mutation within the patient network and availability and cost of this drug, the novelty 
of this study includes: 1) this study provides novel data demonstrating the utility of 
CPET as an outcome measure in clinical trials; 2) analysis at the patient level, which 
is clinically important and this personalised medicine approach allows more 
measurements to be tracked over time; 3) the utilisation of CPET in conjunction with 
the standard clinical outcome measures in clinical trials; 4) the utilisation of a valid 
and reproducible CPET protocol for which the TEs are known; 5) the comprehensive 
simultaneous evaluation of breath-by-breath V̇O2, muscle deoxygenation ([HHb]) and 
thoracic bioimpedance cardiography derived HR, SV, and ?̇? during exercise; 6) the 
investigation of the relationships between these mechanistically important 
parameters of O2 delivery and extraction and the kinetics of pulmonary V̇O2. 
This study provides novel data demonstrating the utility of CPET as an outcome 
measure in clinical trials. Although no clinically meaningful improvement in V̇O2max 
was evident in a patient with relatively mild disease CF disease (despite a 9% 
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improvement), a 30% improvement was demonstrated in the second case with more 
established pulmonary disease, which was substantially greater than the TE of 
measurement for this period established in Chapter 5 (13.3%). Of further importance, 
this patient experienced two successive URTIs during the assessment period and 
her physical activity was much lower than normal due to feeling unwell. Despite this, 
in addition to the improvements in aerobic fitness, her pulmonary function and body 
mass were maintained during a time when she would typically deteriorate and she 
‘felt more energetic’ upon testing.  Notably, this improvement in V̇O2max was out of 
proportion with early changes in pulmonary function. This demonstrated that not only 
is CPET is a sensitive tool to monitor the extent and cause(s) of change following 
clinic interventions, such as Ivacaftor, it may in fact be more sensitive than current 
spirometric indices, however this requires confirmation in trials with more 
participants. Mechanistic data from this study suggest that the observed 
improvement in aerobic exercise function during CFTR potentiator treatment was 
due to both enhanced O2 delivery and O2 extraction, which is an exciting finding 
given that both of these appeared to be impaired during CPET in Chapter 6. These 
findings raise speculations regarding the role of CFTR, which is expressed in 
skeletal muscle, cardiac tissue and the endothelium, to impair aerobic exercise 
function characterising this patient group and highlight the need for further research 
in this area.  
 
9.1.5 Chapter 8 
The purpose of this investigation was to further explore the aerobic exercise 
(dys)function characterising young patients with CF, by exercising participants within 
specific physiologically defined CWR intensity domains. More specifically, this study 
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sought to investigate previous suggestions that pulmonary V̇O2 kinetics are slowed in 
patients with mild-to-moderate CF during moderate intensity exercise (Hebestreit et 
al., 2005; Kusenbach et al., 1999), indicating impaired oxidative metabolism. Of 
additional interest was the response to higher intensity exercise and which factor(s) 
principally limit this response and, by inference, skeletal muscle oxidative 
metabolism.  
The strengths of this study include; 1) the prescription of exercise within defined 
intensity domains; 2) documenting responses during both moderate and very heavy 
intensity exercise; 3) the comprehensive simultaneous evaluation of breath-by-
breath V̇O2, muscle deoxygenation ([HHb]) and HR, SV, and ?̇? during exercise; 4) 
the ensemble averaging and interpolation of at least 4 transitions within each 
intensity domain; 5) the correct modelling and isolation of phase II and the slow 
component (where relevant) within both V̇O2 and [HHb] data; 6) the investigation of 
the relationships between the kinetics of pulmonary V̇O2 and measures of O2 delivery 
(?̇? and SpO2) and O2 extraction and utilisation ([HHb] kinetics and C(a-v)O2 dynamics 
during exercise).  
This study provides new data demonstrating that, contrary to previous reports 
(Hebestreit et al., 2005), the V̇O2 kinetics of children and adolescents with mild-to-
moderate CF are not significantly slower than healthy controls at the onset of 
moderate intensity cycling exercise. Conversely, during exercise performed above 
the GET both the overall V̇O2 MRT and the kinetics of phase II were significantly 
slowed in young patients with CF compared with their healthy peers. Further 
examination of mechanistic parameters of central and peripheral function revealed 
that, while indices of central O2 delivery (SV and ?̇?) and the kinetic parameters of the 
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muscle [HHb] response were not significantly altered in CF, the C(a- v̅ )O2 was 
reduced. This finding, coupled with the fact that ∆C(a-v̅)O2 correlated with the very 
heavy phase II V̇O2 τ and MRT in CF only, suggest that the slowing of the V̇O2 
response at this intensity is mechanistically linked to impaired muscle O2 extraction 
and utilisation rather than central O2 delivery.  
To further the findings in Chapter 6 during ramp incremental exercise, collectively the 
data in Chapter 8 indicate that the modulation of oxidative muscle metabolism in 
young patients with CF is dependent upon the intensity of exercise imposed, with 
significant impairment evident during exercise above but not below the GET. 
Furthermore, alterations in skeletal muscle oxidative metabolism during intense 
exercise appear to be principally regulated by an intrinsic intramyocyte abnormality, 
aspects of which may be specific to CF and not simply a consequence of chronic 
respiratory disease (Rosenthal et al., 2009).  
 
9.2  Synthesis of findings and discussion of candidate mechanism(s) 
responsible for impaired aerobic exercise function in paediatric patients with 
CF  
The following section will synthesise the findings of the experimental chapters and 
the potential mechanism(s) responsible for the observed findings regarding altered 
aerobic exercise function in this patient group.  
 
9.2.1 The development of an exercise testing protocol to assess aerobic exercise 
(dys)function in paediatric patients with mild-to-moderate CF 
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Although comprehensive exercise testing remains underused in the clinical 
management of patients with CF in the UK (Stevens et al., 2010), the recent 
promotion of routine CPET for this patient group by the ECFS Exercise Working 
Group (Hebestreit et al., 2015) and Australasian and North American groups marks 
an international change in stance regarding its value for patients with CF. Prior to 
this thesis, the ECFS Clinical Trials Network Standardisation Committee called for 
assessment of the validity, reproducibility and feasibility of outcomes measures 
utilised in CF and advocated research into the most appropriate exercise test for 
paediatric patients (Bradley et al., 2012). These recent guidelines recommend the 
Godfrey cycle ergometer protocol, incorporating measurement of pulmonary gas 
exchange and SpO2 (and HR and ECG where possible), as the exercise testing 
method of choice for patients with CF over the age of 10 y. However, Chapter 4 of 
this thesis provides compelling evidence, corroborating findings in healthy children 
and adolescents (Barker et al., 2011), that adherence to traditional verification 
criteria and accepting V̇O2peak as a ‘true’ representation of V̇O2max in paediatric groups 
brings with it validity concerns. It is therefore important that the authors of the 
recently published consensus document regarding the use of CPET in CF 
(Hebestreit et al., 2015) acknowledge the findings presented within this thesis.  
Specifically, adherence to traditional verification criteria was shown to drastically 
underestimate V̇ O2max. Conversely, it was demonstrated that a simple Smax 
verification phase can confirm V̇O2max in most cases and, more importantly, can 
identify those patients who may provide a submaximal effort and present with poor 
motivation to exercise to exhaustion. This was of particular interest to the clinician 
involved in this work, since the quantification of a patient’s lack of effort at times was 
related to poor adherence to their treatments and provided data to substantiate 
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discussions with their parents. Furthermore, not only can the combination of a 
traditional ramp and Smax test permit measurement of a valid V̇O2max, but Chapters 4-
8 have demonstrated that this protocol can be safely and effectively administered in 
this patient group within a single hospital visit and may be more sensitive that current 
clinical outcome measures in the assessment of clinical practice and/or interventions 
(Chapter 7). For the findings of this thesis to be implemented within clinical practice, 
the next step is to conduct a well powered study which compares the currently 
available protocols (e.g. Godfrey, SRT, ramp and combined ramp and Smax), in 
addition to other modes of exercise (e.g. the Bruce treadmill protocol).  
To extend the findings in Chapter 4, Chapter 5 has also demonstrated that V̇O2max 
can be repeatedly determined with no learning effect. The reproducibility of 
additional parameters of aerobic exercise function and clinical utility were also 
established. Prior to this thesis, only a single study had reported the reproducibility of 
CPET in children with CF, using the Godfrey protocol and with several other 
methodological issues confounding the data (Kent et al., 2012). This thesis now 
provides clear guidelines concerning the clinically meaningful change required in 
these outcome measures over the short- and medium term, to enable inferences 
regarding therapeutic interventions, such as a course of IVABs, nutritional 
intervention, or inspiratory muscle or whole-body training programmes. These TEs 
can also be compared with disease-related changes over time, however there is a 
need to establish the typical changes in aerobic fitness in this patient group using a 
longitudinal follow-up design. Whilst the recent position stand from the ECFS 
Exercise Working Group (Hebestreit et al., 2015) does represent an exciting shift in 
clinical practice, this thesis highlights a number of important testing considerations 
that should be considered by those looking to implement clinical CPET. 
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Furthermore, Chapters 6-8 have also provided clear evidence of how useful non-
invasive techniques such as thoracic bioelectrical impedance cardiography and 
NIRS can be used to provide insight into the adequacy of O2 delivery and utilisation 
relative to the metabolic demand during exercise in this patient group. Chapter 7 
provided evidence, through a case based approach, of how easily a comprehensive 
CPET can be used to further understand the mechanism(s) by which clinical 
interventions influence patients’ physiological (dys)function and/or QoL. Further 
research is now needed in larger scale clinical trials. Furthermore, CPET was shown 
to detect changes earlier than a number of the current routinely used clinical 
outcome measures. The recent recommendation for clinical CPET by the ECFS now 
marks an opportunity for international assessments of a number of routine clinical 
interventions in this patient group. There is a clear need to investigate further how 
ground breaking treatments such as Kalydeco® and Orkambi® may influence aerobic 
exercise function in individuals with CF and the mechanism(s) responsible. This is 
particularly timely given that at the time of writing this, the European Medicines 
Agency recommend the use of both treatments across the European Union; with 
Orkambi® licensed in those ≥ 12 y with two copies of ΔF508 and that Kalydeco® 
should be licensed for use in those with one copy of R117H aged ≥ 18 y, in addition 
to being extended to children age ≥ 2 y with one of the other 9 gating mutations that 
are covered by the current license.  
There is also a need to utilise these more detailed CPET guidelines in the 
assessment of exercise training programmes. Although the Cochrane review by 
Bradley and Moran (2008) suggested that there are some short- and long-term 
benefits of exercise training for individuals with CF; disappointingly this was only 
based on the findings from seven trials. There is, therefore considerable scope for 
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more robust training studies with better, more comprehensive and standardised 
exercise assessments to evaluate the optimal training strategies for health and 
aerobic fitness of individuals with CF.  
 
9.2.2  The aerobic exercise (dys)function characterising paediatric patients with 
cystic fibrosis 
Based on early evidence that maximal exercise performance is reduced in 
individuals with CF (e.g. Almajed & Lands, 2012; Cerny et al., 1982; Cropp et al., 
1982; Godfrey & Mearns, 1971; Hjeltnes et al., 1984; Klijn et al., 2003; Moser et al., 
2000; Shah et al., 1998), it was unsurprising that Chapter 6 observed a reduced 
V̇ O2max in children and adolescents with CF. However, this confirmation was 
essential given the protocol issues outlined in Chapter 4. This thesis has provided for 
the first time evidence that even relatively well, habitually active young people with 
CF present with impaired aerobic exercise function during ramp incremental 
exercise, with maximal parameters verified supramaximally rather than using the 
currently recommended Godfrey protocol (Hebestreit et al., 2015). Although 
Hebestreit et al. (2005) reported similar V̇O2peak values for patients with CF and 
healthy controls, in a mixed adult and paediatric group, and Wells et al. (2011) made 
similar observations in adolescents with similar habitual activity patterns, it is 
possible that there may have been issues with the testing protocols, given the 
requirement to verify V̇O2peak even in healthy children and adolescents (Barker et al., 
2011). There is, however, a need to examine further the influence of CF-related 
comorbidities (e.g. CFRD, osteoporosis, cardiac abnormalities) and age upon the 
impaired aerobic exercise function characterising these patients.   
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Chapter 6 provides for the first time data indicating a slowing of the V̇O2 MRT during 
incremental exercise, which has since been confirmed (Fielding et al., 2015). This 
study by Fielding and colleagues also confirms the present finding (Saynor et al., 
2014a – Chapter 6) that a shallower functional V̇O2 gain appears to characterise this 
patient group. Prior to this thesis, the limited evidence regarding the V̇O2 kinetic 
response in CF was reported during CWR and PBRS exercise (e.g., Hebestreit et 
al., 2005; Kusenbach et al., 1999). Of additional interest was how this patient group 
respond during exercise within physiological defined intensity domains. Based on 
previous reports of a slowing of the phase II V̇O2 τ during moderate intensity semi-
recumbent cycling (Hebestreit et al., 2005), it was hypothesised that children and 
adolescents with CF would present with slower V̇O2 kinetics during both moderate 
and very heavy intensity cycling, suggesting a slower adjustment of oxidative muscle 
metabolism and increased requirement of substrate level phosphorylation ([PCr] 
breakdown and anaerobic glycolysis).  
Chapter 8 has provided novel insight into an exercise intensity-dependence on the 
impaired oxidative muscle metabolism characterising children and adolescents with 
CF during cycling exercise. This is of clinical and practical importance, since slower 
V̇O2 kinetics will incur a greater O2 deficit and a greater degree of intracellular 
perturbation. Ultimately, this may well result in an earlier termination of exercise that 
is performed at these higher intensities. Interestingly, this finding does correspond 
with an earlier observation by Wells et al. (2011). Using 31P-MRS derived 
measurements of the m. vastus lateralis during three different exercise protocols, 
Wells and colleagues sought to determine the bioenergetic function at rest and 
following low-, moderate- and high-intensity leg extrension exercise. Interestingly, 
skeletal muscle oxidative capacity was impaired in adolescents with CF following 90 
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s of high-intensity exercise, but not shorter or less intense exercise (Wells et al., 
2011). This was suggested to reflect the greater physiological challenge to 
mitochondrial aerobic metabolism elicited by higher intensities.  
Since exercise performed above the LT may also mandate the recruitment of higher-
order muscle fibres. From a practical perspective, there is compelling evidence that 
endurance athletes tend to have a later occurance of the LT and CP (Jones & Poole, 
2008), which causes a reduction in the magnitude of the V̇O2 slow-component. There 
is a need for further research to determine the most-effective and tolerable type of 
endurance training (i.e., mode, duration, volume, intensity) to improve aerobic fitness 
in this patient group, however shifting the GET should perhaps also be a primary 
goal of this interventional work. This may consequent patients training at these 
higher intensities of exercise in order to improve. Higher intensity training specifically 
aimed at improving the metabolic efficiency of fatiguing and, particularly, higher-
order fibres may also be of benefit to this patient group and has been shown to be 
more effective than moderate-intensity training in healthy individuals (e.g Bailey et 
al., 2009; Krustrup et al., 2010) and can improve V̇O2max in adolescents with CF 
(Hulzebos et al., 2011).  
Although the kinetics of V̇O2 in children and adolescents with CF were not impaired 
during moderate intensity exercise, the current thesis cannot rule out the possibility 
of physiological differences during exercise below the GET. Whilst this thesis shows 
that the control of oxidative metabolism is similar between the groups during 
exercise performed below the gas exchange threshold, there were subtle differences 
in the physiological response to exercise which became profoundly different at 
higher exercise intensities. It is possible that subtle differences are evident during 
  
304 
 
moderate intensity exercise. Given that a close temporal coupling has been reported 
between the kinetics of phase II V̇O2 and muscle [PCr] in children and adolescents 
during exercise (Barker et al., 2008), future research should now utilise techniques 
such as 31P-MRS to further develop the work conducted by Wells and colleagues 
(2011) and information presented in this thesis, to further characterise the potential 
exercise-intensity dependence of impaired muscle metabolism apparently 
characterising young, relatively well patients with CF.  
 
9.2.3  The factor(s) modulating aerobic exercise (dys)function in paediatric patients 
with cystic fibrosis 
This thesis provides important simultaneous measurements at both the central and 
peripheral levels to enable us to further understand the dynamic matching of O2 
delivery-to-O2 utilisation during exercise testing which spans a range of exercise 
intensities, which previous studies have largely neglected to do (e.g., Divangahi et 
al., 2009; Ionescu et al., 2001; Lands et al., 1992). The present thesis also provides 
novel data concerning the V̇O2 kinetic response in young people with CF. It was 
beyond the scope of this thesis to further investigate the potential role of genotype 
upon exercise (dys)function, given the large patient numbers that would be required. 
Furthermore, since recent work in paediatric patients with milder airway obstruction 
(Bongers et al., 2014; Borel et al., 2014) suggests that signs of pulmonary 
insufficiency do not typically characterise children and adolescents with CF disease 
and the ventilatory response is adequate, the present thesis focused on further 
explaining the role of “other factors”, such as cardiac (dys)function, arterial 
hypoxaemia and the dynamic balance between O2 delivery and utilisation within the 
microvasculature of exercising skeletal muscle to impair aerobic exercise function.  
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In individuals with chronic diseases such as CF, it has been proposed that a ‘tipping 
point’ may exist, following which the oxidative muscle metabolism (inferred from the 
phase II kinetics of V̇ O2) becomes dependent on the delivery of O2. Although 
Hebestreit et al. (2005) observed an inverse correlation between end-exercise SpO2 
and the phase II V̇O2 τ, in line with our initial observations between V̇O2max and 
∆SpO2 during ramp exercise (Chapter 6), implying that V̇O2 kinetics are principally 
modulated by muscle O2 availability, the present data (Chapter 8) during moderate 
intensity CWR cycling present an opposing viewpoint. Perhaps an important 
methodological consideration concerning the suggestions of Hebestreit and 
colleagues (2005) is that children, adolescents and adults with CF were pooled 
together within the same patient sample, within which a wide spectrum of disease 
severities was likely present. This issue was minimised within the present thesis, by 
using a more homogenous sample. Supporting this, correlations were also evident 
between the kinetics of V̇ O2 and pulmonary function and V̇ O2max in the study 
conducted by Hebestreit and colleagues (2005), suggesting an additional role of 
deconditioning and respiratory factors in their sample. Although Chapter 6 reported a 
very likely reduced SpO2 in young patients with CF at V̇O2max and the phase II V̇O2 τ 
of patients with CF has previously been mechanistically linked to inadequate O2 
delivery, inferred by an inverse relationship between SpO2 (Hebestreit et al., 2005), 
elevating SpO2 through inspiration of hyperoxic gas does not appear to improve 
either V̇O2peak (Nixon et al., 1990) or speed V̇O2 kinetics during PRBS exercise 
(Kusenbach et al., 1999) in patients with CF. These findings imply that arterial 
hypoxaemia is not likely a primary modulator of aerobic exercise (dys)function in 
relatively well children and adolescents with CF, thereby implicating cardiovascular 
and muscular factors.  
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In Chapter 8, bulk blood flow (SVI and CI) was not significantly reduced during either 
moderate or very heavy CWR exercise. Furthermore, parameters of pulmonary V̇O2 
kinetics were not mechanistically linked to parameters of O2 delivery in this group of 
patients, despite previous reports that early signs of cardiac dysfunction may be 
present in paediatric patients with CF (Giacchi et al., 2015; Chapter 6 – Saynor et al., 
2014a). However, the non-invasive technique employed in the present thesis is less 
sensitive and comprehensive than exercise echocardiographic measurements and 
these may warrant further investigation in children and adolescents with CF.  
Cardiac (dys)function should not be excluded completely as a contributing factor to 
exercise (dys)function in young patients with CF until this further research is 
undertaken, given that CFTR is involved in the regulation of cardiomyocyte 
contraction (Sellers et al., 2010). To provide further support, Chapter 7 
demonstrated, albeit through a case study approach, that CFTR targeted 
pharmacological therapies may have the potential to improve estimated SV in 
adolescents with CF in the absence of any exercise training. Furthermore, Chapter 6 
highlighted the potential role of a centrally mediated O2 delivery limitation to limit 
young people with CF at exhaustion during an exhaustive ramp incremental cycling, 
with a most likely lower SpO2 and reduced O2 pulse, although a similar maximal HR 
could be achieved, in line with previous findings (Lands et al., 1992).  
For the first time, Chapters 6 and 8 have documented the O2 extraction dynamics of 
paediatric patients with CF during ramp incremental and CWR exercise, with similar 
[HHb] kinetics observed between the groups during all exercise challenges. 
However, of particular interest 1) the sigmoidal [HHb] response was not shifted by 
CF disease during ramp exercise despite central O2 delivery being reduced (Chapter 
6) and 2) C(a-v̅)O2, considered to reflect the amount of O2 extraction, was significantly 
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reduced early on during exercise in CF during very heavy CWR cycling, 
corresponding with the phase II region of the V̇ O2 response (Chapter 8). 
Furthermore, ΔC(a-v̅)O2 significantly correlated with the very heavy phase II V̇O2 τ 
and MRT in children and adolescents with CF. Additionally, the phase II V̇O2 τ also 
correlated with Δ[HHb] during moderate intensity exercise. The present thesis 
therefore extends previous observations using respiratory mass spectroscopy 
(Rosenthal et al., 2009) that, even in the face of inadequate O2 availability, the 
exercising skeletal muscle of children and adolescents with mild-to-moderate CF 
does not appear able to respond by increasing the rate of fractional O2 extraction, as 
has been hypothesised (Ferreira et al., 2007).  
The impaired oxidative metabolism during CWR exercise above the GET therefore 
appears to be principally regulated by a more local issue regarding the capacity of 
skeletal muscle to extract and utilise O2. In line with the present observations, a role 
of peripheral limitation to mediate the V̇O2 kinetics of patients with CF has also 
previously been implicated (Hebestreit et al., 2005).  Since both structural and 
functional changes in skeletal muscle are evident in CF (e.g., de Meer et al., 1995; 
Lamhonwah et al., 2010; Wells et al., 2011), this role is conceivable. Of additional 
interest is whether there may be a genetic component to the muscle bioenergetic 
abnormalities evident in individuals with CF during exercise. Although this 
information is outside the scope of this thesis, a recent study conducted by Wells 
and colleagues (2011), which included both healthy and a non-CF respiratory 
diseased (primary ciliary dyskinesia (PCD)) control groups, demonstrated that whilst 
both respiratory disease groups presented with significantly slower [PCr] recovery 
kinetics following high-intensity exercise, CF-specific muscle metabolic abnormalities 
were also observed. Specifically, CF patients exhibited a lower resting [ATP]:[PCr] 
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ratio and significantly higher end-exercise pH values compared to both healthy 
children and adolescents and those with PCD.  
Additional support for altered skeletal muscle oxidative metabolism comes from 31P-
MRS based measures of both the m. vastus lateralis and exercising forearm muscle, 
which have reported slower [PCr] recovery kinetics following exercise and, thereby, 
impaired muscle oxidative metabolism in adolescents with CF (de Meer et al., 1995; 
Wells et al., 2011). More recently, reduced skeletal muscle oxidative capacity was 
documented using NIRS (Erickson et al., 2015). Erickson et al. (2015) measured a 
15% reduction in m. vastus lateralis O2 consumption following 15 s of electrical 
stimulation and subsequent repeated transient arterial occlusions. However, recent 
opposing data by Werkman and colleagues (2015) again questions the extent of 
these potential intramyocyte abnormalities.  
Impaired muscle metabolism in paediatric patients with CF is not inconceivable and 
would likely be multifactorial. Reduced antioxidant capacity, arising from systemic 
inflammation and/or oxidative damage, may lower mitochondrial efficiency (Wells et 
al., 2011). However, altered function may also be a direct consequence of the CFTR 
genetic mutation, given than CFTR has been shown to be expressed in skeletal 
muscle cells (Lamhonwah et al., 2010).  Furthermore, in vitro study of leucocyte 
mitochondria in patients with CF demonstrates that properties of complex I of the 
respiratory chain are significantly altered (Dechecci et al., 1988). Absence of CFTR 
from skeletal muscle has also been shown to dysregulate Ca2+ homeostasis, 
augment inflammatory or atrophic gene expression signatures and increase 
diaphragm weakness (Divangahi et al., 2009). In support of this mechanism, Chapter 
7 has demonstrated the potential of Ivacaftor to improve aerobic exercise function in 
adolescents with CF, albeit using a case study design, through both augmented SV 
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and O2 extraction (C(a-v̅)O2) occurring within the microvasculature of the m. vastus 
lateralis during exercise.  
Furthermore, a recent larger scale study (Edgeworth et al., 2015 unpublished 
abstract) substantiates the potential of Ivacaftor to significantly improve V̇O2max in 
adults (18-65 y) with more severe CF (FEV1 21-110% predicted), in the absence of 
exercise training. Edgeworth et al. (2015, unpublished abstract) enrolled 20 adult 
patients with CF into a placebo-controlled crossover study of Ivacaftor over a 4 
month period, with a further 3 month open-label extension. A stepwise increase in 
V̇O2max was observed, with a percentage increase from baseline of 8.0% at the end 
of the trial and 12.1% following the open label extension. Whilst this is within the TE 
determined in children with CF within the present thesis, further research is needed 
to confirm whether this is similar in adults with CF. Importantly, these improvements 
occurred independent of exercise training, changes in pulmonary function and sweat 
Cl-, suggesting that these CFTR therapies are having their effect on the 
cardiovascular and/or muscular systems, as suggested by Chapter 7 of the present 
thesis.  
 
9.3  Recommendations for future research  
As previously highlighted, there is now a need for further well-powered research 
directly comparing the accuracy of the Godfrey protocol, SRT, ramp testing and a 
combined ramp and Smax protocol to determine V̇O2max, in addition to the other key 
parameters of aerobic exercise function, in paediatric and adult patients with CF. 
Establishing this information will then enable us to explicitly provide a toolkit of CPET 
protocols, which are ranked on their accuracy and the comprehensive data that they 
can provide the user with. Confirming the findings regarding the utility of Smax 
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verification in adults with CF will also then allow us to further develop our 
understanding of how the progression of CF disease may further impair aspects of 
aerobic exercise function.  
 
There is also a need to employ additional investigative techniques to further 
document the impact of CF disease at both the central and peripheral level during 
exercise. Since NIRS only indicates the dynamic balance between O2 delivery and 
utilisation within the microvaculature of the skeletal muscle, there is a need for 
further research to investigate the influence of CF disease on the skeletal muscle 
metabolic, pH and blood oxygenation response to exercise of different intensities, 
demarcated by physiologically defined thresholds (i.e., the GET or its equivalent 
when using 31P-MRS; the intracellular threshold). It is a suggested that further 
utilisation of 31P-MRS imaging techniques will provide the necessary non-invasive 
window to monitor, in real time, the key variables involved in energy metabolism 
under both rest and exercise conditions. Specifically, in vivo interrogation of the 
muscle phosphates and pH during rest and exercise at a high sampling resolution 
will enable further investigation of any influence of CF disease upon muscle 
metabolism. Since recent data by Werkman et al. (2015) has further added to the 
debate regarding whether a skeletal muscle abnormality is present in individuals with 
mild CF, this work is warranted. Inclusion of a non-CF bronchiectatic respiratory 
disease control group, a limitation in the present thesis, would also enable any CF-
specific abnormities to be further characterised. Furthermore, other non-invasive 
imaging techniques, such as blood oxygen level-dependent (BOLD) imaging could 
be used to detect any alteration in the muscle tissue temporal dynamics (i.e., 
perfusion and oxygenation) during exercise of different intensities.  
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Given the conflicting findings between the present thesis and Hebestreit and 
colleagues (2005) concerning the V̇O2 kinetic response of individuals with CF, there 
is a need to further clarify the control of skeletal muscle metabolism at the onset of 
different exercise intensities in paediatric patients spanning the disease severity 
spectrum. There is also a need to explore the role of other CF co-conditions, such as 
CFRD, to further impact aerobic exercise function. The role of vascular endothelial 
(dys)function and inflammation on the aerobic exercise (dys)function of this patient 
group also warrants further attention. Recent evidence has proposed a role of 
endothelial (dys)function to modulate the aerobic fitness of children and adolescents 
with CF (Poore et al., 2013). Using the flow-mediated dilation technique, Poore et al. 
(2013) documented vascular endothelial dysfunction in paediatric patients with CF 
compared with their healthy counterparts, which was associated with aerobic fitness 
status (V̇O2max). It is currently unclear whether endothelial dysfunction may also be a 
direct consequence of the CFTR gene polymorphism or rather a consequence of a 
CF-related inflammation and oxidative stress. However, currently unpublished data 
(Scott-Ward et al., unpublished abstract) suggests that the genetically defective 
protein (CFTR) in vascular endothelial cells does contribute to endothelial 
dysfunction. Given that endothelial function is an important clinical concern, given 
the risk of vascular complication in end-stage CF, its role in the impaired aerobic 
exercise function documented in this thesis and the potential of exercise as a low-
cost intervention to improve this therefore warrants further investigation. The role of 
altered cardiac function and contribution of CFTR to this also requires further 
investigation using more advanced techniques, such as echocardiography, genetic 
profiling and animal/human tissue models.  
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One factor that was not considered in the present thesis is the potential role of fibre 
type differences and altered recruitment patterns during exercise. Unfortunately, 
there are few studies measuring the muscle activity of patients with CF during 
exercise (Gruet et al., 2010; Vallier et al., 2011) and, to our knowledge, there is no 
data concerning the fibre type recruitment strategies of young CF patients compared 
with their healthy counterparts during moderate and very heavy exercise. Since fibre 
type composition and recruitment strategies were not measured in this thesis, 
discrepancies between the groups and a role in the altered V̇O2 kinetics at higher 
work rates cannot be excluded. It is known that cycling at higher work rates 
mandates the recruitment of muscle fibres with increased metabolic diversity (i.e. 
type II, IIa and IIx fibres) and, therefore, features of the underlying muscle fibre type 
distribution influence V̇ O2 kinetics above the GET (Pringle et al., 2003). 
Slower V̇O2 kinetics characterise humans with a higher proportion of ‘less efficient’ 
type II fibres during heavy-severe intensity exercise (Pringle et al., 2003) and type II 
fibres have a greater O2 extraction requirement to increase V̇O2. Given that O2 
extraction dynamics were impaired in CF in this thesis (Chapters 6 and 8), fibre type 
differences is not likely a primary factor regulating the response. However, 
differential recruitment of muscle fibres either at the onset and/or during exercise 
may contribute to the intensity dependence of the CF-related differences in muscle 
energetics evident in Chapter 8. Further research in this area is therefore warranted.  
 
 
10.4  Recommendations for clinical practice  
Obtaining a valid V̇ O2max measurement is critical and particularly important in 
paediatric groups. Whilst the importance of calibration of metabolic carts is widely 
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acknowledged with regard to the accuracy of CPET-derived data, thorough 
familiarisation and the choice of testing protocol should be vital considerations for 
those choosing to implement CPET as a clinical assessment tool in patients with CF. 
From a practical viewpoint, familiarisation with the expectations of the protocol and 
what it feels like to maintain a steady cadence is essential and should not be 
overlooked. The choice of protocol and verification criteria are also fundamental 
considerations to obtain a ‘true’ representation of V̇O2max. However, at a time when 
the ECFS are recommending the Godfrey protocol, the present thesis has 
demonstrated that a verification phase should be included to confirm V̇ O2max. 
Furthermore, a key benefit of the ramp incremental protocol is that 1) the test spans 
the range of exercise intensities and, therefore, 2) derives both important maximal 
and submaximal parameters of aerobic exercise (dys)function and the mechanism(s) 
regulating this. This can help to prevent premature test termination and short test 
durations, which have previously been observed with the CF exercise testing 
literature (e.g., Kent et al., 2012). There is, therefore, a need for research that 
directly compares the different CPET protocols, in addition to different modes of 
exercise, to enable further recommendations regarding the best protocol for this 
patient group. 
These recommendations have significant implications for the assessment and 
interpretation of CPET in clinical and research settings. To utilise V̇ O2max in 
prognostic stratification and the assessment of clinical of research interventions in 
CF, it is essential that ‘true’ measurements are obtained. Accepting submaximal 
efforts with significantly distort the clinical interpretation of patients’ aerobic fitness 
status. From a practical viewpoint, Smax is straightforward to implement and, 
clinically, may minimise the costs associated with re-tests when the validity of a test 
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is questionable. There is, however, a need to assess the appropriateness of this 
form of testing in older patients with more advanced respiratory disease, who may 
also have more serious cardiac (dys)function (e.g. Giacchi et al., 2015).  
Interpreting data in relation to normative values and established TEs enables 
researchers and clinicians to determine meaningful changes. Reproducibility over 
time is critical when evaluating the efficacy of CF treatments (e.g., antimicrobials, 
mucolytics and gene mutation targeted therapies) which may accrue over weeks or 
months, as well as monitoring exercise training interventions. Data in this thesis has 
provided the reproducibility of CPET derived submaximal and maximal parameters 
using a valid protocol, the TE of which was also improved when compared with an 
incremental test using traditional verification criteria. Determining the extent to which 
changes in outcome measures relate to normative data is fundamental to the utility 
of CPET. Establishing robust normative data for both young people with CF and their 
healthy counterparts therefore represents an important next step.  
Furthermore, it is recommended that the wealth of parameters provided by CPET is 
not ignored. Although these indices are often overlooked in favour of maximal end-
exercise measurements, submaximal parameters should assist with diagnostic and 
prognostic evaluations. Furthermore, no single parameter should be used 
exclusively, rather it is the integration of the exercise responses as a whole which 
will add value when utilising CPET to assess physiological (dys)function.  
 
10.4  Conclusion  
The present thesis provides a series of experimental studies addressing issues 
relating to the assessment of aerobic exercise (dys)function, typical clinical 
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presentation and the factor(s) modulating this response in paediatric patients with 
mild-to-moderate CF. Consequently, this thesis has made a significant and novel 
contribution to our understanding of how to assess and interpret aerobic exercise 
(dys)function in this patient group. New and original insights are presented regarding 
an apparent exercise intensity-dependence of the influence of mild-to-moderate CF 
disease on skeletal muscle oxidative metabolism in children and adolescents. This 
thesis is timely, given the recent promotion of CPET within the clinical management 
of patients with CF by the European, North American and Australasian CF 
associations and recognition regarding the importance of exercise and physical 
activity within CF management:  
 
“…Over the past years, evidence for the benefical effects of exercise on lung health 
and aerobic exercise capacity is strengthening. Despite the fact that most of the 
knowledge is based on small studies, the observed effects are encouraging and 
there is no reason why exercise should not be implemented in all patients’ care.” 
- Hebestreit et al. (2015a). 
 
“…Children with cystic fibrosis should be encouraged to take part in as much 
physical activity as possible, ideally types of exercise that leave you out of breath, 
like running, swimming, football or tennis.” 
- UK Cystic Fibrosis Trust, 2015. 
 
In view of this, it is important that those utilising exercise testing consider and 
understand the validity and utility of their chosen outcome measures and their 
associated error, to make decisions regarding clinically meaningful changes in 
patients’ function with better clarity. Furthermore, those conducting exercise testing 
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as an outcome measure, particularly in the research environment, should include 
additional key parameters of aerobic exercise function and consider the use of other 
non-invasive assessment techniques, such as NIRS and V̇O2 kinetics, to provide 
mechanistic insight into the response to pharmacological and/or physiotherapy 
intervention practices. This will enable further understanding of the physiological 
mechanism(s) responsible for changes in patients’ function, as a result of disease 
progression and/or pharmacological or therapeutic interventions. Systematic 
exercise testing and training will also enable a larger, more comprehensive 
epidemiological profile of the exercise (dys)function characterising this new 
generation of aging patients with CF and national normative reference data, such as 
that established in the Netherlands (Bongers, 2013), to be established for UK based 
patients.   
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APPENDIX B 
Ethics Approval for Studies 1 - 6 
 
Studies 1 and 2 
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Study 3 
 
Dear Craig, 
 
Thank you for your application for ethical approval:  
 
Proposal 5 2012/111 (26/10/11) 
Title: Oxidative and cardiovascular responses during exercise in patients with cystic 
fibrosis compared to age and gender matched controls 
Applicant: Associate Professor Craig Williams with Dr Alan Barker, Dr Partrick Oades 
(Consultant Paediatrician_ and Zoe Saynor (Research Student) 
 
The proposal (reviewed on the e-Ethics system) was discussed by the Committee. The 
Committee advised that the application should be amended as follows:  
 
i. The parent/guardian information sheet needs to be reduced from 8 pages to 2-3 
and should include less technical terminology and abbreviations and lay titles. 
ii. This section of the study does not require detailed information regarding cystic 
fibrosis, or information specifically related to the NHS and its procedures, such as 
reference to keeping the information gathered for 15 years, it is usually 5.  
iii. A risk assessment needs to be completed for the study of lung function using a 
micro loop.  
iv. Craig Williams should be listed as Dr or Associate Professor rather than Professor 
v. It needs to be made clear on the information sheet where the study is taking place, 
is it at CHERC or at the RD&E hospital? 
vi. There is a discrepancy between the adult and the child forms, the adult forms 
suggest that they will be able to complete their child’s form with them, whereas the 
child’s form suggests they will be able to complete the form separately. Please 
also ensure the information in these sheets match that in the child sheets. Point 12 
should read “what if my child or I”. 
vii. In the parent’s letter it states that the study will be a “novel insight for both you and 
your child”. This appears to try and sell the study and may not be the case. 
 
Decision: The Committee agreed to PROVISIONALLY APPROVE the proposal until 
July 2012 but required the amendments to be returned to Lauren Hitchman for 
approval by DW prior to the commencement of the study. 
 
 
  
365 
 
Studies 5 and 6 
 
 
  
366 
 
 
  
367 
 
 
  
368 
 
APPENDIX C 
Funding 
 
Studies 1 and 2 
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Studies 4 and 5  
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APPENDIX D 
Written Supportive Information for Participants and 
Parents/Guardians (Studies 1 and 2) 
 
 
 
A study about fitness of children  
        Study Number        
                     Version 2 
          Date 20/12/2010 
 
Children’s Letter 
 
Dear Child, 
We would like to ask you to take part in a study at the hospital. Please read this 
sheet very carefully before you decide to take part or not. 
 
What is the study about? 
 The study will help us find out how fit you are by looking at how much oxygen you 
use during and after three exercise tests.  
 
 
What will happen? 
 
 Each exercise test will involve you pedalling on an exercise bike. 
 During the exercise tests you will wear a mouthpiece and nose clip.  
 Before and after each test you will breathe out into a plastic tube so we can see 
what your lungs are doing.  
 You will also be asked if you would like to do a fingertip prick test. This is where 
we take a small spot of blood from a tiny prick of your fingertip.  
 This would be no more than one on each of the 3 visits.  
 You do not have to do the fingertip prick test if you don’t want to and you can still 
take part in the exercise tests.  
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Are the exercise tests safe? 
 
 The exercise tests are very safe.  
 Your doctor will look at your health records before you start any exercise tests to 
see if it is safe for you to take part.  
 A medical team will be ready during the exercise tests just in case there are any 
problems. 
 
 
What else will happen on each visit to the hospital? 
 
First Visit 
 On your first visit to the hospital we will measure your height, your height when 
you are sitting down and your weight.  
 We will measure your skin folds at your arm, back and hip. This is done by very 
gently pinching the skin using a small instrument. This does not hurt but may 
tickle.  
 You will then be shown the equipment that will be used during the following visits 
 Finally, you will be given the chance to practice cycling on the exercise bikes and 
feel what it is like when pedalling is both easy and hard 
 
Second Visit 
 The second visit will involve your first exercise test 
 Before you have to do any exercise you will be asked to rest  
 The exercise test will involve you first pedalling on an exercise bike for 6 minutes 
when the pedals are quite easy to turn 
 You will then be asked to pedal on the exercise bike for as long as you can until 
you can’t pedal anymore.  
 The pedals on the bike will get harder to turn the longer you pedal.  
 You will wear a mouthpiece and nose piece during the cycling. 
 You will then stay on the bike and pedal easily for 5 minutes, then you will sit 
down and rest for 10 minutes while still wearing the mouthpiece and nose clip.  
 You will then be asked if you would like to do the fingertip prick test. 
 You will then get back onto the bike and be asked to cycle for as long as you can 
again, to check that you cannot go for longer than you did before 
 We will then give you a drink and a biscuit and you can rest before going home. 
 
Third and Fourth Visits 
 The next 2 visits will be exactly the same as your 2nd visit  
 You will simply be asked to perform the same exercise test and the same 
measurements will taken  
 
After you have finished taking part in the study 
 If you are a girl aged 8 or over or a boy aged 10 or over, we also need to 
know how developed your body is. To do this we will ask you to go into a private 
room, look at yourself and answer a question about how far your body has 
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developed. The question is an easy choice out of 5, and nobody will be present in 
the room. 
 
 
What else will you have to do if you do decide to take part? 
 
1. For 2 – 3 days before each visit you must not do any hard exercise.  
2. You can eat and drink as normal but do not drink or eat foods which contain 
caffeine such as tea, coffee, coca-cola, dark/milk chocolate for the 3 hours before 
coming to see us.  
3. Please wear the same clothing (e.g. PE kit, T-shirt, shorts and trainers) each time 
you visit. 
 
Do you have to take part? 
 
 It is up to you to decide whether or not to take part.  
 If you take part you are still free to drop out at any time and without giving a 
reason.  
 If you drop out or do not take part it will not affect the way your doctor and 
healthcare team treat you.  
 If you do not want to have the fingertip prick tests done you can still take part. 
 
 
What should you do if you want to take part or have any questions? 
 
1. If you would like to take part you must have your parent/carer’s permission by 
getting them to complete the consent form.  
2. You must also complete a form and return it to a member of the research team.  
3. If you have any questions please get in touch with a member of the research 
team who are on the bottom of this page. 
 
 
 
 
Thank you for reading this sheet. 
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The Research Team. 
 
Miss. Zoe Louise Saynor  
(Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): (01392) 264889 
Tel (mobile): (07984) 638788 
E-mail: zls202@exeter.ac.uk 
 
Dr. Patrick J. Oades  
(Consultant Paediatrician, Royal Devon and Exeter Healthcare NHS Trust) 
Tel: (01392) 402665 
E-mail: patrick.oades@rdehc-tr.swest.nhs.uk 
 
Professor Craig. A. Williams  
(Children’s Health & Exercise Research Centre, University of Exeter) 
Tel: (01392) 724809 
E-mail: c.a.williams@ex.ac.uk 
 
Dr. Alan Barker  
(Children’s Health & Exercise Research Centre, University of Exeter) 
Tel: (01392) 722766 
E-mail: a.r.barker@exeter.ac.uk  
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PATIENT (16-18 yrs) INFORMATION SHEET 
FOR 
THE RELIABILITY AND VALIDITY OF MAXIMAL CARDIOPULMONARY 
EXERCISE TESTING AS A PROGNOSTIC TOOL WITHIN THE YOUNG CYSTIC 
FIBROSIS POPULATION 
Version number: 1 
Date: 20/12/10 
 
 
1. Study Title 
 
The reliability and validity of maximal cardiopulmonary exercise testing as a prognostic tool 
within the young cystic fibrosis population.  
 
2. Invitation paragraph  
 
You are being invited to take part in a research study. Before you decide whether or not to be 
involved, it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it with 
friends, relatives and your clinician/GP if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not you wish to 
take part. 
 
If you would like more information regarding participation in research you can access the 
public information pack published by INVOLVE (a non-profit organization promoting public 
involvement in the NHS, public health and social care research). This is freely available on 
their website www.involve.org.uk/ or you can obtain a paper copy by writing to: Involve, 
Royal London House, 22-25 Finsbury Square, London, EC2A 1DX.  
 
More specialized information regarding participation in clinical research is published by the 
UK Clinical Research Collaboration (UKCRC). You can access this information on the 
UKCRC website www.ukcrc.org or request a printed copy from: UKCRC, 20 Park Crescent, 
London, W1B 1AL.  
 
 
Thank you for reading this.  
 
 
3. What is the purpose of the study?  
CHILDREN’S HEALTH AND 
EXERCISE RESEARCH CENTRE 
 
Sport and Health Sciences 
St Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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It is recommended that children and teenagers with cystic fibrosis (CF) take part in sports and 
games to stay fit and healthy. Exercise not only helps improve fitness and enhances their 
quality of life through socialising with peers and friends, but it may also help them to cope 
better with their disease. 
Exercise testing for children with CF is also held in high regard by clinicians. It may provide 
clinicians with additional prognostic information relating to your child’s disease. Much 
remains to be clarified, however, regarding the most feasible tests to implement into clinical 
practice. 
 
Exercise testing offers potential prognostic value that common clinical assessments you may 
be familiar with, such as measuring resting lung function with a spirometer, cannot. This 
study will form the basis of future work examining exercise testing and training for children 
with CF. It is proposed that this study will initiate implementation of annual exercise testing 
within the paediatric unit (Bramble ward) of the Royal Devon & Exeter hospital (RD&E). 
Whilst the main aim of this study is to establish the reliability and validity of a particular 
exercise test, it will also provide information regarding your child’s exercise toleration which 
may offer a novel insight for both you and your child.  
 
During exercise breathing becomes faster and harder because your body needs more oxygen 
to produce energy to move faster. The study will look at how much oxygen your child 
breathes in and uses during an exercise test performed on an exercise bike.   
 
The results of the study will help to better inform clinicians regarding what exercise tests are 
suitable for this patient group and to develop better exercise testing procedures for children 
with CF.  
 
 
4. Why have I been chosen? 
 
We are interested in looking at children with cystic fibrosis, aged between 7-18 years old, 
who regularly take part in physical activity.  
 
 
5. Do I have to take part? 
 
Taking part is entirely voluntary and it is up to you to decide whether or not you wish to take 
part. If you do choose to take part you will be given this information sheet to keep, and be 
asked to sign a consent form giving your permission to participate. If you do decide to take 
part you are still free to withdraw from the study at any time and without giving a reason. A 
decision to withdraw at any time or a decision not to take part will not affect the standard 
clinical care you receive. 
 
 
6. What will happen to me if I take part? 
 
The study will involve 4 trips to an exercise laboratory within the RD&E, spread across a 
period of approximately 1 month. The initial visit will be a familiarisation session to discuss 
any queries you may have, obtain informed consent and to familiarise you with the 
equipment/testing procedures that subsequent exercise testing will involve. We will also use 
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this session to obtain some information regarding your body composition and to practice 
exercising on the bike at different intensities. All times will be at times which are suitable for 
you. This initial familiarisation session should not exceed 2 hours. The 3 subsequent exercise 
testing sessions will last ~50 minutes each. On each visit to the centre you will be required to 
complete an exercise test and the following measurements will be taken: 
 
 
 
 
Respiratory function: 
The volume of oxygen you are breathing in (VO2)  
The volume of carbon dioxide you are breathing out (VCO2) 
The ratio between the amounts of oxygen you are breathing in and carbon dioxide you are breathing 
out (RER) 
The number of breaths you are taking (fv) 
 
Lung function 
The volume of air your lungs can hold (VC) 
The volume of air you can breathe out (FVC) 
The volume of air you can breathe out in one second (FEV1) 
The volume of air you are breathing in and out (PEF) 
 
Other measurements 
Your heart rate (HR) 
How tired you think you feel (RPE) 
How breathless you think you feel (RPD) 
The amount of lactate in your blood ([La
-
]B) (optional) 
Changes in the concentrations of oxy-[Hb+Mb] and deoxy-[Hb+Mb] 
haemoglobin/myoglobin within the quadriceps muscles of your right leg 
 
Visit 1 
On the first visit to the laboratory your height, sitting height, and weight will be taken. You 
will also have your skin folds measured at your arm, back and hip. This is done by very 
gently pinching the skin and measuring the width of the skin folds. You will then have your 
lung function measured, this will involve you taking a big breath and breathing into a plastic 
tube.  
 
You will be familiarised with the equipment to be used during testing and will be encouraged 
to practice cycling at different intensities on the stationary bike. You can also take this 
opportunity to ask any questions to the research staff regarding what would be required at the 
subsequent exercise testing sessions.  
 
Visit 2 
The second visit will involve the first of the exercise tests. This first exercise test will involve 
you pedalling on an exercise bike for as long as you can. This exercise test starts off easy but 
gradually the pedals get harder to turn making the exercise test progressively more difficult. 
During this exercise test you will have to breathe through a mouthpiece and wear a nose clip, 
this may seem strange at first but you will soon get used to it. The amount of oxygen present 
in your blood will also be monitored throughout the session.  
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During the exercise you will be shown a list of numbers on a chart numbered 6-20, and will 
be asked to point to a number on the chart which shows how hard or easy you are finding the 
exercise test. You will also be asked to rate on a different chart how breathless you feel.  
After you have finished the first exercise test you will remain on the bike for a 5 minute cool-
down period of unloaded pedalling and then be seated down and rested for 10 minutes whilst 
still wearing the mouthpiece and nose clip. After the exercise test you will have your lung 
function measured again. You will then be asked for a spot of blood, which will be drawn 
from your fingertip by a tiny needle prick. This is optional and even if you wish not to give a 
spot of blood you will still be allowed to participate in the study. The fingertip prick test is 
used to examine how hard you worked during the exercise test. 
Following the 15 minutes rest you will be asked to get back onto the bike and to pedal again 
for as long as possible. The aim of this is to clarify whether or not you could have continued 
for any longer during the 1
st
 part of the test. This section will last approximately 2 minutes. 
During both the rest and the second part of the exercise test you will be wearing the same 
mouthpiece and nose clip as before in the first exercise test. You lung function will be 
measured before and after both parts.  
 
Visit 3 
Forty-eight hours later you will be asked to complete the second exercise testing which will 
be identical to visit 2.  
 
Visit 4 
You will be required to complete the fourth and final exercise test ~4 weeks after their 
previous (2
nd
) exercise test. This visit will again be identical to the previous exercise testing 
sessions, whilst wearing the mouthpiece and nose clip. Again, your lung function will be 
measured before and after the third exercise test, and afterwards you will have a choice 
whether or not to do a final fingertip prick test. 
 
Post-testing 
We also need to know your maturation (growth and development). This will require you to 
self-assess your pubertal stage by giving you 5 options. Self-assessment will take place at 
your home and you will be asked to return the scale in a sealed envelope you will be provided 
with. N.B. This will only be asked of boys from age 10 and girls from the age of 8.  
 
Please see the diagram on the following page for a full summary of what will happen during 
each visit.  
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Visit 2: Exercise session 1  
 Baseline lung function, deoxy-[Hb+Mb] and HR 
 CPET protocol 
 Exercise cessation assessment of RPE, RPD and ([La]B) 
 15 min seated rest  
 Supramaximal testing 
TOTAL TIME: Approx. 50 minutes 
N.B. Lung function and SaO2 will be assessed throughout both 
exercise and rest 
 
Visit 1: Familiarisation session 
- SS obtained by Dr. Patrick Oades prior to this 
- Run through PIS and protocol once more with  
  patient & parent/guardian 
- Obtain age, pubertal maturation and   
  anthropometric measurements 
- Cycle ergometry familiarisation 
- Familiarisation with assessment equipment 
and scales 
TOTAL TIME: Maximum 2 hours 
 
Exclusion or postponement 
may occur if a change in 
health status, such as acute 
infections or an unstable 
chronic health deems the 
patient unsafe to take part.   
Visit 3: 48 hours post-exercise session 1 
 Baseline lung function, deoxy-[Hb+Mb] and HR 
 CPET protocol  
 Exercise cessation assessment of RPE, RPD and ([La]B) 
 15 min seated rest  
 Supramaximal testing 
TOTAL TIME: Approx. 50 minutes 
N.B. Lung function and SaO2 will be assessed throughout both 
exercise and rest 
 
Visit 4: 6 weeks post-exercise session 1 
 Baseline lung function, deoxy-[Hb+Mb] and HR 
 CPET protocol 
 Exercise cessation assessment of RPE, RPD and ([La]B) 
 15 min seated rest  
 Supramaximal testing 
TOTAL TIME: Approx. 50 minutes 
N.B. Lung function and SaO2 will be assessed throughout both 
exercise and rest 
 
Post-testing: 
- Pubertal maturity self-assessed at home at  
  returned in a sealed envelope to ZS 
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Figure 1. The assessment procedures for each participant. 
7. What else will I have to do? 
 
If you wish to take part in the study we would like you to attend all 4 visits to the laboratory. 
We ask that you be in a rested state on arrival, and have performed no strenuous exercise in 
the 2-3 days prior to visits.  
 
On each visit to the laboratory we also ask that you have had sufficient food and drink before 
you arrive, and wear the same or similar clothes for each exercise test. We also ask that you 
don’t eat or drink any caffeine 3 hours prior to each visit. However, it is important that you 
do eat a light meal or snack before each visit (i.e. sandwich, cereal etc.). 
 
 
8. What are the possible risks of taking part? 
 
The exercise testing is very safe. An assessment of your health will be made before you start 
the exercise tests to see if it is safe for you to take part. During the exercise tests you will be 
carefully monitored and observed to ensure your safety and well-being.  
 
 
9. What are the potential benefits of taking part?  
 
The research is intended to enhance our understanding of how the lung and respiratory 
function of children and teenagers with CF respond during and after exercise testing. The 
information we obtain from the study may help to develop better exercise testing programmes 
with UK CF clinics.  
 
Hopefully, you will take away a positive and enjoyable experience from your involvement in 
the exercise tests. You will be tested on equipment that is used to monitor the fitness of sports 
people, and you will get to see how fit you currently are and what intensity of exercise you 
can tolerate. You will be given the results of your exercise tests and talked through them by a 
member of the research team. This will hopefully prove an interesting and constructive 
exercise, particularly if you have a strong interest or involvement in sport and may wish to 
increase the amount of physical activity you participate in.  
 
 
10. What happens if I don’t want to continue in the study? 
 
You are free to withdraw from the study at any point without giving a reason. Dropping out 
of the study will not affect your clinical care in any way or your relationship with the 
paediatric staff.  
 
If you do decide to not continue with the study then you will not be required to complete any 
additional exercise tests, or attend any additional visits to the centre that are associated with 
the research. Results from the exercise tests that you have previously completed will still be 
available to you. 
 
 
11. What if something goes wrong? 
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There are no special compensation arrangements if taking part in this study harms you.  Your 
rights are the same as undergoing research i.e. if you are harmed due to someone’s 
negligence, then you may have grounds for legal action, but you may have to pay for it.  
Regardless of this, if you wish to complain, or have any concerns about any aspect of the way 
you have been approached or treated during the course of this study, the normal University 
complaints procedures will be available to you.  
 
 
12. Will my taking part in this study be kept confidential? 
 
We have a responsibility to inform you of how we will collect, store and use you information 
that we gather during the study. The primary concern is that any information that we collect 
about you will be confidential. All of the this information collected such as your name, date 
of birth, contact details, details of your health and test results will be transferred to a paper 
study file, which will be kept in a secure room in the centre in a locked filing cabinet. 
 
Your exercise results will be kept anonymous by assigning them a unique study code and 
participant number. Only your date of birth will be used to identify the results. The results 
from the exercise tests are collected on paper and stored in a locked filing cabinet. The 
exercise results are then transferred from paper and stored on a computer. The only personal 
information stored on computer will be your date of birth and participant number. Your 
exercise results will be password protected, as will the computer used to store the 
information. All the paper and computer files will be stored for 15 years, after this period 
paper files will be destroyed and computer files erased. Only the researchers involved in the 
study will have access to your medical records and exercise results. 
 
 
13. What will happen to the results of the study? 
 
Once the study is completed, which is targeted to be September 2011, you will be sent a 
summary of our research findings. The research is undertaken with the intention of being 
submitted as a PhD thesis. It is also the intention to submit the results of the research to 
relevant journals for publication, and to inform our colleagues of the findings at scientific 
meetings. In publishing and talking about the study you will not be identifiable. 
 
You will be given the opportunity to comment on the research protocol and testing procedure. 
This information will be collated and may inform future studies. You will also receive the 
results and conclusions from the research and are free to request information regarding your 
individual data.  
 
 
14. Who is organising and funding the research? 
 
The study is a collaboration between the Paediatric Unit of the Royal Devon and Exeter 
(RD&E) NHS Foundation Trust Hospital and the Children’s Health and Exercise Research 
Centre at the University of Exeter. The study is sponsored by the RD&E NHS Foundation 
Trust. None of the researchers or doctors involved personally receives money for including 
you in the study. 
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As a result, a monetary contribution will be provided to go some way towards covering travel 
expenses.  
 
15. Who has reviewed the study? 
 
The scientific content of the study has been reviewed by the Peninsula Research and 
Development Support Unit. All research within the National Health Service (NHS) is looked at 
by an independent group of people, called a Research Ethics Committee (REC). RECs 
safeguard the rights, safety, dignity and well-being of people participating in research in the 
NHS. They review applications for research and give an opinion about the proposed 
participant involvement and whether the research is ethical. The present study has been 
reviewed and given favourable opinion by the South West 5 (or Frenchay) REC. 
 
 
16. What should I do if I would like to take part? 
 
If you would like to take part in the study you must give your permission by completing the 
consent form. You should this form to a member of the research team.  
 
 
17. What if I have any questions? 
 
If you have any questions please do not hesitate to get in touch with a member of the research 
team. 
 
 
18. Contact for further information 
 
If you need further information please contact: 
The Research Team 
Miss. Zoe Louise Saynor (Children’s Health & Exercise Research Centre, University of 
Exeter) 
Tel (work): (01392) 264889 
Tel (mobile): (07984) 638788 
E-mail: zls202@exeter.ac.uk 
 
Dr. Patrick J. Oades (Consultant Paediatrician, Royal Devon and Exeter Healthcare NHS 
Trust) 
Tel (work): 01392 402665 
E-mail: patrick.oades@rdehc-tr.swest.nhs.uk 
 
Professor. Craig A. Williams (Children’s Health & Exercise Research Centre, University of 
Exeter) 
Tel (work): 01392 724809 
E-mail: c.a.Williams@ex.ac.uk 
 
Dr. Alan Barker (Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): (01392) 722766 
E-mail: a.r.barker@exeter.ac.uk  
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PARENT/GUARDIAN INFORMATION SHEET 
FOR 
THE RELIABILITY AND VALIDITY OF MAXIMAL CARDIOPULMONARY 
EXERCISE TESTING AS A PROGNOSTIC TOOL WITHIN THE YOUNG CYSTIC 
FIBROSIS POPULATION 
Version number: 2 
Date: 20/12/10 
 
 
1. Study Title 
 
The reliability and validity of maximal cardiopulmonary exercise testing as a prognostic tool 
within the young cystic fibrosis population.  
 
2. Invitation paragraph  
 
Your child is being invited to take part in a research study. Before you decide whether or not 
to be involved, it is important for you to understand why the research is being done and what 
it will involve. Please take time to read the following information carefully and discuss it 
with friends, relatives and your clinician/GP if you wish. Ask us if there is anything that is 
not clear or if you would like more information. Take time to decide whether or not you wish 
to take part. 
 
If you would like more information regarding participation in research you can access the 
public information pack published by INVOLVE (a non-profit organization promoting public 
involvement in the NHS, public health and social care research). This is freely available on 
their website www.involve.org.uk/ or you can obtain a paper copy by writing to: Involve, 
Royal London House, 22-25 Finsbury Square, London, EC2A 1DX.  
 
More specialized information regarding participation in clinical research is published by the 
UK Clinical Research Collaboration (UKCRC). You can access this information on the 
UKCRC website www.ukcrc.org or request a printed copy from: UKCRC, 20 Park Crescent, 
London, W1B 1AL.  
 
 
Thank you for reading this.  
 
 
3. What is the purpose of the study?  
 
CHILDREN’S HEALTH AND 
EXERCISE RESEARCH CENTRE 
 
Sport and Health Sciences 
St Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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It is recommended that children and teenagers with cystic fibrosis (CF) take part in sports and 
games to stay fit and healthy. Exercise not only helps improve fitness and enhances their 
quality of life through socialising with peers and friends, but it may also help them to cope 
better with their disease. 
Exercise testing for children with CF is also held in high regard by clinicians. It may provide 
clinicians with additional prognostic information relating to your child’s disease. Much 
remains to be clarified, however, regarding the most feasible tests to implement into clinical 
practice. 
 
Exercise testing offers potential prognostic value that common clinical assessments you may 
be familiar with, such as measuring resting lung function with a spirometer, cannot. This 
study will form the basis of future work examining exercise testing and training for children 
with CF. It is proposed that this study will initiate implementation of annual exercise testing 
within the paediatric unit (Bramble ward) of the Royal Devon & Exeter hospital (RD&E). 
Whilst the main aim of this study is to establish the reliability and validity of a particular 
exercise test, it will also provide information regarding your child’s exercise toleration which 
may offer a novel insight for both you and your child.  
 
During exercise breathing becomes faster and harder because your body needs more oxygen 
to produce energy to move faster. The study will look at how much oxygen your child 
breathes in and uses during an exercise test performed on an exercise bike.   
 
The results of the study will help to better inform clinicians regarding what exercise tests are 
suitable for this patient group and to develop better exercise testing procedures for children 
with CF.  
 
 
4. Why has my child been chosen? 
 
We are interested in looking at children with cystic fibrosis, aged between 7-18 years old, 
who regularly take part in physical activity.  
 
 
5. Does my child have to take part? 
 
Taking part is entirely voluntary and it is up to you to decide whether or not your child takes 
part. If you do allow your child to take part you will be given this information sheet to keep, 
and be asked to sign a consent form giving your child permission to participate. If you do 
decide to allow your child to take part you are still free to withdraw your child from the study 
at any time and without giving a reason. A decision to withdraw your child at any time or a 
decision not to take part will not affect the standard clinical care your child receives. 
 
 
6. What will happen to my child if I allow them to take part? 
 
The study will involve 4 trips to an exercise laboratory within the RD&E, spread across a 
period of approximately 1 month. The initial visit will be a familiarisation session to discuss 
any queries you or your child may have, obtain informed consent/assent and to familiarise 
both you and your child with the equipment/testing procedures that subsequent exercise 
testing will involve. We will also use this session to obtain some information regarding your 
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child’s body composition and to practice exercising on the bike at different intensities. All 
times will be at times which are suitable for you. This initial familiarisation session should 
not exceed 2 hours. The 3 subsequent exercise testing sessions will last ~50 minutes each. On 
each visit to the centre your child will be required to complete an exercise test and the 
following measurements will be taken: 
 
 
 
Respiratory function: 
The volume of oxygen your child is breathing in (VO2)  
The volume of carbon dioxide your child is breathing out (VCO2) 
The ratio between the amounts of oxygen your child is breathing in and carbon dioxide he/she is 
breathing out (RER). 
The number of breaths your child is taking (fv). 
 
Lung function 
The volume of air your child’s lungs can hold (VC). 
The volume of air your child can breathe out (FVC). 
The volume of air your child can breathe out in one second (FEV1). 
The volume of air your child is breathing in and out (PEF). 
 
Other measurements 
Your child’s heart rate (HR). 
How tired your child thinks he/she feels (RPE). 
How breathless your child thinks he/she feels (RPD) 
The amount of lactate in your child’s blood ([La-]B) (optional) 
Changes in the concentrations of oxy-[Hb+Mb] and deoxy-[Hb+Mb] 
haemoglobin/myoglobin within the quadriceps muscles of your child’s right leg 
 
Visit 1 
On the first visit to the laboratory your child’s height, sitting height, and weight will be taken. 
They will also have their skin folds measured at their arm, back and hip. This is done by very 
gently pinching the skin and measuring the width of the skin folds. They will then have their 
lung function measured, this will involve your child taking a big breath and breathing into a 
plastic tube.  
 
Your child will be familiarised with the equipment to be used during testing and will be 
encouraged to practice cycling at different intensities on the stationary bike. You can also 
take this opportunity to ask any questions to the research staff regarding what would be 
required at the subsequent exercise testing sessions.  
 
Visit 2 
The second visit will involve the first of the exercise tests. This first exercise test will involve 
your child pedalling on an exercise bike for as long as they can. This exercise test starts off 
easy but gradually the pedals get harder to turn making the exercise test progressively more 
difficult. During this exercise test they will have to breathe through a mouthpiece and wear a 
nose clip, this may seem strange at first but they soon get used to it. The amount of oxygen 
present in your child’s blood will also be monitored throughout the session.  
 
During the exercise your child will be shown a list of numbers on a chart numbered 6-20, and 
will be asked to point to a number on the chart which shows how hard or easy they are 
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finding the exercise test. They will also be asked to rate on a different chart how breathless 
they feel.  
After they have finished the first exercise test they will remain on the bike for a 5 minute 
cool-down period of unloaded pedalling and then be seated down and rested for 10 minutes 
whilst still wearing the mouthpiece and nose clip. After the exercise test your child will have 
their lung function measured again. They will then be asked for a spot of blood, which will be 
drawn from their fingertip by a tiny needle prick. This is optional and even if your child 
wishes not to give a spot of blood they will still be allowed to participate in the study. The 
fingertip prick test is used to examine how hard they worked during the exercise test. 
Following the 15 minutes rest your child will be asked to get back onto the bike and to pedal 
again for as long as possible. The aim of this is to clarify whether or not they could have 
continued for any longer during the 1
st
 part of the test. This section will last approximately 2 
minutes. During both the rest and the second part of the exercise test your child will be 
wearing the same mouthpiece and nose clip as before in the first exercise test. Your child’s 
lung function will be measured before and after both parts.  
 
Visit 3 
Forty-eight hours later your child will be asked to complete the second exercise testing which 
will be identical to visit 2.  
 
Visit 4 
Your child will be required to complete the fourth and final exercise test ~4 weeks after their 
previous (2
nd
) exercise test. This visit will again be identical to the previous exercise testing 
sessions, whilst wearing the mouthpiece and nose clip. Again, their lung function will be 
measured before and after the third exercise test, and afterwards they will have a choice 
whether or not to do a final fingertip prick test. 
 
Post-testing 
We also need to know your child’s maturation (growth and development). This will require 
them to self-assess their pubertal stage by giving them 5 options. Self-assessment will take 
place at home and you will be asked to return the scale in a sealed envelope you will be 
provided with. N.B. This will only be asked of boys from age 10 and girls from the age of 
8.  
 
Please see the diagram on the following page for a full summary of what will happen during 
each visit.  
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Visit 2: Exercise session 1  
 Baseline lung function, deoxy-[Hb+Mb] and HR 
 CPET protocol 
 Exercise cessation assessment of RPE, RPD and ([La]B) 
 15 min seated rest  
 Supramaximal testing 
TOTAL TIME: Approx. 50 minutes 
N.B. Lung function and SaO2 will be assessed throughout both 
exercise and rest 
 
Visit 1: Familiarisation session 
- SS obtained by Dr. Patrick Oades prior to this 
- Run through PIS and protocol once more with  
  patient & parent/guardian 
- Obtain age, pubertal maturation and   
  anthropometric measurements 
- Cycle ergometry familiarisation 
- Familiarisation with assessment equipment 
and scales 
TOTAL TIME: Maximum 2 hours 
 
Exclusion or postponement 
may occur if a change in 
health status, such as acute 
infections or an unstable 
chronic health deems the 
patient unsafe to take part.   
Visit 3: 48 hours post-exercise session 1 
 Baseline lung function, deoxy-[Hb+Mb] and HR 
 CPET protocol  
 Exercise cessation assessment of RPE, RPD and ([La]B) 
 15 min seated rest  
 Supramaximal testing 
TOTAL TIME: Approx. 50 minutes 
N.B. Lung function and SaO2 will be assessed throughout both 
exercise and rest 
 
Visit 4: 6 weeks post-exercise session 1 
 Baseline lung function, deoxy-[Hb+Mb] and HR 
 CPET protocol 
 Exercise cessation assessment of RPE, RPD and ([La]B) 
 15 min seated rest  
 Supramaximal testing 
TOTAL TIME: Approx. 50 minutes 
N.B. Lung function and SaO2 will be assessed throughout both 
exercise and rest 
 
Post-testing: 
- Pubertal maturity self-assessed at home at  
  returned in a sealed envelope to ZS 
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Figure 1. The assessment procedures for each participant. 
7. What else will my child have to do? 
 
If your child wishes to take part in the study and he/she has your permission we would like 
your child to attend all 4 visits to the laboratory. We ask that they be in a rested state on 
arrival, and have performed no strenuous exercise in the 2-3 days prior to visits.  
 
On each visit to the laboratory we also ask that they have had sufficient food and drink before 
he/she arrives, and wear the same or similar clothes for each exercise test. We also ask that 
they don’t eat or drink any caffeine 3 hours prior to each visit. However, it is important that 
they do eat a light meal or snack before each visit (i.e. sandwich, cereal etc.). 
 
 
8. What are the possible risks of my child taking part? 
 
The exercise testing is very safe. An assessment of your child’s health will be made before 
they start the exercise tests to see if it is safe for them to take part. During the exercise tests 
your child will be carefully monitored and observed to ensure their safety and well-being.  
 
 
9. What are the potential benefits of my child taking part?  
 
The research is intended to enhance our understanding of how the lung and respiratory 
function of children and teenagers with CF respond during and after exercise testing. The 
information we obtain from the study may help to develop better exercise testing programmes 
with UK CF clinics.  
 
Hopefully, your child will take away a positive and enjoyable experience from their 
involvement in the exercise tests. They will be tested on equipment that is used to monitor the 
fitness of sports people, and they will get to see how fit they currently are and what intensity 
of exercise they can tolerate. They will be given the results of their exercise tests and talked 
through them by a member of the research team. This will hopefully prove an interesting and 
constructive exercise, particularly if they have a strong interest or involvement in sport and 
may wish to increase the amount of physical activity they participate in.  
 
 
10. What happens if my child doesn’t want to continue in the study? 
 
Your child is free to withdraw from the study at any point without giving a reason. Dropping 
out of the study will not affect your child’s clinical care in any way or your relationship with 
the paediatric staff.  
 
If your child does decide to not continue with the study then they will not be required to 
complete any additional exercise tests, or attend any additional visits to the centre that are 
associated with the research. Results from the exercise tests that they have previously 
completed will still be available to them. 
 
 
11. What if something goes wrong? 
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There are no special compensation arrangements if taking part in this study harms your child.  
Your rights are the same as undergoing research i.e. if your child is harmed due to someone’s 
negligence, then you may have grounds for legal action, but you may have to pay for it.  
Regardless of this, if you wish to complain, or have any concerns about any aspect of the way 
you have been approached or treated during the course of this study, the normal University 
complaints procedures will be available to you.  
 
 
12. Will my child’s taking part in this study be kept confidential? 
 
We have a responsibility to inform you of how we will collect, store and use your child’s 
information that we gather during the study. The primary concern is that any information that 
we collect about your child will be confidential. All of the this information collected such as 
their name, date of birth, contact details, details of their health and test results will be 
transferred to a paper study file, which will be kept in a secure room in the centre in a locked 
filing cabinet. 
 
Your child’s exercise results will be kept anonymous by assigning them a unique study code 
and participant number. Only your child’s date of birth will be used to identify the results. 
The results from the exercise tests are collected on paper and stored in a locked filing cabinet. 
The exercise results are then transferred from paper and stored on a computer. The only 
personal information stored on computer will be your child’s date of birth and participant 
number. Their exercise results will be password protected, as will the computer used to store 
the information. All the paper and computer files will be stored for 15 years, after this period 
paper files will be destroyed and computer files erased. Only the researchers involved in the 
study will have access to your child’s medical records and exercise results. 
 
 
13. What will happen to the results of the study? 
 
Once the study is completed, which is targeted to be September 2011, your child will be sent 
a summary of our research findings. The research is undertaken with the intention of being 
submitted as a PhD thesis. It is also the intention to submit the results of the research to 
relevant journals for publication, and to inform our colleagues of the findings at scientific 
meetings. In publishing and talking about the study your child will not be identifiable. 
 
You and your child will be given the opportunity to comment on the research protocol and 
testing procedure. This information will be collated and may inform future studies. You and 
your child will also receive the results and conclusions from the research and are free to 
request information regarding your child’s individual data.  
 
 
14. Who is organising and funding the research? 
 
The study is a collaboration between the Paediatric Unit of the Royal Devon and Exeter 
(RD&E) NHS Foundation Trust Hospital and the Children’s Health and Exercise Research 
Centre at the University of Exeter. The study is sponsored by the RD&E NHS Foundation 
Trust. None of the researchers or doctors involved personally receives money for including 
your child in the study. 
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As a result, a monetary contribution will be provided to go some way towards covering travel 
expenses.  
 
15. Who has reviewed the study? 
 
The scientific content of the study has been reviewed by the Peninsula Research and 
Development Support Unit. All research within the National Health Service (NHS) is looked at 
by an independent group of people, called a Research Ethics Committee (REC). RECs 
safeguard the rights, safety, dignity and well-being of people participating in research in the 
NHS. They review applications for research and give an opinion about the proposed 
participant involvement and whether the research is ethical. The present study has been 
reviewed and given favourable opinion by the South West 5 (or Frenchay) REC. 
  
16. What should I do if my child would like to take part? 
 
If your child would like to take part in the study you must give your permission by 
completing the consent form and your child must complete the assent form. You should then 
return the two forms to a member of the research team.  
 
17. What if my child or me have a question? 
 
If you or your child has any questions please do not hesitate to get in touch with a member of 
the research team. 
 
18. Contact for further information 
 
If you need further information please contact: 
 
The Research Team 
Miss. Zoe Louise Saynor (Children’s Health & Exercise Research Centre, University of 
Exeter) 
Tel (work): (01392) 264889 
Tel (mobile): (07984) 638788 
E-mail: zls202@exeter.ac.uk 
 
Dr. Patrick J. Oades (Consultant Paediatrician, Royal Devon and Exeter Healthcare NHS 
Trust) 
Tel (work): 01392 402665 
E-mail: patrick.oades@rdehc-tr.swest.nhs.uk 
 
Professor. Craig A. Williams (Children’s Health & Exercise Research Centre, University of 
Exeter) 
Tel (work): 01392 724809 
E-mail: c.a.Williams@ex.ac.uk 
 
Dr. Alan Barker (Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): (01392) 722766 
E-mail: a.r.barker@exeter.ac.uk  
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The reliability and validity of maximal cardiopulmonary exercise testing as a 
prognostic tool within the young cystic fibrosis population 
 
 
Participant interest form 
 
Name Address Telephone number Age/DOB 
 
 
 
 
 
 
   
 
Medical conditions: 
 
Activity levels: 
 
 
Availability: 
 
 
Other notes: 
 
Zoe Saynor 
M.Phil./Ph.D. Researcher 
Tel: +44 (0) 1392 264889 / 07748207099 
Email: zls202@exeter.ac.uk 
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APPENDIX E 
Written Supportive Information for Participants and 
Parents/Guardians (Study 3 – Healthy Controls) 
 
 
 
A study about fitness of children  
        Study Number        
                     Version 2 
          Date 02/01/2012 
Children’s Letter 
 
Dear Child, 
We would like to ask you to take part in a study being conducted by the Children’s 
Health & Exercise research Centre, Exeter. Please read this sheet very carefully 
before you decide to take part or not. 
 
What is the study about? 
 The study will help us find out how fit you are by looking at how much oxygen you use 
during and after an exercise test.  
 
 
What will happen? 
 
 The exercise test will involve you pedalling on an exercise bike. 
 During the exercise test you will wear a rubber face mask over your nose and mouth.  
 Before and after each test you will breathe out into a plastic tube so we can see what your 
lungs are doing.  
 You will also be asked if you would like to do a fingertip prick test. This is where we take 
a small spot of blood from a tiny prick of your fingertip.  
 This would be no more than one.  
 You do not have to do the fingertip prick test if you don’t want to and you can still take 
part in the exercise test.  
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Are the exercise tests safe? 
 
 The exercise tests are very safe.  
 We will check a number of parts of your health records before you start any 
exercise tests to see if it is safe for you to take part.  
 First aiders will be ready during the exercise tests just in case there are any 
problems. 
 
 
What else will happen on each visit to the hospital? 
 
Lab Visit – Part 1 (Familiarisation) 
 On your visit to the laboratory we will measure your height, your height when you 
are sitting down and your weight.  
 We will measure your skin folds at your arm, back and hip. This is done by very 
gently pinching the skin using a small instrument. This does not hurt but may 
tickle.  
 You will then be shown the equipment that will be used during the following visits 
 Finally, you will be given the chance to practice cycling on the exercise bikes and 
feel what it is like when pedalling is both easy and hard 
 
Lab Visit - Part 2 (Exercise Test) 
 The next part of your visit will involve your exercise test 
 Before you have to do any exercise you will be asked to rest  
 The exercise test will involve you first pedalling on an exercise bike for 3 minutes 
when the pedals are quite easy to turn 
 You will then be asked to pedal on the exercise bike for as long as you can until 
you can’t pedal anymore.  
 The pedals on the bike will get harder to turn the longer you pedal.  
 You will wear a rubber face mask over your nose and mouth during the cycling. 
 You will then stay on the bike and pedal easily for 5 minutes, and then you will sit 
down and rest for 10 minutes while still wearing the face mask.  
 You will then be asked if you would like to do the fingertip prick test. 
 You will then get back onto the bike and cycle for 3 minutes when the pedals are 
quite easy to turn 
 You will then be asked to cycle for as long as you can again, to check that you 
cannot go for longer than you did before – this bit of the test will be shorter than 
the first bit 
 We will then give you a drink and a biscuit and you can rest before going home. 
 
 
After you have finished taking part in the study 
 If you are a girl aged 8 or over or a boy aged 10 or over, we also need to 
know how developed your body is. To do this we will ask you to go into a private 
room, look at yourself and answer a question about how far your body has 
developed. The question is an easy choice out of 5, and nobody will be present in 
the room. 
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What else will you have to do if you do decide to take part? 
 
4. For 2 – 3 days before each visit you must not do any hard exercise.  
5. You can eat and drink as normal but do not drink or eat foods which contain 
caffeine such as tea, coffee, coca-cola, dark/milk chocolate for the 3 hours before 
coming to see us.  
6. Please wear sports clothing (e.g. PE kit, T-shirt, shorts and trainers) when you 
visit 
 
 
Do you have to take part? 
 It is up to you to decide whether or not to take part.  
 If you take part you are still free to drop out at any time and without giving a 
reason.  
 If you do not want to have the fingertip prick tests done you can still take part. 
 
What should you do if you want to take part or have any questions? 
 
4. If you would like to take part you must have your parent/carer’s permission by 
getting them to complete the consent form.  
5. You must also complete a form and return it to a member of the research team.  
6. If you have any questions please get in touch with a member of the research 
team who are on the bottom of this page. 
 
 
 
 
Thank you for reading this sheet. 
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The Research Team. 
 
Miss Zoe Louise Saynor  
(Children’s Health & Exercise Research Centre, University of Exeter; Honorary PhD 
Student, Royal Devon and Exeter NHS Foundation Trust Hospital) 
Tel (work): (01392) 264889 
Tel (mobile): (07984) 638788 
E-mail: zls202@exeter.ac.uk 
 
Associate Professor Craig. A. Williams  
(Children’s Health & Exercise Research Centre, University of Exeter) 
Tel: (01392) 724809 
E-mail: c.a.williams@ex.ac.uk 
 
Dr. Alan Barker  
(Children’s Health & Exercise Research Centre, University of Exeter) 
Tel: (01392) 722766 
E-mail: a.r.barker@exeter.ac.uk  
 
Dr. Patrick J. Oades  
(Consultant Paediatrician, Royal Devon and Exeter NHS Foundation Trust Hospital) 
Tel: (01392) 402665 
E-mail: patrick.oades@rdehc-tr.swest.nhs.uk 
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PARTICIPANT (16-18 YEARS) INFORMATION SHEET 
FOR 
OXIDATIVE AND CARDIOVASCULAR RESPONSES DURING EXERCISE IN 
PATIENTS WITH CYSTIC FIBROSIS COMPATED TO AGE AND GENDER 
MATCHED CONTROLS 
Version number: 2 
Date: 02/01/12 
 
 
1. Study Title: Oxidative and cardiovascular responses during exercise in patients with cystic 
fibrosis compared to age and gender matched controls.  
 
2. Invitation paragraph  
You are being invited to take part in a research study as they may be a match to compare with 
one of our young cystic fibrosis (CF) patients. Before you decide whether or not to be 
involved, it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it with 
friends, relatives and your clinician/GP if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not you wish to 
take part. Thank you for reading this.  
 
3. What is the purpose of the study?  
This research is intended to enhance our understanding of how children and teenagers with 
CF respond during and after exercise testing. We know that children with CF find it more 
tiring to exercise and comparison with somebody who is healthy (i.e. you) will allow us to try 
and see if there are any differences in the way their body’s respond to exercise.  
 
4. Why have I been chosen? 
You are a similar age, height, weight and gender to one of our patients who has been tested.   
 
5. Do I have to take part? 
Taking part is entirely voluntary and it is up to you to decide whether or not to be involved. If 
you do decide to take part you will be given this information sheet to keep and asked to sign a 
consent form giving your permission and get your parent/guardian to do the same. Following 
this you are still free to withdraw at any time, without giving a reason.  
 
6. What will happen to me if I allow them to take part? 
The study will involve 1 trip to an exercise laboratory within the Children’s Health & 
Exercise Research Centre, or within your respective school at a time suitable for you and 
your parent/guardian. The entire testing session will last ~1-1.5 hours. The session will be 
split into (a) an initial familiarisation session / obtaining some baseline information and (c) 
the exercise test:  
CHILDREN’S HEALTH AND 
EXERCISE RESEARCH CENTRE 
 
Sport and Health Sciences 
St Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel (Office): +44 (0) 1392 264889 
Tel (Mobile): +44 (0) 7984 638788 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
 
X1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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(a) Upon arrival to the laboratory your height, sitting height, and weight will be taken. 
You will also have your skin folds measured at your arm, back and hip. This is done 
by very gently pinching the skin and measuring the width of the skin folds. We will 
then measure your lung function, which simply involves taking a big breath and 
breathing into a plastic tube. You will be familiarised with the equipment to be used 
during testing and encouraged to practice cycling at different intensities on the 
stationary bike. You can also take this opportunity to ask any questions to the research 
staff.  
 
(b) You will then be required to complete the exercise test and a number of measurements 
will be taken. This 1
st
 part of the exercise test will involve you pedalling on an 
exercise bike for as long as you can. This exercise test starts off easy but gradually the 
pedals get harder to turn making the test progressively more difficult. After you have 
finished this initial exercise test you will remain on the bike for 5 minutes to allow 
you to catch your breath. You will then be seated down and rested for 10 minutes, 
during which we will measure your lung function again. This is optional and you will 
still be allowed to participate in the study if you decide against this measurement. 
Following this rest you will be asked to get back onto the bike and to pedal again for 
as long as possible. The aim of this is to clarify whether or not you could have 
continued for any longer during the 1
st
 part of the test – this exercise will only last a 
couple of minutes. Finally, when you have recovered we will assess your lung 
function for a final time.  
 
Measurements taken: 
During exercise you will breathe through a facemask, this may seem strange at first 
but you soon get used to it. The amount of oxygen present in your blood will also be 
monitored throughout the session with a sensor taped on their index finger. You will 
also wear 6 sticky pads, on their forehead, neck and torso to assess your heart’s 
response to exercise; you will not feel anything during this. You will also wear a 
small plastic unit on your right thigh, which will be bandaged in place and allows us 
to examine how much oxygen that you breathe in is being used by the working 
muscles. During exercise you will be shown a list of numbers on a chart numbered 0-
10 and asked to point to the number or picture which shows how hard or easy you 
think you are exercising. On a different chart you will rate how out of breath you feel. 
Following the 1
st
 bit of exercise you will be asked for a spot of blood, which will be 
drawn from your fingertip by a tiny needle prick. Finally, we need to know your  
maturation (growth and development), requiring you to self-assess your pubertal stage 
by giving them 5 options. Self-assessment will take place at home and you will be 
asked to return the scale in a sealed envelope you will be provided with. N.B. This 
will only be asked of boys from age 10 and girls from the age of 8.  
 
7. What else will I have to do? 
If you wish to take part, we ask that you be in a rested state on arrival to the laboratory, 
having performed no strenuous exercise in the 2-3 days prior. We also ask that you have had 
sufficient food (i.e. a light snack such as a sandwich) and drink and wear suitable clothing for 
performing the exercise test. Finally, we ask that you avoid caffeine 3 hours before testing.  
 
8. What are the possible risks of me taking part? 
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The exercise testing is very safe. An assessment of your health will be made before any 
involvement to confirm it is safe for you to take part. You will be carefully monitored and 
observed to ensure your safety and well-being during all testing.  
 
9. What are the potential benefits of me taking part?  
Whilst the main aim of this study is to help develop better understanding regarding exercise 
for young CF patients, it is also hoped that you will take away a positive and enjoyable 
experience from your involvement. You will be tested on equipment used to monitor the 
fitness of sports people, and you will get to see how fit you currently are and what intensity 
of exercise you can tolerate. You will be given the results of your exercise tests and talked 
through them by a member of the research team. This will hopefully prove an interesting and 
constructive exercise, particularly if you have a strong interest or involvement in sport and 
may wish to increase the amount of physical activity you participate in.  
 
10. What if something goes wrong? 
There are no special compensation arrangements if taking part in this study harms you.  Your 
rights are the same as undergoing research i.e. if you are harmed due to someone’s 
negligence, then you may have grounds for legal action, but you may have to pay for it.  
Regardless of this, if you wish to complain, or have any concerns about any aspect of the way 
you have been approached or treated during the course of this study, the normal University 
complaints procedures will be available to you.  
 
11. Will my taking part in this study be kept confidential? 
We have a responsibility to inform you of how we will collect, store and use your 
information obtained during the study. All information (such as your name, date of birth, 
contact details, and test results) will be transferred to a paper study file, which will be kept in 
a secure room in the centre in a locked filing cabinet and you will be assigned a unique study 
code and participant number to keep you anonymous. Only your date of birth will be used to 
identify you. Data will be transferred from paper to be stored on a password protected 
computer and you will not be identifiable. All files will be stored for 5 years, after which the 
paper files will be destroyed and computer files erased. Only the researchers involved in the 
study will have access to your exercise results. 
 
12. What will happen to the results of the study? 
Once the study is completed, your parent/guardian will be sent a summary of our research 
findings. Although this research is undertaken with the intention of being submitted as a PhD 
thesis, it is also intended that results will be submitted to relevant scientific journals for 
publication, and to inform our colleagues of the findings at scientific meetings. In publishing 
and talking about the study, you will not be identifiable. You and your parent/guardian are 
free to request information regarding your individual data. 
 
13. Who is organising and funding the research? 
The study is a part of a larger collaboration between the Paediatric Unit of the Royal Devon 
and Exeter (RD&E) NHS Foundation Trust Hospital and the Children’s Health and Exercise 
Research Centre at the University of Exeter. The study is sponsored by the RD&E NHS 
Foundation Trust. None of the researchers or doctors involved personally receives money for 
including you in the study. 
 
14. Who has reviewed the study? 
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The present study has been reviewed and given favourable opinion by the departmental ethics 
committee within Sport & Health Sciences, University of Exeter.  
 
15. What should I do if I would like to take part? 
If you would like to take part in the study you must give your permission by completing the 
consent form and your parent/guardian must also complete their consent form. You should 
then return the two forms to a member of the research team.  
 
16. What if I have a question? 
If you or your parent/guardian have any questions please do not hesitate to get in touch with 
the principle investigator (Miss Zoe Saynor) as outlined at the top of page 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for considering taking part in this study. Please read this information carefully, before 
you sign the consent form. Please take this leaflet home for reference. 
  
400 
 
 
 
 
 
 
PARENT/GUARDIAN INFORMATION SHEET 
FOR 
OXIDATIVE AND CARDIOVASCULAR RESPONSES DURING EXERCISE IN 
PATIENTS WITH CYSTIC FIBROSIS COMPATED TO AGE AND GENDER 
MATCHED CONTROLS 
Version number: 2 
Date: 02/01/12 
 
 
1. Study Title: Oxidative and cardiovascular responses during exercise in patients with cystic 
fibrosis compared to age and gender matched controls.  
 
2. Invitation paragraph  
Your child is being invited to take part in a research study as they may be a match to compare 
with one of our young cystic fibrosis (CF) patients. Before you decide whether or not to be 
involved, it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it with 
friends, relatives and your clinician/GP if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not you wish to 
take part. Thank you for reading this.  
 
3. What is the purpose of the study?  
This research is intended to enhance our understanding of how children and teenagers with 
CF respond during and after exercise testing. We know that children with CF find it more 
tiring to exercise and comparison with somebody who is healthy will allow us to try and see 
if there are any differences in the way their body’s respond to exercise.  
 
4. Why has my child been chosen? 
Your child is a similar age, height, weight and gender to one of our patients who has been 
tested.   
 
5. Does my child have to take part? 
Taking part is entirely voluntary and it is up to you to decide whether or not your child is 
involved. If you do allow your child to take part you will be given this information sheet to 
keep and asked to sign a consent form giving your permission. Following this you are still 
free to withdraw your child at any time, without giving a reason.  
 
6. What will happen to my child if I allow them to take part? 
The study will involve 1 trip to an exercise laboratory within the Children’s Health & 
Exercise Research Centre, or within their respective school at a time suitable for you. The 
entire testing session will last ~1-1.5 hours. The session will be split into (a) an initial 
familiarisation session / obtaining some baseline information and (c) the exercise test:  
CHILDREN’S HEALTH AND 
EXERCISE RESEARCH CENTRE 
 
Sport and Health Sciences 
St Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel (Office): +44 (0) 1392 264889 
Tel (Mobile): +44 (0) 7984 638788 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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(a) Upon arrival to the laboratory your child’s height, sitting height, and weight will be 
taken. They will also have their skin folds measured at their arm, back and hip. This is 
done by very gently pinching the skin and measuring the width of the skin folds. They 
will then have their lung function measured, this will involve your child taking a big 
breath and breathing into a plastic tube. Your child will be familiarised with the 
equipment to be used during testing and will be encouraged to practice cycling at 
different intensities on the stationary bike. You can also take this opportunity to ask 
any questions to the research staff.  
 
(b) Your child will then be required to complete the exercise test and a number of 
measurements will be taken. This 1
st
 part of the exercise test will involve your child 
pedalling on an exercise bike for as long as they can. This exercise test starts off easy 
but gradually the pedals get harder to turn making the test progressively more 
difficult. After they have finished this initial exercise test they will remain on the bike 
for 5 minutes to allow them to catch their breath. They will then be seated down and 
rested for 10 minutes, during which we will measure their lung function again. This is 
optional and your child will still be allowed to participate in the study if they decide 
against this measurement. Following this rest your child will be asked to get back 
onto the bike and to pedal again for as long as possible. The aim of this is to clarify 
whether or not they could have continued for any longer during the 1
st
 part of the test 
– this exercise will only last a couple of minutes. Finally, when your child has 
recovered we will assess their lung function for a final time.  
 
Measurements taken: 
During exercise your child will breathe through a facemask, this may seem strange at 
first but they soon get used to it. The amount of oxygen present in your child’s blood 
will also be monitored throughout the session with a sensor taped on their index 
finger. Your child will also wear 6 sticky pads, on their forehead, neck and torso to 
assess their heart’s response to exercise; your child will not feel anything during this. 
They will also wear a small plastic unit on their right thigh, which will be bandaged in 
place and allows us to examine how much oxygen that your child breathes in is being 
used by the working muscles. During exercise your child will be shown a list of 
numbers on a chart numbered 0-10 and asked to point to the number or picture which 
shows how hard or easy they think they are exercising. On a different chart they will 
rate how out of breath they feel. Following the 1
st
 bit of exercise your child will be 
asked for a spot of blood, which will be drawn from their fingertip by a tiny needle 
prick. Finally, we need to know your child’s maturation (growth and development), 
requiring them to self-assess their pubertal stage by giving them 5 options. Self-
assessment will take place at home and you will be asked to return the scale in a 
sealed envelope you will be provided with. N.B. This will only be asked of boys 
from age 10 and girls from the age of 8.  
 
7. What else will my child have to do? 
If your child wishes to take part, we ask that they be in a rested state on arrival to the 
laboratory, having performed no strenuous exercise in the 2-3 days prior. We also ask that 
they have had sufficient food (i.e. a light snack such as a sandwich) and drink and wear 
suitable clothing for performing the exercise test. Finally, we ask that they avoid caffeine 3 
hours before testing.  
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8. What are the possible risks of my child taking part? 
The exercise testing is very safe. An assessment of your child’s health will be made before 
any involvement to confirm it is safe for them to take part. Your child will be carefully 
monitored and observed to ensure their safety and well-being during all testing.  
 
9. What are the potential benefits of my child taking part?  
Whilst the main aim of this study is to help develop better understanding regarding exercise 
for young CF patients, it is also hoped that your child will take away a positive and enjoyable 
experience from their involvement. They will be tested on equipment used to monitor the 
fitness of sports people, and they will get to see how fit they currently are and what intensity 
of exercise they can tolerate. They will be given the results of their exercise tests and talked 
through them by a member of the research team. This will hopefully prove an interesting and 
constructive exercise, particularly if they have a strong interest or involvement in sport and 
may wish to increase the amount of physical activity they participate in.  
 
10. What if something goes wrong? 
There are no special compensation arrangements if taking part in this study harms your child.  
Your rights are the same as undergoing research i.e. if your child is harmed due to someone’s 
negligence, then you may have grounds for legal action, but you may have to pay for it.  
Regardless of this, if you wish to complain, or have any concerns about any aspect of the way 
you have been approached or treated during the course of this study, the normal University 
complaints procedures will be available to you.  
 
11. Will my child’s taking part in this study be kept confidential? 
We have a responsibility to inform you of how we will collect, store and use your child’s 
information obtained during the study. All information (such as their name, date of birth, 
contact details, and test results) will be transferred to a paper study file, which will be kept in 
a secure room in the centre in a locked filing cabinet and assigning a unique study code and 
participant number to keep it anonymous. Only your child’s date of birth will be used to 
identify them. Data will be transferred from paper to be stored on a password protected 
computer and your child will not be identifiable. All files will be stored for 5 years, after 
which the paper files will be destroyed and computer files erased. Only the researchers 
involved in the study will have access to your child’s exercise results. 
 
12. What will happen to the results of the study? 
Once the study is completed, your will be sent a summary of our research findings. Although 
this research is undertaken with the intention of being submitted as a PhD thesis, it is also 
intended that results will be submitted to relevant scientific journals for publication, and to 
inform our colleagues of the findings at scientific meetings. In publishing and talking about 
the study, your child will not be identifiable. You and your child and are free to request 
information regarding your child’s individual data.  
 
13. Who is organising and funding the research? 
The study is a part of a larger collaboration between the Paediatric Unit of the Royal Devon 
and Exeter (RD&E) NHS Foundation Trust Hospital and the Children’s Health and Exercise 
Research Centre at the University of Exeter. The study is sponsored by the RD&E NHS 
Foundation Trust. None of the researchers or doctors involved personally receives money for 
including your child in the study. 
 
14. Who has reviewed the study? 
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The present study has been reviewed and given favourable opinion by the departmental ethics 
committee within Sport & Health Sciences, University of Exeter.  
 
15. What should I do if my child would like to take part? 
If your child would like to take part in the study you must give your permission by 
completing the consent form and your child must complete the assent form. You should then 
return the two forms to a member of the research team.  
 
16. What if my child or me have a question? 
If you or your child has any questions please do not hesitate to get in touch with the principle 
investigator (Miss Zoe Saynor) as outlined at the top of page 1.  
 
 
 
 
 
Thank you for considering taking part in this study. Please read this information carefully, before 
you sign the consent form. Please take this leaflet home for reference. 
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APPENDIX F 
Written Supportive Information for Participants and 
Parents/Guardians (Studies 5 and 6) 
 
 
 
Exercise Study for Young Cystic Fibrosis Patients  
        Study Number: 12/SW/0270       
                     Version 3 
          Date 02/10/2012 
Patient’s Letter (10-15 years) 
 
Dear Patient, 
We would like to ask you to take part in a study at the hospital. Please read this 
sheet very carefully before you decide to take part or not. 
 
What is the study about? 
 The study will help us find out how fit you are by looking at how much oxygen you 
use during and after a number of exercise tests and how well you cope when you 
change from resting to begin some exercise. 
 
 
What will happen? 
 
 You will visit the hospital 5 times to exercise on a bike 
 During the exercise tests you will wear a rubber face mask that covers your nose 
and chin, a small plastic box will be bandaged onto your right leg, and you will 
have 2 sticky pads on your head, neck, chest and back which will be attached to 
plastic wires.  
 You will not feel anything from these things other than that they are there and the 
mask may make your face a bit sweaty  
 Before and after each test you will breathe out into a plastic tube (spirometer) so 
we can see what your lungs are doing – just like you do at the CF clinics 
 The first visit will be an exercise test to see how fit you are 
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 Visits 2-5 will be 2 x 30 minutes of cycling on the bike, with a number of easy 
rests in between.  
 The people who will be testing you will be different to your usual direct care team 
at the hospital, however they are trained in exercise testing like this and regularly 
exercise test young people.  
 
 
Are the exercise tests safe? 
 
 The exercise tests are very safe.  
 Your doctor will look at your health records before you exercise to check that it is 
safe for you to take part.  
 A medical team will be ready during the exercise tests just in case there are any 
problems. 
 
 
What else will happen on each visit to the hospital? 
 
Visit 1 
 On your first visit to the hospital we will measure how tall you are and how much 
you weigh.  
 We will measure your skin folds at your arm, back and hip. This is done by very 
gently pinching the skin using a small instrument. This does not hurt but may 
tickle.  
 You will then be shown the equipment we will use  
 Finally, you will practice cycling on the exercise bike and feel what it is like when 
pedalling is both easy and hard 
 You will then complete your first exercise test 
 Before you have to do any exercise you will be asked to rest  
 The exercise test will involve you first pedalling on an exercise bike for 3 minutes 
when the pedals are quite easy to turn 
 You will then be asked to pedal on the exercise bike for as long as you can until 
you can’t pedal anymore.  
 The pedals on the bike will get harder to turn the longer you pedal  
 You will wear the face mask and other equipment during the cycling. 
 You will then stay on the bike and pedal easily for 5 minutes, then you will sit 
down and rest for 10 minutes while still wearing the black box and sticky pads – 
but we will remove the face mask.  
 We will then pop the face mask back on 
 You will then get back onto the bike and be asked to cycle for as long as you can 
again, to check that you cannot go for longer than you did before (this will usually 
only last 1-2 minutes) 
 We will then give you a drink and you can rest before going home. 
 
Visits 2-5 
 The next 4 visits will all be exactly the same as each other   
 You will perform exercise on the bike and the same measurements will taken  
 The test will be different to visit 1 
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 You will be cycling on the bike for just under 30 minutes twice, with a 30 minute 
rest in between  
 The exercise will be made up of bits which are easy, bits which are a little harder 
and one bit where you will cycle for 6 minutes and it will be quite hard 
 
 
After you have finished taking part in the study 
 We also need to know how developed your body is. To do this we will ask you to 
go look at yourself at home and answer a question about how far your body has 
developed. The question is an easy choice out of 5. We would also like you to 
wear an elastic belt with a little plastic box for a week after you have finished your 
testing, to see how much exercise/play you usually do. 
 
 
 
 
What else will you have to do if you do decide to take part? 
 
7. For 2 – 3 days before each visit you must not do any really hard exercise (if 
possible).  
8. You can eat and drink as normal but do not drink or eat foods which contain 
caffeine such as tea, coffee, Coca-Cola for 3 hours before coming to see us.  
9. You will also be asked if you would like to have your photograph taken during 
testing, for us to use when talking about the findings from this study in the future. 
This is completely up to you and you do not have to say yes.  
 
Do you have to take part? 
 
 It is up to you if you take part.  
 If you take part you can drop out at any time and don’t have to give us a reason.  
 
 
What should you do if you want to take part or have any questions? 
 
7. If you would like to take part you must have your parent/carer’s permission by 
getting them to complete the consent form.  
8. You must also complete a form which tells us you would like to take part and 
return it to a member of the research team.  
9. If you have any questions please get in touch with a member of the research 
team who are on the bottom of this page. 
 
 
Thank you for reading this letter. 
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The Research Team. 
Miss. Zoe Louise Saynor  
(Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): (01392) 264889 
E-mail: zls202@exeter.ac.uk 
 
Dr. Patrick J. Oades  
(Consultant Paediatrician, Royal Devon and Exeter Healthcare NHS Trust) 
Tel: (01392) 402665 
E-mail: patrick.oades@nhs.net 
 
Professor Craig. A. Williams  
(Children’s Health & Exercise Research Centre, University of Exeter) 
Tel: (01392) 724809 
E-mail: c.a.williams@ex.ac.uk 
 
Dr. Alan Barker  
(Children’s Health & Exercise Research Centre, University of Exeter) 
Tel: (01392) 722766 
E-mail: a.r.barker@exeter.ac.uk  
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PATIENT (16-18 y) INFORMATION SHEET 
FOR 
THE INFLUENCE OF DISEASE STATUS AND ‘PRIMING’ EXERCISE ON 
PULMONARY OXYGEN UPTAKE AND MUSCLE DEOXYGENATION KINETICS 
DURING MODERATE AND HIGH-INTENSITY CYCLING EXERCISE IN 
PAEDIATRIC PATIENTS WITH CYSTIC FIBROSIS 
Version number: 3 
Date: 02/10/12 
 
 
1. Study Title 
 
The influence of disease status and ‘priming’ exercise on pulmonary oxygen uptake and 
muscle deoxygenation kinetics during moderate and high-intensity cycling exercise in 
paediatric patients with cystic fibrosis.  
 
 
2. Invitation paragraph  
 
You are being invited to take part in a research study. Before you decide whether or not to be 
involved, it is important for you and your parent/guardian to understand why the research is 
being done and what it will involve. Please take time to read the following information 
carefully and discuss it with friends, relatives and your clinician/GP if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. 
 
 
Thank you for reading this information sheet. 
 
 
3. What is the purpose of the study?  
 
It is recommended that children and teenagers with cystic fibrosis (CF) take part in sports and 
games to stay fit and healthy. Exercise not only helps improve fitness and enhances their 
quality of life through socialising with peers and friends, but it may also help them to cope 
better with aspects of their disease. It has been reported that CF patients are characterised by 
reduced aerobic fitness when compared with their healthy counterparts. However, the extent 
and cause(s) for why patients with CF may find it more tiring during exercise than a healthy 
person of the same age remains an area of debate.  
 
CHILDREN’S HEALTH AND EXERCISE 
RESEARCH CENTRE 
 
Sport and Health Sciences 
St Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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During exercise, breathing becomes faster and harder because the body needs more oxygen to 
produce energy to move faster. When we go from rest or performing light exercise to harder 
exercise necessitating our body to work harder, then the energy (and therefore oxygen) our 
muscles need to keep working must change quickly. During this change from rest to exercise 
all of the bodily systems (e.g. the heart, lungs and muscles) which are important during 
exercise must work together in co-ordination to increase the amount of oxygen/energy which 
is needed by the muscles working during exercise. If someone can ‘switch on’ this system to 
produce the necessary energy more quickly when they start to exercise then we know that 
they will be able to exercise for longer before they become tired.  
 
This study will look at how well you respond during these changes from rest to exercise of 
different difficulties and how fast you can ‘switch on’ this ‘aerobic energy system’. 
Understanding this is of importance, as it will help us to know where to focus intervention 
strategies (e.g exercise training) to improve the ability of CF patients to tolerate exercise and, 
subsequently, improve their quality of life.   
 
Whilst the main aim of this study is to gather the above information, it will also provide 
information regarding your exercise tolerance/fitness which may offer a novel insight for 
both you and your parent/guardian. Additionally, we know that participating in regular 
exercise is beneficial to patients with CF and participating in this research project will also 
serve as 5 sessions of supervised moderate- and high-intensity cycling exercise training for 
you.  
 
 
4. Why have I been chosen? 
 
We are interested in young cystic fibrosis patients, aged between 10-18 years old, who have 
stable disease and regularly take part in physical activity.  
 
 
5. Do I have to take part? 
 
Taking part is entirely voluntary and it is up to you to decide whether or not you take part. If 
you do decide to be involved and your parent/guardian give permission, you will be given 
this information sheet to keep, and be asked to sign a consent form giving your permission to 
participate (your parent/guardian will do the same). If you do decide to take part you are still 
free to withdraw from the study at any time and without giving a reason. A decision to 
withdraw from the study or a decision not to take part will not affect the standard clinical care 
you receive. 
 
 
6. What will happen to me if I do decide to take part? 
 
The study will involve 5 trips to an exercise laboratory within the Royal Devon and Exeter 
NHS Foundation Trust Hospital (RD&E), separated by at least 48 h and ideally completed 
over a maximum 2 week period (to minimise the chance of any significant in your clinical 
status or fitness levels). All testing will take place at times which are suitable for you and 
your parent/guardian and this can be at weekends or after school if preferred. On all 5 visits 
to the centre, you will be required to complete an exercise test and the following 
measurements will be taken: 
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Respiratory function: 
The volume of oxygen you are breathing in (V̇O2)  
The volume of carbon dioxide you are breathing out (V̇CO2) 
The ratio between the amounts of oxygen you are breathing in and carbon dioxide you are 
breathing out (RER). 
How much air you are taking in each minute (V̇E). 
 
Lung function 
The volume of air you can breathe out (FVC). 
The volume of air you can breathe out in one second (FEV1). 
The volume of air you are breathing in and out (PEF). 
 
Other measurements 
How fast your heart is beating (HR) 
How much blood your heart pumps out each time it contracts (SV) 
How tired you think you are feeling (RPE). 
How breathless you think you feel (RPD) 
Changes in the concentration of oxygenated and deoxygenated haemoglobin/myoglobin 
within the quadriceps muscles of your right leg 
The amount of oxygen present in your blood (SaO2) 
 
 
Visit 1 
The initial visit will consist of two parts:  
 
1: Familiarisation session / baseline assessments 
You and your parent/guardian will be given the opportunity to discuss any queries you may 
have, give your informed consent/assent and to familiarise you and your parent/guardian with 
the equipment and testing procedures that will be used during exercise testing visits. We will 
then obtain some information regarding your body composition. Your height, sitting height, 
and weight will be measured. You will also have your skin folds measured at the front and 
back of your arm, just below your shoulder blade and at the front of your hip. This is done by 
very gently pinching the skin and measuring the width of the skin folds. You will then have 
your resting lung function measured, this will involve you taking a big breath and breathing 
into a plastic tube and is no different to the lung function tests you routinely perform in 
clinics. You will then be familiarised with the equipment to be used during testing and 
encouraged to practice cycling at different intensities on the stationary exercise bike. You can 
then also take this opportunity to ask any questions to the research staff regarding the 
requirements of the next exercise testing sessions.  
 
 
2: Incremental Exercise Test 
Following the above, you will be required to perform your first exercise test. This initial 
exercise test will be an ‘incremental ramp cycle test to exhaustion’. This test requires you 
to pedal on an exercise bike for as long as you can. This exercise test starts off easy but 
gradually the pedals get harder to turn making the exercise test progressively more difficult, 
this will feel like you are cycling up a hill which is getting steeper.  
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During this exercise test you will be required to wear a rubber face mask which covers your 
nose and chin, which will be connected to a device measuring the oxygen you are breathing 
in and carbon dioxide you are breathing out. This may seem strange at first but you will soon 
get used to it and this is a standard piece of kit used when performing this form of exercise 
test on young people. The amount of oxygen present in your blood will also be monitored 
throughout the session using a small rubber device placed on the end of your index fingertip. 
In addition to this, you will wear 6 electrode pads (similar to an ECG if you have ever had or 
seen one of these), placed on your head, neck, chest and back. These are simply gel pads 
which will stick to your skin and, when attached to wires, will tell us how your heart is 
responding during exercise. Finally, you will have a small black plastic device taped and 
bandaged securely onto your right thigh. This device will simply shine light into the working 
muscle and allows us to estimate how much of the oxygen you breathe in is being delivered 
to the muscles that need it when you are working during exercise. Throughout the exercise 
test (every minute) you will be shown a list of numbers (0-10) corresponding to pictures of a 
child running up stairs and getting more and more tired. You will be asked to point on the 
chart to tell us how hard or easy you are finding the exercise. You will also be asked to rate 
on a different chart how out of breath you feel, again using words and numbers (0-10). This 
exercise test usually lasts ~8-12 minutes.  
 
After you finish this exhaustive exercise test, you will stay on the bike for a 5 minute ‘cool-
down’ period of easy pedalling to recover and then will sit down and rest for 10 minutes. The 
electrodes and black box will still be attached, however the face mask will be removed when 
sitting down recovering. During this rest you will have your lung function measured again.  
 
Following this 15 minute rest, you will be asked to get back onto the bike and to pedal again 
for as long as possible. Unlike the first test, this test will not get gradually harder and harder. 
This will be set at a similar difficulty to where you stopped during the first test and will 
typically only last approximately 1-2 minutes. When you become exhausted you will again be 
asked to stay on the bike and pedal lightly for 5 minutes to allow your body to recovery 
gradually, as you will have been working hard during the test. The aim of this test is check 
whether or not you could have continued for any longer during the 1
st
 test. During the second 
part of the exercise test you will wear the same equipment as in the first part test. Your lung 
function will be measured one last time when you get off the bike.  
 
This first visit will last 1-1.5 h.  
 
Visit 2, 3, 4 and 5: 
 
At least forty-eight hours later you will be asked to complete your second exercise testing 
session which will be identical to visits 3, 4 and 5 to follow.  This visit will again last 
approximately 1.5 hours, however we will not need to collect the skin fold measurements 
again or practice using the exercise bike.  
 
These sessions will require you to exercise for 2 x ~30 minutes. However, only 12 minutes of 
each will be exercise that makes you feel like you are working reasonably hard, the rest will 
be light exercise which will feel nice and easy to turn the pedals.  
 
The exercise session 
You will begin with a 4-minute ‘warm-up’ of easy pedalling. You will then cycle for 6 
minutes at an intensity we call ‘moderate’ (this will feel like you are having to work to turn 
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the pedals, however it should not be too hard or cause you to become exhausted). This will be 
followed by 6 minutes easy cycling like the warm-up. The ‘intensity’ will then increase to 
one that is ‘moderate’ again for a further 6 minutes, which will finally finish with 6 minutes 
of easy cycling. You will then get off the bike and sit down and rest for 30 minutes.  
 
Following this 30 minute rest period, you will get back onto the bike for the second and last 
part of the exercise test. Again, this will begin with 4 minutes of easy pedalling and then the 
‘intensity’ will be increased for the next 6 minutes. However, this time it will be ‘very-
heavy’, which means that you will have to work a bit harder to turn the pedals and will feel a 
bit more out of breath. Following this you will again cycle for 6 minutes which will be nice 
and easy and the pedals will feel much lighter to turn. The ‘intensity’ will then be increased 
to the ‘moderate’ one again. Following this you will stay on the bike and recover for a few 
minutes.  
 
The session will then be complete. 
 
During this exercise session you will have to wear the rubber face mask again. The amount of 
oxygen present in your blood will also be monitored throughout the session using the same 
small rubber device placed on the end of your index fingertip during their 1
st
 visit. You will 
also wear the 6 electrode pads on your head, neck, chest and back and the small black plastic 
box on your right thigh. At various time points during exercise and at the end of the 4 harder 
periods of exercise you will be shown the chart which shows how hard or easy you are 
finding the exercise and  asked to rate on the breathlessness chart whether you are feeling out 
of breath. 
 
Visits 3, 4 and 5 will be identical to visit 2 and will be separated by at least 48 h (ideally 
within 2-3 days) at a time suitable to you and your parent/guardian.  
 
 
Post-testing 
We also need to know your maturation (growth and development). This will require you to 
self-assess your pubertal stage by selecting from 5 options on a chart which shows different 
pictures of pubic hair through the stages of maturation. Self-assessment will take place at 
your home and your parent/guardian will be asked to return the scale in a sealed envelope 
they will be provided with. We are also interested in assessing how physically active you are 
during a typical week, if you and your parent/guardian agree to do so. This will be assessed 
by wearing a small hip-mounted plastic box on an elastic belt for 7 days, whilst completing a 
brief diary of the physical activities you perform from the time you wake up to the time you 
go to bed. The monitor would be removed if you swim or take a bath/shower and when in 
bed.   
 
 
7. What else will I have to do? 
 
If you do decide to take part in the study and your parent/guardian has given their permission, 
we would like you to attend all 5 visits at the exercise laboratory. We ask that you be rested 
when you arrive, having performed no exhaustive exercise in the 2-3 days before you visit 
(other than involvement in this study). Any specific questions regarding any exercise training 
or sport you may be doing prior to testing sessions can be discussed with the research team 
prior to any involvement in this research study.  
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On each visit to the laboratory we also ask that you have had enough to eat and drink before 
you arrive, and that you wear the same or similar clothes for each exercise test (that is sports 
kit, usually shorts, t-shirt and trainers). We also ask that you don’t eat or drink any caffeine 3 
hours prior to each visit. However, it is important that you do eat a light meal or snack before 
each visit (i.e. sandwich, cereal etc.). 
 
We may ask you if we can take photographs during your exercise tests. The purpose of these 
photographs is to be possibly used within University of Exeter publicity materials, in Miss 
Saynor’s PhD thesis and in conference presentations such as posters and PowerPoint 
presentation. This is entirely voluntary and will in no way affect any subsequent involvement 
in the study if you and/or your parent/guardian should decline. Permission to take any 
photographs will be obtained in writing prior to involvement in the study. 
 
 
8. What are the possible risks of me taking part in this study? 
 
The exercise testing is very safe. An assessment of your health will be made before you start 
the exercise tests to see if it is safe for you to take part. During the exercise tests, you will be 
carefully monitored and observed to ensure your safety and well-being.  
 
 
9. What are the potential benefits of me taking part in this study?  
 
This research is intended to enhance our understanding of how children with CF tolerate 
exercise and, more specifically, the rapid changes their bodies must deal with when they 
change between rest and exercise of difference intensities. The information we obtain from 
the study will help to improve our understanding regarding whether CF disease makes it more 
challenging for patients to exercise without becoming tired earlier on that someone without 
CF. It can also help to develop better exercise testing programmes within CF clinics.  
 
Hopefully you will enjoy your experience if you are involved in the exercise tests. You will 
be tested on equipment that is used to monitor the fitness of sports people, and will get to see 
how fit you currently are and what intensity of exercise you can tolerate. Visits 2-5 will also 
act as supervised exercise sessions, which we know to be beneficial for young people with 
CF. You will be given the results of their exercise tests and talked through them by a member 
of the research team. This will hopefully prove an interesting and constructive exercise, 
particularly if you have a strong interest or involvement in sport and may wish to increase 
how physically active you are. You can also use the 30 minute break to discuss any questions 
you may have regarding exercise with an exercise physiologist, if you wish to do so.  
 
 
10. What happens if I do not want to continue in the study? 
 
You are free to withdraw from the study at any point without giving a reason. Dropping out 
of the study will not affect your clinical care in any way or your relationship with the 
paediatric staff.  
 
If you do decide not to continue with the study then you will not be required to complete any 
additional exercise tests, or attend any additional visits to the centre that are associated with 
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the research. Results from any exercise tests that you have previously completed will still be 
available to you.  
 
 
11. What if something goes wrong? 
 
Should taking part in this study harm you in any way, compensation arrangements are under 
the directive of the University of Exeter.  Your rights are the same as any person undergoing 
research i.e. if you are harmed due to someone’s negligence, then you may have grounds for 
legal action.  If you wish to complain, or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the normal University 
complaints procedures will be available to you. In any such case, complaints should be 
directed to Professor Adrian Taylor, Director of Research for Sport and Health Sciences, 
University of Exeter [+44 (0) 1392 724747; Adrian.Taylor@exeter.ac.uk]. 
 
 
12. Will my involvement in this study be kept confidential? 
 
We have a responsibility to inform you of how we will collect, store and use your 
information that we gather during the study. The primary concern is that any information that 
we collect about you will be confidential. All of this information collected such as your 
name, date of birth, contact details, details of your health and test results will be transferred to 
a paper study file, which will be kept in a secure room in a locked filing cabinet. Members of 
the research team will be outside your direct standard care team and will have access to your 
data. However, your exercise results will be kept anonymous by assigning them a unique 
study code and participant number. Only your date of birth will be used to identify the results. 
The results from the exercise tests are collected on paper and stored in a locked filing cabinet. 
The exercise results are then transferred from paper and stored on a computer. The only 
personal information stored on computer will be your date of birth and participant number. 
Your exercise results will be password protected, as will the computer used to store the 
information. All the paper and computer files will be stored for 15 years, after this period 
paper files will be destroyed and computer files erased. Only the researchers involved in the 
study will have access to your medical records and exercise results. 
 
 
13. What will happen to the results of the study? 
 
Once the study is completed, which is targeted to be the end of December 2012, the results 
will be analysed and interpreted and your parent/guardian will subsequently be sent a 
summary of our research findings. The research is undertaken with the intention of being 
submitted as a PhD thesis. It is also the intention to submit the results of the research to 
relevant journals for publication, and to inform our colleagues of the findings at scientific 
meetings. In publishing and talking about the study you will not be identifiable. 
 
You and your parent/guardian will be given the opportunity to comment on the research 
protocol and testing procedure. This information will be collated and may inform future 
studies. You and your parent/guardian will also receive the results and conclusions from the 
research and are free to request information regarding your individual data.  
 
 
  
416 
 
14. Who is organising and funding the research? 
 
The study is a collaboration between the Paediatric Unit of the Royal Devon and Exeter 
(RD&E) NHS Foundation Trust Hospital and the Children’s Health and Exercise Research 
Centre at the University of Exeter. The study is sponsored by the RD&E NHS Foundation 
Trust and has been supported financially by a small grant award from the RD&E. A monetary 
contribution will be provided to your parent/guardian to go some way towards covering your 
travel expenses (45p/miles for first 100 miles travelled and 25p/mile thereafter) and/or 
parking costs, bus or rail fares when attending testing sessions at the RD&E.  
 
 
15. Who has reviewed the study? 
 
The scientific content of the study has been reviewed by the Peninsula Research and 
Development Support Unit. All research within the National Health Service (NHS) is looked 
at by an independent group of people, called a Research Ethics Committee (REC). RECs 
safeguard the rights, safety, dignity and well-being of people participating in research in the 
NHS. They review applications for research and give an opinion about the proposed 
participant involvement and whether the research is ethical. The present study has been 
reviewed and given favourable opinion by the South West 5 (or Frenchay) REC.  
 
 
 
16. What should I do if I would like to take part? 
 
If you would like to take part in the study you must give your permission by completing the 
consent form and your parent guardian must do the same. You should then return the two 
forms to a member of the research team.  
 
 
 
17. What if I have a question? 
 
If you or your parent/guardian have any questions please do not hesitate to get in touch with a 
member of the research team using the details provided on page 9 and at the top of page 1. 
 
 
 
18. Contact for further information 
 
If you need further information please contact the research time using the details presented on 
page 9 and at the top of page 1.  
 
For more information regarding participation in research you can access the public 
information pack published by INVOLVE (a non-profit organization promoting public 
involvement in the NHS, public health and social care research). Visit their website 
www.involve.org.uk/ or obtain a paper copy by writing to: Involve, Royal London House, 22-
25 Finsbury Square, London, EC2A 1DX.  
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More specialised information regarding participation in clinical research is published by the 
UK Clinical Research Collaboration (UKCRC). For further information visit www.ukcrc.org 
or request a printed copy from: UKCRC, 20 Park Crescent, London, W1B 1AL.  
 
 
 
 
The Research Team 
 
Miss Zoe L. Saynor (Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): (01392) 264889 
E-mail: zls202@exeter.ac.uk 
 
Dr. Patrick J. Oades (Consultant Paediatrician, Royal Devon and Exeter Healthcare NHS 
Trust) 
Tel (work): 01392 402665 
E-mail: patrick.oades@nhs.net 
 
Prof. Craig A. Williams (Children’s Health & Exercise Research Centre, University of 
Exeter) 
Tel (work): 01392 724809 
E-mail: c.a.williams@exeter.ac.uk 
 
Dr. Alan Barker (Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): (01392) 722766 
Email: a.r.barker@exeter.ac.uk 
 
N.B. Contact outside of office hours should be made to Miss Zoe Louise Saynor.  
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PARENT/GUARDIAN INFORMATION SHEET 
FOR 
THE INFLUENCE OF DISEASE STATUS AND ‘PRIMING’ EXERCISE ON 
PULMONARY OXYGEN UPTAKE AND MUSCLE DEOXYGENATION KINETICS 
DURING MODERATE AND HIGH-INTENSITY CYCLING EXERCISE IN 
PAEDIATRIC PATIENTS WITH CYSTIC FIBROSIS 
Version number: 3 
Date: 02/10/12 
 
 
1. Study Title 
 
The influence of disease status and ‘priming’ exercise on pulmonary oxygen uptake and 
muscle deoxygenation kinetics during moderate and high-intensity cycling exercise in 
paediatric patients with cystic fibrosis.  
 
 
2. Invitation paragraph  
 
Your child is being invited to take part in a research study. Before you and your child decide 
whether or not to be involved, it is important for you to understand why the research is being 
done and what it will involve. Please take time to read the following information carefully 
and discuss it with friends, relatives and your clinician/GP if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to decide whether 
or not you wish to take part. 
 
 
Thank you for reading this information sheet. 
 
 
3. What is the purpose of the study?  
 
It is recommended that children and teenagers with cystic fibrosis (CF) take part in sports and 
games to stay fit and healthy. Exercise not only helps improve fitness and enhances their 
quality of life through socialising with peers and friends, but it may also help them to cope 
better with aspects of their disease. It has been reported that CF patients are characterised by 
reduced aerobic fitness when compared with their healthy counterparts. However, the extent 
and cause(s) for why patients with CF may find it more tiring during exercise than a healthy 
person of the same age remains an area of debate.  
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During exercise, breathing becomes faster and harder because the body needs more oxygen to 
produce energy to move faster. When we go from rest or performing light exercise to harder 
exercise necessitating our body to work harder, then the energy (and therefore oxygen) our 
muscles need to keep working must change quickly. During this change from rest to exercise 
all of the bodily systems (e.g. the heart, lungs and muscles) which are important during 
exercise must work together in co-ordination to increase the amount of oxygen/energy which 
is needed by the muscles working during exercise. If someone can ‘switch on’ this system to 
produce the necessary energy  more quickly when they start to exercise then we know that 
they will be able to exercise for longer before they become tired.  
 
This study will look at how well your child responds during these changes from rest to 
exercise of different difficulties and how fast they can ‘switch on’ their ‘aerobic energy 
system’. Understanding this is of importance, as it will help us to know where to focus 
intervention strategies (e.g exercise training) to improve the ability of CF patients to tolerate 
exercise and, subsequently, should improve their quality of life.   
 
Whilst the main aim of this study is to gather the above information, it will also provide 
information regarding your child’s exercise tolerance/fitness which may offer a novel insight 
for both you and your child. Additionally, we know that participating in regular exercise is 
beneficial to patients with CF and participating in this research project will also serve as 5 
sessions of supervised moderate- and high-intensity cycling exercise training for your child.  
 
 
4. Why has my child been chosen? 
 
We are interested in young cystic fibrosis patients, aged between 10-18 years old, who have 
stable disease and regularly take part in physical activity.  
 
 
5. Does my child have to take part? 
 
Taking part is entirely voluntary and it is up to you to decide whether or not your child takes 
part. If you do allow your child to take part you will be given this information sheet to keep, 
and be asked to sign a consent form giving permission for your child to participate (they will 
do the same). If you do decide to allow your child to take part you are still free to withdraw 
them from the study at any time and without giving a reason. A decision to withdraw your 
child at any time or a decision not to take part in the first place will not affect the standard 
clinical care they receive. 
 
 
6. What will happen to my child if I allow them to take part? 
 
The study will involve 5 trips to an exercise laboratory within the Royal Devon and Exeter 
NHS Foundation Trust Hospital (RD&E), separated by at least 48 h and ideally completed 
over a maximum 2 week period (to minimise the chance of any significant change in your 
child’s clinical status or fitness levels). All testing will take place at times which are suitable 
for you and your child and this can be at weekends or after school if preferred. On all 5 visits 
to the centre, your child will be required to complete an exercise test and the following 
measurements will be taken: 
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Respiratory function: 
The volume of oxygen your child is breathing in (V̇O2)  
The volume of carbon dioxide your child is breathing out (V̇CO2) 
The ratio between the amounts of oxygen your child is breathing in and carbon dioxide 
he/she is breathing out (RER). 
How much air your child is taking in each minute (V̇E). 
 
 
Lung function 
The volume of air your child can breathe out (FVC). 
The volume of air your child can breathe out in one second (FEV1). 
The volume of air your child is breathing in and out (PEF). 
 
Other measurements 
How fast your child’s heart is beating (HR) 
How much blood your child’s heart pumps out each time it contracts (SV) 
How tired your child thinks he/she feels (RPE). 
How breathless your child thinks he/she feels (RPD) 
Changes in the concentration of oxygenated and deoxygenated haemoglobin/myoglobin 
within the quadriceps muscles of your child’s right leg 
The amount of oxygen present in your child’s blood (SaO2) 
 
 
Visit 1 
The initial visit will consist of two parts:  
 
1: Familiarisation session / baseline assessments 
You and your children will be given the opportunity to discuss any queries you may have, 
give your informed consent/assent and to familiarise you/your child with the equipment and 
testing procedures that will be used during exercise testing visits. We will then obtain some 
information regarding your child’s body composition. Your child’s height, sitting height, and 
weight will be measured. They will also have their skin folds measured at the front and back 
of their arm, just below their shoulder blade and at the front of their hip. This is done by very 
gently pinching the skin and measuring the width of the skin folds. They will then have their 
resting lung function measured, this will involve your child taking a big breath and breathing 
into a plastic tube and is no different to the lung function tests they routinely perform in 
clinics. Your child will then be familiarised with the equipment to be used during testing and 
encouraged to practice cycling at different intensities on the stationary exercise bike. You and 
your child can then also take this opportunity to ask any questions to the research staff 
regarding the requirements of the next exercise testing sessions.  
 
 
2: Incremental Exercise Test 
Following the above, your child will be required to perform their first exercise test. This 
initial exercise test will be an ‘incremental ramp cycle test to exhaustion’. This test requires 
your child to pedal on an exercise bike for as long as they can. This exercise test starts off 
easy but gradually the pedals get harder to turn making the exercise test progressively more 
difficult, this will feel like your child is cycling up a hill which is getting steeper.  
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During this exercise test they will be required to wear a rubber face mask which covers their 
nose and chin, which will be connected to a device measuring the oxygen they are breathing 
in and carbon dioxide they are breathing out. This may seem strange at first but they will 
soon get used to it and this is a standard piece of kit used when performing this form of 
exercise test on young people. The amount of oxygen present in your child’s blood will also 
be monitored throughout the session using a small rubber device placed on the end of their 
index fingertip. In addition to this, they will wear 6 electrode pads (similar to an ECG if you 
have ever had or seen one of these), placed on their head, neck, chest and back. These are 
simply gel pads which will stick to the skin and, when attached to wires, will tell us how your 
child’s heart is responding during exercise. Finally, your child will have a small black plastic 
device taped and bandaged securely onto their right thigh. This device will simply shine light 
into the working muscle and allows us to estimate how much of the oxygen your child 
breathes in is being delivered to the muscles that need it when they are working during 
exercise. Throughout the exercise test (every minute) your child will be shown a list of 
numbers (0-10) corresponding to pictures of a child running up stairs and getting more and 
more tired. They will be asked to point on the chart to tell us how hard or easy they are 
finding the exercise at that time. They will also be asked to rate on a different chart how out 
of breath they feel, again using words and numbers (0-10). This exercise test usually lasts 
~8-12 minutes.  
 
After your child has finished this exhaustive exercise test, they will remain on the bike for a 5 
minute ‘cool-down’ period of easy pedalling to recover and then will sit down and rest for 10 
minutes. The electrodes and black box will still be attached, however the face mask will be 
removed when sitting down recovering. During this rest your child will have their lung 
function measured again.  
 
Following this 15 minute rest, your child will be asked to get back onto the bike and to pedal 
again for as long as possible. Unlike the first test, this test will not get gradually harder and 
harder. This will be set at a similar difficulty to where your child terminated the first test and 
will typically only last ~ 1-2 minutes. When your child becomes exhausted they will again be 
asked to stay seated on the bike and pedal lightly for 5 minutes to allow their body to 
recovery gradually, as they will have been working hard during the test. The aim of this test 
is to clarify whether or not they could have continued for any longer during the 1
st
 test. 
During the second part of the exercise test your child will be wearing the same equipment as 
in the first exercise test. Your child’s lung function will be measured one last time when they 
get off the bike.   
 
This initial visit will last 1-1.5 h.  
 
Visit 2, 3, 4 and 5 
 
At least forty-eight hours later your child will be asked to complete the second exercise 
testing session which will be identical to visits 3, 4 and 5 to follow.  This visit will again last 
approximately 1.5 hours, however we will not need to collect the skin fold measurements 
again or practice using the exercise bike.  
 
These sessions will require your child to perform 2 x ~30 minute periods of exercise. 
However, only 12 minutes of each will be exercise that makes your child feel like they are 
working reasonably hard, the rest will be light exercise during which it will feel nice and easy 
to turn the pedals.  
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The exercise session 
Your child will begin with a 4-minute ‘warm-up’ of easy pedalling. They will then cycle for 
6 minutes at an intensity we call ‘moderate’ (this will feel like they are having to work to turn 
the pedals, however it should not be too hard or cause them to become exhausted). This will 
be followed by 6 minutes easy cycling like the warm-up. The ‘intensity’ will then increase to 
one that is ‘moderate’ again for a further 6 minutes, which will finally finish with 6 minutes 
of easy cycling. Your child will then get off the bike and sit down and rest for 30 minutes.  
 
Following this 30 minute rest period, your child will get back onto the bike for the second 
and last part of the exercise test. Again, this will begin with 4 minutes of easy pedalling and 
then the ‘intensity’ will be increased for the next 6 minutes. However, this time it will be 
‘very-heavy’, which means that your child should have to work a bit harder to turn the pedals 
and will feel a bit more out of breath. Following this your child will again cycle for 6 minutes 
which will be nice and easy and the pedals will feel much lighter to turn. The ‘intensity’ will 
then be increased to the ‘moderate’ one again, which is easier and the same as the 2 moderate 
periods your child competed at the start of the session. Following this your child will stay on 
the bike and recover for a few minutes.  
 
The session will then be complete. 
 
 
 
During this exercise session your child will have to wear the rubber face mask again. The 
amount of oxygen present in your child’s blood will also be monitored throughout the session 
using the same small rubber device placed on the end of their index fingertip during their 1
st
 
visit. They will also wear the 6 electrode pads on their head, neck, chest and back and the 
small black plastic box on their right thigh. At various time points during exercise and at the 
end of the 4 harder periods of exercise your child will be shown the chart which shows how 
hard or easy they are finding the exercise and  asked to rate on the breathlessness chart 
whether they are feeling out of breath. 
 
 
Visits 3, 4 and 5 will be identical to visit 2 and will be separated by at least 48 h (ideally 
within 2-3 days) at a time suitable to you.  
 
 
Post-testing 
We also need to know your child’s maturation (growth and development). This will require 
them to self-assess their pubertal stage by selecting from 5 options on a chart which shows 
different pictures of pubic hair through the stages of maturation. Self-assessment will take 
place at home and you will be asked to return the scale in a sealed envelope you will be 
provided with. We are also interested in assessing how physically active your child is during 
a typical week, if you and they agree to do so. This will be assessed by wearing a small hip-
mounted plastic box on an elastic belt for 7 days, whilst completing a brief diary of the 
physical activities they perform from the time they wake up to the time they go to bed. The 
monitor would be removed if they swim or take a bath/shower and when in bed.   
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7. What else will my child have to do? 
 
If your child wishes to take part in the study and he/she has your permission we would like 
them to attend all 5 visits at the exercise laboratory. We ask that they be in a rested state on 
arrival, and have performed no exhaustive exercise in the 2-3 days prior to visits (other than 
involvement in this study). Any specific questions regarding any exercise training or sport 
your child may be doing prior to testing sessions can be discussed with the research team 
prior to any involvement in this research study.  
 
On each visit to the laboratory we also ask that your child has had sufficient food and drink 
before he/she arrives, and that they wear the same or similar clothes for each exercise test 
(that is sports kit, usually shorts, t-shirt and trainers). We also ask that they don’t eat or drink 
any caffeine 3 hours prior to each visit. However, it is important that they do eat a light meal 
or snack before each visit (i.e. sandwich, cereal etc.). 
 
We may ask your child if we can take photographs during their exercise tests. The purpose of 
these photographs is to possibly be used within University of Exeter publicity materials, in 
Miss Saynor’s PhD thesis and in conference presentations such as posters and PowerPoint 
presentation. This is entirely voluntary and will in no way affect any subsequent involvement 
in the study if you and/or your child should decline. Permission to take any photographs will 
be obtained in writing prior to involvement in the study. 
 
 
8. What are the possible risks of my child taking part? 
 
The exercise testing is very safe. An assessment of your child’s health will be made before 
they start the exercise tests to see if it is safe for them to take part. During the exercise tests 
your child will be carefully monitored and observed to ensure their safety and well-being.  
 
 
9. What are the potential benefits of my child taking part?  
 
This research is intended to enhance our understanding of how children with CF tolerate 
exercise and, more specifically, the rapid changes their bodies must deal with when they 
change between rest and exercise of difference intensities. The information we obtain from 
the study will help to improve our understanding regarding whether CF disease makes it more 
challenging for patients to exercise without becoming tired earlier on that someone without 
CF. It can also help to develop better exercise testing programmes within CF clinics.  
 
Hopefully, your child will take away a positive and enjoyable experience from their 
involvement in the exercise tests. They will be tested on equipment that is used to monitor the 
fitness of sports people, and they will get to see how fit they currently are and what intensity 
of exercise they can tolerate. Visits 2-5 will also act as supervised exercise sessions, which 
we know to be beneficial for your child. They will be given the results of their exercise tests 
and talked through them by a member of the research team. This will hopefully prove an 
interesting and constructive exercise, particularly if they have a strong interest or 
involvement in sport and may wish to increase the amount of physical activity in which they 
participate. They can also take the 30 minute break to discuss any questions they may have 
regarding exercise with an exercise physiologist if they wish to do so.  
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10. What happens if my child does not want to continue in the study? 
 
Your child is free to withdraw from the study at any point without giving a reason. Dropping 
out of the study will not affect their clinical care in any way or your relationship with the 
paediatric staff.  
 
If your child does decide not to continue with the study then they will not be required to 
complete any additional exercise tests, or attend any additional visits to the centre that are 
associated with the research. Results from any exercise tests that they have previously 
completed will still be available to them/you. 
 
 
11. What if something goes wrong? 
 
If taking part in this study harms your child, compensation arrangements are under the 
directive of the University of Exeter.  Your rights are the same as any person undergoing 
research, i.e. if your child is harmed due to someone’s negligence, then you may have 
grounds for legal action, but you may have to pay for it.  If you wish to complain, or have any 
concerns about any aspect of the way you have been approached or treated during the course 
of this study, the normal University complaints procedures will be available to you. In any 
such case, complaints should be directed to Professor Adrian Taylor, Director of Research for 
Sport and Health Sciences, University of Exeter [+44 (0) 1392 724747; 
Adrian.Taylor@exeter.ac.uk].  
 
 
 
12. Will my child’s involvement in this study be kept confidential? 
 
We have a responsibility to inform you of how we will collect, store and use your child’s 
information that we gather during the study. The primary concern is that any information that 
we collect about your child will be confidential. All of the information collected such as their 
name, date of birth, contact details, details of their health and test results will be transferred to 
a paper study file, which will be kept in a secure room in a locked filing cabinet. Members of 
the research team will be outside your child’s direct standard care team and will have access 
to their data. However, your child’s exercise results will be kept anonymous by assigning 
them a unique study code and participant number. Only your child’s date of birth will be used 
to identify the results. The results from the exercise tests are collected on paper and stored in 
a locked filing cabinet. The exercise results are then transferred from paper and stored on a 
computer. The only personal information stored on computer will be your child’s date of 
birth and participant number. Their exercise results will be password protected, as will the 
computer used to store the information. All the paper and computer files will be stored for 15 
years, after this period paper files will be destroyed and computer files erased. Only the 
researchers involved in the study will have access to your child’s medical records and 
exercise results. 
 
 
13. What will happen to the results of the study? 
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Once the study is completed, which is targeted to be December 2012, the results will be 
analysed and interpreted and you will subsequently be sent a summary of our research 
findings. The research is undertaken with the intention of being submitted as a PhD thesis. It 
is also the intention to submit the results of the research to relevant journals for publication, 
and to inform our colleagues of the findings at scientific meetings. In publishing and talking 
about the study your child will not be identifiable. 
 
You and your child will be given the opportunity to comment on the research protocol and 
testing procedure. This information will be collated and may inform future studies. You and 
your child will also receive the results and conclusions from the research and are free to 
request information regarding your child’s individual data.  
 
 
14. Who is organising and funding the research? 
 
The study is a collaboration between the Paediatric Unit of the Royal Devon and Exeter 
(RD&E) NHS Foundation Trust Hospital and the Children’s Health and Exercise Research 
Centre at the University of Exeter. The study is sponsored by the RD&E NHS Foundation 
Trust and has been supported financially by a small grant award from the RD&E. A monetary 
contribution will be provided to go some way towards covering your travel expenses 
(45p/mile for first 100 miles travelled and 25p/mile thereafter) and/or parking costs, bus or 
rail fares when attending testing sessions at the RD&E.  
 
 
 
 
15. Who has reviewed the study? 
 
The scientific content of the study has been reviewed by the Peninsula Research and 
Development Support Unit. All research within the National Health Service (NHS) is looked 
at by an independent group of people, called a Research Ethics Committee (REC). RECs 
safeguard the rights, safety, dignity and well-being of people participating in research in the 
NHS. They review applications for research and give an opinion about the proposed 
participant involvement and whether the research is ethical. The present study has been 
reviewed and given favourable opinion by the South West 5 (or Frenchay) REC.  
 
 
16. What should I do if my child would like to take part? 
 
If your child would like to take part in the study you must give your permission by 
completing the consent form and your child must also complete their assent (<16 y) / consent 
(16-18 y) form (depending on their age). You should then return the two forms to a member 
of the research team.  
 
 
17. What if my child or I have a question? 
 
If you or your child have any questions please do not hesitate to get in touch with a member 
of the research team using the details provided on page 9 and at the top of page 1. 
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18. Contact for further information 
 
If you need further information please contact the research time using the details presented on 
page 9 and at the top of page 1.  
 
For more information regarding participation in research you can access the public 
information pack published by INVOLVE (a non-profit organization promoting public 
involvement in the NHS, public health and social care research). Visit their website 
www.involve.org.uk/ or obtain a paper copy by writing to: Involve, Royal London House, 22-
25 Finsbury Square, London, EC2A 1DX.  
 
More specialised information regarding participation in clinical research is published by the 
UK Clinical Research Collaboration (UKCRC). For further information visit www.ukcrc.org 
or request a printed copy from: UKCRC, 20 Park Crescent, London, W1B 1AL.  
 
 
 
The Research Team 
 
Miss Zoe L. Saynor (Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): (01392) 264889 
E-mail: zls202@exeter.ac.uk 
 
Dr. Patrick J. Oades (Consultant Paediatrician, Royal Devon and Exeter Healthcare NHS 
Trust) 
Tel (work): 01392 402665 
E-mail: patrick.oades@nhs.net 
 
Prof. Craig A. Williams (Children’s Health & Exercise Research Centre, University of 
Exeter) 
Tel (work): 01392 724809 
E-mail: c.a.williams@exeter.ac.uk 
 
Dr. Alan Barker (Children’s Health & Exercise Research Centre, University of Exeter) 
Tel (work): (01392) 722766 
E-mail: a.r.barker@exeter.ac.uk  
 
N.B. Contact outside of office hours should be made to Miss Zoe Louise Saynor.  
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APPENDIX G 
Consent and Assent Forms for Studies 1 and 2 
 
 
 
 
Study Number:  
Patient Identification Number for this trial: 
 
 
ASSENT FORM FOR CHILDREN 
(To be completed by the child and their parent/guardian) 
The reliability and validity of maximal cardiopulmonary exercise testing as a prognostic tool 
within the young cystic fibrosis population 
                                                                                                                            
 
Child (or if unable, parent on their behalf) /young person to circle all they agree with please: 
Have you read (or had read to you) about this project [Version 2 dated 20/12/10]     Yes/No 
Has somebody else explained this project to you?         Yes/No 
Do you understand what this project is about?                Yes/No 
Have you asked all the questions you want?       Yes/No 
Have you had your questions answered in a way you understand? Yes/No 
Do you understand it’s OK to stop taking part at any time?  Yes/No 
Are you happy to take part?                                    Yes/No 
If any answers are ‘no’ or you don’t want to take part, don’t sign your name! 
If you do want to take part, please write your name and today’s date  
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Your name       ___________________________ 
   
 Date              ___________________________ 
 
Your parent or guardian must write their name here too if they are happy for you to do the project 
 
 
 Print Name  ___________________________ 
 
 Sign               ___________________________ 
 
 Date              ___________________________ 
 
 
The doctor who explained this project to you needs to sign too: 
 
Print Name    ___________________________ 
 
Sign               ___________________________ 
 
Date              ___________________________ 
 
 
 
Thank you for your help. 
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Study Number:  
Patient Identification Number for this trial: 
 
 
PATIENT (16-18yrs) CONSENT FORM 
 
Title of Project: The reliability and validity of maximal cardiopulmonary 
exercise testing as a prognostic tool within the young cystic fibrosis 
population 
Name of Researchers: Dr. Patrick J. Oades, Dr. Craig A. Williams, Dr Alan 
Barker and Miss. Zoe Louise Saynor 
 
Please initial box 
1 I have read and understand the information sheet [Version 2 dated 20/12/10] for the above 
study and have had the opportunity to ask questions. 
 
2 I understand that my taking part is voluntary and that I am free to withdraw at any time, 
without giving any reason and without my medical care or legal rights being affected. 
 
3 I understand that sections of my medical records may be looked at by the researchers in the 
study where it is relevant to my participation, and that this information will be kept secure. 
 
4 I understand that during the period of my participation that hard exercise is to be avoided but 
that I should eat and drink normally. 
 
5 I am aware that my exercise results will be kept anonymous by giving them a unique study 
code and participant number, only my date of birth will be used to identify the results. I give 
consent for my medical records and exercise results to be used as indicated in the 
parent/guardian information sheet [Version 2 dated 20/12/10]. I understand that my exercise 
results will be stored for 15 years after which they will be destroyed. 
 
6 I give my consent for to take part in the above study.  
____________________  ______________  ________________ 
Name of participant    Date     Signature 
_____________________  ______________  ________________ 
Name of parent/guardian   Date    Signature  
_____________________  ______________  ________________ 
Researcher     Date     Signature 
CHILDREN’S HEALTH AND EXERCISE 
RESEARCH CENTRE 
 
Sport and Health Sciences 
St Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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Study Number:  
Patient Identification Number for this trial: 
 
 
PARENT/GUARDIAN CONSENT FORM 
 
Title of Project: The reliability and validity of maximal cardiopulmonary 
exercise testing as a prognostic tool within the young cystic fibrosis 
population 
Name of Researchers: Dr. Patrick J. Oades, Dr. Craig A. Williams, Dr Alan 
Barker and Miss. Zoe Louise Saynor 
 
Please initial box 
1 I have read and understand the information sheet [Version 2 dated 20/12/10] for the above 
study and have had the opportunity to ask questions. 
 
2 I understand that my child’s taking part is voluntary and they are free to withdraw at any time, 
without giving any reason and without his/her medical care or legal rights being affected. 
 
3 I understand that sections of any of my child’s medical records may be looked at by the 
researchers in the study where it is relevant to his/her participation, and that this information 
will be kept secure. 
 
4 I understand that during the period of his/her participation that hard exercise is to be avoided 
but that he/she should eat and drink normally. 
 
5 I am aware that my child’s exercise results will be kept anonymous by giving them a unique 
study code and participant number, only my child’s date of birth will be used to identify the 
results. I give consent for his/her medical records and exercise results to be used as 
indicated in the parent/guardian information sheet [Version 2 dated 20/12/10]. I understand 
that my child’s exercise results will be stored for 15 years after which they will be destroyed. 
 
6 I give my consent for my child to take part in the above study.  
____________________  ______________  _________________ 
Name of participant    Date     Signature 
_____________________  ______________  _________________ 
Name of parent/guardian   Date    Signature  
_____________________  ______________  _________________ 
Researcher     Date     Signature 
CHILDREN’S HEALTH AND EXERCISE 
RESEARCH CENTRE 
 
Sport and Health Sciences 
St Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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APPENDIX H 
Consent and Assent Forms for Study 3 
 
 
 
Study Number:  
Participant Identification Number for this trial: 
 
 
ASSENT FORM FOR CHILDREN 
(To be completed by the child and their parent/guardian) 
Oxidative and cardiovascular responses during exercise in patients with cystic fibrosis 
compared to age and gender matched controls 
 
 
Child (or if unable, parent on their behalf) /young person to circle all they agree with please: 
Have you read (or had read to you) about this project [Version 2 dated 02/01/12]     Yes/No 
Has somebody else explained this project to you?         Yes/No 
Do you understand what this project is about?                Yes/No 
Have you asked all the questions you want?       Yes/No 
Have you had your questions answered in a way you understand? Yes/No 
Do you understand it’s OK to stop taking part at any time?  Yes/No 
Are you happy to take part?                                    Yes/No 
If any answers are ‘no’ or you don’t want to take part, don’t sign your name! 
If you do want to take part, please write your name and today’s date  
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 Your name       ___________________________ 
   
 Date              ___________________________ 
 
 
Your parent or guardian must write their name here too if they are happy for you to do the project 
 
 
 Print Name  ___________________________ 
 
 Sign               ___________________________ 
 
 Date              ___________________________ 
 
 
The researcher who explained this project to you needs to sign too: 
 
Print Name    ___________________________ 
 
Sign               ___________________________ 
 
Date              ___________________________ 
 
 
 
Thank you for your help. 
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Study Number:  
Participant Identification Number for this trial: 
 
 
PARTICIPANT (16-18 y) CONSENT FORM 
 
Title of Project: Oxidative and cardiovascular responses during exercise in 
patients with cystic fibrosis compared to age and gender matched controls  
Name of Researchers: Miss Zoe Louise Saynor, Dr. Alan R. Barker, Dr. Patrick 
J. Oades and Associate Professor Craig A. Williams 
 
 
Please initial box 
1 I have read and understand the information sheet [Version 1 dated 02/01/12] for the above 
study and have had the opportunity to ask questions. 
 
2 I understand that my child’s taking part is voluntary and they are free to withdraw at any time, 
without giving any reason and without his/her medical care or legal rights being affected. 
 
3 I understand that sections of any of my child’s medical records may be looked at by the 
researchers in the study where it is relevant to his/her participation, and that this information 
will be kept secure. 
 
4 I understand that during the period of his/her participation that hard exercise is to be avoided 
but that he/she should eat and drink normally. 
 
5 I am aware that my child’s exercise results will be kept anonymous by giving them a unique 
study code and participant number, only my child’s date of birth will be used to identify the 
results. I give consent for his/her medical records and exercise results to be used as 
indicated in the parent/guardian information sheet [Version 1 dated 02/01/12]. I understand 
that my child’s exercise results will be stored for 15 years after which they will be destroyed. 
 
6 I give my consent for my child to take part in the above study.  
____________________  ______________  _________________ 
Name of participant    Date     Signature 
_____________________  ______________  _________________ 
Name of parent/guardian   Date    Signature  
_____________________  ______________  _________________ 
Researcher     Date     Signature 
CHILDREN’S HEALTH AND EXERCISE 
RESEARCH CENTRE 
 
Sport and Health Sciences 
St Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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Study Number:  
Participant Identification Number for this trial: 
 
 
PARENT/GUARDIAN CONSENT FORM 
 
Title of Project: Oxidative and cardiovascular responses during exercise in 
patients with cystic fibrosis compared to age and gender matched controls  
Name of Researchers: Miss Zoe Louise Saynor, Dr. Alan R. Barker, Dr. Patrick 
J. Oades and Associate Professor Craig A. Williams 
 
 
Please initial box 
1 I have read and understand the information sheet [Version 2 dated 02/01/12] for the above 
study and have had the opportunity to ask questions. 
 
2 I understand that my child’s taking part is voluntary and they are free to withdraw at any time, 
without giving any reason and without his/her medical care or legal rights being affected. 
 
3 I understand that sections of any of my child’s medical records may be looked at by the 
researchers in the study where it is relevant to his/her participation, and that this information 
will be kept secure. 
 
4 I understand that during the period of his/her participation that hard exercise is to be avoided 
but that he/she should eat and drink normally. 
 
5 I am aware that my child’s exercise results will be kept anonymous by giving them a unique 
study code and participant number, only my child’s date of birth will be used to identify the 
results. I give consent for his/her medical records and exercise results to be used as 
indicated in the parent/guardian information sheet [Version 2 dated 02/01/12]. I understand 
that my child’s exercise results will be stored for 15 years after which they will be destroyed. 
 
6 I give my consent for my child to take part in the above study.  
____________________  ______________  _________________ 
Name of participant    Date     Signature 
_____________________  ______________  _________________ 
Name of parent/guardian   Date    Signature  
_____________________  ______________  _________________ 
Researcher     Date     Signature 
CHILDREN’S HEALTH AND EXERCISE 
RESEARCH CENTRE 
 
Sport and Health Sciences 
St Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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APPENDIX I 
Consent and Assent Forms for Studies 5 and 6 
 
 
 
 
Study Number: 12/SW/0270  
Patient Identification Number for this trial: 
 
 
ASSENT FORM FOR PATIENTS (10-15 y) 
(To be completed by the patient and their parent/guardian) 
The influence of disease status and ‘priming’ exercise on pulmonary oxygen uptake and 
muscle deoxygenation kinetics during moderate and high-intensity cycling exercise in 
paediatric patients with cystic fibrosis 
                                                                                                                            
 
Child (or if unable, parent on their behalf) /young person to circle all they agree with please: 
Have you read (or had read to you) about this project [Version 3 dated 02/10/12]     Yes/No 
Has somebody else explained this project to you?         Yes/No 
Do you understand what this project is about?                Yes/No 
Have you asked all the questions you want?       Yes/No 
Have you had your questions answered in a way you understand? Yes/No 
Do you understand that you will be working with people different to your usual care team at the 
hospital? 
                                                                                                          Yes/No 
Do you understand it’s OK to stop taking part at any time?  Yes/No 
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Are you happy to take part?                                    Yes/No 
If any answers are ‘no’ or you don’t want to take part, don’t sign your name! 
 
If you do want to take part, please write your name and today’s date  
 
 Your name       ___________________________ 
   
 Date              ___________________________ 
 
Your parent or guardian must write their name here too if they are happy for you to do the project 
 
 Print Name  ___________________________ 
 
 Sign               ___________________________ 
 
 Date              ___________________________ 
 
The person from the research team who explained this project to you needs to sign too: 
 
Print Name    ___________________________ 
 
Sign               ___________________________ 
 
Date              ___________________________ 
 
 
Thank you for your help. 
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Study Number: 12/SW/0270  
Patient Identification Number for this trial: 
 
 
PATIENT (16-18 y) CONSENT FORM 
 
Title of Project: The influence of disease status and ‘priming’ exercise on 
pulmonary oxygen uptake and muscle deoxygenation kinetics during 
moderate and high-intensity cycling exercise in paediatric patients with cystic 
fibrosis 
Name of Researchers: Miss Zoe L. Saynor, Dr. Patrick J. Oades, Dr. Alan R. 
Barker and Prof. Craig A. Williams 
 
 
Please initial box 
1 I have read and understand the information sheet [Version 3 dated 02/10/12] for the above 
study and have had the opportunity to ask questions. 
 
2 I understand that taking part is voluntary and I am free to withdraw at any time, without giving 
any reason and without my medical care or legal rights being affected. 
 
3 I understand that sections of my medical records may be looked at by the researchers (who 
are outside my usual direct clinical care team at the hospital) in the study where it is relevant 
to my participation, and that this information will be kept secure. 
 
4 I understand that during the period of my participation that hard exercise is to be avoided but 
that I should eat and drink normally. 
 
5 I am aware that my exercise results will be kept anonymous by giving them a unique study 
code and participant number, only my date of birth will be used to identify the results. I give 
consent for my medical records and exercise results to be used as indicated in the patient 
(16-18 y) information sheet [Version 3 dated 02/10/12]. I understand that my exercise results 
will be stored for 15 years after which they will be destroyed. 
 
6 I give my consent to take part in the above study.  
____________________  ______________  _________________ 
Name of participant    Date     Signature 
_____________________  ______________  _________________ 
Name of parent/guardian   Date    Signature  
_____________________  ______________  _________________ 
Researcher     Date     Signature 
CHILDREN’S HEALTH AND EXERCISE 
RESEARCH CENTRE 
 
Sport and Health Sciences 
St Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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Study Number: 12/SW/0270  
Patient Identification Number for this trial: 
 
 
PARENT/GUARDIAN CONSENT FORM 
 
Title of Project: The influence disease status and ‘priming’ exercise on 
pulmonary oxygen uptake and muscle deoxygenation kinetics during 
moderate and high-intensity cycling exercise in paediatric patients with cystic 
fibrosis 
Name of Researchers: Miss Zoe L. Saynor, Dr. Patrick J. Oades, Dr. Alan R. 
Barker and Prof. Craig A. Williams 
 
 
Please initial box 
1 I have read and understand the information sheet [Version 3 dated 02/10/12] for the above 
study and have had the opportunity to ask questions. 
 
2 I understand that my child’s taking part is voluntary and they are free to withdraw at any t ime, 
without giving any reason and without his/her medical care or legal rights being affected. 
 
3 I understand that sections of any of my child’s medical records may be looked at by the 
researchers (who are outside their usual direct clinical care team at the hospital) in the study 
where it is relevant to his/her participation, and that this information will be kept secure. 
 
4 I understand that during the period of his/her participation that hard exercise is to be avoided 
but that he/she should eat and drink normally. 
 
5 I am aware that my child’s exercise results will be kept anonymous by giving them a unique 
study code and participant number, only my child’s date of birth will be used to identify the 
results. I give consent for his/her medical records and exercise results to be used as 
indicated in the parent/guardian information sheet [Version 3 dated 02/10/12]. I understand 
that my child’s exercise results will be stored for 15 years after which they will be destroyed. 
 
6 I give my consent for my child to take part in the above study.  
____________________  ______________  _________________ 
Name of participant    Date     Signature 
_____________________  ______________  _________________ 
Name of parent/guardian   Date    Signature  
_____________________  ______________  _________________ 
Researcher     Date     Signature 
CHILDREN’S HEALTH AND EXERCISE 
RESEARCH CENTRE 
 
Sport and Health Sciences 
St Luke’s Campus 
Heavitree Road 
Exeter 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
 
EX1 2LU 
 
Tel: +44 (0) 1392 264889 
Email: zls202@ex.ac.uk 
Web: www.sshs.ex.ac.uk 
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APPENDIX J 
Pubertal Maturation Assessment Documentation 
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MATURATION ASSESSMENT  
PROCEDURES (FEMALES) – 
PARENT/GUARDIAN 
 
The assessment of physiological and physical change during growth is essential for the valid 
interpretation of human performance.  
 
 
Pubertal maturity will be self-assessed at home following completion of the exercise 
testing protocol. 
 
Drawings of male and female pubic hair developed by Morris and Udry (1980) made 
from photographs by Tanner (1975) will be used. A written description of each of the 5 
stages of male and female pubic hair development will be given on the chart as how to 
select the correct pubertal stage.  
 
The most practical approach to assess maturation was developed by Tanner (1962). Tanner 
developed a 5-point scale to assess ‘biological maturity’ through observation of secondary 
sexual characteristics. The scales depicted five or more stages of breast and pubic hair (girls), 
pubic hair and genitalia development (boys). A limitation is that trained health professionals 
such as paediatricians and school nurses are typically employed to assess the scales. 
Subsequently Morris and Udry (1980) developed a self-assessment scale based on Tanner 
stages and found that children were able to accurately assess their own stage of maturation 
with correlation coefficients in the range of 60-70% (Matsudo & Matsudo, 1993).  
 
The secondary sex characteristics described by Tanner (1962) will be used to assess 
pubertal maturity. Pubertal stage 1 will be identified as pre-pubertal, stages 2, 3 and 4 
circum-pubertal, and stage 5 post-pubertal.  
 
(Please find these below and circle the drawing which you feel best represents you) 
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MATURATION ASSESSMENT  PROCEDURES (MALES) – 
PARENT/GUARDIAN 
 
The assessment of physiological and physical change during growth is essential for the valid 
interpretation of human performance.  
 
 
Pubertal maturity will be self-assessed at home following completion of the exercise 
testing protocol. 
 
Drawings of male and female pubic hair developed by Morris and Udry (1980) made 
from photographs by Tanner (1975) will be used. A written description of each of the 5 
stages of male and female pubic hair development will be given on the chart as how to 
select the correct pubertal stage.  
 
The most practical approach to assess maturation was developed by Tanner (1962). Tanner 
developed a 5-point scale to assess ‘biological maturity’ through observation of secondary 
sexual characteristics. The scales depicted five or more stages of breast and pubic hair (girls), 
pubic hair and genitalia development (boys). A limitation is that trained health professionals 
such as paediatricians and school nurses are typically employed to assess the scales. 
Subsequently Morris and Udry (1980) developed a self-assessment scale based on Tanner 
stages and found that children were able to accurately assess their own stage of maturation 
with correlation coefficients in the range of 60-70% (Matsudo & Matsudo, 1993).  
 
The secondary sex characteristics described by Tanner (1962) will be used to assess 
pubertal maturity. Pubertal stage 1 will be identified as pre-pubertal, stages 2, 3 and 4 
circum-pubertal, and stage 5 post-pubertal.  
 
(Please find these below and circle the drawing which you feel best represents you) 
 
 
 
 
 
 
 
 
  
444 
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APPENDIX K 
Physical Activity Assessment Documentation 
 
PHYSICAL ACTIVITY 
ASSESSMENT  PROCEDURES – PARENT/GUARDIAN 
 
Please find enclosed an ActiGraph physical activity monitor (little red unit attached 
on a black waist belt).  
 
 
 
 
 
 
 
The monitor is already programmed to record your movement and physical activity 
patterns. Simply attach the black belt around your waist, clipping in place and 
ensuring this is reasonably tight so as to not move around too much. The red monitor 
should have the little sticker at the top (make sure it is the right way up) and should 
be locating just above the hip of your dominant leg – i.e. the leg you would prefer to 
kick a ball with. Please ensure that monitors are removed when swimming, bathing, 
showering and before bedtime. Then pop them back on when you wake up the 
next day.  
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Activity Log Book 
(EXAMPLE) DAY 1: 
Time Activity 
06:00 – 07:00  
07:00 – 08:00  
08:00 – 09:00  
09:00 – 10:00  
10:00 – 11:00  
11:00 – 12:00   
12:00 – 13:00   
13:00 – 14:00   
14:00 – 15:00  
15:00 – 16:00  
16:00 – 17:00   
17:00 – 18:00  
18:00 – 19:00  
19:00 – 20:00   
20:00 – 21:00  
21:00 – 22:00  
22:00 – 23:00  
23:00 – 00:00  
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APPENDIX L 
Children’s Effort Rating Scale (P-CERT) 
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APPENDIX M 
Rating of Perceived Dyspnoea Measurement Scale 
 
 
Borg’s 0-10 Category-ratio (CR-10) rating of perceived dyspnoea scale 
(Modification of Borg’s 1962 RPE Scale) 
 
0 Nothing at all 
0.5 Very, very slight (just noticeable) 
1 Very slight 
2 Slight (light) 
3 Moderate 
4 Somewhat severe 
5 Severe (heavy) 
6  
7 Very severe 
8  
9  
10 Very, very severe (almost maximum) 
 
The 0-10 category-ratio (CR-10) scale modified for use to measure dyspnoea. The scale 
incorporates nonlinear spacing of verbal descriptors of severity that correspond to specific 
numbers and ratio properties of intensities. A number greater than 10 can be selected by the 
patient if his or her dyspnoea exceeds ‘very, very severe (almost maximum)’  
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APPENDIX N 
Patient Medical Profile Form 
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